
<html lang="en"     class="pb-page"  data-request-id="993d09e8-0b7c-4896-bbf2-90c34cbd169d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-20;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b01202;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches" /></meta><meta name="dc.Creator" content="Wei  Hu" /></meta><meta name="dc.Creator" content="Xu-Sheng  Huang" /></meta><meta name="dc.Creator" content="Ji-Feng  Wu" /></meta><meta name="dc.Creator" content="Liang  Yang" /></meta><meta name="dc.Creator" content="Yong-Tang  Zheng" /></meta><meta name="dc.Creator" content="Yue-Mao  Shen" /></meta><meta name="dc.Creator" content="Zhi-Yu  Li" /></meta><meta name="dc.Creator" content="Xun  Li" /></meta><meta name="dc.Description" content="DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair. Despite the popular applications of topo II inhibitors in cancer therapy, there is stil..." /></meta><meta name="Description" content="DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair. Despite the popular applications of topo II inhibitors in cancer therapy, there is stil..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 5, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01202" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01202" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01202" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01202" /></link>
        
    
    

<title>Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01202" /></meta><meta property="og:title" content="Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0037.jpeg" /></meta><meta property="og:description" content="DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair. Despite the popular applications of topo II inhibitors in cancer therapy, there is still an urgent need to upgrade topo II inhibitors to cope with drug resistance and severe adverse effects. Accordingly, novel topo II catalytic or multitarget topo II inhibitors are gaining more attention and make it possible to ease the toxic limitations of topo II poisons. In this review, medicinal chemistry approaches are mainly discussed toward the development of potent topo II inhibitors with low toxicities." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01202"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01202">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01202&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01202&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01202&amp;href=/doi/10.1021/acs.jmedchem.7b01202" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8947-8980</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b00159" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wei Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Microbial Technology, School of Life Science, Shandong University, 27 South Shanda Road, 250100 Jiânan, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Hu">Wei Hu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xu-Sheng Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xu-Sheng Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Science and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xu-Sheng++Huang">Xu-Sheng Huang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ji-Feng Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ji-Feng Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Criminal Science and Technology, Jiânan Public Security Bureau, 21 South QiliShan Road, 250000 Jiânan, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ji-Feng++Wu">Ji-Feng Wu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Liang Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Jiânan, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Yang">Liang Yang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yong-Tang Zheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong-Tang Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Science and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China</div></div><span class="conrtib-corresp"><strong>*</strong>For Y.-T.Z. E-mail: <a href="/cdn-cgi/l/email-protection#add7c5c8c3cad4d9edc0ccc4c183c6c4d783d7ce83cec3"><span class="__cf_email__" data-cfemail="a4deccc1cac3ddd0e4c9c5cdc88acfcdde8adec78ac7ca">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong-Tang++Zheng">Yong-Tang Zheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yue-Mao Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yue-Mao Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Jiânan, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yue-Mao++Shen">Yue-Mao Shen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3881-0135" title="Orcid link">http://orcid.org/0000-0002-3881-0135</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Zhi-Yu Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhi-Yu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Philadelphia, Pennsylvania 19104, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhi-Yu++Li">Zhi-Yu Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Xun Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xun Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Jiânan, Shandong, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>For X.L. Tel: 86-531-88382005; fax: 86-531-88382548; e-mail: <a href="/cdn-cgi/l/email-protection#136779667f6b21232327536077663d7677663d707d"><span class="__cf_email__" data-cfemail="d9adb3acb5a1ebe9e9ed99aabdacf7bcbdacf7bab7">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xun++Li">Xun Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5582-8628" title="Orcid link">http://orcid.org/0000-0002-5582-8628</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01202&amp;href=/doi/10.1021%2Facs.jmedchem.7b01202" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8947â8980</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 5, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 August 2017</li><li><span class="item_label"><b>Published</b> online</span>5 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 October 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01202" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01202</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8947%26pageCount%3D34%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei%2BHu%252C%2BXu-Sheng%2BHuang%252C%2BJi-Feng%2BWu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D20%26contentID%3Dacs.jmedchem.7b01202%26title%3DDiscovery%2Bof%2BNovel%2BTopoisomerase%2BII%2BInhibitors%2Bby%2BMedicinal%2BChemistry%2BApproaches%26numPages%3D34%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8980%26publicationDate%3DOctober%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01202"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3509</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">40</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01202" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Xu-Sheng&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Ji-Feng&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Yong-Tang&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Yue-Mao&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Zhi-Yu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xun&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;8947-8980&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01202&quot;},&quot;abstract&quot;:&quot;DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair. Despite the popular applications of topo II inhibitors in cancer therapy, there is still an urgent need to upgrade topo II inhibitors to cope with drug resistance and severe adverse effects. Accordingly, novel topo II catalytic or multitarget topo II inhibitors are gaining more attention and make it possible to ease the toxic limitations of topo II poisons. In this review, medicinal chemistry approaches are mainly discussed toward the development of potent topo II inhibitors with low toxicities.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01202&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01202" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01202&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01202" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01202&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01202" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01202&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01202&amp;href=/doi/10.1021/acs.jmedchem.7b01202" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01202" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01202" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01202%26sid%3Dliteratum%253Aachs%26pmid%3D29870668%26genre%3Darticle%26aulast%3DHu%26date%3D2018%26atitle%3DDiscovery%2Bof%2BNovel%2BTopoisomerase%2BII%2BInhibitors%2Bby%2BMedicinal%2BChemistry%2BApproaches%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D20%26spage%3D8947%26epage%3D8980%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/jmcmar.2018.61.issue-20/20181025/jmcmar.2018.61.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0037.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">DNA topoisomerase II (topo II) is an important enzyme involved in DNA replication, recombination, and repair. Despite the popular applications of topo II inhibitors in cancer therapy, there is still an urgent need to upgrade topo II inhibitors to cope with drug resistance and severe adverse effects. Accordingly, novel topo II catalytic or multitarget topo II inhibitors are gaining more attention and make it possible to ease the toxic limitations of topo II poisons. In this review, medicinal chemistry approaches are mainly discussed toward the development of potent topo II inhibitors with low toxicities.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Globally, cancer is a major health problem that will affect approximately 22 million people by 2030 and has become the second leading cause of morbidity and mortality after cardiac disease.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Accordingly, effective chemotherapeutic agents to treat cancers with fewer adverse effects that counteract multidrug resistance (MDR) are still urgently desirable. Among the variety of molecular targets for cancer therapy, DNA topoisomerases (topos) are well-characterized targets owing to their essential roles in triggering, controlling, and modifying a wealth of topological DNA problems during cell proliferation, differentiation, and survival.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  Topoisomerases</h3><div class="NLM_p">Topoisomerases are ubiquitous enzymes responsible for resolving sophisticated DNA topological intermediates generated during DNA recombination, replication, transcription, and repair processes, such as relaxed, supercoiled, knotted, and catenated DNA.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> All topoisomerases exert their biochemical functions by catalyzing DNA cleavage and religation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p last">On the basis of their mechanisms, topoisomerases can be classified into two major classes: type I and type II DNA topoisomerases. Type I DNA topoisomerases cleave one single-stranded DNA during each catalytic cycle. Type II topoisomerases break one double-stranded DNA strand, allowing another segment of duplex DNA to pass through the transient breakage before resealing the broken strand to resolve DNA knots and tangles. Type II topoisomerases induce topological changes via multiple steps that require Mg<sup>2+</sup> and ATP hydrolysis.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The human genome possesses two type II topoisomerases: topoisomerase IIÎ± and topoisomerase IIÎ² (topo IIÎ± and topo IIÎ²). Apparently, they are encoded by two different genes and fulfill different cellular functions. In contrast, lower eukaryotes, e.g., single-celled yeast, insects, vertebrates, and <i>Xenopus laevis</i>, only possess one type II topoisomerase (topo II). Topo IIÎ± is overexpressed in many rapidly proliferating cancer cells. Inhibiting the function of topo IIÎ± by either inducing double-stranded DNA breaks or blocking ATP hydrolysis is a common approach for cancer therapy.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">1.2.  Catalytic Mechanism and Functions of Topo II</h3><div class="NLM_p">Topo II finishes one round of a catalytic reaction via multiple steps at the compensation of ATP hydrolysis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> A catalytic cycle of topo II is roughly composed of seven steps:<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> (i) topo II recognizes and binds to the first double-stranded DNA (G-segment) to form a transient DNA-enzyme complex; (ii) traps the second double-stranded DNA (T-segment) and then binds two ATP molecules, which results in the dimerization of the ATPase domain and closure of the N-gate; (ii) recruits Mg<sup>2+</sup> and cleaves the G-segment resulting in a transient DNA-enzyme covalent complex; (iv) passes the T-segment through the transient break in the G-segment by utilizing energy released from the hydrolysis of one ATP molecule; (v) reconnects the G-segment break facilitated by the hydrolysis of another ATP molecule; (vi) discharges two ADP molecules and induces the opening of the C-gate to release the T-segment; and (vii) disassociates the G-segment and opens the N-gate for another round of reactions.</div><div class="NLM_p last">Despite sharing a similar primary sequence and tertiary structure, human topo IIÎ± and Î² distribute in different tissues, cells, and subcellular locations. They also take different cellular functions. Topo IIÎ± is mainly located in the nuclear plasma and is preferentially overexpressed in proliferating cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Moreover, as a specific and sensitive biomarker for cell proliferation, topo IIÎ± is essential for tumor cell growth and division and abundantly functions in rapidly growing solid tumors. Topo IIÎ± is also essential for chromosomal segregation in mitosis to disentangle two sister chromosomes during the late G2 and M phases, a function that cannot be replaced by topo IIÎ². In addition, topo IIÎ± is a cell cycle-dependent enzyme that has the lowest expression levels during the G0/G1 phase. The expression of topo IIÎ± starts to increase in the S phase, reaches its peak in the G2/M phase, and then sharply decreases at the end of mitosis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In contrast, topo IIÎ² is mainly distributed within nucleoli in both normal and malignant tumor cells; however, its expression appears to be consistent in proliferating and normal cells. Topo IIÎ² is expressed at relatively low and steady levels during all stages of the cell cycle. Although topo IIÎ² is not essential for cell survival and proliferation, it plays apparent roles in cell development, transcriptional regulation, and differentiation and is implicated in neuronal differentiation and longevity.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Moreover, human topo IIÎ± relaxes positively supercoiled plasmids faster than negatively supercoiled plasmids; however, this was not observed for topo IIÎ².<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> For these reasons, topo IIÎ± seems to be the more attractive biotarget for exploiting potent antineoplastic drugs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.3.  Structure of Topo II</h3><div class="NLM_p">Human topo IIÎ± is a homodimer. Its monomer is composed of 1531 amino acids including four sections, N-gate, central-gate (DNA-gate), C-gate, and CTD.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The N-terminal portion possesses an ATPase domain, which belongs to the GHKL (<u class="uu">G</u>yrase, <u class="uu">H</u>SP90, histidine <u class="uu">K</u>inase, mut<u class="uu">L</u>) superfamily of proteins. Upon ATP binding, two ATPase domains from each monomer move to close the N-gate via dimerization. The central core DNA gate, also known as the DNA binding/cleavage gate, contains a Mg<sup>2+</sup>-binding TOPRIM (Topoisomerase/Primase) fold, a winged helix domain (WHD), which includes the tyrosine active site, and a âTOWERâ domain, which interacts with another monomer of the dimer. The C-gate holds and controls the passage of the T-segment. The CTD is essential for nuclear localization and possesses sites subject to post-translational modifications.</div><div class="NLM_p">The ATPase domain is situated at the <i>N</i>-terminus of topo II, and it is highly conserved between human topo IIÎ± and topo IIÎ². Although the DNA gate is the principal target of topo II inhibitors, because it is highly conserved between the topo II isoforms, it is a challenge to design topo II inhibitors with high specificity against topo IIÎ±. The differences between these two isoforms are mainly reflected in the C-terminal portion. The C-terminus of topo IIÎ² contains 443 amino acid residues and is slightly longer than that of topo IIÎ± (360 amino acids).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Detailed structural studies of topo II provide a valuable guide to discover topo II inhibitors to inhibit different catalytic steps. Among the many drug discovery strategies, rational drug design based on the tertiary structure is an efficient and economical practice. Targeting the ATPase domain is one of the most widely accepted approaches to obtain potent topo II catalytic inhibitors that interfere with the ATP-dependent catalytic steps instead of inducing double-stranded DNA breaks.</div><div class="NLM_p">For clarity, a crystallographic structure of the ATP binding domain of topo IIÎ± complexed with an ATP analogue AMPPNP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) and the major H-bonding contacts between topo IIÎ± and ligand was provided, which is shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. The ATP binding domain of topo IIÎ± is illustrated as a T-shaped cavity that is composed of three binding pockets. The relatively broad and shallow pocket I is surrounded by Ser149, Asn150, Arg98, Ser148, Lys157, and Tyr34. Among these residues, Ser149 and Tyr34 are the key residues. Tyr34 binds with the 3-N of the adenine ring of ATP through water bridges, whereas the ribose ring of AMPPNP is stabilized by H-bonding interactions between the 2â²- and 3â²-hydroxyl groups and side chains of Ser149. Pocket II, which is composed of Asn91, Gln97, Asn120, Pro126, Ile125, and Thr215, appears to form a long and narrow channel, and Asn91 and Asn120 take on important roles. Asn 91 not only generates a H-bonding interaction with the phosphate part of the ligand but also contributes to a coordinative bond with the catalytic Mg<sup>2+</sup>. As for the Asn120, it interacts with the adenine ring through both direct H-bonding and water-mediated contacts. Solvent-exposed pocket III is a binding region for polar groups and is encircled by Ala167, Gly166, Lys168, Tyr165, and Thr147, which are all favorable contributors to the binding affinity by producing effective interactions with the phosphate moieties of the ligand. Additionally, a Mg<sup>2+</sup> ion is also situated in pocket III.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. ATP binding domain of topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) complexed with an ATP analogue AMPPNP (left) and the major H-bonding interactions between topo IIÎ± and AMPPNP (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The âenhancing protein backbone bindingâ concept, by identifying binding factors (e.g., hydrogen bonds, electrostatic interactions, steric effects, etc.) and their essential influences on bioactivity and specificity, has been considered as an effective means of identifying potent drug candidates with the capability to cope with drug resistance.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Many novel topo II inhibitors have been developed following this strategy.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">2.  Topo II Poisons and Catalytic Inhibitors/Suppressors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Evidence has shown that topo I and topo II are expressed at different levels in different cancer types. For example, topo I is mainly expressed in colorectal cancer, whereas topo II is mostly expressed in ovarian and breast carcinomas.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Accordingly, both topo I and topo II inhibitors have been clinically used in cancer therapy. Topo I inhibitors stabilize the covalent cleavage complexes of topo I and DNA and generate single-stranded DNA cleavages. Although Topo I can be removed from these topo I and DNA covalent adducts by tyrosyl-DNA phosphodiesterase 1 (TDP1) followed by DNA repairing to heal single-stranded DNA nicks, this DNA repair pathway is inefficient for removing all topo I inhibitor-induced DNA adducts. Eventually, DNA replication forks collapse after encountering these DNA adducts and then generate double-stranded DNA breaks. This is why topo I inhibitors in clinical studies, such as camptothecin (CPT) and its derivatives topotecan, 10-hydroxy camptothecin (OPT), irinotecan (CPT-11), and rubitecan (9-NC), are normally toxic for rapidly growing tissues. Moreover, the cytotoxic essence of these drugs easily induces significant therapy-related secondary effects, including cardiotoxicity, myelosuppression, gastrointestinal toxicity, and even secondary leukemia.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Hence, recent studies have concentrated on the exploitation of drugs or agents targeting topo II.</div><div class="NLM_p">On the basis of different modes of action, topo II inhibitors are classified into two broad categories: topo II poisons and topo II catalytic inhibitors. The first type, which covers the majority of clinical antitumor agents (e.g., etoposide, doxorubicin, mitoxantrone, salvicine, and teniposide) and represents frontline therapies for a wide spectrum of solid and hematological malignancies, can kill cancer cells by increasing the level of covalent âtopo II-DNA complexesâ and prevents the cleaved DNA strand(s) from religation, allowing the accumulation of undesired double strand breaks. Because these agents can convert functional topos into lethal âlesionsâ, which induces DNA strand breaks that eventually lead to apoptosis of tumor cells, they are termed topo poisons.  On the basis of the differing DNA binding patterns, topo II poisons can be further divided into two types: DNA intercalating and nonintercalating agents. DNA nonintercalating agents (e.g., etoposide (<b>1</b>), teniposide (<b>2</b>), and quinolone) have relatively weak interactions with DNA and exert their functions by trapping âtopo II-DNA complexesâ. In contrast, DNA intercalating agents, which usually contain coplanar aromatic frameworks such as adriamycin, amsacrine, and mitoxantrone (MTZ), can reversibly insert into the base pairs of DNA and disrupt enzymes involved in DNA transcription and replication.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">For explaining the binding patterns of two types of topo II poisons better, the 3D crystallographic structures of ternary âdrug-enzyme-DNAâ complexes (A: etoposide, PDB iD: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3">3QX3</a>; B: MTZ, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0V">4G0V</a>) are exemplified, respectively, in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. For the DNA nonintercalating agent etoposide (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A and C), the insertion of etoposide affects the stacking interaction of DNA base pairs and maintains the scissile phosphate groups away from the DC-8 portion at a distance of 7.9 Ã, with the polycyclic core (rings AâD) lying between base pairs, and the glycosidic moiety and the E-ring individually extending into the DNA major and minor grooves. As a result, the formation of this stable but reversible ternary complex upgrades the binding affinity between drug and the active cleavage site of topo II by forming H-bonding, hydrophobic and ÏâÏ stacking interactions, leading to the blockade of DNA repair.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As far as the DNA intercalating agent MTZ-involved complex is concerned (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B and D), the incorporation of MTZ also affects the stacking interaction of DNA base pairs and maintains the phosphate groups away from the DC-8 part at a distance of 7â8 Ã with the two polyamine side chains on the C-ring projecting into the DNA major and minor grooves, respectively. Interestingly, the polycyclic anthraquinone nucleus (rings AâC) plays a dual role. It not only prevents DNA repair by physically blocking the stacking effect of base pairs but also stabilizes the structure by forming effective H-bonding contacts with Gln778 and Gly504 in the DNA major and minor grooves. Additionally, the side chain on the C-ring that stretches into the DNA minor groove makes a major contribution to the stability of the enzyme-DNA adduct by adjusting its flexibility with a preponderant conformation while also forming more favorable H-bonding interactions with several key residues, including Glu522, Asn520, and Arg503. In contrast, the side chain on the C-ring that inserts into the DNA major groove fails to take full advantage of the extra space and only generates several water-mediated interactions.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structures of ternary âdrug-enzyme-DNAâ complexes (A: etoposide, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3">3QX3</a>; B: MTZ, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0V">4G0V</a>), and the binding contacts are also schematized in a simplified form (C: DNA nonintercalating agent etoposide; D: DNA intercalating agent MTZ).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unlike topo II poisons, the other class, which is described as topo II âcatalytic inhibitorsâ or âsuppressorsâ, is thought to kill tumor cells by inhibiting the essential enzymatic activity of topo II. These inhibitors work by impeding the conjunction of topo II with DNA without generating increased levels of topo II covalent complexes, blocking the enzyme ATP-binding site (e.g., purine analogues), preventing the cleavage of DNA (e.g., merbarone), or inhibiting the hydrolysis of ATP (e.g., bisdioxipiperazine analogues), thus showing decreased cytotoxicity relative to that of topo II poison and confronting MDR.</div><div class="NLM_p">Between the two topo II isoforms, the inhibition of topo IIÎ±, rather than topo IIÎ², has been recognized as a well-defined approach to develop novel antineoplastic agents. The reason, to a certain degree, is that topo IIÎ± is necessary for the hypercompaction of mitotic chromosomes in human cells, whereas inhibitors that target topo IIÎ² are frequently found to be associated with undesirable side effects, such as drug resistance, cardiotoxicity, or secondary malignancies.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> In recent years, efforts aimed at interfering with topo II-mediated processes have exploited numerous small molecule topo II inhibitors. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> presents the chemical structures of some representative compounds that have been approved for the treatment of varied malignancies or which have entered into clinical trials. Among them, the imidazoacridinone derivative C-1311 (<b>13</b>, Symadex) was recommended for phase II a few years ago.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> The quinolone derivative vosaroxin (<b>12</b>, SNS-595), which is considered as a first-in-class antineoplastic drug, has entered phase III trials for the treatment of relapsed and refractory acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26â28)</a> The quinoxaline derivative XK469 (<b>9</b>, NSC697887), as a selective topo IIÎ² inhibitor, has entered phase I evaluation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The third generation synthetic topo II inhibitor 9-aminoanthracycline derivative amrubicin (<b>10</b>, SM-5887) has been shown to have comparable efficacy to doxorubicin in adult soft tissue sarcoma (STS) without obvious cardiac toxicity in a phase II study.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Acting as DNA intercalators, two naphthalimide derivatives, amonafide (<b>11</b>, AS1413) and mitonafide (<b>14</b>, NSC 300288), have been studied in phase III and phase II clinical trials, respectively.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Illustrative examples of representative topo II inhibitors that have been used in clinical trials or are at various stages of development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Resistance to chemotherapeutic drugs has been a major obstacle in cancer chemotherapy. Most topo II poisons have frequently suffered from MDR, which is related to the overexpression of MDR-associated proteins (i.e., P-gp, MDR1, MRP1, and BCRP), resulting in enhanced efflux of chemotherapeutic drugs out of the cells.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Moreover, topo II poisons may also trigger chromosomal translocations that lead to specific secondary leukemias.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Thus, the development of topo II catalytic inhibitors that will not only kill cancer cells but also generate much less DNA damage due to topo II-mediated DNA cleavage, lower cytotoxicity to normal cells, and lower risk of secondary tumors, has become a key focus of recent research.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">3.  Strategies to Identify and Develop Chemical Agents Targeting Topo II with High Efficacy and Specificity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25606" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25606" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of the pivotal role of topo II in correlation with various malignant carcinomas, intensive efforts attempting to explore effective tumor therapeutics have led to a panel of chemical agents with diversified structures that are capable of modulating the function of topo II. In this Perspective, we elucidate the design strategies, binding modes, as well as the SAR exploration of recently reported topo II inhibitors (2013â2017), including both topo II poisons and catalytic inhibitors, on the basis of their different mechanisms of action and structural scaffolds with the expectation of providing useful insight into the identification of more diversified topo II inhibitors as potent antitumor leads.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.1.  Strategies for the Identification of Novel Topo II Inhibitors/Poisons</h3><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">3.1.1.  Using Available SAR Results to Guide the Exploration of Novel Topo II Inhibitors</h4><div class="NLM_p">Using available SAR outcomes has always been a quick, simple but effective approach to detect pharmacophores and/or structural segments that can be directly utilized for exploiting new topo II inhibitors. In the process of identifying novel chemotypes, clear pharmacophoric elements, whether working as scaffolding cores or peripheral substitutions, are useful structural determinants to improve drug properties and avoid the shortfalls of prototypes. For this reason, topo II inhibitors identified recently have largely benefited from available SAR studies.</div><div id="sec3_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i10" class="anchor-spacer"></div><h5 class="article-section__title" id="_i10">3.1.1.1.  Î±-Terpyridine Analogues</h5><div class="NLM_p">2,4,6-Triarylpyridines (Î±-terpyridines) containing a phenolic moiety at the 2- and 4-positions have been established as a promising skeleton for developing novel topo II inhibitors. Leeâs investigations on the Î±-terpyridine chemotype have presented several series of derivatives (compounds <b>15</b>â<b>17</b>). Taking compound <b>17</b> as an example (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), it can be observed that the position of the hydroxyl group in the 2-phenyl ring affects inhibitory potency. Specifically, a <i>meta</i>- or <i>para</i>-phenolic moiety at the 2-position in conjunction with a 6-chlorophenyl group is more favorable for topo I/II inhibition and cytotoxicity. The monophenolic moiety, which is indispensable for bioactivity, was retained at the 2-position of the pyridine backbone, and the addition of hydroxyl groups at different positions was also explored. In addition, because chlorinated compounds are frequently included in drug design and might contribute to increased proteinâligand binding affinity and binding site specificity, chlorophenyl moieties were introduced at the 6-position of the pyridine core. Moreover, a small set of 4-aryl substituents were fixed at the 6-position to determine its influence on activity from which the 2-furyl moiety demonstrated the best binding affinity for topo II and had higher selectivity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. 2,4,6-Triarylpyridine (Î±-terpyridine) is a promising backbone for exploring dual topo inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Kwon and co-workers also exploited a spectrum of diphenyl-6-thiophen-2-yl-pyridine derivatives (<b>18</b>), which manifested excellent inhibition and superior inhibitory specificity toward topo II over topo I.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> SAR exploration demonstrated that, when the phenyl ring at the 6-position of the central pyridine is replaced by a thienyl or furyl unit or when the phenyl groups at the 2- and 4-positions are substituted with a hydroxyl group, potent and specific topo inhibition could be achieved. The orientation of the hydroxyl group has a marked influence on the potency and cytotoxicity. Specifically, compound <b>18a</b> manifested the most potent and elevated efficacy compared with the controls (<b>1</b> and <b>86</b>) and can be regarded as a potential lead for further optimization. On the whole, systematic QSAR analysis demonstrated that both the hydrogen-bond donor and acceptor elements of the hydroxyl group contribute to the potency and cytotoxicity; it also supported the pivotal roles of the <i>meta</i>- and/or <i>para</i>-hydroxyl groups in enhancing the integral bioactivity. However, extended SAR investigation of these pyridine-based inhibitors by making subtle modifications to the disposition of the hydroxyl substituents and altering the aryl groups changed the mechanism of action of the compounds.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> For example, compound <b>18a</b> acts as a topo II catalytic inhibitor with high selectivity toward topo IIÎ± (more than 98% inhibition) over the Î²-isoform. In contrast, compound <b>18b</b> has been shown to act as a topo II poison. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> displays the design and SAR patterns associated with topo II inhibition by <b>18</b> as well as the binding mode of <b>18a</b> complexed with human topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>), indicating that the <i>p</i>-phenolic hydroxyl at the 2-position of pyridine core forms two important H-bonding interactions with Lys123 and Asn120.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR investigation of the Î±-terpyridine motif led to a series of diphenyl-6-thiophen-2-yl-pyridine derivatives (<b>18</b>) with high selectivity against topo II over topo I and the X-ray crystallographic structure of <b>18a</b> complexed with human topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i11" class="anchor-spacer"></div><h5 class="article-section__title" id="_i11">3.1.1.2.  Naphthalimide Analogues</h5><div class="NLM_p">Naphthalimides have been characterized as a class of DNA intercalators and topo II inhibitors; many mononaphthalimides (e.g., <b>11</b> and <b>14</b>, see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), bisnaphthalimides (e.g., <b>19</b> and <b>20</b>), and fused naphthalimides (e.g., <b>R16</b>, <b>B1</b> and <b>21</b>)<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> have been reported to display remarkable antineoplastic properties, and some of them have entered clinical trials,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> as illustrated in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of naphthalimide-bearing topo II inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Xu et al. have presented a pool of naphthalimide-based derivatives (<b>22</b>)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> by combining the merits of a cytotoxic topo inhibitor and a cytostatic antiangiogenic agent directed toward producing advantageous complementarity. This is based on the fact that antiangiogenic agents can normalize tumor vessels and promote the delivery of cytotoxic agents to tumor sites.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> However, because tumors are involved in complicated physiological and pathological networks, it is not easy to produce long-term curative effects only using antiangiogenic agents. In the target compounds shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, long alkyl chains and polyamines are contributors to antiproliferative activity and the naphthalimide backbone contributes to the cytotoxic efficacy by inhibiting topo II. As expected, the target compounds, especially <b>22a</b>, have been shown to be effective chemotherapeutics by targeting both topo II and angiogenesis-related receptor tyrosine kinases (KDR and EGFR1).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Naphthalimide-based derivatives <b>22</b> were designed as multifunctional molecules by targeting both topo II and receptor tyrosine kinases (RTKs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i12" class="anchor-spacer"></div><h5 class="article-section__title" id="_i12">3.1.1.3.  2-Phenylnaphthalene Analogues</h5><div class="NLM_p">2-Phenylnaphthalene was found to be another attractive pharmacophoric skeleton for the development of potent topo II inhibitors, ideally topo IIÎ±-targeting inhibitors. Shen et al. have reported a spectrum of 2-aryl-substituted naphthalenoids (<b>23</b>) to expand the molecular diversity and enrich the SAR exploration on 2-phenylnaphthalene-based pharmaceuticals.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The SAR results of these derivatives on the topo II-sensitive breast cancer cell line MDA-MB-231 delineated that the hydroxyl substitution at the 6-position of the phenylnaphthalene moiety was required for cytotoxicity. For example, compound <b>23b</b> with a 6-hydroxyl substituent gave increased potency compared to the 6-methoxyl counterpart <b>23c</b>. As far as the substituents on the 2-phenyl ring are concerned, polar substituents (e.g., methoxycarbonyl, hydroxymethyl, and hydroxyl) are generally favorable for antiproliferative activity, whereas the strong hydrophilic acidic groups (e.g., carboxyl and carboxymethyl), in contrast, seriously impaired the bioactivity. As to the impact of the 4â²-substitution on the 2-phenyl ring, polar substituents are still applicable with an activity order of hydroxyl (<b>23a</b>, <b>23d</b>, <b>23e, 23f</b>) > amino (<b>23g</b>) > 1-hydroxymethyl (<b>23h</b>), as evinced in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. SAR exploration of 2-phenylnaphthalene-based derivatives (<b>23</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13">3.1.1.4.  1,3,4-Thiadiazole Analogues</h5><div class="NLM_p">The 1,3,4-thiadiazole skeleton with a 2,5-disubstituted pattern has been validated as an attractive structural motif for identifying potent topo II inhibitors with weaker cytotoxicity toward normal cells. Inspired by this, Plech and co-workers have developed a limited spectrum of 1,3,4-thiadiazole derivatives (<b>24</b>) and evaluated their antiproliferative activities on two kinds of breast cancer cell lines, MDA-MB-231 and MCF-7, which are sensitive to topo II inhibitors.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The SAR exploration, as shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, demonstrated that the incorporation of the 1,3,4-thiadiazole core with a 5-phenyl motif is essential for acquiring potent antitumor potency, as evidenced by the insertion of a â-O-CH<sub>2</sub>-â linker between the 2â²,4â²-dichloro phenyl fragment and thiadiazole core (<b>24e</b> and <b>24f</b>), leading to a loss in both activity and DNA biosynthesis in normal fibroblast cells. As to the substituents on the 5-phenyl motif, both the substitution pattern and electronic environment were explored. This survey showed that the electron-donating <i>meta</i>-hydroxyl substituent provided higher affinity than the electron-withdrawing <i>meta</i>-chlorine counterpart (<b>24a</b> vs <b>24b</b>). Furthermore, the hydroxyl group has the ability to enable the potential formation of a hydrogen bond, resulting in increased bioactivity. Compounds with 2â²,4â²-dichloro substituents (<b>24c</b> and <b>24d</b>) displayed better potencies than their monosubstituted counterpart <b>24b</b>, which confirmed that the second chloro has a conducive effect on binding affinity. As far as the impact of the substituents on the phenylamine group are concerned, there is a general trend with an order of decreasing activity Br > Cl. Most notably, compound <b>24c</b>, with a bulkier bromine substituent that has lower electronegativity, is equipotent to control <b>1</b> against the two tested breast cancer cell lines. Further investigation of the mechanism of action revealed that compounds with electron-withdrawing substituents (e.g. 2â²,4â²-dichloro, <b>24c</b> and <b>24d</b>) on the 5-phenyl group of the 1,3,4-thiadiazole core were identified to be topo II poisons, whereas the electron-donating group-bearing compounds (e.g. <i>meta</i>-hydroxyl, <b>24a</b>) were shown to be topo II catalytic inhibitors. Nevertheless, limited by the number of available 1,3,4-thiadiazole derivatives, a definitive correlation between the structural elements and target recognition requires further validation.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Modification of the 1,3,4-thiadiazole core with 2,5-disubstituted groups led to a series of derivatives (<b>24</b>) with different topo II-interacting patterns.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i14" class="anchor-spacer"></div><h5 class="article-section__title" id="_i14">3.1.1.5.  Acridine Analogues</h5><div class="NLM_p">The acridine moiety has emerged as a promising chemotype for exploring new bioactive molecules based on the fact that amsacrine is the first and only approved topo II poison for treating AML so far. However, some amsacrine deficiencies, such as its ineffectivity for solid tumors, poor bioavailability, and drug resistance, have stimulated further chemical optimization of this skeleton. In addition, the thiosemicarbazide (TSC) motif is known as an important scaffold due to its various biological properties. However, the precise mechanism of action of TSC derivatives against tumors is not fully understood. The current majority viewpoints are that TSC derivatives exert antitumor effects by inhibiting the increased activity of iron-associated proteins, such as ribonucleotide reductase (RR), which is a crucial enzyme in DNA synthesis and has a high correlation with tumor cell proliferation by catalyzing the rate-limiting step of dNTP synthesis<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> or as an iron chelator.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">With these observations in mind, Almeida et al. explored a spectrum of acridine-thiosemicarbazone derivatives by incorporating a variety of TSC units into an acridine backbone. A SAR investigation revealed that compound <b>25</b> with an unsubstituted phenyl group gave the best potency in antiproliferative assays. They further developed two acridine-based compounds <b>26a</b> and <b>26b</b> from the lead <b>25</b> via linker transformation and subsequent spontaneous spirocyclization (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), which were then subjected to further biochemical and antiproliferative assessments.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The results showed that both compounds are topo IIÎ±-targeted poisons without any topo I inhibition and displayed significant antiproliferative activities toward melanoma and prostate tumor cell lines. With respect to the AMTAC series, the introduction of <i>para</i>-methoxy on the phenyl ring (<b>26b</b>) provided enhanced potency and selectivity in contrast with its unsubstituted counterpart (<b>26a</b>). This may be due to the methoxy group, which contributes to the stabilization of the ternary complex, resulting in elevated topo II inhibition. Further molecular binding studies were conducted by using <b>26b</b> as a tool compound. The result was that the methoxyl O and the N atom of the C=N bond participate in the formation of H-bonding interactions with the key Ser149 residue while the carbonyl O atom chelates with the catalytic Mg<sup>2+</sup> in the active binding domain. In addition, several hydrophobic contacts between <b>26b</b> and the residues Tyr34, Asn91, Asp94, Arg98, Ile141, Phe142, and Thr215 were also favorable contributors to the enhanced binding affinity.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Discovery of the novel spiro-acridines <b>26a</b> and <b>26b</b> as topo IIÎ±-mediated poisons derived from the acridine and TSC chemotypes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15">3.1.1.6.  Fused Aryl Phenazine Analogues</h5><div class="NLM_p">Compounds containing fused aryl phenazine skeletons, including but not limited to benzo[<i>a</i>]phenazine, pyrido[<i>a</i>]phenazine, benzo[<i>a</i>]phenazine diones, and tetrahydropyrido[<i>a</i>]phenazine, are capable of interfering with DNA metabolism by intercalating between DNA base pairs; therefore, these skeletons are typically used in the design of topo inhibitors. For example, the benzophenazine derivatives XR11576 (<b>27</b>), NC-190 (<b>28</b>), and NC-182 (<b>29</b>) have entered clinical studies based on their broad antitumor activity that is not affected by MDR. Among these, the NC series exhibited selective and superior topo II inhibition upon induction of topo II-dependent DNA fragmentation, whereas XR11576 works as a topo I/II poison.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Enlightened by these findings, Huang et al. have developed an array of benzophenazine derivatives (<b>30</b>) by initially modifying rings B and D in the benzo[<i>a</i>]phenazine core.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> By introducing various terminal amino groups (e.g., dimethylamino, diethylamino, piperidinyl, <i>N</i>-methylpiperazinyl, and pyrrolidinyl) onto ring B and decorating ring D with substituents with different electronic properties (e.g., NO<sub>2</sub>, F, Cl, and OCH<sub>3</sub>), the resulting SAR profile revealed that the basic terminal alkylamino groups on ring B have more significant effects on activity than the substituents on ring D, as the removal of these basic side chains resulted in a complete loss of activity. Moreover, it appears that the disposition and electronic effects of the substituents on the D ring as well as the length of the side chain did not have an impact on the cytotoxic effects.</div><div class="NLM_p">For gaining further insight into the SAR profile, subsequent chemical modifications, which occurred on rings A, C, and D of the benzo[<i>a</i>]phenazine backbone by transferring the alkylamino groups from the 5- to 7-position of ring C, with or without installing substituents on rings A and D, further clarified the indispensable effects of the alkyl amino groups for cellular activity.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> It is also notable that all benzo[<i>a</i>]phenazine derivatives (<b>30</b> and <b>31</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) have been shown to be dual topo I and II inhibitors. Therefore, exploration of these benzo[<i>a</i>]phenazine derivatives has the potential to identify potent antineoplastic agents with improved antitumoral regimens.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Benzo[<i>a</i>]phenazine heterocycle has been shown as a promising backbone for exploring dual topo I and II inhibitors (e.g., <b>30</b> and <b>31</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">3.1.2.  Conformational Restriction Approach Constitutes a Core Aspect of Drug Discovery</h4><div class="NLM_p">In connection with a recent work on the exploitation of novel topo inhibitors, researchers from Kwonâs lab exploited several 2,4,6-trisubstituted pyridines via a conformational restriction (or rigidification) strategy using a cyclization approach at the 5,6-position of the pyridine core (<b>32</b>â<b>36</b>). The resultant compounds showed enhanced topo inhibition as well as cytotoxicity when compared to their flexible terpyridine prototypes (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). It is very likely that the reconstructed rigid structure tends to have less conformational entropy than the flexible prototypes. Therefore, a molecule with a rigid architecture usually has more chance to realize a desired selectivity for certain isoforms and also has a reduced possibility of drug metabolism compared with its flexible counterparts. It goes without saying that this rule also applies to the identification of topo II inhibitors with improved metabolic stability. In other words, more rigid topo II inhibitors with less conformational entropy are thus more easily able to insert into the DNA-enzyme complex as possible DNA intercalators.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Discovery of terpyridine-based libraries <b>32</b>â<b>36</b> through a conformational restriction approach and methylation modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The systematic SAR exploration manifested that substituents at both the 2- and 4-positions of the pyridine core have a marked influence on the potency and selectivity of topo inhibition. When the 4-substitution was fixed as a heterocyclic furyl or thienyl motif, compound <b>32a</b> with a hydroxyphenyl group at the 2-position of the 5<i>H</i>-indeno[1,2-<i>b</i>]pyridine moiety was identified as a dual topo I and IIÎ± inhibitor, whereas the replacement of the 2-hydroxyphenyl with a 2-furyl or thienyl unit (<b>32b</b>) exhibited topo II-selective inhibition. In compounds <b>32c</b>â<b>32f</b>, the 4-substituent was anchored as a <i>m</i>-hydroxyphenyl group, and chemical diversity was achieved by installing a thienyl or furyl motif at the 2-position. The result was that they generally showed preferential and strong inhibition toward topo IIÎ±. Compared with compounds <b>32g</b>â<b>32i</b>, the position of the hydroxyl groups in the 4-phenyl ring as well as the disposition of the 2-fury substituent had an impact on binding affinity. Compounds <b>32g</b> and <b>32h</b> displayed dual topo I and topo IIÎ± inhibition, whereas <b>32i</b> exhibited lower enzyme inhibitory activity, implying that the 2â²-furyl motif is essential for cytotoxicity.</div><div class="NLM_p">Following up these discoveries, they continuously put forth two series of terpyridine-based analogues: benzo[4,5]furo[3,2-<i>b</i>]pyridine (<b>35</b>) and chromeno[4,3-<i>b</i>]pyridine (<b>36</b>).<a onclick="showRef(event, 'ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54">(52â54)</a> In these series, compound <b>35a</b> was validated as a nonintercalating topo IIÎ±-specific inhibitor, and <b>36a</b> was determined to be a nonintercalating dual topo I and IIÎ± inhibitor. It is interesting that, although the methoxy-substituted compounds <b>35b</b> and <b>36b</b> lost topo inhibitory potency, they generally gave significant improvements in metabolic stability and PK properties, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Comparison of Stability, Metabolic, and PK Parameters between the Methylated Compounds (<b>35b</b> and <b>36b</b>) and Their Hydroxyl Precursors (<b>35a</b> and <b>36a</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center"><b>35a</b></th><th class="colsep0 rowsep0" align="center"><b>35b</b></th><th class="colsep0 rowsep0" align="center"><b>36a</b></th><th class="colsep0 rowsep0" align="center"><b>36b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">Stability<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">0.30Â Â±Â 0.08</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">1.34Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">2.28Â Â±Â 0.27</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">4.29Â Â±Â 0.70</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">1.50Â Â±Â 0.31</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">1.50Â Â±Â 0.31</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">4.55Â Â±Â 5.61</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">4.58Â Â±Â 5.58</td><td class="colsep0 rowsep0" align="left">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">Half-Lives (<i>t</i><sub>1/2</sub>)/h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">31.1Â min</td><td class="colsep0 rowsep0" align="left">1.81Â h</td><td class="colsep0 rowsep0" align="left">31.4Â min</td><td class="colsep0 rowsep0" align="left">1.79Â h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">37.6Â min</td><td class="colsep0 rowsep0" align="left">2.26Â h</td><td class="colsep0 rowsep0" align="left">38.9Â min</td><td class="colsep0 rowsep0" align="left">2.25Â h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">36.3Â min</td><td class="colsep0 rowsep0" align="left">1.09Â h</td><td class="colsep0 rowsep0" align="left">37.7Â min</td><td class="colsep0 rowsep0" align="left">0.92Â h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">16.7Â min</td><td class="colsep0 rowsep0" align="left">0.82Â h</td><td class="colsep0 rowsep0" align="left">14.0Â min</td><td class="colsep0 rowsep0" align="left">0.72Â h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">PK Parameters<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0â24</sub> (Î¼gÂ h<sup>â1</sup>Â mL<sup>â1</sup>)</td><td class="colsep0 rowsep0" align="left">0.15Â Â±Â 0.00</td><td class="colsep0 rowsep0" align="left">0.50Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.10Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.42Â Â±Â 0.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (Î¼g/mL)</td><td class="colsep0 rowsep0" align="left">0.02Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.04Â Â±Â 0.00</td><td class="colsep0 rowsep0" align="left">0.02Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.03Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.00Â Â±Â 0.00</td><td class="colsep0 rowsep0" align="left">1.33Â Â±Â 0.59</td><td class="colsep0 rowsep0" align="left">4.00Â Â±Â 0.00</td><td class="colsep0 rowsep0" align="left">1.33Â Â±Â 0.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">12.4Â Â±Â 1.32</td><td class="colsep0 rowsep0" align="left">20.10Â Â±Â 0.29</td><td class="colsep0 rowsep0" align="left">5.49Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="left">17.40Â Â±Â 0.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT (h)</td><td class="colsep0 rowsep0" align="left">15.3Â Â±Â 1.2</td><td class="colsep0 rowsep0" align="left">31.50Â Â±Â 0.31</td><td class="colsep0 rowsep0" align="left">6.11Â Â±Â 0.24</td><td class="colsep0 rowsep0" align="left">28.82Â Â±Â 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i><sub>t</sub> (%)</td><td class="colsep0 rowsep0" align="left">2.70</td><td class="colsep0 rowsep0" align="left">33.20</td><td class="colsep0 rowsep0" align="left">0.85</td><td class="colsep0 rowsep0" align="left">41.30</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">For <b>35a</b> and <b>36a</b>, stability means % remaining after 60 min, whereas for <b>35b</b> and <b>36b</b>, stability means % remaining after 120 min.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Compounds <b>35a</b> and <b>36a</b> were given by oral administration at 5 mg/kg to male rats, and <b>35b</b> and <b>36b</b> were given by oral administration at 3 mg/kg to rats (<i>n</i> = 5).</p></div></div></div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.1.3.  Scaffold-Hopping Strategy through Optimization of Parent Molecules</h4><div class="NLM_p">Scaffold-hopping, also called lead hopping, has been widely applied in the discovery of novel chemotypes with equipotent or improved potencies.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> For example, the therapeutic effectiveness of the topo I inhibitor CPT has been severely compromised to some extent by rapid inactivation through hydrolysis of the E-ring lactone under physiological conditions. To overcome this deficiency, You et al. developed a wealth of lomefloxacin analogues via a step-by-step structural optimization,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> as displayed in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. They initially simplified the CPT framework and separated it into two bioactive fragments, the benzimidazole (fragment A) and quinolone (fragment B). The subsequent incorporation of two fragments led to the formation of a new molecular hybrid (<b>37</b>) as a topo I inhibitor, and the most active compound <b>37a</b> was eventually established as a potent lead. For furthering the potential of this lead and identifying more chemical entities with improved efficacy, the 1-ethylquinolin-4(1<i>H</i>)-one backbone remained unchanged while fluoro atoms and 3-methylpiperazine substituent were introduced. As a functional surrogate of the nitrile, carbinol, and carbonyl groups, a fluoro atom can endow a molecule with improved metabolic stability.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> As for the piperazine moiety, it is frequently found in pharmacological agents owing to its ability to increase water solubility.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Subsequently, a ring-opening modification on the benzo[<i>d</i>]oxazole unit was implemented to expose the amide functionality, which was beneficial to the amelioration of issues associated with metabolic stability and water solubility. This resulted in the lomefloxacin derivatives <b>38</b> as potent topo II inhibitors with electron-withdrawing substitutions (R<sup>1</sup> to R<sup>4</sup>) on the heteroaryl ring conducive to both selectivity and efficacy.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Systematic optimization of CPT led to a range of lomefloxacin derivatives (<b>38</b>) with potent topo II inhibitory potencies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another example is from the 2-phenylbenzofuranoid derivatives <b>39</b>, which also confirmed the effectiveness of this approach. The newly discovered 2-phenylbenzofuranoids <b>40</b> were shown to produce dramatically increased topo IIÎ± inhibition as well as improved antiproliferative efficacy (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. An illustrative example of 2-phenylbenzofuranoid <b>40</b> designed from 2-phenylnaphthalenoids <b>39</b> using a scaffold-hopping strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">3.1.4.  The Molecular Hybridization Strategy Appears to be a Simple but Powerful Way To Identify Bioactive Molecules</h4><div class="NLM_p">In the pursuit of new molecular hybrids with desirable bioactivities toward specific biotargets, the search and selection of two or more complementary chemical entities is critical to generate a synthetic benefit and fewer side effects. For example, the five-membered heterocycle pyrazole and its bioisosteres, including pyrazoline, pyrazol-3-one, and pyrazoline-3,5-dione, have been frequently utilized in drug development programs. The chalcone unit has been shown to play an important role in producing a catalytic inhibitory activity toward topo IIÎ±. To address the need for more effective topo inhibitors, Rahman et al. hypothesized that the incorporation of a chalcone element (or its analogues) into the pyrazoline core might afford a new hybrid with synergistic effects on potency while also offering high affinity for topo IIÎ±.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The resulting pyrazoline derivatives <b>41</b> turned out to be selective ATP-competitive catalytic topo II inhibitors.</div><div class="NLM_p">In addition to the aforementioned five-membered skeletal structures, the nitrogen-containing fused heterocycles benzimidazole and pyrrolo[2,3-<i>b</i>]pyrazine are also pharmacophoric functionalities that are frequently used in designing potential catalytic topo II inhibitors. In the benzimidazole structure, the phenyl ring is especially essential and indispensable for the bioactivity, which may exert topo II inhibitory effects by blocking the enzyme ATP-binding domain. Similar to the pyrrolo[2,3-<i>b</i>]pyrazine motif, it probably plays a role in topo and kinase inhibition by competitively interacting with the ATP-binding site of the enzymes. Inspired by their structural characteristics as well as topo II inhibitory strengths, the two skeletons (benzimidazole and pyrrolo[2,3-<i>b</i>]pyrazine), which share similar mechanisms of action and binding modes, were combined into a new structural hybrid according to the combination principle.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> As expected, the resulting 1,3-benzoazolyl-substituted pyrrolo[2,3-<i>b</i>]pyrazine derivatives <b>42</b> functioned as nonintercalative topo II catalytic inhibitors and were determined to be more potent than the single framework, as depicted in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Application of a molecular hybridization strategy led to new chemotypes with equipotent or more potent topo II inhibitory efficacies owing to the synergistic effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Amsacrine (<b>5</b>) and ametantrone (<b>7</b>) are two identified topo II poisons that have a broad spectrum of antitumor activities. Acting as excellent DNA intercalators, both planar-fused ring systems can intercalate into DNA, leading to alterations in the groove proportions and prevention binding of topo II. Zagotto et al. have reported ametantrone-amsacrine-related hybrids <b>43</b> by incorporating the methanesulfonamidoaniline substituent of <b>5</b> into the anthracenedione core of <b>7</b>. The resulting hybrids were identified to be topo IIÎ²-preferring poisons and DNA-intercalating agents, and the properties of the lateral groups linked to the anthracenedione backbone play a major role in modulating DNA binding as well as cellular cytotoxicity.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Although all hybrids showed decreased potencies when compared with compound <b>7</b>, three compounds (<b>43a</b>â<b>c</b>) bearing tertiary noncyclic amine groups, particularly <b>43b</b>, demonstrated comparable cytotoxic effects to compound <b>5</b>, suggesting the opportunity for development into potent isoform-selective topo II inhibitors. The binding pattern of compound <b>43b</b> with topo IIÎ±, as evinced in <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, revealed that the effective H-bonding contacts formed between the inhibitor and several key residues (Tyr34, Asn150, Asp94, and Tyr186) contribute to the bioactivity.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures of the ametantrone-amsacrine-related hybrid (<b>43</b>) as topo II-induced poisons. The binding mode of compound <b>43b</b> in complex with topo II (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) was also shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The acridine skeleton decorated with a 9-anilino motif, e.g., compound <b>5</b>, displayed DNA binding abilities and topo II-mediated cytotoxicity through interplaying with the DNA-enzyme ternary complex. In terms of the linkers between the acridine and phenyl ring, methyleneamine (NHCH<sub>2</sub>) can enhance topo II affinity in comparison with a simple amine linker. Additionally, the incorporation of 6-chloro and 2-methoxyl substituents into the acridine scaffold produced significant antiproliferative efficacy. Thus, a suite of 9-benzylamino acridine derivatives <b>44</b> was developed as effective DNA intercalators based on the hypothesis that the combination of an acridine core with 9-benzylamino, 6-chloro and 2-methoxyl substitution patterns might afford improved efficacy. As expected, all of the derivatives exhibited strong topo II inhibition. In particular, compound <b>44a</b> displayed the most potent DNA-intercalating affinity and potent cytotoxicity and could induce DNA damage and A549 cell apoptosis by blocking tumor cells in the G2/M phase.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Indenoisoquinoline-5,11-dione has also been shown to be a useful framework in topo inhibitor design.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> Notably, the most potent DNA binding affinity can be acquired by introducing a basic tertiary amino pattern to the indenoisoquinoline core via an ethoxy linker. Meanwhile, the sandwich-type ferrocenyl functional group, which possesses a good reversible redox profile, suitable lipophilicity, and kinetic stability, has been regarded as a promising pharmacophore among bioorganometallic compounds. Research on ferrocifen chemotypes, which contain a tamoxifen diphenylmethylene pharmacophoric fragment, e.g., compound <b>45</b>, has been rapidly increasing in recent years due to their remarkable antiproliferative activity in cancer cells.<a onclick="showRef(event, 'ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68 ref69">(66â69)</a> Ferrocene and tertiary amino units were incorporated into the indenoisoquinoline-5,11-dione core with the expectation of achieving a synergistic and/or complementary benefit.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The results demonstrated that hybrids <b>45</b>â<b>49</b> were topo II inhibitors, and the monoferrocenyl unit is indeed a favorable contributor in controlling topo II inhibition when it is located at the end of the lactam side chain (<b>47</b>). However, when the ferrocenyl group acts as a linker (entries <b>46</b> and <b>48</b>), the length of lactam side chain, disposition, and size of the ferrocenyl unitâs neighboring substituents were all important determinants of the bioactivity with the best one (<b>47a</b>) possessing a four-methylene spacer and a terminal monoferrocenyl group. It is noteworthy that, although the ferrocenyl motif is very important, it is not âthe more, the betterâ in controlling the bioactivity. Taking <b>47a</b> and <b>49a</b> as examples, <b>49a</b>, which has a terminal diferrocenyl group, showed impaired potency compared with its monoferrocenyl counterpart <b>47a</b>, indicating certain space requirements of the biotarget. The same situation also occurred in the cases of <b>46a</b>â<b>c</b>, where the replacement of the terminal dimethylamino group in <b>46a</b> by a piperidine (<b>46b</b>) or <i>N</i>-methylpiperazine (<b>46c</b>) with a larger volume led to decreased activity. As far as the topo II inhibition associated with <b>47a</b>â<b>c</b> was concerned, <b>47a</b> with a free amine (Râ=H) displayed similar potency to its alkylated analogues <b>47b</b> (Râ=CH<sub>3</sub>) and <b>47c</b> (Râ=C<sub>2</sub>H<sub>5</sub>), suggesting that the monoferrocenyl group might play a leading part in affecting bioactivity. Collectively, the indenoisoquinoline-5,11-dione skeleton, four carbon-based spacer, and terminal monoferrocenyl motif are all beneficial elements to promote topo II inhibition (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Design of acridine <b>44</b> and indeno[1,2-<i>c</i>]isoquinoline-5,11(6<i>H</i>)-dione derivatives <b>46</b>â<b>49</b> involves the combination of several topo II-oriented fragments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Î²-Carboline (9<i>H</i>-pyrido[3,4-<i>b</i>]indole), also known as norharmane, has been recognized as an important pharmacophoric structure for obtaining potent cytotoxicity, as its planar N-containing heterocycle can serve as an effective DNA intercalator and stack between DNA base pairs. Additionally, introducing substituents at the 1-, 3- and 9-positions of the Î²-carboline backbone is conducive to cytotoxic activity. Many Î²-carboline derivatives with appropriate substitutions at these positions have been shown to exhibit impressive topo II inhibition by damaging DNA.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Meanwhile, the biologically active dithiocarbamate (DTC) motif is characterized as another frequently utilized pharmacophore for the design of novel molecules with diverse biological activities. For example, both brassinin, an indole-derived dithiocarbamate that is isolated from cruciferous vegetables, and sulforamate, a phase II enzyme inducer, have been shown to possess chemopreventive activities.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Moreover, because of the presence of the zinc-binding CS<sub>2</sub>Me group, the DTC unit can also be exploited in the design of potent inhibitors of zinc-dependent metalloenzymes, e.g., carbonic anhydrase (CA) and tyrosinase, which have been verified to be associated with various pathological conditions, such as epilepsy, osteoporosis, glaucoma, neoplasia, and carcinoma progression.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p">For expanding the chemical diversity and SAR profiles of Î²-carboline derivatives, a spectrum of molecular hybrids <b>50</b> was explored as topo II inhibitors via conjugation of Î²-carboline and the DTC segments (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Further modifications were mainly implemented on the Î²-carboline nucleus by incorporating the R<sup>1</sup>-substituted phenyl ring at the 1-position and an R<sup>3</sup> group (H or methyl) at the 9-position. The SAR investigation revealed that most of the derivatives showed significant synergistic cytotoxicity in the DU-145 prostate cancer cell line over other cell types, such as A549, MCF-7, and HeLa. Moreover, the incorporation of a DTC group at the R<sup>2</sup> position facilitated the cytotoxicity (<b>50d</b> vs <b>50i</b>; <b>50g</b> vs <b>50h</b>), which can be comparable with the control Doxo, implying the importance of the DTC portion. The lipophilic as well as electronic profiles are basic influencing factors that affect bioactivity. The results, to a certain extent, also validated the effectiveness of the molecular hybridization protocol for the development of potential topo II inhibitors. Additionally, the nature of the substituents at the 1-, 3-, and 9-positions also impacts the cytotoxicity to a large extent. Generally, for R<sup>1</sup> substituents, the lipophilic groups, 4-fluoro (<b>50a</b>), 4-trifluoromethyl (<b>50b</b>), and 4-methoxyl (<b>50d</b> and <b>50e</b>) favorably contribute to potency, whereas for R<sup>2</sup> and R<sup>3</sup> substituents, methyl substitution (<b>50b</b> and <b>50e</b>) seems to play a crucial role for cellular bioactivity, suggesting that a methyl group is suitable for this sort of derivative. Further bioactivity evaluation of <b>50a</b> and <b>50b</b> indicated that, although both presented similar topo II inhibition and cytotoxicity, they have different mechanisms of action. Specifically, <b>50a</b> acts as a catalytic inhibitor, whereas <b>50b</b> functions as a poison.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Optimization of the pharmacophoric Î²-carboline ring by incorporating the biologically active DTC and trifluoromethylphenyl moieties, which are spatially adaptive to the active binding domain of topo II, led to the hybrid Î²-carboline derivatives (<b>50a</b>, <b>50b</b>, <b>50d</b>, <b>50e</b>) with selective cytotoxicity toward DU-145 prostate cancer cell.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The ligandâprotein interactions were rationalized in detail through docking simulations utilizing <b>50b</b> as a tool to acquire the pharmacophore for further structural optimization. The AutoDock 4.2 program was used, and the results, which were visualized through the PyMOL software (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>), evinced that each part of the molecule fits well into the topo II ATP binding cavity (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXN">1ZXN</a>) and generates favorable interactions with topo II. Specifically, the Î²-carboline backbone not only forms a ÏâÏ stacking contact with Phe142 but also forms hydrophobic interactions with Tyr34, Asn91, and so forth, whereas the terminal methyldithiocarbamate chain contributes to the hydrophobic contact and forms two hydrogen bonds with neighboring amino acids. Additionally, the trifluoromethylphenyl moiety participates in the hydrophobic contacts with Asp94, Ser149, and Arg98.</div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">3.1.5.  Natural Products Offer Great Promise for Unearthing Potent Topo II Inhibitors</h4><div id="sec3_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21">3.1.5.1.  DMEP Analogues</h5><div class="NLM_p">Natural product-based drug exploration is an attractive but challenging way to discover novel drug-like molecules because, in most cases, a naturally occurring extract needs step-by-step chemical optimization to make it a lead or drug candidate. In the past few years, a large fraction of topo II inhibitors, either originated directly from natural extracts or more often chemically modified from natural prototypes, have been explored. For example, many podophyllotoxin derivatives (e.g., <b>1</b> and <b>2</b>) are derived from the 4â²-demethylepipodophyllotoxin (DMEP) framework, which is a natural aryltetralin lignan with antitumor activity.</div><div class="NLM_p">Recently, Tang et al. have applied a prodrug strategy followed by a bioisosteric exchange of the prototype DMEP, aiming to procure new DMEP derivatives with improved pharmacological and therapeutic potency, bioavailability, and pharmacokinetics profiles as well as attenuated toxicity.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> Specifically, following esterification and amidation modifications at the cyclohexane (C ring) of the DMEP motif, the 9-hydroxyl group was transformed into ester <b>51</b> and bivalent bioisostere amides <b>52</b>, respectively, as displayed in <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>. Generally, most of the new DMEP analogues, with the exception of <b>52d</b>, had improved antiproliferative efficacies, enhanced water solubility, and attenuated toxicity compared with the parent DMEP and the control <b>1</b> at submicromolar concentrations in cellular assays. According to the IC<sub>50</sub> values against various tumor cells and octanolâwater partition coefficients (log<i>P</i>) of each compound, the introduction of an ester group gave better potency than the amide counterparts (compounds <b>51a</b>â<b>c</b> vs <b>52a</b>â<b>c</b>). In addition, electron-withdrawing substituents, e.g., F and Cl (<b>51d</b>), are beneficial contributors to the antitumor potency and selective index (SI) toward normal cells. It is noteworthy that compound <b>52d</b> displayed the worst antitumor activity among these DMEP analogues, but offered the best water solubility, which might be attributable to the presence of the three phenolic hydroxyl groups. The most potent compound, <b>51a</b>, showed strong topo II inhibitory activity and blocked HeLa cells in the G<sub>2</sub>/M phase by inducing apoptosis, providing a new promising template for further lead optimization.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical modification of the 9-hydroxyl group of the DMEP prototype led to the DMEP esters <b>51</b> and amides <b>52</b> by means of prodrug principles combined with bioisosteric manipulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For learning about the strong topo II inhibition of these analogues, a molecular modeling analysis of the topo II active domain (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3">3QX3</a>) with <b>51a</b> was examined, as shown in <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>. The result revealed that <b>51a</b> adopted a very similar binding pattern as <b>1</b> by forming three H-bonds with Asp479 and one H-bond with Arg503. Hydrophobic interactions between the trisubstituted phenyl moiety (E ring) and a relatively empty hydrophobic cavity surrounded by six residues, Arg503, Lys456, Asp479, Leu502, Gly478, and Gly504, completed the binding interactions. Furthermore, a ÏâÏ stacking interaction between the coplanar DMEP backbone (C ring) and the adjacent pyrazine moiety was also observed. All of these driving forces were believed to account for remarkable topo II affinity by forming a stable âDNA-topo II-inhibitorâ ternary complex.</div><div class="NLM_p">The incorporation into DMEP of three nitrogen mustard alkylating agents chlorambucil (<b>53</b>), melphalan (<b>54</b>), and bendamustine (<b>55</b>) at the C-4 hydroxyl group of the cyclohexane also led to the three epipodophyllotoxin-<i>N</i>-mustard hybrids <b>57</b>â<b>59</b> and the five piperazine-bearing derivatives <b>60</b>â<b>64</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The <i>N</i>-mustard modulators were expected to exert antineoplastic effects through attachment of the alkyl portion to uncomplexed or complexed DNA (âDNA-topoII inhibitorâ covalent ternary adduct), resulting in irreversible inactivation of topo II.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> These hybrids <b>56</b>â<b>59</b> and <b>62</b> that were submitted for NCI-60 cellular screening displayed markedly improved potencies compared with the controls (<b>1</b>, 12 Î¼M; <b>53</b>, 60 Î¼M; <b>54</b>, 29 Î¼M; and <b>55</b>, 70 Î¼M) with GI<sub>50</sub> values in a low submicromolar range. All of the hybrids exhibited strong topo II inhibitory activities and some of them, compound <b>62</b> in particular, providing enhanced cellular growth inhibitory effects toward K562 and etoposide-resistant K/VP.5 cells.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Combination of naturally available topo II inhibitor DMEP backbone with nitrogen mustard alkylating agents led to several DMEP analogues (<b>56</b>â<b>64</b>) with strong topo II inhibitory activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As one of the most effective topo II poisons in the clinic that targets both topo IIÎ± and Î², DMEP analogue <b>1</b> frequently suffers from a risk of therapy-related secondary malignancies following long-term treatment. The nonspecific-isoform targeting of topo II, to a great extent, might account for this limitation.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> To overcome these shortcomings and determine the precise binding pattern of <b>1</b> with topo II, Chan and co-workers determined a high-resolution X-ray crystal structure of topo IIÎ² in complex with DNA and <b>1</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> According to this cocrystal structure, although most drug-interacting residues are conserved between the Î± and Î² isoforms, the glycosidic part of <b>1</b> anchors next to the polar Q778 residue in topo IIÎ², which is a key drug-interacting position for this enzyme, as shown in <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>. However, for the Î± isozyme, this position is taken up by M762 residue, a structural variation that might offer the opportunity to explore isoform-selective topo II inhibitors. For example, because of the fact that the sulfur atom of methionine readily reacts with Pt(II), Pt(II)-coordinative compounds with suitable stereochemistry might be introduced into the DMEP core to deliver the reactive Pt(II) center toward M762 by forming a stable Pt(II)-thioether coordinative bond, making it possible to accomplish selectivity for topo IIÎ± over the Î² isoform.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Design and SAR for topo IIÎ²-specific DMEP analogues <b>65</b> and <b>66</b> that involved replacing the prototype sugar motif with 1,2,3-triazole-bridging segments, which highlights the importance of effective interaction with the polar topo IIÎ² Q778 residue, a position that is different between topo IIÎ± and Î² subtypes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another example comes from the discovery of the DMEP analogues <b>65</b> and <b>66</b> as potent and selective topo IIÎ² inhibiting agents by replacing the sugar unit with triazole-bearing side chains.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> As displayed in <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, the design concept is summarized as follows: (1) the 1,2,3-triazole entity, which can readily be prepared by a CuAAc click reaction of azides and terminal alkynes, has been verified as a useful pharmacophore and building block in drug design owing to its notable biocompatibility and target-specificity profile. More importantly, this motif might generate binding interactions with the key Q778 residue through any of the three N atoms similar to the sugar motif; (2) introducing various substituents (R<sup>2</sup> and R<sup>3</sup>) with different physicochemical properties (polarity, steric hindrance, and linker length) to the 1,2,3-triazole unit to simulate the interaction between the glycosidic part of <b>1</b> with the polar Q778; and (3) the R<sup>1</sup> group is comprised of the 4â²-demethyl and -methylated analogues to further examine the topo II-targeting effect and achieve chemical diversity. The biological assays showed that the 4â²-methylated counterparts totally lost their bioactivity, implying an indispensable function for the 4â-OH group via the formation of effective interactions with the protein. For example, when the R<sup>2</sup> or R<sup>3</sup> group was fixed as polar substituents that were negatively charged at physiological pH (e.g., carboxylic acid), the resulting compound (e.g., <b>66b</b>) displayed impaired affinity presumably due to electrostatic repulsion with the DNA phosphate motif. Compounds with positively charged substituents (e.g., <b>65a</b> and <b>66a</b>), by contrast, contributed to topo IIÎ²-related selectivity and toxicity.</div><div class="NLM_p">Similarly, according to the determined ternary complex structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3">3QX3</a>), in which two molecules of <b>1</b> complexed with a cleaved DNA-topo IIÎ², two intercalated molecules of <b>1</b> were separated by four DNA base pairs. Meanwhile, both glycosidic motifs from the two molecules of <b>1</b> fill the spacious domains in the complex, suggesting that the glycosidic part can be replaced by other appropriate substituents to provide strong interactions with the active binding region. This binding mode hinted that an analogue of <b>1</b> decorated with two DMEP segments separated by linkers of varying sizes may promote effective bis-intercalation into the two binding sites and subsequently promote stronger topo II inhibition with more a selective and cytotoxic effect toward tumor cells (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Regarding the linkers, two piperazines were selected and connected by a methylene of varying lengths (C3, C6, C8, C10, and C12) with the aim of procuring increased solubility while allowing the polyamine transport system (PTS) to selectively deliver the molecule to tumor sites similar to the polyamine-containing analogue of <b>1</b>, F14512.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Moreover, for validating the two-site intercalation hypothesis and determining the optimum linker length, monoepipodophyllotoxin derivatives were also prepared and compared with bis- epipodophyllotoxin counterparts.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Design of mono- and bis-epipodophyllotoxin derivatives <b>67a</b>â<b>c</b> and <b>68a</b>â<b>e</b> involved replacement of the glycosidic part of archetype <b>1</b> with methylene-linked piperazines to enhance activity by allowing more effective interactions with the topo II active binding area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SAR explorations on the obtained products <b>67a</b>â<b>c</b> and <b>68a</b>â<b>e</b> revealed that the diepipodophyllotoxins, as predicted, were generally more active than their monosubstituted counterparts in inhibiting both leukemia K562 cell growth and <b>1</b>-resistant K/VP.5 cells at lower micromolar concentrations. For the bisubstituted derivatives <b>68a</b>â<b>e</b>, the length of the methylene linkers indeed influenced cellular activity. The minimum chain length was six (<b>68b</b>) and the optimum was eight methylenes (<b>68c</b>), which was â¼10-fold more active than <b>1</b>. This SAR result was in agreement with that for the epipodophyllotoxin-acridine hybrids identified in the preceding work, which confirmed the structure-based design hypothesis to a certain extent. In terms of the monosubstituted derivatives <b>67a</b>â<b>c</b>, the SAR tendencies differ slightly from the disubstituted ones.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Although the longer linker enhanced cellular potency, the ten methylene-bearing derivative <b>67c</b> showed the best activity, which was 6-fold more potent than the control. The activities of the monosubstituted derivatives might be due to the presence of dipiperazine moieties that can be forwardly transported by the PTS similar to polyamines.</div><div class="NLM_p last">Three compounds, <b>68a</b>, <b>68b</b>, and <b>68d</b>, were selected for examination with the NCI-60 cell line screening to determine which tumor types were sensitive to these compounds and identify possible mechanisms by which these compounds exerted their activity. As a consequence, the ten methylene-containing bis-epipodophyllotoxin derivative <b>68d</b> afforded the best average activity, which was 25-fold more active than prototype <b>1</b>. Finally, a preliminary mechanism study indicated that all of the mono- and bis-epipodophyllotoxin derivatives were topo IIÎ± poisons that could inhibit topo IIÎ± decatenation and cause DNA DSBs in tumor cells.</div></div><div id="sec3_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22">3.1.5.2.  Andrographolide Analogues</h5><div class="NLM_p">Andrographolide (<b>69</b>), a diterpenoid lactone from <i>Andrographis paniculata</i>, is an herbal medicine that can inhibit tumor growth and proliferation as well as induce caspase-independent cell death via inhibition of topo IIÎ± activity. Piyachaturawat et al. have semisynthesized several andrographolide analogues <b>70</b>â<b>74</b> via a step-by-step etherification process (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Further studies of these andrographolide analogues revealed that five of them (<b>70b</b>, <b>72c</b>, <b>74a</b>â<b>c</b>) presented potent topo IIÎ± inhibition and led to cytotoxicity toward several tumor cell lines (BCA1, CHO, HeLa, and HepG2) in vitro.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Semisynthetic processes for the desired ether intermediates (<b>71</b> and <b>73</b>) and silyl ethers (<b>70</b>, <b>72</b>, and <b>74</b>) from naturally available <b>69</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23">3.1.5.3.  Naphthoquinone Analogues</h5><div class="NLM_p">1,4-Naphthoquinones and 1,2-naphthoquinones are pharmacophoric fragments initially identified by the National Cancer Institute (NCI) that have functions in counteracting or preventing the formation of malignant tumors. Mansonone E (ME, <b>75</b>) and F (MF, <b>76</b>) are two naturally occurring sesquiterpene <i>o</i>-quinones that contain a fused pyran ring. These fused pyran or furan units are especially important owing to their irreplaceable roles in retaining the cytotoxic effects as well as topo inhibitory activities. A systematic SAR exploration of the mansonone skeleton confirmed that the 3- and 9-substituted mansonone derivatives displayed heightened cytotoxic and topo inhibitory potencies. A halogenation modification at the C-9 position generated a strengthened efficacy compared with the 9-alkyl or 9-aryl counterparts. Inspired by these findings, Huang et al. equipped the ME backbone with a C-3 triazole unit as well as C-9 halogenated substituents (Cl or Br). The resulting ME derivatives <b>77</b> produced comparable or even better antitumor efficacies toward the tumor lines A549, HL-60, K562, and Hela, as summarized in <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Combination of a sesquiterpene ME ring and a 1,2,3-triazole motif led to novel ME derivatives <b>77</b> with decent antitumoral efficacies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24">3.1.5.4.  <i>p</i>-Terphenyl Analogues</h5><div class="NLM_p">To unravel the basic pharmacophore as well as the detailed mechanism of action of <i>p</i>-terphenyl, which mainly exists in mycomycetes from <i>A. candidus</i>, Shen et al. discovered a subset of <i>p</i>-terphenyl derivatives (<b>78</b>), as evinced in <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Cytotoxicity studies elucidated that compound <b>78a</b>, which has phenolic hydroxyl groups at the distal end, displayed the most potent antineoplastic potency toward tumor cells (MDA-MB-435, IC<sub>50</sub> < 1 Î¼M) by strongly inhibiting both topo I and topo IIÎ±. In contrast, compounds <b>78b</b> and <b>78c</b> with hydroxyl groups at both the proximal and distal ends only furnished selective inhibition against topo IIÎ±, though they were less efficient than <b>78a</b>, suggesting that they might be used as potential hits for further chemical optimization.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. <i>p</i>-Terphenyl derivatives <b>78</b> with phenolic hydroxyl groups at different positions gave differing selectivity of inhibition toward topo IIÎ± and Î² isoforms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25">3.1.5.5.  Pentacyclic triterpenoid analogues</h5><div class="NLM_p">Pentacyclic triterpenoids, e.g., betulinic acid (<b>79</b>), boswellic acid (<b>80</b>), ursolic acid (<b>81</b>), and oleanolic acid (<b>82</b>), are oleanane-type antineoplastic agents that target both topo I and topo IIÎ±. An SAR exploration revealed that the common pentacyclic ring is a strong determinant for achieving topo inhibition, whereas carboxylation of this pentacyclic structure has been suggested to be another determining factor. For identifying more potent topo inhibitors from the oleanolic skeleton, a computer-aided molecular modeling method was applied to analyze the active binding site characteristics of topo I and topo IIÎ± and dock the proposed analogues into this domain. By this approach, ten desired inhibitors <b>83</b> and <b>84a</b>â<b>i</b> with optimal parameters (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>), e.g., electrostatic and H-bonding interactions and spatial topology, were selected and subjected to semi- or total synthesis. The subsequent bioevaluation showed that compounds <b>84a</b>, <b>84b</b>, <b>80d</b>, <b>80f</b>, and <b>80h</b> showed higher topo I inhibitory activities than CPT, whereas compounds <b>84a</b>, <b>84b</b>, <b>84d</b>, and <b>80e</b> gave increased topo II inhibition compared with <b>1</b>. Collectively, <b>84a</b>, <b>84b</b>, and <b>84d</b> stood out among these oleanolic analogues and might be used for exploring more dual topo I and topo IIÎ± inhibitors with heightened antitumor efficacies and MDR reversal potency.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structures of several oleanane-type triterpenoids (<b>79</b>â<b>82</b>) and oleanolic acid-based analogues <b>83</b> and <b>84a</b>â<b>i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26">3.1.5.6.  Curcumin Analogues</h5><div class="NLM_p">Curcumin is an active component of phytochemical turmeric (<i>Curcuma longa</i>) that has been used for centuries as a food additive or dietary supplement. Although curcumin and its derivatives have been used extensively in pharmaceutical applications with negligible toxicity issues, its shortcoming, such as poor metabolic stability (<i>t</i><sub>1/2</sub> < 5 min), bioavailability, pharmacokinetic/pharmacodynamic (PK/PD) properties owing to the tautomerimic nature to a large extent have greatly hindered the clinical use of this compound.<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88,89)</a> Jha et al. have explored a variety of curcumin derivatives and concluded that derivatives with the keto-form (or oxygenation pattern) were more potent than those with the enol-form with respect to the antioxidant and antineoplastic efficacy. Additionally, because topo IIÎ± is a thiol-rich enzyme and is crucial for sustained cell proliferation, Michael acceptors (e.g., an Î±,Î²-unsaturated carbonyl group) and the enone unit are suitable for incorporation into the curcumin motif with the expectation of furnishing selective affinity for topo IIÎ± upon forming interactions with auxiliary binding sites. On the basis of these data, a spectrum of keto-type curcumin derivatives with a maleic diamide tether (<b>85</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) were prepared and assessed.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> These derivatives manifested heightened top IIÎ±-related cytotoxicity by approximately 93- to 280-fold compared with the controls (curcumin and melphalan), suggesting the possibility, although questionable, of developing more potent curcumin-derived compounds. Moreover, acting as a structural and functional analogue of curcumin, diarylheptanoid hirsutanone, which is isolated from <i>Alnus glutinosa</i> leaves and contains a Michael acceptor (Î±,Î²-unsaturated ketone structure), was shown to be a topo II-mediated poison.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structural modification of naturally occurring keto-type curcumin led to a myriad of curcumin-inspired analogues <b>85</b> with significantly elevated cytotoxicity compared with curcumin and melphalan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27">3.1.5.7.  Ellipticine Analogues</h5><div class="NLM_p">Ellipticine (5,11-dimethyl-6<i>H</i>-pyrido[4,3-<i>b</i>]carbazole, <b>86</b>), an alkaloid isolated from <i>Ochrosia elliptica</i>, is a polyaromatic DNA intercalating inhibitor of topo II that forms covalent adducts with DNA. Although its cytotoxicity has a marked influence on the antineoplastic potency, <b>86</b> has difficulty in clinical applications due to its poor bioavailability, lack of target specificity, and drug resistance in prolonged treatment. Even though derivatizing <b>86</b> will compensate for these deficiencies to a certain degree, the derivatives of <b>86</b> still suffer from a cluster of undesirable adverse effects, such as weight loss, renal toxicity, and hemolysis.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> It is plausible that salification may be a good alternative to avoid these pitfalls as exemplified by celiptium (<b>87</b>), the most clinically successful acetate salt of elliptinium, that displays both increased aqueous solubility and enhanced antineoplastic efficacy. More endeavors to address these limitations led to the identification of several ellipticine-derived bromonium salts (<b>89</b>, <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>) derived from <b>86</b> by quaternization with alkyl bromides at N-1 of the pyridine ring. Among the obtained ellipticinium salts, both <b>89a</b> and <b>89b</b> showed strong topo II inhibition and comparable antiproliferative effect to irinotecan and <b>1</b>. However, both modified ellipticinium salts and two controls showed attenuated antiproliferative activities compared with their N-1-unsubstituted counterpart 6-methylellipticine (<b>88</b>), which displayed submicromolar cellular potency. This result suggested that the balance between cellular efficacy and water solubility should be considered by further modifying <b>86</b>.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structures of ellipticine-derived analogues <b>89</b>â<b>92</b> and the binding mode of <b>92a</b> with topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>). Some of these compounds, exemplified by <b>90b</b> and <b>92</b>, presented significant antineoplastic improvements compared with the parent ellipticine for targeting topo IIÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To acquire further insights into the SAR profile of <b>86</b>, Vann et al. attempted to prepare the two analogues <b>90a</b> and <b>90b</b>, where the methyl group at the C5 position was removed with the intention of generating improved antineoplastic properties compared to <b>86</b> by targeting topo IIÎ±.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Compound <b>90b</b> is a quaternary ammonium salt of <b>90a</b> that aimed to improve its water solubility and enhance its bioavailability. The subsequent topo II-mediated kinetoplast DNA (<i>k</i>NDA) decatenation evaluation of <b>90a</b> and its salt <b>90b</b> revealed that they are approximately 5- to 25-fold more potent than prototype <b>86</b>, respectively, and both act as catalytic inhibitors of topo IIÎ±. It appears that such inhibition toward topo IIÎ± is associated with their ascending ability to intercalate into the double helix of DNA with their intercalating potency in the order of <b>90b</b> > <b>90a</b> â¥ <b>86</b>.</div><div class="NLM_p last">Guided by these discoveries, the four carbazole derivatives <b>91a</b>, <b>91b</b>, <b>92a</b>, and <b>92b</b>, inspired by the structure of <b>86</b>, were prepared. Screening revealed that the urea-linked analogues <b>92a</b> and <b>92b</b> exhibited notable thermal stability, strong and selective topo II inhibitory potencies, as well as low cytotoxicity toward normal cells, emphasizing the fundamental role of the urea functionality in promoting topo II inhibition.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The binding mode of <b>92a</b> with topo IIÎ±, as shown in <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>, clearly illustrates that, apart from efficacious H-bonds between the compound and residues Asp94, Asn150, Ser149, and Lys157, the coordinative force between the methoxyl O and catalytic Mg<sup>2+</sup>, together with a Ï-cation contact between the aromatic backbone and Lys157, are all beneficial contributors to the bioactivity. In addition, several residues (Tyr34, Ile33, Thr159, and Arg98) participated in the formation of hydrophobic interactions, which were also beneficial contributors to the improved binding affinity.</div></div><div id="sec3_1_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28">3.1.5.8.  Evodiamine Analogues</h5><div class="NLM_p">Evodiamine (EVO) is a natural quinazolinocarboline alkaloid extracted from the fruit of <i>Evodia rutaecarpa</i> Benth. (Rutaceae)<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> has been shown to have multitarget and broad-spectrum antineoplastic profiles via multiple mechanisms of action, including apoptosis,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Î²-catenin-mediated angiogenesis,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> cell cycle progression, and the induction of oxidative stress.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> It is therefore a potentially useful lead for modifying and exploring additional chemotypes. For example, the Sheng group has developed the spectrum of EVO-inspired diverse scaffolds <b>93</b>â<b>105</b> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Some important SAR information on these EVO-derived backbones is summarized as follows: (1) Generally, among the 11 novel EVO-inspired scaffolds, the oxo- and thio-bearing scaffolds presented predominant efficacy. Installation of a 10-hydroxyl group could induce elevated antitumor activity compared with the 10-methoxyl counterparts. (2) With respect to structural changes on the B/C ring, surprisingly, when the indole motif (<b>93</b>) was transformed into a benzofuran core (<b>94</b>), the same R substituent gave an opposite result, presumably due to a different antitumor mechanism. (3) When the D ring remained constant as a 2<i>H</i>-1,3-oxazin-4(3<i>H</i>)-one core (<b>95</b>), only moderate potency was acquired. The only exceptions are the 3-chloro substituted analogues <b>95a</b> and <b>95b</b>, which expressed nanomolar inhibitory activity toward A549 cells. In contrast, the 3-fluoro (<b>95c</b>) and 3-bromo (<b>95d</b>) substituted analogues were less potent, whereas the 3-nitro counterpart <b>95e</b> lost activity. When the nitro group was transformed into an amino group at the same position, the resulting compound <b>95f</b> demonstrated elevated potency. However, further acylation or substitution of the amino functionality led to an overall decrease in bioactivity (<b>95g</b> and <b>95h</b>). Moreover, both the thiocarbonyl group (<b>96</b>) and five-membered pyrrolidin-2-one <b>97</b> were unfavorable moieties for bioactivity. Intriguingly, among the modifications to the D ring, the 2<i>H</i>-1,3-thiazin-4(3<i>H</i>)-one scaffold <b>98</b> demonstrated the most potent antitumor profile. Unfortunately, when the sulfur was oxidized to a sulfone (<b>99</b>) or a phenyl moiety was replaced by pyridinyl (<b>100</b>), the corresponding derivatives were almost inactive. Collectively, 10-hydroxyl was found to be the favorite unit for determining cellular activity, closely followed by the 3-chloro and 3-amino substituents on the phenyl (E) ring. (4) When the E ring was modified, both the pyrrole and thiophene series <b>101</b>â<b>103</b> and <b>105</b> exhibited broad-spectrum antitumor potencies and had a similar SAR profile to the EVO archetype. However, replacement of the pyrrole and thiophene rings with a furan scaffold (<b>104</b>) attenuated activity. Moreover, for the thiophene series <b>101</b>â<b>103</b>, movement of the S atom in the thiophene ring resulted in a significant antitumor improvement.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Natural product evodiamine (EVO) inspired scaffold diversity and led to a large variety of derivatives <b>93</b>â<b>105</b> via multiple design protocols. Among them, the 3-chloro-10-hydroxyl derivatives <b>98d</b>â<b>h</b> showed particularly excellent potencies, highlighting their promise as leads for further exploitation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">3.1.6.  Combination of High Throughput and in Silico Screening</h4><div class="NLM_p">High-throughput screening (HTS) by means of an in silico approach is a growing and efficient method in drug discovery that involves performing systematic screening to predict the bioactivity between molecules and drug targets, aiming to discover potent hits and/or leads for further exploitation. Using a virtual screening protocol, Perdih et al. explored a category of 4-amino-6-(phenylamino)-1,3,5-triazines (<b>106</b>) that function as monocyclic mimetics of the purine motif and act as potent topo IIÎ± inhibitors by targeting the ATP binding site.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> To do this, as shown in <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>A, the crystal structure of human topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) was initially selected from the PDB database, and a subsequent reconstruction and calibration was performed to successfully redock the ligand (purine-based compound A) into the ATPase pocket of the target protein. The validated binding mode was then utilized to generate a structure- and ligand-based pharmacophore model, which was finally employed for further virtual screening procedures. As a consequence, three types of hits (monocyclic scaffold triazines (<b>106</b>), triazoles (<b>107</b>), and pyrimidines (<b>108</b>)) were eventually chosen and subjected to biological assessments based on the orientations obtained from the docking study, the âLipinski rule of fiveâ, and ligand efficiency selection. When a fluorophenyl or methoxyphenyl was appended onto the 1,3,5-triazine motif, significant topo IIÎ± inhibitory enhancement was observed. Additionally, the bicyclic heterosystems, e.g., 9<i>H</i>-purines (<b>109</b>) and 1<i>H</i>-pyrazolo[3,4]pyrimidines (<b>110</b>), created by fusing 1,3,5-triazines with other chemotypes that behave as isosteres of the purine ring as exemplified by compounds <b>109a</b> and <b>110a</b>, were also shown to be topo IIÎ± inhibitors comparable with positive control <b>1</b>.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> The binding patterns of these two compounds with human topo IIÎ±, as presented in <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>B, suggested that, in addition to the hydrophobic interactions, several H-bonding contacts mainly contribute to the topo IIÎ± binding affinity.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. (A) Schematic flowchart for the discovery of potent topo IIÎ± inhibitors possessing the skeletons of triazines (<b>106</b>), triazoles (<b>107</b>), pyrimidines (<b>108</b>), 9<i>H</i>-purines (<b>109</b>), and 1<i>H</i>-pyrazolo[3,4]pyrimidines (<b>110</b>) via an in silico protocol. (B) Binding modes of the two representative examples <b>109a</b> and <b>110a</b> with human topo IIÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Xanthones are naturally oxygenated flavonoids with a variety of pharmaceutical applications as antitumor, antidepressant, hepato-protective, and antioxidant agents. Even though their antitumor potency was once thought to be relevant to the inhibition of topo IIÎ±, the exact biotarget(s) of antineoplastic xanthones have not been clearly elucidated. To better understand the SAR and find more effective inhibitors of this type, Khan et al. explored a number of xanthone-derived hits (<b>111a</b>â<b>d</b>) with higher topo IIÎ± docking scores (120.382â138.108) than the control <b>3</b> (71.47) from a 50-member xanthone combinatorial library via a hierarchical computational screening (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>A).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> A QSAR model with good predictable outcomes was built, and this model was utilized as a guide for the further development of structurally diverse molecules from the xanthone family. The putative binding modes of these compounds, as shown in <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>B, manifested that the H-bonding interactions are beneficial factors to the enhancement of binding affinity.</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. (A) A hierarchical computational screening used for the discovery of xanthone derivatives <b>111a</b>â<b>d</b> with potent topo IIÎ± inhibitory potencies from a 50-member xanthone combinatorial library; the X-ray structures of <b>111a</b> and <b>111b</b> complexed with topo IIÎ± (PBD ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) are also presented. (B) Putative binding modes of xanthone derivatives <b>111a</b>â<b>d</b> with topo IIÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">3.1.7.  Isoelectronic or Isostructural Replacement Is a Typical but Effective Approach to Identify Potent Topo II Inhibitors</h4><div class="NLM_p">Guided by the tetracyclic indenoquinoline-derived ellipticine (<b>86</b>) and batracylin (BAT, NSC320846, <b>112</b>),<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> which have emerged as notable DNA intercalators with significant topo II inhibitory activities, Chen and co-workers developed a panel of tetracyclic indeno[1,2-<i>c</i>]quinoline derivatives <b>113</b> via structural replacement of the tetracyclic backbone of <b>112</b> and subsequent oximation to the corresponding <i>O</i>-substituted oximes. Among them, <b>113a</b>â<b>c</b> had the most potent antiproliferative activities toward A549 or HeLa cells, acting as DNA intercalating agents. Further exploration on the SAR led to the discovery of a new series of indeno[1,2-<i>b</i>]quinoxaline analogues <b>114</b> via bioisosteric modification and subsequent local manipulation of substituents (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>). It is noteworthy that these changes significantly improved the antiproliferative potencies, although only having moderate topo II inhibition at 10 Î¼M by the incorporation of the aminoalkyl fragments. Compound <b>114a</b>, with the <i>N</i>,<i>N</i>-dimethyl-propan-1-amine side chain, had the best in vitro cellular and in vivo antitumor activity as well as topo II affinity and could be a potential lead for further structural optimization.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Design of indeno[1,2-<i>b</i>]quinoxaline analogues <b>113</b> and <b>114</b> via bioisosteric modification protocol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">3.1.8.  Mining Novel Candidates from Inorganic Complexes</h4><div class="NLM_p">Inorganic coordination compounds or metal complexes, which typically consist of a central metal ion (called the coordination center) and a surrounding pool of bound molecules (called ligands or complexing agents), are extensively found in nature, including animals, plants, and minerals. Recently, the chemistry of biologically important ligands and their metal complexes is gaining increasing attention. Given that the biological activities of newly formed complexes rely heavily on the nature of organic ligands, bioligands with excellent bioactivity and biocompatibility should be selected to coordinate to central metal ion(s). In addition, for building a structurally stable chelation complex, the ligands should have well-defined stereochemistry, and the coordination sites should have suitable allocation and disposition.</div><div class="NLM_p">For instance, Tabassum and colleagues set out to develop a variety of biocompatible carbohydrate-conjugate heterobimetallic Cu(II)âSn(IV) and Ni(II)âSn(IV) complexes <b>115</b>â<b>118</b> (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> To accomplish this, they utilized nontoxic saccharides, which are readily recognized by cell-surface receptors as ligands (L<sub>1</sub>) and coordinate with biologic elements such as Cu(II), Ni(II), and Sn(IV). These elements, often referred to as bioelements, are validated to demonstrate remarkable antiproliferative profiles and preferential selective affinity toward tumor cells. In the newly obtained complexes, an ethylenediamine unit was introduced to function as the coordination site, and a bridging linkage was inserted to connect the two carbohydrate functionalities. A DNA binding affinity assay showed that heterobimetallic complexes are more prominent DNA binders than their monometallic counterparts with an affinity order of <b>117</b> > <b>118</b> > <b>115</b> > <b>116</b> followed by the free ligand. This result evinced that bioelements as hard Lewis acids (particularly transition metals) are well-suited for covalent coordination with DNA double helix nucleobases. Similarly, evidence has shown that, when the bioactive thiosemicarbazones (e.g., <b>APY</b> and <b>APZ</b>), which can block the cell cycle in the G2/M phase or inhibit ATPase hydrolysis by targeting topo IIÎ±, were utilized as ligands, the resulting copper(II) complexes <b>119</b> and <b>120</b> were more potent antiproliferative agents than the parent ligands.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a></div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Formation of complexes provided more potent DNA binding affinities with an affinity order of heterobimetallic complexes > monometallic counterparts > free ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, there has emerged evidence that topo IIÎ± is very sensitive to soft metal-containing thiol-reactive agents based on the fact that topo IIÎ± possesses at least two disulfide-bonded Cys pairs and five free Cys residues. Additionally, an electrophilic reaction between the sulfhydryl groups and the metal center is believed to be responsible for the inhibitory potency. Rocha et al. investigated the topo II inhibitory potencies of the four palladium(II)-based, cationic thiol-reactive complexes <b>121a</b>â<b>d</b> (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>)<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> because Pd(II) appears to be an appropriate candidate owing to its high affinity for sulfur-bearing ligands. Moreover, the four Pd(II) complexes were also able to inhibit cathepsin B, another Cys-containing cysteine protease that is also closely connected to tumor invasion.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The four complexes were initially subjected to cytotoxic assessment using three tumor cell lines, two murine-derived cell lines (mammary adenocarcinoma LM3 and lung adenocarcinoma LP07), and one human MCF-7 (breast adenocarcinoma) cell line. The results showed that the Pd(II) complexes displayed remarkable and elevated cytotoxicities compared with the positive controls (cisplatin and <b>1</b>) in the LM3 and MCF-7 cells, and they exhibited comparable cytotoxicity to cisplatin in LP07 cells at submicromolar concentrations. A preliminary mechanistic investigation showed that the Pd(II) complexes <b>121a</b>â<b>d</b> did not inhibit topo I and cathepsin B. Instead, these molecules were more inclined to be ATP competitive catalytic inhibitors of topo IIÎ±. The SAR results indicate that the polarity, strength of the coordinative Pd-X bond, spatial volume and kinetic differences among different ligands, and steric hindrance derived from thiosemicarbazide ligand might play a key role in achieving topo II inhibition.</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Pd(II)-based thiol-reactive complex has great potential to be developed as potent topo IIÎ± inhibitor <b>121</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a category of novel organometallic alternatives for platinum-derived chemotherapeutics, ruthenium-based compounds also function as topo-targeting catalytic inhibitors or poisons, which is supported by the evidence that some limitations of Pt-derived complexes might be overcome by the use of a ruthenium (Ru) substitute.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Although organoruthenium-based complexes are usually designed to simulate the spatial configuration of platinum drugs, they have more advantages than platinum-derived complexes. On one hand, ruthenium has three oxidation states (II, III, and IV), which are all available in physiological environments. The nontoxic but less active Ru(III) complex can be easily transformed into its toxic and active Ru(II) counterpart. Despite this transformation, both Ru(II) and Ru(III) complexes exhibit relatively slower ligand exchange rates than most of the transition metal complexes, endowing Ru complexes with higher kinetic stability and minimized side effects. On the other hand, Ru complexes typically adopt octahedral geometries, which are more stable than the square planar geometry of platinum complexes. More importantly, this geometry allows the central Ru atom to coordinate more ligands, thereby expanding the chemical diversity and also regulating the complexesâ steric and/or electronic properties.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p">To date, two ruthenium-based candidates, NAMI-A (<b>122</b>) and KP1019 (<b>123</b>), have entered clinical trials, and another two compounds, RAPTA-C (<b>124</b>) and RM175 (<b>125</b>), are currently in preclinical evaluation (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>). As a prodrug, <b>122</b> is activated by the reduction of Ru(III) to Ru(II) and exerts its anticancer effects upon entering tumor cells, and <b>123</b> is particularly effective for metastatic and cisplatin-resistant tumors.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> As a pH-dependent DNA damage agent, <b>124</b> only functions under hypoxic conditions with antimetastatic hypotoxicity.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Compound <b>125</b> displays comparable or greater cytotoxicity than carboplatin and induces tumor growth arrest and apoptosis without any cross-resistance to other platinum drugs.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Inspired by the favorable antitumor efficacies of <b>124</b> and <b>125</b>, Lida et al. prepared two Ru(II)-coordinated analogues, 1,4-phenylenediammine-containing <b>126</b> and 1,4- benzoquinonediimine-bearing <b>127</b>, via the structural integration of two prototype drugs <b>110</b> and <b>111</b>.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The result was that <b>126</b> displayed superior efficacy at inhibiting tumor growth with EC<sub>50</sub> values of 50â160 Î¼M without affecting normal cells, implying that the free amine groups might play an indispensable role in maintaining the antitumor efficacy compared with the oxidation product, diimine-containing <b>127</b>.</div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. For the Ru-based complexes, coplanar aromatic conjugation and hydrophobicity are fundamental elements for achieving both notable DNA binding affinities and topo IIÎ± inhibitory profiles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As far as other ruthenium-based complexes are concerned, Ru(II)-arene complexes with polypyridyl ligands (i.e., bidentate 2,2â²-bipyridine and 1,10-phenanthroline) that can furnish two N atoms as coordination sites to create chiral ring structures are especially heightened. These complexes typically display notable antitumor effects owing to their strong DNA-intercalating abilities, leading to effective inhibition of topo II. For example, the four chiral Ru(II) enantiomers bearing 2-furanyl-imidazo[4,5-<i>f</i>][1,10]phenanthroline and 2,2â²-bipyridine ligands <b>128</b>â<b>131</b> were developed as topo IIÎ± poisons. The five-membered heterocyclic entities (e.g., furan and 1<i>H</i>-imidazole), which are verified to have DNA binding affinities, were introduced into the ligand with the expectation of acquiring enhanced topo II inhibitory efficacy. Among them, the best iodofuran <b>131</b> gave decent topo II inhibition, antiproliferation, as well as cytotoxic effects comparable with VP-16 and cisplatin.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><div class="NLM_p">For gaining insight into a detailed SAR of Ru(II)-polypyridyl complexes, which would provide clues for the exploration of optimal ligands, six novel Ru(II)-based DNA-intercalative complexes, <b>132a</b>, <b>132b</b>, and <b>132d</b>â<b>g</b>, were prepared and subjected to activity assessment as well as quantum-chemistry calculations. Generally, compound <b>132a</b> with the cyclohexane unit had the weakest DNA binding affinity and enzymatic inhibition compared with its aromatic-bearing counterparts <b>132b</b> and <b>132d</b>â<b>g</b>, suggesting that a coplanar aromatic conjugation with fewer steric effects is favorable for arene-based ligand design. Compounds with electron-withdrawing F and NO<sub>2</sub> groups (<b>132e</b> and <b>132f</b>) were found to be more potent than electron-donating CH<sub>3</sub> groups (<b>132d</b>), implying that the electronic effect greatly affects DNA binding interactions. Among them, compound <b>132b</b> stands out from all the bioevaluations, suggesting that DNA intercalative ligands with less steric hindrance and better planarity are beneficial to DNA binding affinity as well as DNA-dependent enzyme inhibition.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><div class="NLM_p">Enlightened by this SAR information, He et al. have reported a Ru(II)-polypyridyl complex with an unsubstituted phenyl ring (<b>133a</b>) and its ester-containing counterpart <b>133b</b> and evaluated their topo inhibitory and cytotoxic activities.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> The results showed that both of the complexes possess moderate cytotoxicity toward tumor cells (HeLa and HepG2) and can induce apoptosis in HepG2 cells by acting as dual inhibitors against topo I and II via intercalation into DNA base pairs. However, <b>133b</b> showed weaker DNA affinity and topo inhibition due to a possible steric effect from an ester functional group. The DNA binding order of the Ru(II)-centered complexes <b>134</b>â<b>138</b> containing asymmetric tridentate <i>N</i>-based ligands (<b>134</b> < <b>135</b> < <b>136</b> < <b>137</b> < <b>138</b>) further confirmed the important role of coplanar aromatic conjugation in ligand design through enhancing DNA binding affinity and cytotoxicity. Typically, larger Ï frameworks afford higher DNA affinity. Complex <b>134</b> gave the lowest affinity because the two phenyl groups on the 1,2,4-triazine core are noncoplanar. In contrast, other attachments on the 1,2,4-triazine motif complex demonstrated better planarity and higher hydrophobicity, leading to elevated DNA affinities. As far as topo inhibition was concerned, among the test complexes with notable DNA binding activities (<b>137</b> and <b>138</b>), compound <b>137</b> exhibited the best topo IIÎ± inhibitory activity with an IC<sub>50</sub> value of 10 Î¼M.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><div class="NLM_p">To date, the majority of Ru(II)-based arene complexes are mononuclear-type and demonstrate relatively higher cytotoxicities. MuthnÃ¡ et al. exploited a dinuclear, thiolato-bridged, arene Ru-complex <b>139</b> by incorporating <i>p</i>-cymene and phenol functional groups as coordinative ligands with the expectation of achieving improved water solubility and bioavailability as well as decreased cytotoxicity compared with mononuclear-type Ru complexes. A systematic evaluation showed that <b>139</b> can significantly inhibit the growth of tested tumor cells in vitro as well as the growth of a solid Ehrlich tumor in vivo. Although the efficacy of compound <b>139</b> is weaker than that of control cisplatin, it is still a promising candidate for further evaluation.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p">Metal-centered coordinated compounds serve as important complements to organic molecules and have played a key role that cannot be ignored in the development of anticancer drugs. Enlightened by the successfully developed platinum-based metallodrugs, concerns about the exploration of novel complexes has aroused many researchersâ interests.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Chaoâs lab has explored the preliminary SAR of a limited series of Ru(II) complexes with polypyridyl phenolic hydroxyl ligands (<b>140</b> and <b>141</b>) by varying the number and disposition of the hydroxyl groups (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Biological evaluation demonstrated that the complexes act as dual topo I and topo IIÎ± poisons with prominent and elevated topo-mediated DNA binding properties relative to those of the controls (CPT, <b>1</b>, and novobiocin); more potent topo inhibition was achieved with increased numbers of hydroxyl groups.</div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Ru(II)-chelated compounds <b>140</b> and <b>141</b> are topo I/IIÎ± poisons, note that the mode of action of Au(III) complex <b>142</b> changes with the concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Isoelectronic gold(III) complexes that have a similar square-planar configuration to platinum(II) counterparts are expected to exert a similar mode of action as platinum(II) analogues and can overcome cisplatin resistance. Munro et al. have reported four Au(III) complexes in which the Au<sup>III</sup> ion was chelated to a bidentate ligand via an anionic amido and pyridyl or isoquinolylamido <i>N</i>-donor atom, leaving a pair of <i>cis</i>-chlorine ions to complete the square-planar coordination geometry. Au(III) complexes with this chelation mode have been found to have promising cytotoxic effects via DNA binding.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Notably, the isoquinolylamido-containing complex <b>142</b>, which gave the best cytotoxicity in the NCI-60 screening with an average IC<sub>50</sub> value of 23 Î¼M, demonstrated a rare mode of action toward topo based on the drug concentration. It can act as either a topo IIÎ± poison below 1 Î¼M or a dual catalytic inhibitor of topo I/II at relatively high concentrations (>5 Î¼M).</div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">4.  Conclusions and Future Research Prospects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compared with traditional topo I inhibitors (e.g., CPT) that have significant dose-limiting toxicities and drug resistance, topo II inhibitors with lower nonspecific toxicities are more desirable. Two subclasses of human topo II, Î± and Î² isoforms, which share â¼70% sequence identity, have distinct functions in the cell. The Î± isoform is a cell cycle-dependent enzyme that is highly expressed in proliferating cells, whereas Î² isoform expression does not change during the cell cycle. More recently, there is evidence that inhibition of topo IIÎ² might lead to some unwanted side effects, including secondary leukemias, myelodysplastic syndrome (MDS), and cardiac toxicity, which have been the major limitations associated with clinical applications of topo II inhibitors. For these reasons, topo IIÎ± has been validated as an important cellular biotarget for exploiting potential antiproliferation agents.</div><div class="NLM_p">At present, most topo II-related antineoplastic agents in clinical use are topo II poisons that target both the Î±- and Î²-isoforms, including anthracycline-derived <b>3</b>, <b>4</b>, <b>6</b>, and <b>10</b> as well as epipodophyllotoxin-based <b>1</b> and <b>2</b>. However, these drugs are frequently associated with unwanted drawbacks, including the induction of cumulative cardiotoxic side effects (e.g., cardiomyopathy), the potential development of therapy-related drug resistance and secondary malignancies.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> This is based on the fact that topo II poisons can transform the enzyme into a DNA-damaging toxin by inducing the formation of a stable âDrug-Topo-DNAâ complex and promote the accumulation of irreversible âdouble-stranded breaksâ that are highly toxic to cells, resulting in permanent DNA damage and triggering apoptotic cell death in both normal and cancer cells.</div><div class="NLM_p">Given that long-term treatment with topo II poisons might cause therapy-related side effects, e.g., drug resistance and secondary malignancies, one of the strategies to overcome this drawback is to develop topo II catalytic agents that do not serve as topo II-mediated DNA âtoxinsâ but still effectively inhibit enzyme activity by disturbing the catalytic cycle, which may expand the antitumor spectrum and offer an optimal therapeutic outcome. However, because cancer is an exceedingly complex, multigenetic, and multifactorial disease involving numerous processes that cause a variety of physiological and pathological changes, topo II-targeted chemotherapeutics, either poisons or catalytic inhibitors, might not provide the optimal curative effects for cancer management when used alone as a monotherapy.</div><div class="NLM_p">Combination therapy with different mechanisms (e.g., topo II/I, topo II/microtubule inhibitors, etc.) is in many cases an effective regimen to achieve synergistic effects while avoiding possible drug resistance. On the other hand, the risk of complicated drug metabolism owing to the inherent PK profiles of individual drugs makes it difficult to determine the best remedy in terms of dosing and scheduling. In contrast to combination therapy using two or more therapeutics, a hybrid molecule that simultaneously modulates two or more biotargets (e.g., topo II/I or topo II/microtubule) through proper hybridization of two or more bioactive fragments may exert complementary or improved efficacy and reduced drug resistance when compared with single-target agents. At present, this approach still remains largely empirical.</div><div class="NLM_p">Although the efficacy of topo II poisons is limited, topo II poisons are still popular in cancer treatment owing to their strong ability to induce DNA damage. Hence, the exploration of novel chemotypes serving as topo II poisons is still an active area of research. The quinolone-based <b>12</b>, for example, is a topo II poison and first-in-class chemotherapeutic agent that has been studied in phase III clinical trials for both relapsed or refractory and previously untreated AML and platinum-resistant ovarian carcinoma.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Even more intriguing, although <b>12</b> exhibits comparable antitumor efficacy to anthracyclines, <b>12</b> has a stronger capacity to counteract drug resistance, a lower potential to conflict with other treatments, and less cardiotoxicity than most anthracyclines. It is thereby a promising new agent for the treatment of AML in both monotherapy and combination regimens.</div><div class="NLM_p">Supporting the quest for new topo II inhibitors, the emphasis of this review focused on the elucidation of possible strategies, such as scaffold hopping, molecular hybridization, bioisosteric replacement, conformational restriction, and so forth for the design of topo II inhibitors. Meanwhile, the SAR profiles and binding patterns of representative compounds were also described to explore detailed covalent and/or noncovalent interactions (e.g. H-bonds, hydrophobic forces, electrostatic attractions, ÏâÏ stacking contacts), which may offer inspiration for discovering more potent topo II inhibitors.</div><div class="NLM_p">For more potent topo II inhibitors to be discovered, selection of proper hits or leads is particularly important. To this end, a library of pharmacophoric entities that have been shown to possess topo II inhibition and/or antiproliferative profiles, including but not limited to Î±-terpyridine, naphthalimide, 2-phenylnaphthalene, 1,3,4-thiadiazole, benzimidazole, pyrrolo[2,3-<i>b</i>]pyrazine motifs as well as the naturally available DMEP, 1,4- or 1,2-naphthoquinones, pentacyclic triterpenoids, ellipticine, xanthones, and so forth in conjunction with various medicinal chemistry approaches can be reasonably utilized to generate new chemotypes with more beneficial efficacies and fewer adverse effects. There is no doubt that metal-based inorganic complexes are also of primary relevance, identifying potent topo II-directed antineoplastic metallodrugs.</div><div class="NLM_p last">Novel topo II-targeting compounds, whether catalytic inhibitors or poisons, are still urgently needed for optimal outcomes in cancer therapy. It should also be noted that topo IIÎ± inhibitors with lower toxicity and a broader anticancer spectrum are actually more desirable compared with topo II-mediated DNA poisons, which might be correlated with undesirable side effects. Nevertheless, topo IIÎ± inhibitors are also toxic to normal cells. In this respect, the research of topo II inhibitor-tethered drug delivery vehicles through installation of tumor-targeting conjugates or attachments has been the subject of extensive research.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01202" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76087" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76087" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong-Tang Zheng</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Animal Models and Human Disease Mechanisms of the Chinese
Academy of Science and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cfb5a7aaa1a8b6bb8fa2aea6a3e1a4a6b5e1b5ace1aca1"><span class="__cf_email__" data-cfemail="8cf6e4e9e2ebf5f8cce1ede5e0a2e7e5f6a2f6efa2efe2">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xun Li</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Chemical Biology (Ministry of Education), School of
Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Jiânan, Shandong, P. R. China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5582-8628" title="Orcid link">http://orcid.org/0000-0002-5582-8628</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3c48564950440e0c0c087c4f584912595849125f52"><span class="__cf_email__" data-cfemail="57233d223b2f656767631724332279323322793439">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Hu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Microbial Technology, School of Life Science, Shandong University, 27 South Shanda Road, 250100 Jiânan, Shandong, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xu-Sheng Huang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Animal Models and Human Disease Mechanisms of the Chinese
Academy of Science and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ji-Feng Wu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Criminal Science and Technology, Jiânan
Public Security Bureau, 21 South QiliShan Road, 250000 Jiânan, Shandong, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Yang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Chemical Biology (Ministry of Education), School of
Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Jiânan, Shandong, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yue-Mao Shen</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Chemical Biology (Ministry of Education), School of
Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Jiânan, Shandong, P. R. China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3881-0135" title="Orcid link">http://orcid.org/0000-0002-3881-0135</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhi-Yu Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, Philadelphia
College of Pharmacy, Philadelphia, Pennsylvania 19104, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.H. and X.-S.H. contribute equally to this manuscript. All figures illustrating binding patterns were generated by Sylbyl and displayed with PyMol (www.pymol.org).</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Wei Hu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3491-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wei Hu</b> obtained his Ph.D. degree in microbial sciences from Shandong University, China, in 2004. He is now a professor at the School of Life Science, Shandong University. His research interests involve the discovery of novel molecules with antitumor and antibacterial properties.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Xu-Sheng Huang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3496-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xu-Sheng Huang</b> obtained his bachelorâs degree of Pharmacy at Gannan Medical University in 2015. He is now a Ph.D. student at the University of Chinese Academy of Sciences. His research interests involve antiviral agents and molecular immunopharmacology.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Ji-Feng Wu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3501-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ji-Feng Wu</b> obtained his M.Sc. degree in Analytical Chemistry from Shandong University, China, in 2006. His research interests involve the determination of bioactive components from naturally available products.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Liang Yang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3506-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Liang Yang</b> obtained his B.Sc. degree in pharmaceutical science from Jiânan University, China, in 2015. He is now an M.S. candidate at the College of Pharmacy, Shandong University. His research interests involve the design and synthesis of small molecules with antitumor and antiviral properties.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Yong-Tang Zheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3511-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yong-Tang Zheng</b> obtained his M.D. degree at Jiangxi Medical College in 1983 and Ph.D. at Kunming Institute of Zoology, Chinese Academy of Sciences, in 1997. He is now a professor at the Kunming Institute of Zoology, Chinese Academy of Sciences. His research interests include antiviral agents, molecular immunopharmacology, and primate models.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Yue-Mao Shen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3516-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yue-Mao Shen</b> obtained his Ph.D. degree at Kunming Institute of Botany, Chinese Academy of Sciences, China, in 1999. He has awarded the Distinguished Young Scholars of China and is now a professor at the College of Pharmacy, Shandong University. His research interests involve the discovery and biosynthesis of novel microbial natural products.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Zhi-Yu Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3521-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhi-Yu Li</b> obtained his Ph.D. degree at the College of Pharmacy, University of Maryland, USA, in 1999. He is now an associate professor at the University of the Sciences in Philadelphia. His research interests involve the evaluation of novel molecules with antitumor properties.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Xun Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=BIO-d7e3526-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xun Li</b> obtained her M.Sc. degree at Shandong University in 2001 and Ph.D. at Tianjing University, China, in 2004. She then worked for the College of Pharmacy, Shandong University as a senior associate professor to date. From 2007 to 2008, she worked as a visiting scholar at Tokyo University, Japan, funded by the Japan Medical Association. From 2012 to 2013, she further worked as a visiting scholar in the Department of Chemistry, Texas A&M University, USA. Her research interests include rational design, synthesis, and evaluation of bioactive molecules with antitumor, antiviral, and antibacterial agents.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21347" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21347" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Authors are thankful for the financial support from the Natural Science Foundation of Shandong Province (No. ZR2018MH042 to X.L.), the Key Research and Development Programs of Shandong Province (No. 2016GSF201175 to X.L.; No. 2017CXGC1401 to X.Y.L.; No. 2015ZDJS04001 to F.S.W.), the Fundamental Research Funds for the Central Universitiesâ âCACHSR for ChinaâAustraliaâ (No. 2018GJ07 to X.L.), the National Natural Science Foundation of China (No. 31370110 to W.H.), and the Rolling program of âChangJiang Scholars and Innovative Research Team in Universityâ (No. IRT_17R68 to Y.M.S.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADR</td><td class="NLM_def"><p class="first last">adriamycin</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">CA</td><td class="NLM_def"><p class="first last">carbonic anhydrase</p></td></tr><tr><td class="NLM_term">CPT</td><td class="NLM_def"><p class="first last">camptothecin</p></td></tr><tr><td class="NLM_term">CPT-11</td><td class="NLM_def"><p class="first last">irinotecan</p></td></tr><tr><td class="NLM_term">CuAAC</td><td class="NLM_def"><p class="first last">copper(I)-catalyzed azideâalkyne cycloaddition</p></td></tr><tr><td class="NLM_term">DMEP</td><td class="NLM_def"><p class="first last">4â²- demethylepipodophyllotoxin</p></td></tr><tr><td class="NLM_term">DSBs</td><td class="NLM_def"><p class="first last">double-strand breaks</p></td></tr><tr><td class="NLM_term">DTC</td><td class="NLM_def"><p class="first last">dithiocarbamate</p></td></tr><tr><td class="NLM_term">EPT</td><td class="NLM_def"><p class="first last">ellipticine</p></td></tr><tr><td class="NLM_term">EVO</td><td class="NLM_def"><p class="first last">Evodiamine</p></td></tr><tr><td class="NLM_term">HAP</td><td class="NLM_def"><p class="first last">hypoxia-activated prodrug</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">MDS</td><td class="NLM_def"><p class="first last">myelodysplastic syndrome</p></td></tr><tr><td class="NLM_term">MTZ</td><td class="NLM_def"><p class="first last">mitoxantrone</p></td></tr><tr><td class="NLM_term">9-NC</td><td class="NLM_def"><p class="first last">rubitecan</p></td></tr><tr><td class="NLM_term">NCI</td><td class="NLM_def"><p class="first last">National Cancer Institute</p></td></tr><tr><td class="NLM_term">OPT</td><td class="NLM_def"><p class="first last">10-hydroxy camptothecin</p></td></tr><tr><td class="NLM_term">PTS</td><td class="NLM_def"><p class="first last">polyamine transport system</p></td></tr><tr><td class="NLM_term">RR</td><td class="NLM_def"><p class="first last">ribonucleotide reductase</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">SI</td><td class="NLM_def"><p class="first last">selective index</p></td></tr><tr><td class="NLM_term">STS</td><td class="NLM_def"><p class="first last">soft tissue sarcoma</p></td></tr><tr><td class="NLM_term">TDP1</td><td class="NLM_def"><p class="first last">tyrosyl-DNA phosphodiesterase 1</p></td></tr><tr><td class="NLM_term">Topo</td><td class="NLM_def"><p class="first last">topoisomerase</p></td></tr><tr><td class="NLM_term">TSC</td><td class="NLM_def"><p class="first last">thiosemicarbazide</p></td></tr><tr><td class="NLM_term">WHD</td><td class="NLM_def"><p class="first last">winged helix domain.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 125 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, D.</span></span> <span> </span><span class="NLM_article-title">Global cancer transitions according to the Human Development Index (2008â2030): a population-based study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">790</span>â <span class="NLM_lpage">801</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(12)70211-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS1470-2045%2812%2970211-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=22658655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A280%3ADC%252BC38notlaktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=790-801&author=F.+Brayauthor=A.+Jemalauthor=N.+Greyauthor=J.+Ferlayauthor=D.+Forman&title=Global+cancer+transitions+according+to+the+Human+Development+Index+%282008%E2%80%932030%29%3A+a+population-based+study&doi=10.1016%2FS1470-2045%2812%2970211-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer transitions according to the Human Development Index (2008-2030): a population-based study</span></div><div class="casAuthors">Bray Freddie; Jemal Ahmedin; Grey Nathan; Ferlay Jacques; Forman David</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">790-801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cancer is set to become a major cause of morbidity and mortality in the coming decades in every region of the world.  We aimed to assess the changing patterns of cancer according to varying levels of human development.  METHODS:  We used four levels (low, medium, high, and very high) of the Human Development Index (HDI), a composite indicator of life expectancy, education, and gross domestic product per head, to highlight cancer-specific patterns in 2008 (on the basis of GLOBOCAN estimates) and trends 1988-2002 (on the basis of the series in Cancer Incidence in Five Continents), and to produce future burden scenario for 2030 according to projected demographic changes alone and trends-based changes for selected cancer sites.  FINDINGS:  In the highest HDI regions in 2008, cancers of the female breast, lung, colorectum, and prostate accounted for half the overall cancer burden, whereas in medium HDI regions, cancers of the oesophagus, stomach, and liver were also common, and together these seven cancers comprised 62% of the total cancer burden in medium to very high HDI areas.  In low HDI regions, cervical cancer was more common than both breast cancer and liver cancer.  Nine different cancers were the most commonly diagnosed in men across 184 countries, with cancers of the prostate, lung, and liver being the most common.  Breast and cervical cancers were the most common in women.  In medium HDI and high HDI settings, decreases in cervical and stomach cancer incidence seem to be offset by increases in the incidence of cancers of the female breast, prostate, and colorectum.  If the cancer-specific and sex-specific trends estimated in this study continue, we predict an increase in the incidence of all-cancer cases from 12Â·7 million new cases in 2008 to 22Â·2 million by 2030.  INTERPRETATION:  Our findings suggest that rapid societal and economic transition in many countries means that any reductions in infection-related cancers are offset by an increasing number of new cases that are more associated with reproductive, dietary, and hormonal factors.  Targeted interventions can lead to a decrease in the projected increases in cancer burden through effective primary prevention strategies, alongside the implementation of vaccination, early detection, and effective treatment programmes.  FUNDING:  None.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4RsIpOg2j3kNoizSOkG_FfW6udTcc2eaoMhKU8bvqIrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38notlaktA%253D%253D&md5=e4d8ab5b9b8c2e6bd1387ceaf9458f35</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970211-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970211-5%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DGrey%26aufirst%3DN.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DForman%26aufirst%3DD.%26atitle%3DGlobal%2520cancer%2520transitions%2520according%2520to%2520the%2520Human%2520Development%2520Index%2520%25282008%25E2%2580%25932030%2529%253A%2520a%2520population-based%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D790%26epage%3D801%26doi%3D10.1016%2FS1470-2045%2812%2970211-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-methyl-10-hydroxyhomocamptothecins with 1,2,3-triazole moiety as potent topoisomerase I inhibitors</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">398</span>â <span class="NLM_lpage">403</span>, <span class="refDoi">Â DOI: 10.1111/cbdd.12767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1111%2Fcbdd.12767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27062430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt1Oiurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2016&pages=398-403&author=X.+Xuauthor=Y.+Wuauthor=W.+Liuauthor=C.+Shengauthor=J.+Yaoauthor=G.+Dongauthor=K.+Fangauthor=J.+Liauthor=Z.+Yuauthor=X.+Minauthor=H.+Zhangauthor=Z.+Miaoauthor=W.+Zhang&title=Discovery+of+7-methyl-10-hydroxyhomocamptothecins+with+1%2C2%2C3-triazole+moiety+as+potent+topoisomerase+I+inhibitors&doi=10.1111%2Fcbdd.12767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-Methyl-10-Hydroxyhomocamptothecins with 1,2,3-Triazole Moiety as Potent Topoisomerase I Inhibitors</span></div><div class="casAuthors">Xu, Xiguo; Wu, Yuelin; Liu, Wenfeng; Sheng, Chuanquan; Yao, Jianzhong; Dong, Guoqiang; Fang, Kun; Li, Jin; Yu, Zhiliang; Min, Xiao; Zhang, Huojun; Miao, Zhenyuan; Zhang, Wannian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">398-403</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Homocamptothecin is emerging as an important topoisomerase I inhibitor originating in natural product camptothecin.  We report the modifications and SAR of homocamptothecin on position C10 to develop potent topoisomerase I inhibitors for anticancer drug discovery.  Based on click chem., twenty-one 1,2,3-triazole-substituted homocamptothecin derivs. were readily synthesized in two steps.  For A549, cycloalkyl- and alkyl-substituted compds. 6j, 6l, and 6o revealed highly antiproliferative inhibitory activities with IC50 value of 30, 30, and 50 nm, resp.  In addn., cyclopropyl 6j exhibited greater Topo I inhibitory activity than 20(S)-Camptothecin, which indicated suitability for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplUX2aW_CMILVg90H21EOLACvtfcHk0li67XGfPWD38A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt1Oiurc%253D&md5=9564084132e83d833dc4cf3c71a6723e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12767%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25207-methyl-10-hydroxyhomocamptothecins%2520with%25201%252C2%252C3-triazole%2520moiety%2520as%2520potent%2520topoisomerase%2520I%2520inhibitors%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2016%26volume%3D88%26spage%3D398%26epage%3D403%26doi%3D10.1111%2Fcbdd.12767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Cellular roles of DNA topoisomerases: A molecular perspective</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">430</span>â <span class="NLM_lpage">440</span>, <span class="refDoi">Â DOI: 10.1038/nrm831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2Fnrm831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=12042765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=430-440&author=J.+C.+Wang&title=Cellular+roles+of+DNA+topoisomerases%3A+A+molecular+perspective&doi=10.1038%2Fnrm831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular roles of DNA topoisomerases: a molecular perspective</span></div><div class="casAuthors">Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the magicians of the DNA world , by allowing DNA strands or double helixes to pass through each other, they can solve all of the topol. problems of DNA in replication, transcription and other cellular transactions.  Extensive biochem. and structural studies over the past three decades have provided mol. models of how the various subfamilies of DNA topoisomerase manipulate DNA.  In this review, the cellular roles of these enzymes are examd. from a mol. point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ptPGi1NWFLVg90H21EOLACvtfcHk0li67XGfPWD38A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D&md5=5b9641a6d78a019ebad9307c854a7f7e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm831%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCellular%2520roles%2520of%2520DNA%2520topoisomerases%253A%2520A%2520molecular%2520perspective%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fnrm831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II and its growing repertoire of biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">327</span>â <span class="NLM_lpage">333</span>, <span class="refDoi">Â DOI: 10.1038/nrc2608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2Fnrc2608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=19377505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=327-333&author=J.+L.+Nitiss&title=DNA+topoisomerase+II+and+its+growing+repertoire+of+biological+functions&doi=10.1038%2Fnrc2608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II and its growing repertoire of biological functions</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are enzymes that disentangle the topol. problems that arise in double-stranded DNA.  Many of these can be solved by the generation of either DNA single- or double-strand breaks.  However, where there is a clear requirement to alter DNA topol. by introducing transient double-strand breaks, only DNA topoisomerase II (I) can carry out this reaction.  Extensive biochem. and structural studies have provided detailed models of how I alters DNA structure, and recent mol. studies have greatly expanded knowledge of the biol. contexts in which I functions, such as DNA replication, transcription, and chromosome segregation, processes that are essential for preventing tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAj0wiBApAc7Vg90H21EOLACvtfcHk0lhmpMlmlJNPEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D&md5=4be33ccf2701425ef3933b894b31e7fd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2608%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520topoisomerase%2520II%2520and%2520its%2520growing%2520repertoire%2520of%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D327%26epage%3D333%26doi%3D10.1038%2Fnrc2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2894</span>â <span class="NLM_lpage">2902</span>, <span class="refDoi">Â DOI: 10.1021/cr900097c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900097c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFals7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2894-2902&author=Y.+Pommier&title=DNA+topoisomerase+I+inhibitors%3A+chemistry%2C+biology%2C+and+interfacial+inhibition&doi=10.1021%2Fcr900097c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition</span></div><div class="casAuthors">Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2894-2902</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on DNA topoisomerase I inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8qSNXYdDat7Vg90H21EOLACvtfcHk0lhmpMlmlJNPEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFals7o%253D&md5=438bcf21b446a6b87634dd362d9467e4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fcr900097c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900097c%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DDNA%2520topoisomerase%2520I%2520inhibitors%253A%2520chemistry%252C%2520biology%252C%2520and%2520interfacial%2520inhibition%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2894%26epage%3D2902%26doi%3D10.1021%2Fcr900097c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vann, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedgeman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golan-Goldhirsh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Effects of olive metabolites on DNA cleavage mediated by human type II topoisomerases</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4531</span>â <span class="NLM_lpage">4541</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.5b00162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2is7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=4531-4541&author=K.+R.+Vannauthor=C.+A.+Sedgemanauthor=J.+Gopasauthor=A.+Golan-Goldhirshauthor=N.+Osheroff&title=Effects+of+olive+metabolites+on+DNA+cleavage+mediated+by+human+type+II+topoisomerases&doi=10.1021%2Facs.biochem.5b00162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases</span></div><div class="casAuthors">Vann, Kendra R.; Sedgeman, Carl A.; Gopas, Jacob; Golan-Goldhirsh, Avi; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4531-4541</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several naturally occurring dietary polyphenols with chemopreventive or anticancer properties are topoisomerase II poisons.  To identify addnl. phytochems. that enhance topoisomerase II-mediated DNA cleavage, a library of 341 Mediterranean plant exts. was screened for activity against human topoisomerase IIÎ±.  An ext. from Phillyrea latifolia L., a member of the olive tree family, displayed high activity against the human enzyme.  On the basis of previous metabolomics studies, we identified several polyphenols (hydroxytyrosol, oleuropein, verbascoside, tyrosol, and caffeic acid) as potential candidates for topoisomerase II poisons.  Of these, hydroxytyrosol, oleuropein, and verbascoside enhanced topoisomerase II-mediated DNA cleavage.  The potency of these olive metabolites increased 10-100-fold in the presence of an oxidant.  Hydroxytyrosol, oleuropein, and verbascoside displayed hallmark characteristics of covalent topoisomerase II poisons.  (1) The activity of the metabolites was abrogated by a reducing agent.  (2) Compds. inhibited topoisomerase II activity when they were incubated with the enzyme prior to the addn. of DNA.  (3) Compds. were unable to poison a topoisomerase IIÎ± construct that lacked the N-terminal domain.  Because hydroxytyrosol, oleuropein, and verbascoside are broadly distributed across the olive family, exts. from the leaves, bark, and fruit of 11 olive tree species were tested for activity against human topoisomerase IIÎ±.  Several of the exts. enhanced enzyme-mediated DNA cleavage.  Finally, a com. olive leaf supplement and extra virgin olive oils pressed from a variety of Olea europea subspecies enhanced DNA cleavage mediated by topoisomerase IIÎ±.  Thus, olive metabolites appear to act as topoisomerase II poisons in complex formulations intended for human dietary consumption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxFrk851aHGbVg90H21EOLACvtfcHk0lhmpMlmlJNPEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2is7nN&md5=f440917b0a12e90e1d44d77f381a3b45</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00162%26sid%3Dliteratum%253Aachs%26aulast%3DVann%26aufirst%3DK.%2BR.%26aulast%3DSedgeman%26aufirst%3DC.%2BA.%26aulast%3DGopas%26aufirst%3DJ.%26aulast%3DGolan-Goldhirsh%26aufirst%3DA.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DEffects%2520of%2520olive%2520metabolites%2520on%2520DNA%2520cleavage%2520mediated%2520by%2520human%2520type%2520II%2520topoisomerases%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D4531%26epage%3D4541%26doi%3D10.1021%2Facs.biochem.5b00162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA topoisomerase II in cancer chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">338</span>â <span class="NLM_lpage">350</span>, <span class="refDoi">Â DOI: 10.1038/nrc2607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2Fnrc2607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=19377506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=338-350&author=J.+L.+Nitiss&title=Targeting+DNA+topoisomerase+II+in+cancer+chemotherapy&doi=10.1038%2Fnrc2607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA topoisomerase II in cancer chemotherapy</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">338-350</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent mol. studies have expanded the biol. contexts in which topoisomerase II (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation.  Although the biol. functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy.  The mol. tools that have allowed an understanding of the biol. functions of TOP2 are also being applied to understanding the details of drug action.  These studies promise refined targeting of TOP2 as an effective anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7Nq6nIe1RbVg90H21EOLACvtfcHk0liNqGIUSMBOSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D&md5=a787de602687580188cda6a2af7b6a07</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2607%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DTargeting%2520DNA%2520topoisomerase%2520II%2520in%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D338%26epage%3D350%26doi%3D10.1038%2Fnrc2607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escargueil, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skladanowski, A.</span></span> <span> </span><span class="NLM_article-title">Catalytic topoisomerase II inhibitors in cancer therapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1016/S0163-7258(03)00058-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS0163-7258%2803%2900058-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=12888111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=167-181&author=A.+K.+Larsenauthor=A.+E.+Escargueilauthor=A.+Skladanowski&title=Catalytic+topoisomerase+II+inhibitors+in+cancer+therapy&doi=10.1016%2FS0163-7258%2803%2900058-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic topoisomerase II inhibitors in cancer therapy</span></div><div class="casAuthors">Larsen, Annette K.; Escargueil, Alexandre E.; Skladanowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The nuclear enzyme DNA topoisomerase II is a major target for antineoplastic agents.  All topoisomerase II-directed agents are able to interfere with at least one step of the catalytic cycle.  Agents able to stabilize the covalent DNA topoisomerase II complex (also known as the cleavable complex) are traditionally called topoisomerase II poisons, while agents acting on any of the other steps in the catalytic cycle are called catalytic inhibitors.  Thus, catalytic topoisomerase II inhibitors are a heterogeneous group of compds. that might interfere with the binding between DNA and topoisomerase II (aclarubicin and suramin), stabilize noncovalent DNA topoisomerase II complexes (merbarone, ICRF-187, and structurally related bisdioxopiperazine derivs.), or inhibit ATP binding (novobiocin).  Some, such as fostriecin, may also have alternative biol. targets.  Whereas topoisomerase II poisons are used solely for their antitumor activities, catalytic inhibitors are utilized for a variety of reasons, including their activity as antineoplastic agents (aclarubicin and MST-16), cardioprotectors (ICRF-187), or modulators in order to increase the efficacy of other agents (suramin and novobiocin).  In this review, the mechanism and biol. activity of different catalytic inhibitors is described, with emphasis on therapeutically used compds.  We will then discuss future development and applications of this interesting class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGote2bOTWP17bVg90H21EOLACvtfcHk0liNqGIUSMBOSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D&md5=4207fb899e2b98345f97e91983514913</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900058-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900058-5%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DEscargueil%26aufirst%3DA.%2BE.%26aulast%3DSkladanowski%26aufirst%3DA.%26atitle%3DCatalytic%2520topoisomerase%2520II%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26spage%3D167%26epage%3D181%26doi%3D10.1016%2FS0163-7258%2803%2900058-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoniou-Kourounioti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimmack, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, A. C.</span></span> <span> </span><span class="NLM_article-title">The Î± isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4414</span>â <span class="NLM_lpage">4426</span>, <span class="refDoi">Â DOI: 10.1093/nar/gku076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1093%2Fnar%2Fgku076" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=4414-4426&author=C.+J.+Farrauthor=M.+Antoniou-Kourouniotiauthor=M.+L.+Mimmackauthor=A.+Volkovauthor=A.+C.+Porter&title=The+%CE%B1+isoform+of+topoisomerase+II+is+required+for+hypercompaction+of+mitotic+chromosomes+in+human+cells&doi=10.1093%2Fnar%2Fgku076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgku076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgku076%26sid%3Dliteratum%253Aachs%26aulast%3DFarr%26aufirst%3DC.%2BJ.%26aulast%3DAntoniou-Kourounioti%26aufirst%3DM.%26aulast%3DMimmack%26aufirst%3DM.%2BL.%26aulast%3DVolkov%26aufirst%3DA.%26aulast%3DPorter%26aufirst%3DA.%2BC.%26atitle%3DThe%2520%25CE%25B1%2520isoform%2520of%2520topoisomerase%2520II%2520is%2520required%2520for%2520hypercompaction%2520of%2520mitotic%2520chromosomes%2520in%2520human%2520cells%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3D4414%26epage%3D4426%26doi%3D10.1093%2Fnar%2Fgku076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikoletopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deogracias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakurela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirbelauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoerner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boege, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barde, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼beler, D.</span></span> <span> </span><span class="NLM_article-title">Target genes of topoisomerase IIÎ² regulate neuronal survival and are defined by their chromatin state</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">E934</span>â <span class="NLM_lpage">943</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1119798109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.1119798109" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E934-943&author=V.+K.+Tiwariauthor=L.+Burgerauthor=V.+Nikoletopoulouauthor=R.+Deograciasauthor=S.+Thakurelaauthor=C.+Wirbelauerauthor=J.+Kautauthor=R.+Terranovaauthor=L.+Hoernerauthor=C.+Mielkeauthor=F.+Boegeauthor=R.+Murrauthor=A.+H.+Petersauthor=Y.+A.+Bardeauthor=D.+Sch%C3%BCbeler&title=Target+genes+of+topoisomerase+II%CE%B2+regulate+neuronal+survival+and+are+defined+by+their+chromatin+state&doi=10.1073%2Fpnas.1119798109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1119798109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1119798109%26sid%3Dliteratum%253Aachs%26aulast%3DTiwari%26aufirst%3DV.%2BK.%26aulast%3DBurger%26aufirst%3DL.%26aulast%3DNikoletopoulou%26aufirst%3DV.%26aulast%3DDeogracias%26aufirst%3DR.%26aulast%3DThakurela%26aufirst%3DS.%26aulast%3DWirbelauer%26aufirst%3DC.%26aulast%3DKaut%26aufirst%3DJ.%26aulast%3DTerranova%26aufirst%3DR.%26aulast%3DHoerner%26aufirst%3DL.%26aulast%3DMielke%26aufirst%3DC.%26aulast%3DBoege%26aufirst%3DF.%26aulast%3DMurr%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DA.%2BH.%26aulast%3DBarde%26aufirst%3DY.%2BA.%26aulast%3DSch%25C3%25BCbeler%26aufirst%3DD.%26atitle%3DTarget%2520genes%2520of%2520topoisomerase%2520II%25CE%25B2%2520regulate%2520neuronal%2520survival%2520and%2520are%2520defined%2520by%2520their%2520chromatin%2520state%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3DE934%26epage%3D943%26doi%3D10.1073%2Fpnas.1119798109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClendon, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">39337</span>â <span class="NLM_lpage">39345</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M503320200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1074%2Fjbc.M503320200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=39337-39345&author=A.+K.+McClendonauthor=A.+C.+Rodriguezauthor=N.+Osheroff&title=Human+topoisomerase+IIalpha+rapidly+relaxes+positively+supercoiled+DNA%3A+implications+for+enzyme+action+ahead+of+replication+forks&doi=10.1074%2Fjbc.M503320200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M503320200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M503320200%26sid%3Dliteratum%253Aachs%26aulast%3DMcClendon%26aufirst%3DA.%2BK.%26aulast%3DRodriguez%26aufirst%3DA.%2BC.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DHuman%2520topoisomerase%2520IIalpha%2520rapidly%2520relaxes%2520positively%2520supercoiled%2520DNA%253A%2520implications%2520for%2520enzyme%2520action%2520ahead%2520of%2520replication%2520forks%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D39337%26epage%3D39345%26doi%3D10.1074%2Fjbc.M503320200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondka, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manville, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidorczuk-Lesthuruge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span> <span> </span><span class="NLM_article-title">Model for MLL translocations in therapy-related leukemia involving topoisomerase IIÎ²-mediated DNA strand breaks and gene proximity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">8989</span>â <span class="NLM_lpage">8994</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1204406109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.1204406109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=22615413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC38XovF2gtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=8989-8994&author=I.+G.+Cowellauthor=Z.+Sondkaauthor=K.+Smithauthor=K.+C.+Leeauthor=C.+M.+Manvilleauthor=M.+Sidorczuk-Lesthurugeauthor=H.+A.+Ranceauthor=K.+Padgetauthor=G.+H.+Jacksonauthor=N.+Adachiauthor=C.+A.+Austin&title=Model+for+MLL+translocations+in+therapy-related+leukemia+involving+topoisomerase+II%CE%B2-mediated+DNA+strand+breaks+and+gene+proximity&doi=10.1073%2Fpnas.1204406109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Model for MLL translocations in therapy-related leukemia involving topoisomerase IIÎ²-mediated DNA strand breaks and gene proximity</span></div><div class="casAuthors">Cowell, Ian G.; Sondka, Zbyslaw; Smith, Kayleigh; Lee, Ka Cheong; Manville, Catriona M.; Sidorczuk-Lesthuruge, Malgorzata; Rance, Holly Ashlene; Padget, Kay; Jackson, Graham Hunter; Adachi, Noritaka; Austin, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8989-8994, S8989/1-S8989/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Topoisomerase poisons such as the epipodophyllotoxin etoposide are widely used effective cytotoxic anticancer agents.  However, they are assocd. with the development of therapy-related acute myeloid leukemias (t-AMLs), which display characteristic balanced chromosome translocations, most often involving the mixed lineage leukemia (MLL) locus at 11q23.  MLL translocation break-points in t-AMLs cluster in a DNase I hypersensitive region, which possesses cryptic promoter activity, implicating transcription as well as topoisomerase II activity in the translocation mechanism.  We find that 2-3% of MLL alleles undergoing transcription do so in dose proximity to one of its recurrent translocation partner genes, AF9 or AF4, consistent with their sharing transcription factories.  We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIÎ², but that topoisomerase IIÎ± and -Î² occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concn. det. specific clustering of MLL translocation breakpoints in t-AML.  We propose a model where DNA double-strand breaks (DSBs) introduced by topoisomerase lip into pairs of genes undergoing transcription within a common transcription factory become stabilized by antitopoisomerase II drugs such as etoposide, providing the opportunity for illegitimate end joining and translocation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriLDB2Aoa_ibVg90H21EOLACvtfcHk0lhkKPB1B0PN7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovF2gtb8%253D&md5=1ad16dec579b37ef08da76e6520e7222</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1204406109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1204406109%26sid%3Dliteratum%253Aachs%26aulast%3DCowell%26aufirst%3DI.%2BG.%26aulast%3DSondka%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DManville%26aufirst%3DC.%2BM.%26aulast%3DSidorczuk-Lesthuruge%26aufirst%3DM.%26aulast%3DRance%26aufirst%3DH.%2BA.%26aulast%3DPadget%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DAdachi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26atitle%3DModel%2520for%2520MLL%2520translocations%2520in%2520therapy-related%2520leukemia%2520involving%2520topoisomerase%2520II%25CE%25B2-mediated%2520DNA%2520strand%2520breaks%2520and%2520gene%2520proximity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D8989%26epage%3D8994%26doi%3D10.1073%2Fpnas.1204406109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendorff, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">The structure of DNA-bound human topoisomerase IIalpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>424</i></span>,  <span class="NLM_fpage">109</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2012.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jmb.2012.07.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2012&pages=109-124&author=T.+J.+Wendorffauthor=B.+H.+Schmidtauthor=P.+Heslopauthor=C.+A.+Austinauthor=J.+M.+Berger&title=The+structure+of+DNA-bound+human+topoisomerase+IIalpha%3A+conformational+mechanisms+for+coordinating+inter-subunit+interactions+with+DNA+cleavage&doi=10.1016%2Fj.jmb.2012.07.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWendorff%26aufirst%3DT.%2BJ.%26aulast%3DSchmidt%26aufirst%3DB.%2BH.%26aulast%3DHeslop%26aufirst%3DP.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520structure%2520of%2520DNA-bound%2520human%2520topoisomerase%2520IIalpha%253A%2520conformational%2520mechanisms%2520for%2520coordinating%2520inter-subunit%2520interactions%2520with%2520DNA%2520cleavage%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D424%26spage%3D109%26epage%3D124%26doi%3D10.1016%2Fj.jmb.2012.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Champoux, J. J.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerases: structure, function, and mechanism</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">369</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1146/annurev.biochem.70.1.369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1146%2Fannurev.biochem.70.1.369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=11395412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=369-413&author=J.+J.+Champoux&title=DNA+topoisomerases%3A+structure%2C+function%2C+and+mechanism&doi=10.1146%2Fannurev.biochem.70.1.369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerases: structure, function, and mechanism</span></div><div class="casAuthors">Champoux, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">369-413</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 196 refs.  DNA topoisomerases solve the topol. problems assocd. with DNA replication, transcription, recombination, and chromatin remodeling by introducing temporary single- or double-strand breaks in the DNA.  In addn., these enzymes fine-tune the steady-state level of DNA supercoiling both to facilitate protein interactions with the DNA and to prevent excessive supercoiling that is deleterious.  In recent years, the crystal structures of a no. of topoisomerase fragments, representing nearly all of the known classes of enzymes, have been solved.  These structures provide remarkable insights into the mechanisms of these enzymes and complement previous conclusions based on biochem. analyses.  Surprisingly, despite little or no sequence homol., both type IA and type IIA topoisomerases from prokaryotes and the type IIA enzymes from eukaryotes share structural folds that appear to reflect functional motifs within crit. regions of the enzymes.  The type IB enzymes are structurally distinct from all other known topoisomerases but are similar to a class of enzymes referred to as tyrosine recombinases.  The structural themes common to all topoisomerases include hinged clamps that open and close to bind DNA, the presence of DNA binding cavities for temporary storage of DNA segments, and the coupling of protein conformational changes to DNA rotation or DNA movement.  For the type II topoisomerases, the binding and hydrolysis of ATP further modulate conformational changes in the enzymes to effect changes in DNA topol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Y4rDyIYy17Vg90H21EOLACvtfcHk0lhkKPB1B0PN7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D&md5=67c3e38eb4fcb85527b33d7077309482</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.369%26sid%3Dliteratum%253Aachs%26aulast%3DChampoux%26aufirst%3DJ.%2BJ.%26atitle%3DDNA%2520topoisomerases%253A%2520structure%252C%2520function%252C%2520and%2520mechanism%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D369%26epage%3D413%26doi%3D10.1146%2Fannurev.biochem.70.1.369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruthenburg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechis, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdine, G. L.</span></span> <span> </span><span class="NLM_article-title">Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">37041</span>â <span class="NLM_lpage">37047</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M506520200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1074%2Fjbc.M506520200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=16100112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=37041-37047&author=H.+Weiauthor=A.+J.+Ruthenburgauthor=S.+K.+Bechisauthor=G.+L.+Verdine&title=Nucleotide-dependent+domain+movement+in+the+ATPase+domain+of+a+human+type+IIA+DNA+topoisomerase&doi=10.1074%2Fjbc.M506520200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide-dependent Domain Movement in the ATPase Domain of a Human Type IIA DNA Topoisomerase</span></div><div class="casAuthors">Wei, Hua; Ruthenburg, Alexander J.; Bechis, Seth K.; Verdine, Gregory L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37041-37047</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topol. state, chromosome segregation, and chromatin condensation.  These diverse physiol. functions are all accomplished through a common mol. mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex (the G-segment) to yield a double-stranded gap through which another duplex (the T-segment) is passed.  The overall process is orchestrated by the opening and closing of mol. "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorg. phosphate.  Here, we present two crystal structures of the ATPase domain of human DNA topoisomerase IIÎ± in different nucleotide-bound states.  Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a mol. gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp657jcFw3OM7Vg90H21EOLACvtfcHk0ljujnHrntGelQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO&md5=e2672f1ac3605c57f10031edcd5c4584</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M506520200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M506520200%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DH.%26aulast%3DRuthenburg%26aufirst%3DA.%2BJ.%26aulast%3DBechis%26aufirst%3DS.%2BK.%26aulast%3DVerdine%26aufirst%3DG.%2BL.%26atitle%3DNucleotide-dependent%2520domain%2520movement%2520in%2520the%2520ATPase%2520domain%2520of%2520a%2520human%2520type%2520IIA%2520DNA%2520topoisomerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D37041%26epage%3D37047%26doi%3D10.1074%2Fjbc.M506520200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">Enhancing protein backbone binding-a fruitful concept for combating drug-resistant HIV</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1778</span>â <span class="NLM_lpage">1802</span>, <span class="refDoi">Â DOI: 10.1002/anie.201102762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fanie.201102762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOru7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=1778-1802&author=A.+K.+Ghoshauthor=D.+D.+Andersonauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Enhancing+protein+backbone+binding-a+fruitful+concept+for+combating+drug-resistant+HIV&doi=10.1002%2Fanie.201102762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing Protein Backbone Binding-A Fruitful Concept for Combating Drug-Resistant HIV</span></div><div class="casAuthors">Ghosh, Arun K.; Anderson, David D.; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1778-1802</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The evolution of drug resistance is one of the most fundamental problems in medicine.  In HIV/AIDS, the rapid emergence of drug-resistant HIV-1 variants is a major obstacle to current treatments.  HIV-1 protease inhibitors are essential components of present antiretroviral therapies.  However, with these protease inhibitors, resistance occurs through viral mutations that alter inhibitor binding, resulting in a loss of efficacy.  This loss of potency has raised serious questions with regard to effective long-term antiretroviral therapy for HIV/AIDS.  In this context, our research has focused on designing inhibitors that form extensive hydrogen-bonding interactions with the enzyme's backbone in the active site.  In doing so, we limit the protease's ability to acquire drug resistance as the geometry of the catalytic site must be conserved to maintain functionality.  In this Review, we examine the underlying principles of enzyme structure that support our backbone-binding concept as an effective means to combat drug resistance and highlight their application in our recent work on antiviral HIV-1 protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UjK1GY9jV7Vg90H21EOLACvtfcHk0ljujnHrntGelQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOru7k%253D&md5=0751c1ccc5d043f76fe53f7470e7b47e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fanie.201102762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201102762%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DAnderson%26aufirst%3DD.%2BD.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DEnhancing%2520protein%2520backbone%2520binding-a%2520fruitful%2520concept%2520for%2520combating%2520drug-resistant%2520HIV%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D1778%26epage%3D1802%26doi%3D10.1002%2Fanie.201102762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Her, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1652</span>â <span class="NLM_lpage">1670</span>, <span class="refDoi">Â DOI: 10.3390/biom5031652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3390%2Fbiom5031652" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1652-1670&author=Y.+Xuauthor=C.+Her&title=Inhibition+of+topoisomerase+%28DNA%29+I+%28TOP1%29%3A+DNA+damage+repair+and+anticancer+therapy&doi=10.3390%2Fbiom5031652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3390%2Fbiom5031652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom5031652%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHer%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520topoisomerase%2520%2528DNA%2529%2520I%2520%2528TOP1%2529%253A%2520DNA%2520damage%2520repair%2520and%2520anticancer%2520therapy%26jtitle%3DBiomolecules%26date%3D2015%26volume%3D5%26spage%3D1652%26epage%3D1670%26doi%3D10.3390%2Fbiom5031652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zubovych, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M. G.</span></span> <span> </span><span class="NLM_article-title">A novel inhibitor of topoisomerase I is selectively toxic for a subset of non-small cell lung cancer cell lines</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-15-0458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1158%2F1535-7163.MCT-15-0458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26668189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsleruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=23-36&author=I.+O.+Zubovychauthor=A.+Sethiauthor=A.+Kulkarniauthor=V.+Tagalauthor=M.+G.+Roth&title=A+novel+inhibitor+of+topoisomerase+I+is+selectively+toxic+for+a+subset+of+non-small+cell+lung+cancer+cell+lines&doi=10.1158%2F1535-7163.MCT-15-0458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines</span></div><div class="casAuthors">Zubovych, Iryna O.; Sethi, Anirudh; Kulkarni, Aditya; Tagal, Vural; Roth, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">SW044248, identified through a screen for chems. that are selectively toxic for non-small cell lung cancer (NSCLC) cell lines, was found to rapidly inhibit macromol. synthesis in sensitive, but not in insensitive, cells.  SW044248 killed approx. 15% of a panel of 74 NSCLC cell lines and was nontoxic to immortalized human bronchial cell lines.  The acute transcriptional response to SW044248 in sensitive HCC4017 cells correlated significantly with inhibitors of topoisomerases and SW044248 inhibited topoisomerase 1 (Top1) but not topoisomerase 2.  SW044248 inhibited Top1 differently from camptothecin and camptothecin did not show the same selective toxicity as SW044248.  Elimination of Top1 by siRNA partially protected cells from SW044248, although removing Top1 was itself eventually toxic.  Cells resistant to SW044248 responded to the compd. by upregulating CDKN1A and siRNA to CDKN1A sensitized those cells to SW044248.  Thus, at least part of the differential sensitivity of NSCLC cells to SW044248 is the ability to upregulate CDKN1A.  Mol Cancer Ther; 15(1); 23-36. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsSkmg18AaYrVg90H21EOLACvtfcHk0lggatMLvk-3iQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsleruw%253D%253D&md5=b6e46a1257e99484d3459611634ab9d8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0458%26sid%3Dliteratum%253Aachs%26aulast%3DZubovych%26aufirst%3DI.%2BO.%26aulast%3DSethi%26aufirst%3DA.%26aulast%3DKulkarni%26aufirst%3DA.%26aulast%3DTagal%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DM.%2BG.%26atitle%3DA%2520novel%2520inhibitor%2520of%2520topoisomerase%2520I%2520is%2520selectively%2520toxic%2520for%2520a%2520subset%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D23%26epage%3D36%26doi%3D10.1158%2F1535-7163.MCT-15-0458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerases and their poisoning by anticancer and antibacterial drugs</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">433</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2010.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.chembiol.2010.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=20534341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslCjsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=421-433&author=Y.+Pommierauthor=E.+Leoauthor=H.+Zhangauthor=C.+Marchand&title=DNA+topoisomerases+and+their+poisoning+by+anticancer+and+antibacterial+drugs&doi=10.1016%2Fj.chembiol.2010.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs</span></div><div class="casAuthors">Pommier, Yves; Leo, Elisabetta; Zhang, Hong-Liang; Marchand, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-433</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the targets of important anticancer and antibacterial drugs.  Camptothecins and novel noncamptothecins in clin. development (indenoisoquinolines and ARC-111) target eukaryotic type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2Î± and Top2Î²) are the targets of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxantrone.  Bacterial type II topoisomerases (gyrase and Topo IV) are the targets of quinolones and aminocoumarin antibiotics.  This review focuses on the mol. and biochem. characteristics of topoisomerases and their inhibitors.  We also discuss the common mechanism of action of topoisomerase poisons by interfacial inhibition and trapping of topoisomerase cleavage complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr6m1st3bchbVg90H21EOLACvtfcHk0lggatMLvk-3iQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslCjsLY%253D&md5=ab00ffa6d0e8bf0c433b154e2a4b484a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DLeo%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarchand%26aufirst%3DC.%26atitle%3DDNA%2520topoisomerases%2520and%2520their%2520poisoning%2520by%2520anticancer%2520and%2520antibacterial%2520drugs%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D421%26epage%3D433%26doi%3D10.1016%2Fj.chembiol.2010.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">459</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1126/science.1204117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1126%2Fscience.1204117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=21778401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2011&pages=459-462&author=C.+C.+Wuauthor=T.+K.+Liauthor=L.+Farhauthor=L.+Y.+Linauthor=T.+S.+Linauthor=Y.+J.+Yuauthor=T.+J.+Yenauthor=C.+W.+Chiangauthor=N.+L.+Chan&title=Structural+basis+of+type+II+topoisomerase+inhibition+by+the+anticancer+drug+etoposide&doi=10.1126%2Fscience.1204117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide</span></div><div class="casAuthors">Wu, Chyuan-Chuan; Li, Tsai-Kun; Farh, Lynn; Lin, Li-Ying; Lin, Te-Sheng; Yu, Yu-Jen; Yen, Tien-Jui; Chiang, Chia-Wang; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">6041</span>),
    <span class="NLM_cas:pages">459-462</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Type II topoisomerases (TOP2s) resolve the topol. problems of DNA by transiently cleaving both strands of a DNA duplex to form a cleavage complex through which another DNA segment can be transported.  Several widely prescribed anticancer drugs increase the population of TOP2 cleavage complex, which leads to TOP2-mediated chromosome DNA breakage and death of cancer cells.  We present the crystal structure of a large fragment of human TOP2Î² complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex.  The interplay between the protein, the DNA, and the drug explains the structure-activity relations of etoposide derivs. and the mol. basis of drug-resistant mutations.  The anal. of protein-drug interactions provides information applicable for developing an isoform-specific TOP2-targeting strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBC6vqPeyB-bVg90H21EOLACvtfcHk0lhG-wTcAP7SYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D&md5=c2eab1b2e9b8a75322b88e76c62c4b74</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.1204117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1204117%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DFarh%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DL.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DT.%2BJ.%26aulast%3DChiang%26aufirst%3DC.%2BW.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520basis%2520of%2520type%2520II%2520topoisomerase%2520inhibition%2520by%2520the%2520anticancer%2520drug%2520etoposide%26jtitle%3DScience%26date%3D2011%26volume%3D333%26spage%3D459%26epage%3D462%26doi%3D10.1126%2Fscience.1204117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">10630</span>â <span class="NLM_lpage">10640</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkt828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1093%2Fnar%2Fgkt828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24038465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2lsbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=10630-10640&author=C.+C.+Wuauthor=Y.+C.+Liauthor=Y.+R.+Wangauthor=T.+K.+Liauthor=N.+L.+Chan&title=On+the+structural+basis+and+design+guidelines+for+type+II+topoisomerase-targeting+anticancer+drugs&doi=10.1093%2Fnar%2Fgkt828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs</span></div><div class="casAuthors">Wu, Chyuan-Chuan; Li, Yi-Ching; Wang, Ying-Ren; Li, Tsai-Kun; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10630-10640</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Type II topoisomerases (Top2s) alter DNA topol. via the formation of an enzyme-DNA adduct termed cleavage complex, which harbors a transient double-strand break in one DNA to allow the passage of another.  Agents targeting human Top2s are clin. active anticancer drugs whose trapping of Top2-mediated DNA breakage effectively induces genome fragmentation and cell death.  To understand the structural basis of this drug action, we previously detd. the structure of human Top2 Î²-isoform forming a cleavage complex with the drug etoposide and DNA, and described the insertion of drug into DNA cleavage site and drug-induced decoupling of catalytic groups.  By developing a post-crystn. drug replacement procedure that simplifies structural characterization of drug-stabilized cleavage complexes, we have extended the anal. toward other structurally distinct drugs, m-AMSA and mitoxantrone.  Besides the expected drug intercalation, a switch in ribose puckering in the 3'-nucleotide of the cleavage site was robustly obsd. in the new structures, representing a new mechanism for trapping the Top2 cleavage complex.  Anal. of drug-binding modes and the conformational landscapes of the drug-binding pockets provide rationalization of the drugs' structural-activity relationships and explain why Top2 mutants exhibit differential effects toward each drug.  Drug design guidelines were proposed to facilitate the development of isoform-specific Top2-targeting anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMHX9ZEqN2nbVg90H21EOLACvtfcHk0lhG-wTcAP7SYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2lsbjJ&md5=7a94c43460176f7a2bcc65406fd28f34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt828%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLi%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DOn%2520the%2520structural%2520basis%2520and%2520design%2520guidelines%2520for%2520type%2520II%2520topoisomerase-targeting%2520anticancer%2520drugs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2013%26volume%3D41%26spage%3D10630%26epage%3D10640%26doi%3D10.1093%2Fnar%2Fgkt828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">11014</span>â <span class="NLM_lpage">11019</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0704002104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.0704002104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=17578914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=11014-11019&author=A.+M.+Azarovaauthor=Y.+L.+Lyuauthor=C.+P.+Linauthor=Y.+C.+Tsaiauthor=J.+Y.+Lauauthor=J.+C.+Wangauthor=L.+F.+Liu&title=Roles+of+DNA+topoisomerase+II+isozymes+in+chemotherapy+and+secondary+malignancies&doi=10.1073%2Fpnas.0704002104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span></div><div class="casAuthors">Azarova, Anna M.; Lyu, Yi Lisa; Lin, Chao-Po; Tsai, Yuan-Chin; Lau, Johnson Yiu-Nam; Wang, James C.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">11014-11019</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clin. use.  However, Top2-based chemotherapy has been assocd. with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients.  This assocn. is suggestive of a link between carcinogenesis and Top2-mediated DNA damage.  We show here that VP-16-induced carcinogenesis involves mainly the Î² rather than the isoenzyme of Top2.  In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is significantly higher in TOP2Î²+ than in skin-specific top2Î²-knockout mice.  Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are Top2Î²-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degrdn. of the Top2Î²-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements.  VP-16 cytotoxicity in transformed cells expressing both Top2 isoenzymes is, however, primarily Top2Î±-dependent.  These results point to the importance of developing Top2-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqEXje8wQTrVg90H21EOLACvtfcHk0ljzaU4edj_OkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D&md5=f10976e9b0dbb918158916036a0349a7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0704002104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0704002104%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DLyu%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DTsai%26aufirst%3DY.%2BC.%26aulast%3DLau%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DRoles%2520of%2520DNA%2520topoisomerase%2520II%2520isozymes%2520in%2520chemotherapy%2520and%2520secondary%2520malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D11014%26epage%3D11019%26doi%3D10.1073%2Fpnas.0704002104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurosawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iiizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, N.</span></span> <span> </span><span class="NLM_article-title">NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">23711</span>â <span class="NLM_lpage">23720</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M803936200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1074%2Fjbc.M803936200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=18596031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWktr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=23711-23720&author=E.+Toyodaauthor=S.+Kagayaauthor=I.+G.+Cowellauthor=A.+Kurosawaauthor=K.+Kamoshitaauthor=K.+Nishikawaauthor=S.+Iiizumiauthor=H.+Koyamaauthor=C.+A.+Austinauthor=N.+Adachi&title=NK314%2C+a+topoisomerase+II+inhibitor+that+specifically+targets+the+alpha+isoform&doi=10.1074%2Fjbc.M803936200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">NK314, a Topoisomerase II Inhibitor That Specifically Targets the Î± Isoform</span></div><div class="casAuthors">Toyoda, Eriko; Kagaya, Shigehide; Cowell, Ian G.; Kurosawa, Aya; Kamoshita, Keiichi; Nishikawa, Kiyohiro; Iiizumi, Susumu; Koyama, Hideki; Austin, Caroline A.; Adachi, Noritaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">23711-23720</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Topoisomerase II (Top2) is a ubiquitous nuclear enzyme that relieves torsional stress in chromosomal DNA during various cellular processes.  Agents that target Top2, involving etoposide, doxorubicin, and mitoxantrone, are among the most effective anticancer drugs used in the clinic.  Mammalian cells possess two genetically distinct Top2 isoforms, both of which are the target of these agents.  Top2Î± is essential for cell proliferation and is highly expressed in vigorously growing cells, whereas Top2Î² is nonessential for growth and has recently been implicated in treatment-assocd. secondary malignancies, highlighting the validity of a Top2Î±-specific drug for future cancer treatment; however, no such agent has been hitherto reported.  Here we show that NK314, a novel synthetic benzo[c]phenanthridine alkaloid, targets Top2Î± and not Top2Î² in vivo.  Unlike other Top2 inhibitors, NK314 induces Top2-DNA complexes and double-strand breaks (DSBs) in an Î± isoform-specific manner.  Heterozygous disruption of the human TOP2Î± gene confers increased NK314 resistance, whereas TOP2Î² homozygous knock-out cells display increased NK314 sensitivity, indicating that the Î± isoform is the cellular target.  We further show that the absence of Top2Î² does not alleviate NK314 hypersensitivity of cells deficient in non-homologous end-joining, a crit. pathway for repairing Top2-mediated DSBs.  Our results indicate that NK314 acts as a Top2Î±-specific poison in mammalian cells, with excellent potential as an efficacious and safe chemotherapeutic agent.  We also suggest that a series of human knock-out cell lines are useful in assessing DNA damage and repair induced by potential topoisomerase-targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoipLdMB1ovO7Vg90H21EOLACvtfcHk0ljzaU4edj_OkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWktr%252FK&md5=ce9e60205b62f04c65e33b31721ad95d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M803936200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M803936200%26sid%3Dliteratum%253Aachs%26aulast%3DToyoda%26aufirst%3DE.%26aulast%3DKagaya%26aufirst%3DS.%26aulast%3DCowell%26aufirst%3DI.%2BG.%26aulast%3DKurosawa%26aufirst%3DA.%26aulast%3DKamoshita%26aufirst%3DK.%26aulast%3DNishikawa%26aufirst%3DK.%26aulast%3DIiizumi%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DH.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DAdachi%26aufirst%3DN.%26atitle%3DNK314%252C%2520a%2520topoisomerase%2520II%2520inhibitor%2520that%2520specifically%2520targets%2520the%2520alpha%2520isoform%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D23711%26epage%3D23720%26doi%3D10.1074%2Fjbc.M803936200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isambert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbouloux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drouin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loadman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capizzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieshaber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumoleau, P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">729</span>â <span class="NLM_lpage">734</span>, <span class="refDoi">Â DOI: 10.1016/j.ejca.2009.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejca.2009.12.005" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=729-734&author=N.+Isambertauthor=M.+Camponeauthor=E.+Bourboulouxauthor=M.+Drouinauthor=A.+Majorauthor=W.+Yinauthor=P.+Loadmanauthor=R.+Capizziauthor=C.+Grieshaberauthor=P.+Fumoleau&title=Evaluation+of+the+safety+of+C-1311+%28SYMADEX%29+administered+in+a+phase+1+dose+escalation+trial+as+a+weekly+infusion+for+3+consecutive+weeks+in+patients+with+advanced+solid+tumours&doi=10.1016%2Fj.ejca.2009.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DIsambert%26aufirst%3DN.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DBourbouloux%26aufirst%3DE.%26aulast%3DDrouin%26aufirst%3DM.%26aulast%3DMajor%26aufirst%3DA.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DLoadman%26aufirst%3DP.%26aulast%3DCapizzi%26aufirst%3DR.%26aulast%3DGrieshaber%26aufirst%3DC.%26aulast%3DFumoleau%26aufirst%3DP.%26atitle%3DEvaluation%2520of%2520the%2520safety%2520of%2520C-1311%2520%2528SYMADEX%2529%2520administered%2520in%2520a%2520phase%25201%2520dose%2520escalation%2520trial%2520as%2520a%2520weekly%2520infusion%2520for%25203%2520consecutive%2520weeks%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D729%26epage%3D734%26doi%3D10.1016%2Fj.ejca.2009.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laskowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SowiÅski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazerski, J.</span></span> <span> </span><span class="NLM_article-title">Intercalation complex of imidazoacridinone C-1311, a potential anticancer drug, with DNA helix d(CGATCG)2: stereostructural studies by 2D NMR spectroscopy</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">653</span>â <span class="NLM_lpage">663</span>, <span class="refDoi">Â DOI: 10.1080/07391102.2015.1049552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1080%2F07391102.2015.1049552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26211888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFals7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=653-663&author=T.+Laskowskiauthor=J.+Czubauthor=P.+Sowi%C5%84skiauthor=J.+Mazerski&title=Intercalation+complex+of+imidazoacridinone+C-1311%2C+a+potential+anticancer+drug%2C+with+DNA+helix+d%28CGATCG%292%3A+stereostructural+studies+by+2D+NMR+spectroscopy&doi=10.1080%2F07391102.2015.1049552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Intercalation complex of imidazoacridinone C-1311, a potential anticancer drug, with DNA helix d(CGATCG)2: stereostructural studies by 2D NMR spectroscopy</span></div><div class="casAuthors">Laskowski, Tomasz; Czub, Jacek; Sowinski, Pawel; Mazerski, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-663</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Imidazoacridinone C-1311 (Symadex) is a powerful antitumor agent, which successfully made its way through the Phase I clin. trials and has been recommended for Phase II few a years ago.  It has been shown exptl. that during the initial stage of its action C-1311 forms a relatively stable intercalation complex with DNA, yet it has shown no base-sequence specificity while binding to DNA.  In this paper, the d(CGATCG)2:C-1311 intercalation complex has been studied by means of two-dimensional NMR spectroscopy, yielding a full assignment of the resonance lines obsd. in 1H NMR spectra.  The observation of the intermol. NOE contacts between C-1311 and DNA allowed locating the ligand between the guanine and adenine moieties.  Formation of a sym. complex was pointed out on the basis of the lack of a second set of the 1H resonances.  The resulting stereostructure of the complex was then improved by means of mol. dynamics, using the CHARMM force field and GROMACS software.  To this end, distance restraints derived from the NOESY cross-peak vols. were applied to the atomistic model of the d(CGATCG)2:C-1311 complex.  Obtained results are in full agreement with biochem. data on the mechanism of action of C-1311, in particular with the previously postulated post-intercalation enzymic activation of the studied drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9pG4gmpCT87Vg90H21EOLACvtfcHk0ljzaU4edj_OkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFals7vF&md5=cfa97e43853f199b51f57dc3f2b68a23</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1080%2F07391102.2015.1049552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2015.1049552%26sid%3Dliteratum%253Aachs%26aulast%3DLaskowski%26aufirst%3DT.%26aulast%3DCzub%26aufirst%3DJ.%26aulast%3DSowi%25C5%2584ski%26aufirst%3DP.%26aulast%3DMazerski%26aufirst%3DJ.%26atitle%3DIntercalation%2520complex%2520of%2520imidazoacridinone%2520C-1311%252C%2520a%2520potential%2520anticancer%2520drug%252C%2520with%2520DNA%2520helix%2520d%2528CGATCG%25292%253A%2520stereostructural%2520studies%2520by%25202D%2520NMR%2520spectroscopy%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2016%26volume%3D34%26spage%3D653%26epage%3D663%26doi%3D10.1080%2F07391102.2015.1049552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimek, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havelange, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derigs, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carella, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1025</span>â <span class="NLM_lpage">1036</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00201-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS1470-2045%2815%2900201-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26234174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OgsrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1025-1036&author=F.+Ravandiauthor=E.+K.+Ritchieauthor=H.+Sayarauthor=J.+E.+Lancetauthor=M.+D.+Craigauthor=N.+Veyauthor=S.+A.+Stricklandauthor=G.+J.+Schillerauthor=E.+Jabbourauthor=H.+P.+Erbaauthor=A.+Pigneuxauthor=H.+A.+Horstauthor=C.+Recherauthor=V.+M.+Klimekauthor=J.+Cortesauthor=G.+J.+Robozauthor=O.+Odenikeauthor=X.+Thomasauthor=V.+Havelangeauthor=J.+Maertensauthor=H.+G.+Derigsauthor=M.+Heuserauthor=L.+Damonauthor=B.+L.+Powellauthor=G.+Gaidanoauthor=A.+M.+Carellaauthor=A.+Weiauthor=D.+Hoggeauthor=A.+R.+Craigauthor=J.+A.+Foxauthor=R.+Wardauthor=J.+A.+Smithauthor=G.+Actonauthor=C.+Mehtaauthor=R.+K.+Stuartauthor=H.+M.+Kantarjian&title=Vosaroxin+plus+cytarabine+versus+placebo+plus+cytarabine+in+patients+with+first+relapsed+or+refractory+acute+myeloid+leukaemia+%28VALOR%29%3A+a+randomised%2C+controlled%2C+double-blind%2C+multinational%2C+phase+3+study&doi=10.1016%2FS1470-2045%2815%2900201-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study</span></div><div class="casAuthors">Ravandi, Farhad; Ritchie, Ellen K.; Sayar, Hamid; Lancet, Jeffrey E.; Craig, Michael D.; Vey, Norbert; Strickland, Stephen A.; Schiller, Gary J.; Jabbour, Elias; Erba, Harry P.; Pigneux, Arnaud; Horst, Heinz-August; Recher, Christian; Klimek, Virginia M.; Cortes, Jorge; Roboz, Gail J.; Odenike, Olatoyosi; Thomas, Xavier; Havelange, Violaine; Maertens, Johan; Derigs, Hans-Gunter; Heuser, Michael; Damon, Lloyd; Powell, Bayard L.; Gaidano, Gianluca; Carella, Angelo-Michele; Wei, Andrew; Hogge, Donna; Craig, Adam R.; Fox, Judith A.; Ward, Renee; Smith, Jennifer A.; Acton, Gary; Mehta, Cyrus; Stuart, Robert K.; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1025-1036</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Safe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukemia.  We investigated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone deriv., plus cytarabine in patients with relapsed or refractory acute myeloid leukemia.  This phase 3, double-blind, placebo-controlled trial was undertaken at 101 international sites.  Eligible patients with acute myeloid leukemia were aged 18 years of age or older and had refractory disease or were in first relapse after one or two cycles of previous induction chemotherapy, including at least one cycle of anthracycline (or anthracenedione) plus cytarabine.  Patients were randomly assigned 1:1 to vosaroxin (90 mg/m2 i.v. on days 1 and 4 in a first cycle; 70 mg/m2 in subsequent cycles) plus cytarabine (1 g/m2 i.v. on days 1-5) or placebo plus cytarabine through a central interactive voice system with a permuted block procedure stratified by disease status, age, and geog. location.  All participants were masked to treatment assignment.  The primary efficacy endpoint was overall survival and the primary safety endpoint was 30-day and 60-day all-cause mortality.  Efficacy analyses were done by intention to treat; safety analyses included all treated patients.  This study is registered with ClinicalTrials.gov, no. NCT01191801.  Between Dec 17, 2010, and Sept 25, 2013, 711 patients were randomly assigned to vosaroxin plus cytarabine (n=356) or placebo plus cytarabine (n=355).  At the final anal., median overall survival was 7Â·5 mo (95% CI 6Â·4-8Â·5) in the vosaroxin plus cytarabine group and 6Â·1 mo (5Â·2-7Â·1) in the placebo plus cytarabine group (hazard ratio 0Â·87, 95% CI 0Â·73-1Â·02; unstratified log-rank p=0Â·061; stratified p=0Â·024).  A higher proportion of patients achieved complete remission in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group (107 [30%] of 356 patients vs 58 [16%] of 355 patients, p<0Â·0001).  Early mortality was similar between treatment groups (30-day: 28 [8%] of 355 patients in the vosaroxin plus cytarabine group vs 23 [7%] of 350 in the placebo plus cytarabine group; 60-day: 70 [20%] vs 68 [19%]).  Treatment-related deaths occurred at any time in 20 (6%) of 355 patients given vosaroxin plus cytarabine and in eight (2%) of 350 patients given placebo plus cytarabine.  Treatment-related serious adverse events occurred in 116 (33%) and 58 (17%) patients in each group, resp.  Grade 3 or worse adverse events that were more frequent in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group included febrile neutropenia (167 [47%] vs 117 [33%]), neutropenia (66 [19%] vs 49 [14%]), stomatitis (54 [15%] vs 10 [3%]), hypokalemia (52 [15%] vs 21 [6%]), bacteremia (43 [12%] vs 16 [5%]), sepsis (42 [12%] vs 18 [5%]), and pneumonia (39 [11%] vs 26 [7%]).  Although there was no significant difference in the primary endpoint between groups, the prespecified secondary anal. stratified by randomization factors suggests that the addn. of vosaroxin to cytarabine might be of clin. benefit to some patients with relapsed or refractory acute myeloid leukemia.Sunesis Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ivy3DpaLubVg90H21EOLACvtfcHk0lgWEzhnVyj4MA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OgsrrP&md5=5287a03ea15d5dc2f9cb44aa8522ef2d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900201-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900201-6%26sid%3Dliteratum%253Aachs%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DRitchie%26aufirst%3DE.%2BK.%26aulast%3DSayar%26aufirst%3DH.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DCraig%26aufirst%3DM.%2BD.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DSchiller%26aufirst%3DG.%2BJ.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DKlimek%26aufirst%3DV.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DHavelange%26aufirst%3DV.%26aulast%3DMaertens%26aufirst%3DJ.%26aulast%3DDerigs%26aufirst%3DH.%2BG.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DPowell%26aufirst%3DB.%2BL.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DCarella%26aufirst%3DA.%2BM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DCraig%26aufirst%3DA.%2BR.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DWard%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DActon%26aufirst%3DG.%26aulast%3DMehta%26aufirst%3DC.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DVosaroxin%2520plus%2520cytarabine%2520versus%2520placebo%2520plus%2520cytarabine%2520in%2520patients%2520with%2520first%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukaemia%2520%2528VALOR%2529%253A%2520a%2520randomised%252C%2520controlled%252C%2520double-blind%252C%2520multinational%252C%2520phase%25203%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1025%26epage%3D1036%26doi%3D10.1016%2FS1470-2045%2815%2900201-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hotinski, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. M.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1395</span>â <span class="NLM_lpage">1402</span>, <span class="refDoi">Â DOI: 10.1517/14656566.2015.1044437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1517%2F14656566.2015.1044437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25958926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFaitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1395-1402&author=A.+K.+Hotinskiauthor=I.+D.+Lewisauthor=D.+M.+Ross&title=Vosaroxin+is+a+novel+topoisomerase-II+inhibitor+with+efficacy+in+relapsed+and+refractory+acute+myeloid+leukaemia&doi=10.1517%2F14656566.2015.1044437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia</span></div><div class="casAuthors">Hotinski, Anya K.; Lewis, Ian D.; Ross, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1395-1402</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Vosaroxin is a first-in-class anti-cancer quinolone that inhibits topoisomerase-II leading to cell cycle arrest and apoptosis.  It has shown efficacy in a range of solid organ and haematopoietic tumors in vitro, and several clin. trials are underway or completed in the field of Acute Myeloid Leukemia (AML).  The treatment of relapsed and refractory AML is a clin. challenge, where long-term survival is rare without allogeneic haematopoietic stem cell transplantation.  Areas covered: We review the data from the published clin. trials of vosaroxin, including the recently presented Phase III VALOR study.  In combination with intermediate dose cytarabine, vosaroxin almost doubled complete response (CR) rates in relapsed and refractory AML compared with cytarabine alone, and prolonged median survival by 1.4 mo.  Expert opinion: Vosaroxin is a promising new agent in the treatment of AML, with the potential to improve CR rates in a high-risk group of patients with relapsed and refractory AML.  However, higher CR rates have been assocd. with higher rates of treatment-related morbidity and mortality, esp. in elderly/unfit patients.  Maximising the potential of vosaroxin will therefore require the identification of patients most likely to benefit from vosaroxin-contg. combination regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolne5lUqdZYbVg90H21EOLACvtfcHk0lgWEzhnVyj4MA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFaitr0%253D&md5=0cfd1fd4a9b8ab22a43c01bf338c117f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1044437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1044437%26sid%3Dliteratum%253Aachs%26aulast%3DHotinski%26aufirst%3DA.%2BK.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DRoss%26aufirst%3DD.%2BM.%26atitle%3DVosaroxin%2520is%2520a%2520novel%2520topoisomerase-II%2520inhibitor%2520with%2520efficacy%2520in%2520relapsed%2520and%2520refractory%2520acute%2520myeloid%2520leukaemia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D1395%26epage%3D1402%26doi%3D10.1517%2F14656566.2015.1044437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin: a novel antineoplastic quinolone</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1223</span>â <span class="NLM_lpage">1233</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2012.699038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1517%2F13543784.2012.699038" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1223-1233&author=J.+A.+Abbasauthor=R.+K.+Stuart&title=Vosaroxin%3A+a+novel+antineoplastic+quinolone&doi=10.1517%2F13543784.2012.699038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.699038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.699038%26sid%3Dliteratum%253Aachs%26aulast%3DAbbas%26aufirst%3DJ.%2BA.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26atitle%3DVosaroxin%253A%2520a%2520novel%2520antineoplastic%2520quinolone%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1223%26epage%3D1233%26doi%3D10.1517%2F13543784.2012.699038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ­rez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirkov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owzar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulkey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamazon, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Undevia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M. J.</span></span> <span> </span><span class="NLM_article-title">A pharmacogenetic study of aldehyde oxidase I in patients treated withXK469</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">129</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1097/FPC.0000000000000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1097%2FFPC.0000000000000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24300566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislyjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=129-132&author=J.+Ram%C3%ADrezauthor=T.+W.+Kimauthor=W.+Liuauthor=J.+L.+Myersauthor=S.+Mirkovauthor=K.+Owzarauthor=D.+Watsonauthor=F.+Mulkeyauthor=E.+R.+Gamazonauthor=W.+Stockauthor=S.+Undeviaauthor=F.+Innocentiauthor=M.+J.+Ratain&title=A+pharmacogenetic+study+of+aldehyde+oxidase+I+in+patients+treated+withXK469&doi=10.1097%2FFPC.0000000000000023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469</span></div><div class="casAuthors">Ramirez, Jacqueline; Kim, Tae Won; Liu, Wanqing; Myers, Jamie L.; Mirkov, Snezana; Owzar, Kouros; Watson, Dorothy; Mulkey, Flora; Gamazon, Eric R.; Stock, Wendy; Undevia, Samir; Innocenti, Federico; Ratain, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">XK469 (NSC 697887) is a selective topoisomerase II Î² inhibitor eliminated mainly by aldehyde oxidase I (AOX1).  We performed a candidate gene study to investigate whether AOX1 genetic variation contributes to interindividual variability in XK469 clearance.  Forty-one AOX1 single nucleotide polymorphisms (SNPs) and seven liver expression quant. trait loci were genotyped in White patients with advanced refractory solid tumors (n=59) and leukemia (n=33).  We found a significant decrease in clearance (Ï=-0.32, P=0.003) in solid tumor patients with rs10931910, although it failed to replicate in the leukemia cohort (Ï=0.18, P=0.20).  Four other AOX1 SNPs were assocd. with clearance (P=0.01-0.02) in only one of the two cohorts.  Our study provides a starting point for future investigations on the functionality of AOX1 SNPs.  However, variability in XK469 clearance cannot be attributed to polymorphisms in AOX1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqg-LaRfV57Vg90H21EOLACvtfcHk0ljg0Kn6sugsiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislyjtQ%253D%253D&md5=2c77da326aa1c796ea297849671bdea7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2FFPC.0000000000000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0000000000000023%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25ADrez%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMyers%26aufirst%3DJ.%2BL.%26aulast%3DMirkov%26aufirst%3DS.%26aulast%3DOwzar%26aufirst%3DK.%26aulast%3DWatson%26aufirst%3DD.%26aulast%3DMulkey%26aufirst%3DF.%26aulast%3DGamazon%26aufirst%3DE.%2BR.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DUndevia%26aufirst%3DS.%26aulast%3DInnocenti%26aufirst%3DF.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26atitle%3DA%2520pharmacogenetic%2520study%2520of%2520aldehyde%2520oxidase%2520I%2520in%2520patients%2520treated%2520withXK469%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2014%26volume%3D24%26spage%3D129%26epage%3D132%26doi%3D10.1097%2FFPC.0000000000000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouw, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">243</span>â <span class="NLM_lpage">252</span>, <span class="refDoi">Â DOI: 10.1007/s10637-016-0333-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs10637-016-0333-z" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=243-252&author=S.+Guptaauthor=L.+Gouwauthor=J.+Wrightauthor=S.+Chawlaauthor=D.+Pittauthor=M.+Wadeauthor=K.+Boucherauthor=S.+Sharma&title=Phase+II+study+of+amrubicin+%28SM-5887%29%2C+a+synthetic+9-aminoanthracycline%2C+as+first+line+treatment+in+patients+with+metastatic+or+unresectable+soft+tissue+sarcoma%3A+durable+response+in+myxoid+liposarcoma+with+TLS-CHOP+translocation&doi=10.1007%2Fs10637-016-0333-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0333-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0333-z%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGouw%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DChawla%26aufirst%3DS.%26aulast%3DPitt%26aufirst%3DD.%26aulast%3DWade%26aufirst%3DM.%26aulast%3DBoucher%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DPhase%2520II%2520study%2520of%2520amrubicin%2520%2528SM-5887%2529%252C%2520a%2520synthetic%25209-aminoanthracycline%252C%2520as%2520first%2520line%2520treatment%2520in%2520patients%2520with%2520metastatic%2520or%2520unresectable%2520soft%2520tissue%2520sarcoma%253A%2520durable%2520response%2520in%2520myxoid%2520liposarcoma%2520with%2520TLS-CHOP%2520translocation%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26spage%3D243%26epage%3D252%26doi%3D10.1007%2Fs10637-016-0333-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokosza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, D. G.</span></span> <span> </span><span class="NLM_article-title">Design, antiviral and cytostatic properties of isoxazolidine-containing amonafideanalogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3135</span>â <span class="NLM_lpage">3146</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.04.079" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3135-3146&author=K.+Kokoszaauthor=G.+Andreiauthor=D.+Scholsauthor=R.+Snoeckauthor=D.+G.+Piotrowska&title=Design%2C+antiviral+and+cytostatic+properties+of+isoxazolidine-containing+amonafideanalogues&doi=10.1016%2Fj.bmc.2015.04.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DKokosza%26aufirst%3DK.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DPiotrowska%26aufirst%3DD.%2BG.%26atitle%3DDesign%252C%2520antiviral%2520and%2520cytostatic%2520properties%2520of%2520isoxazolidine-containing%2520amonafideanalogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3135%26epage%3D3146%26doi%3D10.1016%2Fj.bmc.2015.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warzocha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egyed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span> <span> </span><span class="NLM_article-title">Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1252</span>â <span class="NLM_lpage">1257</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2014.57.0952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1200%2FJCO.2014.57.0952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25732165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlWhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1252-1257&author=R.+M.+Stoneauthor=E.+Mazzolaauthor=D.+Neubergauthor=S.+L.+Allenauthor=A.+Pigneuxauthor=R.+K.+Stuartauthor=M.+Wetzlerauthor=D.+Rizzieriauthor=H.+P.+Erbaauthor=L.+Damonauthor=J.+H.+Jangauthor=M.+S.+Tallmanauthor=K.+Warzochaauthor=T.+Massziauthor=M.+A.+Sekeresauthor=M.+Egyedauthor=H.+A.+Horstauthor=D.+Selleslagauthor=S.+R.+Solomonauthor=P.+Venugopalauthor=A.+S.+Lundbergauthor=B.+Powell&title=Phase+III+open-label+randomized+study+of+cytarabine+in+combination+with+amonafide+L-malate+or+daunorubicin+as+induction+therapy+for+patients+with+secondary+acute+myeloid+leukemia&doi=10.1200%2FJCO.2014.57.0952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia</span></div><div class="casAuthors">Stone, Richard M.; Mazzola, Emanuele; Neuberg, Donna; Allen, Steven L.; Pigneux, Arnaud; Stuart, Robert K.; Wetzler, Meir; Rizzieri, David; Erba, Harry P.; Damon, Lloyd; Jang, Jun-Ho; Talhnan, Martin S.; Warzocha, Krzysztof; Masszi, Tamas; Sekeres, Mikkael A.; Egyed, Miklos; Horst, Heinz-August; Selleslag, Dominik; Solomon, Scott R.; Venugopal, Parameswaran; Lundberg, Ante S.; Powell, Bayard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1252-1257</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodys-plastic syndrome or after antineoplastic therapy, responds poorly to current therapies.  It is often assocd. with adverse karyotypic abnormalities and overexpression of proteins that mediate drug resistance.  We performed a phase III trial to det. whether induction therapy with cytarabine and amonafide L-malate, a DNA intercalator and non-ATP-dependent topoisomerase II inhibitor that evades drug resistance mechanisms, yielded a superior complete remission rate than std. therapy with cytarabine and daunorubicin in sAML.  Patients and Methods: Patients with previously untreated sAML were randomly assigned at a one-to-one ratio to cytarabine 200 mg/m2 continuous i.v. (IV) infusion once per day on days 1 to 7 plus either amonafide 600 mg/m2 IV over 4 h on days 1 to 5 (A + C arm) or daunorubicin 45 mg/m2 IV over 30 min once per day on days 1 to 3 (D + C arm).  Results: The complete remission (CR) rate was 46% (99 of 216 patients) in A + C arm and 45% (97 of 217 patients) in D + C arm (P = .81).  The 30- and 60-day mortality rates were 19% and 28% in A + C arm and 13% and 21% in D + C arm, resp.  Conclusion: Induction treatment with A + C did not improve the CR rate compared with D + C in patients with sAML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVAceiK2zCfbVg90H21EOLACvtfcHk0lg47WeLyCJTZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlWhu70%253D&md5=1412b402499ecf8fc747ea8de90e6b38</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.57.0952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.57.0952%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DMazzola%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DS.%2BL.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DWetzler%26aufirst%3DM.%26aulast%3DRizzieri%26aufirst%3DD.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DWarzocha%26aufirst%3DK.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DEgyed%26aufirst%3DM.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DSelleslag%26aufirst%3DD.%26aulast%3DSolomon%26aufirst%3DS.%2BR.%26aulast%3DVenugopal%26aufirst%3DP.%26aulast%3DLundberg%26aufirst%3DA.%2BS.%26aulast%3DPowell%26aufirst%3DB.%26atitle%3DPhase%2520III%2520open-label%2520randomized%2520study%2520of%2520cytarabine%2520in%2520combination%2520with%2520amonafide%2520L-malate%2520or%2520daunorubicin%2520as%2520induction%2520therapy%2520for%2520patients%2520with%2520secondary%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1252%26epage%3D1257%26doi%3D10.1200%2FJCO.2014.57.0952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S. F.</span></span> <span> </span><span class="NLM_article-title">Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">439</span>â <span class="NLM_lpage">481</span>, <span class="refDoi">Â DOI: 10.2174/092986711794839197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F092986711794839197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=21143116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=439-481&author=S.+M.+Heauthor=R.+Liauthor=J.+R.+Kanwarauthor=S.+F.+Zhou&title=Structural+and+functional+properties+of+human+multidrug+resistance+protein+1+%28MRP1%2FABCC1%29&doi=10.2174%2F092986711794839197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)</span></div><div class="casAuthors">He, S.-M.; Li, R.; Kanwar, J. R.; Zhou, S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-481</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Multidrug ABC transporters such as P-glycoprotein (P-gp/MDR1/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1) play an important role in the extrusion of drugs from the cell and their overexpression can be a cause of failure of anticancer and antimicrobial chemotherapy.  Recently, the mouse P-gp/Abcb1a structure has been detd. and this has significantly enhanced our understanding of the structure-activity relationship (SAR) of mammalian ABC transporters.  This paper highlights our current knowledge on the structural and functional properties and the SAR of human MRP1/ABCC1.  Although the crystal structure of MRP1/ABCC1 has yet to be resolved, the current topol. model of MRP1/ABCC1 contains two transmembrane domains (TMD1 and TMD2) each followed by a nucleotide binding domain (NBD) plus a third NH2-terminal TMD0.  MRP1/ABCC1 is expressed in the liver, kidney, intestine, brain and other tissues.  MRP1/ABCC1 transports a structurally diverse array of important endogenous substances (e.g. leukotrienes and estrogen conjugates) and xenobiotics and their metabolites, including various conjugates, anticancer drugs, heavy metals, org. anions and lipids.  Cells that highly express MRP1/ABCC1 confer resistance to a variety of natural product anticancer drugs such as vinca alkaloids (e.g. vincristine), anthracyclines (e.g. etoposide) and epipodophyllotoxins (e.g. doxorubicin and mitoxantrone).  MRP1/ABCC1 is assocd. with tumor resistance which is often caused by an increased efflux and decreased intracellular accumulation of natural product anticancer drugs and other anticancer agents.  However, most compds. that efficiently reverse P-gp/ABCB1-mediated multidrug resistance have only low affinity for MRP1/ABCC1 and there are only a few effective and relatively specific MRP1/ABCC1 inhibitors available.  A no. of site-directed mutagenesis studies, biophys. and photolabeling studies, SAR and QSAR, mol. docking and homol. modeling studies have documented the role of multiple residues in detg. the substrate specificity and inhibitor selectivity of MRP1/ABCC1.  Most of these residues are located in the TMs of TMD1 and TMD2, in particular TMs 4, 6, 7, 8, 10, 11, 14, 16, and 17, or in close proximity to the membrane/cytosol interface of MRP1/ABCC1.  The exact transporting mechanism of MRP1/ABCC1 is unclear.  MRP1/ABCC1 and other multidrug transporters are front-line mediators of drug resistance in cancers and represent important therapeutic targets in future chemotherapy.  The crystal structure of human MRP1/ABCC1 is expected to be resolved in the near future and this will provide an insight into the SAR of MRP1/ABCC1 and allow for rational design of anticancer drugs and potent and selective MRP1/ABCC1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7slbZ6tZ2rVg90H21EOLACvtfcHk0lg47WeLyCJTZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtrs%253D&md5=ef2c7f9b64948ef9dd5b3e8b7c4d7837</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2174%2F092986711794839197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839197%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DKanwar%26aufirst%3DJ.%2BR.%26aulast%3DZhou%26aufirst%3DS.%2BF.%26atitle%3DStructural%2520and%2520functional%2520properties%2520of%2520human%2520multidrug%2520resistance%2520protein%25201%2520%2528MRP1%252FABCC1%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D439%26epage%3D481%26doi%3D10.2174%2F092986711794839197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase II and leukemia</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1310</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">110</span>, <span class="refDoi">Â DOI: 10.1111/nyas.12358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1111%2Fnyas.12358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24495080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1310&publication_year=2014&pages=98-110&author=M.+Pendletonauthor=R.+H.+Lindseyauthor=C.+A.+Felixauthor=D.+Grimwadeauthor=N.+Osheroff&title=Topoisomerase+II+and+leukemia&doi=10.1111%2Fnyas.12358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase II and leukemia</span></div><div class="casAuthors">Pendleton, MaryJean; Lindsey, R. Hunter Jr.; Felix, Carolyn A.; Grimwade, David; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1310</span>
        (<span class="NLM_cas:issue">y</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Type II topoisomerases are essential enzymes that modulate DNA under- and overwinding, knotting, and tangling.  Beyond their crit. physiol. functions, these enzymes are the targets for some of the most widely prescribed anticancer drugs (topoisomerase II poisons) in clin. use.  Topoisomerase II poisons kill cells by increasing levels of covalent enzyme-cleaved DNA complexes that are normal reaction intermediates.  Drugs such as etoposide, doxorubicin, and mitoxantrone are frontline therapies for a variety of solid tumors and hematol. malignancies.  Unfortunately, their use also is assocd. with the development of specific leukemias.  Regimens that include etoposide or doxorubicin are linked to the occurrence of acute myeloid leukemias that feature rearrangements at chromosomal band 11q23.  Similar rearrangements are seen in infant leukemias and are assocd. with gestational diets that are high in naturally occurring topoisomerase II-active compds.  Finally, regimens that include mitoxantrone and epirubicin are linked to acute promyelocytic leukemias that feature t(15;17) rearrangements.  The first part of this article will focus on type II topoisomerases and describe the mechanism of enzyme and drug action.  The second part will discuss how topoisomerase II poisons trigger chromosomal breaks that lead to leukemia and potential approaches for dissocg. the actions of drugs from their leukemogenic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiALYgvTJB7LVg90H21EOLACvtfcHk0lg47WeLyCJTZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D&md5=9bb86013f9a010450587baa0c924bfec</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12358%26sid%3Dliteratum%253Aachs%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DLindsey%26aufirst%3DR.%2BH.%26aulast%3DFelix%26aufirst%3DC.%2BA.%26aulast%3DGrimwade%26aufirst%3DD.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DTopoisomerase%2520II%2520and%2520leukemia%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1310%26spage%3D98%26epage%3D110%26doi%3D10.1111%2Fnyas.12358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">228</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2016.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26945111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=228-245&author=R.+Karkiauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=S.+Shinauthor=T.+B.+Thapa+Magarauthor=G.+Bistauthor=A.+Shresthaauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=A+new+series+of+2-phenol-4-aryl-6-chlorophenyl+pyridine+derivatives+as+dual+topoisomerase+I%2FII+inhibitors%3A+Synthesis%2C+biological+evaluation+and+3D-QSAR+study&doi=10.1016%2Fj.ejmech.2016.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study</span></div><div class="casAuthors">Karki, Radha; Jun, Kyu-Yeon; Kadayat, Tara Man; Shin, Somin; Thapa Magar, Til Bahadur; Bist, Ganesh; Shrestha, Aarajana; Na, Younghwa; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a continuous effort to develop novel antitumor agents, a new series of forty-five 2-phenol-4-aryl-6-chlorophenyl pyridine compds. I (R1 = 2-HOC6H4, 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) were synthesized and evaluated for cytotoxicity against four different human cancer cell lines (DU145, HCT15, T47D, and HeLa), and topoisomerase I and II inhibitory activity.  Several compds. I (R1 = 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) displayed strong to moderate dual topoisomerase I and II inhibitory activity at 100 Î¼M.  It was obsd. that hydroxyl and chlorine moiety at meta or para position of Ph ring is favorable for dual topoisomerase inhibitory activity and cytotoxicity.  Most of the compds. I displayed stronger cytotoxicities than those of all pos. controls against the HCT15 and T47D cell lines.  For investigation of the structure-activity relationships, a 3D-QSAR anal. using the method of comparative mol. field anal. (CoMFA) was performed.  The generated 3D contour maps can be used for further rational design of novel terpyridine derivs. I as highly selective and potent cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeg-6-GpSiTrVg90H21EOLACvtfcHk0lhW-6GE8A0KTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D&md5=1d85da38e23e3c8d9e35188d189c64d8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DA%2520new%2520series%2520of%25202-phenol-4-aryl-6-chlorophenyl%2520pyridine%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%253A%2520Synthesis%252C%2520biological%2520evaluation%2520and%25203D-QSAR%2520study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D113%26spage%3D228%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">428</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.04.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2014.04.066" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=428-438&author=K.+Y.+Junauthor=H.+Kwonauthor=S.+E.+Parkauthor=E.+Leeauthor=R.+Karkiauthor=P.+Thapaauthor=J.+H.+Leeauthor=E.+S.+Leeauthor=Y.+Kwon&title=Discovery+of+dihydroxylated+2%2C4-diphenyl-6-thiophen-2-yl-pyridine+as+a+non-intercalative+DNA-binding+topoisomerase+II-specific+catalytic+inhibitor&doi=10.1016%2Fj.ejmech.2014.04.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.066%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520dihydroxylated%25202%252C4-diphenyl-6-thiophen-2-yl-pyridine%2520as%2520a%2520non-intercalative%2520DNA-binding%2520topoisomerase%2520II-specific%2520catalytic%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D428%26epage%3D438%26doi%3D10.1016%2Fj.ejmech.2014.04.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa
Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 2-aryl-4-(4â-hydroxyphenyl)-5<i>H</i>-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">14</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2016.09.019" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=14-28&author=S.+Parkauthor=T.+M.+Kadayatauthor=K.+Y.+Junauthor=T.+B.+Thapa%0AMagarauthor=G.+Bistauthor=A.+Shresthaauthor=E.+S.+Leeauthor=Y.+Kwon&title=Novel+2-aryl-4-%284%E2%80%99-hydroxyphenyl%29-5H-indeno%5B1%2C2-b%5Dpyridines+as+potent+DNA+non-intercalative+topoisomerase+catalytic+inhibitors&doi=10.1016%2Fj.ejmech.2016.09.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DNovel%25202-aryl-4-%25284%25E2%2580%2599-hydroxyphenyl%2529-5H-indeno%255B1%252C2-b%255Dpyridines%2520as%2520potent%2520DNA%2520non-intercalative%2520topoisomerase%2520catalytic%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D14%26epage%3D28%26doi%3D10.1016%2Fj.ejmech.2016.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span> <span> </span><span class="NLM_article-title">R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">484</span>â <span class="NLM_lpage">495</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-06-0584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1158%2F1535-7163.MCT-06-0584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=17308047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=484-495&author=H.+Zhuauthor=M.+Huangauthor=F.+Yangauthor=Y.+Chenauthor=Z.+H.+Miaoauthor=X.+H.+Qianauthor=Y.+F.+Xuauthor=Y.+X.+Qinauthor=H.+B.+Luoauthor=X.+Shenauthor=M.+Y.+Gengauthor=Y.+J.+Caiauthor=J.+Ding&title=R16%2C+a+novel+amonafide+analogue%2C+induces+apoptosis+and+G2-M+arrest+via+poisoning+topoisomerase+II&doi=10.1158%2F1535-7163.MCT-06-0584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II</span></div><div class="casAuthors">Zhu, Hong; Huang, Min; Yang, Fan; Chen, Yi; Miao, Ze-Hong; Qian, Xu-Hong; Xu, Yu-Fang; Qin, Yu-Xin; Luo, Hai-Bin; Shen, Xu; Geng, Mei-Yu; Cai, Yu-Jun; Ding, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">484-495</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amonafide, a naphthalimide deriv., although selected for exploratory clin. trials for its potent anticancer activity, has long been challenged by its unpredictable side effects.  In the present study, a novel amonafide analog (R16, I) was synthesized by substituting 5'-NH2 of the naphthyl with a heterocyclic group to amonafide, with addnl. introduction of a thiol group.  In a panel of various human tumor cell lines, R16 was more cytotoxic than its parent compd. amonafide.  It was also effective against multidrug-resistant cells.  Importantly, the i.p. administration of R16 inhibited tumor growth in mice implanted with S-180 sarcoma and H22 hepatoma.  The mol. and cellular machinery studies showed that the R16 functions as a topoisomerase II (topo II) poison via binding to the ATPase domain of human topo IIÎ±.  The superior cytotoxicity of R16 to amonafide was ascribed to its potent effects on trapping topo II-DNA cleavage complexes.  Moreover, using a topo II catalytic inhibitor aclarubicin, ataxia-telangiectasia-mutated (ATM)/ATM- and Rad3-related (ATR) kinase inhibitor caffeine and topo II-deficient HL-60/MX2 cells, the authors further showed that R16-triggered DNA double-strand breaks, tumor cell cycle arrest, and apoptosis were in a topo II-dependent manner.  Taken together, R16 stood out by its improved anticancer activity, appreciable antimultidrug resistance activities, and well-defined topo II poisoning mechanisms, as comparable with the parent compd. amonafide.  All these collectively promise the potential value of R16 as an anticancer drug candidate, which deserves further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZVr76EHH9i7Vg90H21EOLACvtfcHk0lhW-6GE8A0KTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWku7k%253D&md5=f70d0c13743f421fc9857b6bce9fb384</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0584%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DQian%26aufirst%3DX.%2BH.%26aulast%3DXu%26aufirst%3DY.%2BF.%26aulast%3DQin%26aufirst%3DY.%2BX.%26aulast%3DLuo%26aufirst%3DH.%2BB.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DCai%26aufirst%3DY.%2BJ.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DR16%252C%2520a%2520novel%2520amonafide%2520analogue%252C%2520induces%2520apoptosis%2520and%2520G2-M%2520arrest%2520via%2520poisoning%2520topoisomerase%2520II%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D484%26epage%3D495%26doi%3D10.1158%2F1535-7163.MCT-06-0584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BraÃ±a, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pascual-Teresa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DomÃ­nguez, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozuelo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abradelo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-Stolle, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuste, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡Ã±ez-Coronel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacal, J. C.</span></span> <span> </span><span class="NLM_article-title">New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1391</span>â <span class="NLM_lpage">1399</span>, <span class="refDoi">Â DOI: 10.1021/jm0308850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0308850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1391-1399&author=M.+F.+Bra%C3%B1aauthor=M.+Cachoauthor=M.+A.+Garc%C3%ADaauthor=B.+de+Pascual-Teresaauthor=A.+Ramosauthor=M.+T.+Dom%C3%ADnguezauthor=J.+M.+Pozueloauthor=C.+Abradeloauthor=M.+F.+Rey-Stolleauthor=M.+Yusteauthor=M.+B%C3%A1%C3%B1ez-Coronelauthor=J.+C.+Lacal&title=New+analogues+of+amonafide+and+elinafide%2C+containing+aromatic+heterocycles%3A+synthesis%2C+antitumor+activity%2C+molecular+modeling%2C+and+DNA+binding+properties&doi=10.1021%2Fjm0308850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">New Analogues of Amonafide and Elinafide, Containing Aromatic Heterocycles: Synthesis, Antitumor Activity, Molecular Modeling, and DNA Binding Properties</span></div><div class="casAuthors">Brana, Miguel F.; Cacho, Monica; Garcia, Mario A.; de Pascual-Teresa, Beatriz; Ramos, Ana; Dominguez, M. Teresa; Pozuelo, Jose M.; Abradelo, Cristina; Rey-Stolle, Maria Fernanda; Yuste, Mercedes; Banez-Coronel, Monica; Lacal, Juan Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1391-1399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amonafide- and elinafide-related mono and bisintercalators, e.g. I and II (X = O, S) modified by the introduction of a Ï-excedent furan or thiophene ring fused to the naphthalimide moiety, have been synthesized.  These compds. have shown an interesting antitumor profile.  The best compd., II (X = O), was 2.5-fold more potent than elinafide against human colon carcinoma cells (HT-29).  Mol. dynamic simulations and physicochem. expts. have demonstrated that these compds. are capable of forming stable DNA complexes.  These results, together with those previously reported by us for imidazo- and pyrazinonaphthalimide analogs, have prompted us to propose that the DNA binding process does not depend on the electronic nature of the fused heterocycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghczuS0ltzbVg90H21EOLACvtfcHk0liwMBYY8xmG-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL0%253D&md5=6f0509a3b7984835b5cf5f42f0da6d7e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0308850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0308850%26sid%3Dliteratum%253Aachs%26aulast%3DBra%25C3%25B1a%26aufirst%3DM.%2BF.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%2BA.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DM.%2BT.%26aulast%3DPozuelo%26aufirst%3DJ.%2BM.%26aulast%3DAbradelo%26aufirst%3DC.%26aulast%3DRey-Stolle%26aufirst%3DM.%2BF.%26aulast%3DYuste%26aufirst%3DM.%26aulast%3DB%25C3%25A1%25C3%25B1ez-Coronel%26aufirst%3DM.%26aulast%3DLacal%26aufirst%3DJ.%2BC.%26atitle%3DNew%2520analogues%2520of%2520amonafide%2520and%2520elinafide%252C%2520containing%2520aromatic%2520heterocycles%253A%2520synthesis%252C%2520antitumor%2520activity%252C%2520molecular%2520modeling%252C%2520and%2520DNA%2520binding%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1391%26epage%3D1399%26doi%3D10.1021%2Fjm0308850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolla, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srikanth, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. K.</span></span> <span> </span><span class="NLM_article-title">Naphthalimide derivatives with therapeutic characteristics: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">299</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1517/13543776.2013.746313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1517%2F13543776.2013.746313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=23369185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Sqsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=299-317&author=A.+Kamalauthor=N.+R.+Bollaauthor=P.+S.+Srikanthauthor=A.+K.+Srivastava&title=Naphthalimide+derivatives+with+therapeutic+characteristics%3A+a+patent+review&doi=10.1517%2F13543776.2013.746313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthalimide derivatives with therapeutic characteristics: a patent review</span></div><div class="casAuthors">Kamal, Ahmed; Bolla, Narasimha Rao; Srikanth, Pandala Sindayla; Srivastava, Ajay Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-317</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Naphthalimides are important arom. heterocycles with immense pharmacol. significance as they serve as core scaffold for many antitumor, anti-inflammatory, antidepressant, antiprotozoal and antiviral agents, etc.  The tricyclic planar ring system of naphthalimide is primarily responsible for its intercalation with DNA to perturb the cellular events and the substitution pattern of the mol. leads to several other applications.  The promising pharmacol. activity profile and ease of synthesis have been attractive in design and development of new class of naphthalimides and their conjugates as various potential therapeutic agents.  Few of such mols. are currently under preclin. and clin. evaluations.Areas covered: Important patents focusing on naphthalimides as potential class of therapeutics, published between the period of 2006 - 2011 have been covered.  The reports are presented together with a review of the related structural chem. space.  This review mainly focuses on the therapeutic applications, structural modifications of naphthalimide scaffold, their conjugates and heterocyclics bearing naphthalimide moiety.Expert opinion: The tricyclic planar ring system of naphthalimide restrains important pharmaceutical properties along with excellent fluorescent after proper substitution pattern.  Linking these active naphthalimide derivs. with other active pharmacophore has become an interesting area of research.  The utility of naphthalimide derivs. as novel pharmaceutical and photochem. agents can be further enhanced by introducing polar side chains and fusing functionalized heterocyclic rings with naphthalimide cores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiCS3WT7YqRLVg90H21EOLACvtfcHk0liwMBYY8xmG-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Sqsr0%253D&md5=a04f5f79fd0176e6f2e940f62268648b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.746313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.746313%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DBolla%26aufirst%3DN.%2BR.%26aulast%3DSrikanth%26aufirst%3DP.%2BS.%26aulast%3DSrivastava%26aufirst%3DA.%2BK.%26atitle%3DNaphthalimide%2520derivatives%2520with%2520therapeutic%2520characteristics%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D299%26epage%3D317%26doi%3D10.1517%2F13543776.2013.746313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Naphthalimides exhibit <i>in vitro</i> antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinase (RTKs)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">477</span>â <span class="NLM_lpage">486</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.05.002" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=477-486&author=X.+Wangauthor=Z.+Chenauthor=L.+Tongauthor=S.+Tanauthor=W.+Zhouauthor=T.+Pengauthor=K.+Hanauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xu&title=Naphthalimides+exhibit+in+vitro+antiproliferative+and+antiangiogenic+activities+by+inhibiting+both+topoisomerase+II+%28topo+II%29+and+receptor+tyrosine+kinase+%28RTKs%29&doi=10.1016%2Fj.ejmech.2013.05.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DNaphthalimides%2520exhibit%2520in%2520vitro%2520antiproliferative%2520and%2520antiangiogenic%2520activities%2520by%2520inhibiting%2520both%2520topoisomerase%2520II%2520%2528topo%2520II%2529%2520and%2520receptor%2520tyrosine%2520kinase%2520%2528RTKs%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D477%26epage%3D486%26doi%3D10.1016%2Fj.ejmech.2013.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Quinoxalinone (Part II). Discovery of (<i>Z</i>)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1840</span>â <span class="NLM_lpage">1852</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2016.03.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1840-1852&author=L.+Shiauthor=J.+Zhouauthor=J.+Wuauthor=J.+Caoauthor=Y.+Shenauthor=H.+Zhouauthor=X.+Li&title=Quinoxalinone+%28Part+II%29.+Discovery+of+%28Z%29-3-%282-%28pyridin-4-yl%29vinyl%29quinoxalinone+derivates+as+potent+VEGFR-2+kinase+inhibitors&doi=10.1016%2Fj.bmc.2016.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DQuinoxalinone%2520%2528Part%2520II%2529.%2520Discovery%2520of%2520%2528Z%2529-3-%25282-%2528pyridin-4-yl%2529vinyl%2529quinoxalinone%2520derivates%2520as%2520potent%2520VEGFR-2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1840%26epage%3D1852%26doi%3D10.1016%2Fj.bmc.2016.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Anti-angiogenic therapy: strategies to develop potent VEGFR-2 tyrosine kinase inhibitors and future prospect</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1000</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.2174/0929867323666160210130426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F0929867323666160210130426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26860998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOku70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1000-1040&author=L.+Shiauthor=J.+Zhouauthor=J.+Wuauthor=Y.+Shenauthor=X.+Li&title=Anti-angiogenic+therapy%3A+strategies+to+develop+potent+VEGFR-2+tyrosine+kinase+inhibitors+and+future+prospect&doi=10.2174%2F0929867323666160210130426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect</span></div><div class="casAuthors">Shi, Leilei; Zhou, Jianfeng; Wu, Jifeng; Shen, Yuemao; Li, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1000-1040</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tumor angiogenesis has always been a major gap for effective cancer therapy.  Interruption of aberrant angiogenesis by specific inhibitors targeting receptor tyrosine kinases (RTKs) has been of great interests to medicinal chemists.  Among the factors that are involved in tumor angiogenesis, vascular endothelial growth factor receptor-2 (VEGFR-2) is validated as the most closely related factor which can drive angiogenesis through binding with its natural ligand VEGF.  The well-validated VEGF-driven VEGFR-2 signaling pathway can stimulate many endothelial responses, including increasing vessel permeability and enhancing endothelial cell proliferation, migration and differentiation.  Consequently, circumventing angiogenesis by VEGFR-2 inhibitors represents a promising strategy for counteracting various VEGFR-2-mediated disorders as well as drug resistance.  Over the past decades, a considerable no. of novel small mol. VEGFR-2 inhibitors have been exploited with diverse chem. scaffolds.  Esp., recent frequently launched inhibitors have declared their research values and therapeutic potentials in oncol.  Still, the antiangiogenesis based treatment remains an ongoing challenge.  In this review, a comprehensive retrospective of newly emerged VEGFR-2 inhibitors have been summarized, with the emphasis on the structure-activity relationship (SAR) investigation, and also binding patterns of representative inhibitors with biotargets.  On the basis of all of this information, varied strategies for developing potent VEGFR-2 inhibitors and the future prospect of the clin. application of antiangiogenic inhibitors are discussed hereby.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohrFu9JNyl1LVg90H21EOLACvtfcHk0lgeD6q0SExrgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOku70%253D&md5=3ac7107ac9eaf3657caf83649aea6abf</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160210130426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160210130426%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DAnti-angiogenic%2520therapy%253A%2520strategies%2520to%2520develop%2520potent%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitors%2520and%2520future%2520prospect%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D1000%26epage%3D1040%26doi%3D10.2174%2F0929867323666160210130426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomerase IIÎ± and antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">782</span>â <span class="NLM_lpage">796</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.08.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2014.08.073" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=782-796&author=W.+Chenauthor=Y.+Shenauthor=Z.+Liauthor=M.+Zhangauthor=C.+Luauthor=Y.+Shen&title=Design+and+synthesis+of+2-phenylnaphthalenoids+as+inhibitors+of+DNA+topoisomerase+II%CE%B1+and+antitumor+agents&doi=10.1016%2Fj.ejmech.2014.08.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-phenylnaphthalenoids%2520as%2520inhibitors%2520of%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520and%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D782%26epage%3D796%26doi%3D10.1016%2Fj.ejmech.2014.08.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plech, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KaproÅ, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wujec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotsko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KuÅmierz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneth, P.</span></span> <span> </span><span class="NLM_article-title">Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1021</span>â <span class="NLM_lpage">1026</span>, <span class="refDoi">Â DOI: 10.3109/14756366.2014.995179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3109%2F14756366.2014.995179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25792499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKks73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=1021-1026&author=T.+Plechauthor=B.+Kapro%C5%84author=A.+Panethauthor=M.+Wujecauthor=R.+Czarnomysyauthor=A.+Bielawskaauthor=K.+Bielawskiauthor=N.+Trotskoauthor=E.+Ku%C5%9Bmierzauthor=P.+Paneth&title=Search+for+human+DNA+topoisomerase+II+poisons+in+the+group+of+2%2C5-disubstituted-1%2C3%2C4-thiadiazoles&doi=10.3109%2F14756366.2014.995179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles</span></div><div class="casAuthors">Plech, Tomasz; Kapron, Barbara; Paneth, Agata; Wujec, Monika; Czarnomysy, Robert; Bielawska, Anna; Bielawski, Krzysztof; Trotsko, Nazar; Kusmierz, Edyta; Paneth, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1021-1026</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A series of six 2,5-disubstituted 1,3,4-thiadiazole derivs. was synthesized and examd. for cytotoxic activity in MCF-7 and MDA-MB-231 breast cancer cells.  MTT assay confirmed that 2-(3-fluorophenylamino)-5-(3-hydroxyphenyl)-1,3,4-thiadiazole (I), 2-(4-bromophenylamino)-5-(2,4-dichlorophenyl)-1,3,4-thiadiazole, 2-(4-fluorophenylamino)-5-(2,4-dichlorophenyl)-1,3,4-thiadiazole, had ability to inhibit MCF-7 and MDA-MB-231 cells proliferation.  The IC50 values for the mentioned compds. ranged between 120 and 160 Î¼M (with respect to MCF-7 cells) and from 70 to 170 Î¼M (with respect to MDA-MB-231 cells).  It turned out, moreover, that compd. I is a human topoisomerase II (topoII) catalytic inhibitor whereas the two other compds. (i.e. and ) are capable of stabilizing DNA-topoII cleavage complex and thus are topoII poisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAL7s6ity1XrVg90H21EOLACvtfcHk0li-51TmRw4P1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKks73N&md5=50361e633f5b062395e1e94ae315ae6d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3109%2F14756366.2014.995179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756366.2014.995179%26sid%3Dliteratum%253Aachs%26aulast%3DPlech%26aufirst%3DT.%26aulast%3DKapro%25C5%2584%26aufirst%3DB.%26aulast%3DPaneth%26aufirst%3DA.%26aulast%3DWujec%26aufirst%3DM.%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DK.%26aulast%3DTrotsko%26aufirst%3DN.%26aulast%3DKu%25C5%259Bmierz%26aufirst%3DE.%26aulast%3DPaneth%26aufirst%3DP.%26atitle%3DSearch%2520for%2520human%2520DNA%2520topoisomerase%2520II%2520poisons%2520in%2520the%2520group%2520of%25202%252C5-disubstituted-1%252C3%252C4-thiadiazoles%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2015%26volume%3D30%26spage%3D1021%26epage%3D1026%26doi%3D10.3109%2F14756366.2014.995179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porwal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleinick, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dealwis, C. G.</span></span> <span> </span><span class="NLM_article-title">Identification of non-nucleoside human ribonucleotide reductase modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9498</span>â <span class="NLM_lpage">9509</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00929</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00929" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9498-9509&author=M.+F.+Ahmadauthor=S.+E.+Huffauthor=J.+Pinkauthor=I.+Alamauthor=A.+Zhangauthor=K.+Perryauthor=M.+E.+Harrisauthor=T.+Miskoauthor=S.+K.+Porwalauthor=N.+L.+Oleinickauthor=M.+Miyagiauthor=R.+Viswanathanauthor=C.+G.+Dealwis&title=Identification+of+non-nucleoside+human+ribonucleotide+reductase+modulators&doi=10.1021%2Facs.jmedchem.5b00929"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00929%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DM.%2BF.%26aulast%3DHuff%26aufirst%3DS.%2BE.%26aulast%3DPink%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DPerry%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DM.%2BE.%26aulast%3DMisko%26aufirst%3DT.%26aulast%3DPorwal%26aufirst%3DS.%2BK.%26aulast%3DOleinick%26aufirst%3DN.%2BL.%26aulast%3DMiyagi%26aufirst%3DM.%26aulast%3DViswanathan%26aufirst%3DR.%26aulast%3DDealwis%26aufirst%3DC.%2BG.%26atitle%3DIdentification%2520of%2520non-nucleoside%2520human%2520ribonucleotide%2520reductase%2520modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9498%26epage%3D9509%26doi%3D10.1021%2Facs.jmedchem.5b00929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gumienna-Kontecka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrkosz-Bulska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szebesczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowska, M.</span></span> <span> </span><span class="NLM_article-title">Iron chelating strategies in systemic metal overload, neurodegeneration and cancer</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3741</span>â <span class="NLM_lpage">3767</span>, <span class="refDoi">Â DOI: 10.2174/0929867321666140706143402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F0929867321666140706143402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25005181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=3741-3767&author=E.+Gumienna-Konteckaauthor=M.+Pyrkosz-Bulskaauthor=A.+Szebesczykauthor=M.+Ostrowska&title=Iron+chelating+strategies+in+systemic+metal+overload%2C+neurodegeneration+and+cancer&doi=10.2174%2F0929867321666140706143402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer</span></div><div class="casAuthors">Gumienna-Kontecka, Elzbieta; Pyrkosz-Bulska, Monika; Szebesczyk, Agnieszka; Ostrowska, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3741-3767</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Iron is a trace element required for normal performance of cellular processes.  Because both the deficiency and excess of this metal are dangerous, its absorption, distribution and accumulation must be tightly regulated.  Disturbances of iron homeostasis and an increase in its level may lead to overload and neurodegenerative diseases.  Phlebotomy was for a long time the only way of removing excess iron.  But since there are many possible disadvantages of this method, chelation therapy seems to be a logical approach to remove toxic levels of iron.  In clin. use, there are three drugs: desferrioxamine, deferiprone and deferasirox.  FBS0701, a novel oral iron chelator, is under clin. trials with very promising results.  Developing novel iron-binding chelators is an urgent matter, not only for systemic iron overload, but also for neurodegenerative disorders, such as Parkinson's disease.  Deferiprone is also used in clin. trials in Parkinson's disease.  In neurodegenerative disorders the main goal is not only to remove iron from brain tissues, but also its redistribution in system.  Few chelators are tested for their potential use in neurodegeneration, such as nonhalogeneted derivs. of clioquinol.  Such compds. gave promising results in animal models of neurodegenerative diseases.  Drugs of possible use in neurodegeneration must meet certain criteria.  Their development includes the improvement in blood brain barrier permeability, low toxicity and the ability to prevent lipid peroxidn.  One of the compds. satisfying these requirements is VK28.  In rat models it was able to protect neurons in very low doses without significantly changing the iron level in liver or serum.  Also iron chelators able to regulate activity of monoamine oxidase were tested.  Polyphenols and flavonoids are able to prevent lipid peroxidn. and demonstrate neuroprotective activity.  While cancer does not involve true iron overload, neoplastic cells have a higher iron requirement and are esp. prone to its depletion.  It was shown, that desferrioxamine and deferasirox are antiproliferative agents active in several types of cancer.  Very potent compds. with possible use as anticancer drugs are thiosemicarbazones.  They are able to inhibit ribonucleotide reductase, an enzyme involved in DNA synthesis.  Because the relationship between the development of overload / neurodegenerative disorders, or cancer, and iron are very complex, comprehension of the mechanisms involved in the regulation of iron homeostasis is a crucial factor in the development of new pharmacol. strategies based on iron chelation.  In view of various factors closely involved in pathogenesis of such diseases, designing multifunctional metal-chelators seems to be the most promising approach, but it requires a lot of effort.  In this perspective, the review summarizes systemic iron homeostasis, and in brain and cancer cells, iron dysregulation in neurodegenerative disease and possible chelation strategies in the treatment of metal systemic overload, neurodegeneration and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJpjzfymaGbVg90H21EOLACvtfcHk0lgvliYcj1wKzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3E&md5=a631de27f34e736bcc55bd82c5646180</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140706143402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140706143402%26sid%3Dliteratum%253Aachs%26aulast%3DGumienna-Kontecka%26aufirst%3DE.%26aulast%3DPyrkosz-Bulska%26aufirst%3DM.%26aulast%3DSzebesczyk%26aufirst%3DA.%26aulast%3DOstrowska%26aufirst%3DM.%26atitle%3DIron%2520chelating%2520strategies%2520in%2520systemic%2520metal%2520overload%252C%2520neurodegeneration%2520and%2520cancer%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D3741%26epage%3D3767%26doi%3D10.2174%2F0929867321666140706143402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafayette, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima Serafim, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neves, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BeltrÃ£o, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho JÃºnior, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, M. D.</span></span> <span> </span><span class="NLM_article-title">New spiro-acridines: DNA interaction, antiproliferative activity and inhibition of human DNA topoisomerases</span>. <i>Int. J. Biol. Macromol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">467</span>â <span class="NLM_lpage">475</span>, <span class="refDoi">Â DOI: 10.1016/j.ijbiomac.2016.07.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ijbiomac.2016.07.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27435006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A280%3ADC%252BC2s3isVOquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=467-475&author=S.+M.+Almeidaauthor=E.+A.+Lafayetteauthor=W.+L.+Silvaauthor=V.+Lima+Serafimauthor=T.+M.+Menezesauthor=J.+L.+Nevesauthor=A.+L.+Ruizauthor=J.+E.+Carvalhoauthor=R.+O.+Mouraauthor=E.+I.+Beltr%C3%A3oauthor=L.+B.+Carvalho+J%C3%BAniorauthor=M.+D.+Lima&title=New+spiro-acridines%3A+DNA+interaction%2C+antiproliferative+activity+and+inhibition+of+human+DNA+topoisomerases&doi=10.1016%2Fj.ijbiomac.2016.07.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">New spiro-acridines: DNA interaction, antiproliferative activity and inhibition of human DNA topoisomerases</span></div><div class="casAuthors">Almeida Sinara Monica Vitalino de; Lafayette Elizabeth Almeida; Silva Willams Leal; Lima Maria do Carmo Alves de; Lima Serafim Vanessa de; Menezes Thais Meira; Neves Jorge Luiz; Ruiz Ana Lucia Tasca Gois; Carvalho Joao Ernesto de; Moura Ricardo Olimpio de; Beltrao Eduardo Isidoro Carneiro; Carvalho Junior Luiz Bezerra de</div><div class="citationInfo"><span class="NLM_cas:title">International journal of biological macromolecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">467-475</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Two new spiro-acridines were synthesized by introducing cyano-N-acylhydrazone between the acridine and phenyl rings followed by spontaneous cyclization.  The final compounds (E)-1'-(benzylideneamino)-5'-oxo-1',5'-dihydro-10H-spiro[acridine-9,2'-pyrrole]-4'-carbonitrile (AMTAC-01) and (E)-1'-((4-methoxybenzylidene)amino)-5'-oxo-1',5'-dihydro-10H-spiro[acridine-9,2'-pyrrole]-4'-carbonitrile (AMTAC-02) were evaluated for their interactions with calf thymus DNA, antiproliferative and human topoisomerase I and IIÎ± inhibitory activities.  Both compounds presented ability to bind DNA.  The binding constant determined by UV-vis spectroscopy was found to be 10(4)M(-1).  Antiproliferative assay demonstrated that AMTAC-01 and AMTAC-02 were most active against prostate and melanoma tumor cell lines, respectively.  The compound did not present Topo I inhibitory activity.  However, both derivatives displayed topoisomerase IIÎ± inhibitory activity comparable to amsacrine, and AMTAC-02 was more potent than AMTAC-01 with methoxy substituent group on phenyl ring.  This study demonstrates that the new derivatives are promising molecules with topoisomerase IIÎ± inhibitory and antiproliferative activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS90vbHMeE_Ksve_zCu79I8fW6udTcc2eYFI2reGU0z3Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3isVOquw%253D%253D&md5=14e854cb4d574c616e0df91ecbc501da</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ijbiomac.2016.07.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijbiomac.2016.07.057%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%26aufirst%3DS.%2BM.%26aulast%3DLafayette%26aufirst%3DE.%2BA.%26aulast%3DSilva%26aufirst%3DW.%2BL.%26aulast%3DLima%2BSerafim%26aufirst%3DV.%26aulast%3DMenezes%26aufirst%3DT.%2BM.%26aulast%3DNeves%26aufirst%3DJ.%2BL.%26aulast%3DRuiz%26aufirst%3DA.%2BL.%26aulast%3DCarvalho%26aufirst%3DJ.%2BE.%26aulast%3DMoura%26aufirst%3DR.%2BO.%26aulast%3DBeltr%25C3%25A3o%26aufirst%3DE.%2BI.%26aulast%3DCarvalho%2BJ%25C3%25BAnior%26aufirst%3DL.%2BB.%26aulast%3DLima%26aufirst%3DM.%2BD.%26atitle%3DNew%2520spiro-acridines%253A%2520DNA%2520interaction%252C%2520antiproliferative%2520activity%2520and%2520inhibition%2520of%2520human%2520DNA%2520topoisomerases%26jtitle%3DInt.%2520J.%2520Biol.%2520Macromol.%26date%3D2016%26volume%3D92%26spage%3D467%26epage%3D475%26doi%3D10.1016%2Fj.ijbiomac.2016.07.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jobson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilby, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span> <span> </span><span class="NLM_article-title">Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">889</span>â <span class="NLM_lpage">901</span>, <span class="refDoi">Â DOI: 10.1007/s00280-008-0812-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs00280-008-0812-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=18679685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlWhtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2009&pages=889-901&author=A.+G.+Jobsonauthor=E.+Willmoreauthor=M.+J.+Tilbyauthor=P.+Mistryauthor=P.+Charltonauthor=C.+A.+Austin&title=Effect+of+phenazine+compounds+XR11576+and+XR5944+on+DNA+topoisomerases&doi=10.1007%2Fs00280-008-0812-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases</span></div><div class="casAuthors">Jobson, Andrew G.; Willmore, Elaine; Tilby, Michael J.; Mistry, Prakash; Charlton, Peter; Austin, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">889-901</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Previous in vitro cleavage data showed that XR11576 and XR5944 stabilized topoisomerase I and topoisomerase II complexes on DNA in a dose-dependent fashion.  However, some studies indicated a possible topoisomerase-independent mechanism of action for these drugs.  Methods: Three methods, the TARDIS assay, immunoband depletion and the K+/SDS assay have been used to assess topoisomerase complex formation induced by XR11576 or XR5944 in human leukemic K562 cells.  Results: TARDIS and immunoband depletion assays demonstrated that XR11576 and XR5944 induced complex formation for both topoisomerase I and topoisomerase II (alpha and beta) in a dose- and time-dependent manner, following exposure times of 24 and 48 h at concns. of 1 or 10 Î¼M.  The K+/SDS assay showed the formation of protein/DNA complexes after a 1 h exposure to 1 or 10 Î¼M XR11576.  Conclusion: Our data confirm that XR11576 or XR5944 can form topoisomerase complexes, after long periods of exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsTcFhvBTpqrVg90H21EOLACvtfcHk0ljblZWOgcVI2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlWhtrg%253D&md5=bf3ae39fa7a616150f66b069bdd57ad5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00280-008-0812-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-008-0812-9%26sid%3Dliteratum%253Aachs%26aulast%3DJobson%26aufirst%3DA.%2BG.%26aulast%3DWillmore%26aufirst%3DE.%26aulast%3DTilby%26aufirst%3DM.%2BJ.%26aulast%3DMistry%26aufirst%3DP.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26atitle%3DEffect%2520of%2520phenazine%2520compounds%2520XR11576%2520and%2520XR5944%2520on%2520DNA%2520topoisomerases%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D63%26spage%3D889%26epage%3D901%26doi%3D10.1007%2Fs00280-008-0812-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of benzo[<i>a</i>]phenazine derivatives as a dual inhibitor of topoisomerase I and II</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3989</span>â <span class="NLM_lpage">4005</span>, <span class="refDoi">Â DOI: 10.1039/c3ob40325d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc3ob40325d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=23657605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVegu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=3989-4005&author=S.+T.+Zhuoauthor=C.+Y.+Liauthor=M.+H.+Huauthor=S.+B.+Chenauthor=P.+F.+Yaoauthor=S.+L.+Huangauthor=T.+M.+Ouauthor=J.+H.+Tanauthor=L.+K.+Anauthor=D.+Liauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Synthesis+and+biological+evaluation+of+benzo%5Ba%5Dphenazine+derivatives+as+a+dual+inhibitor+of+topoisomerase+I+and+II&doi=10.1039%2Fc3ob40325d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II</span></div><div class="casAuthors">Zhuo, Shi-Tian; Li, Chun-Yan; Hu, Ming-Hao; Chen, Shuo-Bin; Yao, Pei-Fen; Huang, Shi-Liang; Ou, Tian-Miao; Tan, Jia-Heng; An, Lin-Kun; Li, Ding; Gu, Lian-Quan; Huang, Zhi-Shu</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3989-4005</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Topoisomerases (Topo I and Topo II) are very important players in DNA replication, repair, and transcription, and are a promising class of antitumor target.  In the present study, a series of benzo[a]phenazine derivs. with alkylamino side chains at C-5 were designed, synthesized, and their biol. activities were evaluated.  Most of the derivs. showed good antiproliferative activity with a range of IC50 values of 1-10 Î¼M on the four cancer cell lines HeLa, A549, MCF-7, and HL-60.  Topoisomerase-mediated DNA relaxation assay results showed that the derivs. could effectively inhibit the activity of both Topo I and Topo II, and the structure-activity relationship studies indicated the importance of introducing an alkylamino side chain.  Further mechanism studies revealed that the compds. could stabilize the Topo I-DNA cleavage complexes and inhibit the ATPase activity of hTopo II, indicating that they are a rare class of dual topoisomerase inhibitors by acting as Topo I poisons and Topo II catalytic inhibitors.  Moreover, flow cytometric anal. and caspase-3/7 activation assay showed that this class of compds. could induce apoptosis of HL-60 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBGsS12CM8LVg90H21EOLACvtfcHk0ljblZWOgcVI2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVegu70%253D&md5=60df539bb99986e58ce8e85a5d9e141e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2Fc3ob40325d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob40325d%26sid%3Dliteratum%253Aachs%26aulast%3DZhuo%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DHu%26aufirst%3DM.%2BH.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DAn%26aufirst%3DL.%2BK.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520benzo%255Ba%255Dphenazine%2520derivatives%2520as%2520a%2520dual%2520inhibitor%2520of%2520topoisomerase%2520I%2520and%2520II%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D3989%26epage%3D4005%26doi%3D10.1039%2Fc3ob40325d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">553</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25599951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=540-553&author=B.+L.+Yaoauthor=Y.+W.+Maiauthor=S.+B.+Chenauthor=H.+T.+Xieauthor=P.+F.+Yaoauthor=T.+M.+Ouauthor=J.+H.+Tanauthor=H.+G.+Wangauthor=D.+Liauthor=S.+L.+Huangauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+7-alkylamino+substituted+benzo%5Ba%5Dphenazin+derivatives+as+dual+topoisomerase+I%2FII+inhibitors&doi=10.1016%2Fj.ejmech.2015.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors</span></div><div class="casAuthors">Yao, Bing-Lei; Mai, Yan-Wen; Chen, Shuo-Bin; Xie, Hua-Ting; Yao, Pei-Fen; Ou, Tian-Miao; Tan, Jia-Heng; Wang, Hong-Gen; Li, Ding; Huang, Shi-Liang; Gu, Lian-Quan; Huang, Zhi-Shu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-553</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of benzo[a]phenazine derivs. (e.g. I) bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerase inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549).  These compds. were found to be dual inhibitors of topoisomerase (Topo) I and Topo II, and exhibited excellent antiproliferative activity, in particular against HL-60 cells with submicromolar IC50 values.  Further mechanistic studies showed that this class of compds. acted as Topo I poisons by stabilizing the Topo I-DNA cleavage complexes and Topo II catalytic inhibitors by inhibiting the ATPase activity of hTopo II.  Mol. docking studies revealed the binding modes of these compds. for Topo I and Topo II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxjnEG72_zALVg90H21EOLACvtfcHk0ljViwaZTVTL7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D&md5=01e94691b81dc1185eb5109930b0d41d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BL.%26aulast%3DMai%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DXie%26aufirst%3DH.%2BT.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25207-alkylamino%2520substituted%2520benzo%255Ba%255Dphenazin%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D540%26epage%3D553%26doi%3D10.1016%2Fj.ejmech.2015.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1100</span>â <span class="NLM_lpage">1122</span>, <span class="refDoi">Â DOI: 10.1021/jm501023q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501023q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVChsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1100-1122&author=H.+B.+Kwonauthor=C.+Parkauthor=K.+H.+Jeonauthor=E.+Leeauthor=S.+E.+Parkauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=P.+Thapaauthor=R.+Karkiauthor=Y.+Naauthor=M.+S.+Parkauthor=S.+B.+Rhoauthor=E.+S.+Leeauthor=Y.+Kwon&title=A+series+of+novel+terpyridine-skeleton+molecule+derivants+inhibit+tumor+growth+and+metastasis+by+targeting+topoisomerases&doi=10.1021%2Fjm501023q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Novel Terpyridine-Skeleton Molecule Derivants Inhibit Tumor Growth and Metastasis by Targeting Topoisomerases</span></div><div class="casAuthors">Kwon, Han-Byeol; Park, Chanmi; Jeon, Kyung-Hwa; Lee, Eunyoung; Park, So-Eun; Jun, Kyu-Yeon; Kadayat, Tara Man; Thapa, Pritam; Karki, Radha; Na, Younghwa; Park, Mi Sun; Rho, Seung Bae; Lee, Eung-Seok; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1100-1122</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel terpyridine-skeleton mols. contg. conformational rigidity, 14 contg. benzo[4,5]furo[3,2-b]pyridine core and 15 comprising chromeno[4,3-b]pyridine core, were synthesized, and their biol. activities were evaluated. 3-(4-Phenylbenzo[4,5]furo[3,2-b]pyridin-2-yl)phenol (8, I) was detd. to be a nonintercalative topo I and II dual catalytic inhibitor and 3-(4-phenylchromeno[4,3-b]pyridine-2-yl)phenol (22, II) was detd. to be a nonintercalative topo IIÎ± specific catalytic inhibitor by various assays.  These two catalytic inhibitors induced apoptosis in addn. to G1 arrest in T47D human breast cancer cells with much less DNA toxicity than etoposide.  Compds. 8 and 22 significantly inhibited tumor growth in HCT15 s.c. implanted xenografted mice.  The modification of compds. 8 and 22 with the introduction of a methoxy instead of a hydroxy group enhanced endogenous topo inhibitory activity, metabolic stability in diverse types of liver microsomes and improved pharmacokinetic parameters in rat plasma such as augmentation of bioavailability (41.3% and 33.2% for 2-(3-methoxyphenyl)-4-phenylbenzofuro[3,2-b]pyridine and 3-(4-phenylchromeno[4,3-b]pyridine-2-yl)methoxybenzene, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJTC8jRnzzdLVg90H21EOLACvtfcHk0ljViwaZTVTL7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVChsLw%253D&md5=fa7655031fde52c3ca4eee622c3be203</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm501023q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501023q%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DH.%2BB.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJeon%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DS.%2BE.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DM.%2BS.%26aulast%3DRho%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DA%2520series%2520of%2520novel%2520terpyridine-skeleton%2520molecule%2520derivants%2520inhibit%2520tumor%2520growth%2520and%2520metastasis%2520by%2520targeting%2520topoisomerases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1100%26epage%3D1122%26doi%3D10.1021%2Fjm501023q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6454</span>â <span class="NLM_lpage">6466</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.08.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6454-6466&author=P.+Thapaauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=C.+Parkauthor=Z.+Zhengauthor=T.+B.+Thapa+Magarauthor=G.+Bistauthor=A.+Shresthaauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=Design+and+synthesis+of+conformationally+constrained+hydroxylated+4-phenyl-2-aryl+chromenopyridines+as+novel+and+selective+topoisomerase+II-targeted+antiproliferative+agents&doi=10.1016%2Fj.bmc.2015.08.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520conformationally%2520constrained%2520hydroxylated%25204-phenyl-2-aryl%2520chromenopyridines%2520as%2520novel%2520and%2520selective%2520topoisomerase%2520II-targeted%2520antiproliferative%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6454%26epage%3D6466%26doi%3D10.1016%2Fj.bmc.2015.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel 2,4-diaryl-5<i>H</i>-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">160</span>â <span class="NLM_lpage">173</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2014.11.010" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=160-173&author=T.+M.+Kadayatauthor=C.+Parkauthor=K.+Y.+Junauthor=T.+B.+Magarauthor=G.+Bistauthor=H.+Y.+Yooauthor=Y.+Kwonauthor=E.+S.+Lee&title=Design+and+synthesis+of+novel+2%2C4-diaryl-5H-indeno%5B1%2C2-b%5Dpyridine+derivatives%2C+and+their+evaluation+of+topoisomerase+inhibitory+activity+and+cytotoxicity&doi=10.1016%2Fj.bmc.2014.11.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DYoo%26aufirst%3DH.%2BY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%25202%252C4-diaryl-5H-indeno%255B1%252C2-b%255Dpyridine%2520derivatives%252C%2520and%2520their%2520evaluation%2520of%2520topoisomerase%2520inhibitory%2520activity%2520and%2520cytotoxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D160%26epage%3D173%26doi%3D10.1016%2Fj.bmc.2014.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallqvist, A.</span></span> <span> </span><span class="NLM_article-title">Classification of scaffold hopping approaches</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">310</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2011.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.drudis.2011.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=22056715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=310-324&author=H.+Sunauthor=G.+Tawaauthor=A.+Wallqvist&title=Classification+of+scaffold+hopping+approaches&doi=10.1016%2Fj.drudis.2011.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of scaffold-hopping approaches</span></div><div class="casAuthors">Sun, Hongmao; Tawa, Gregory; Wallqvist, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">310-324</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The general goal of drug discovery is to identify novel compds. that are active against a preselected biol. target with acceptable pharmacol. properties defined by marketed drugs.  Scaffold hopping has been widely applied by medicinal chemists to discover equipotent compds. with novel backbones that have improved properties.  In this article we classify scaffold hopping into four major categories, namely heterocycle replacements, ring opening or closure, peptidomimetics and topol.-based hopping.  We review the structural diversity of original and final scaffolds with respect to each category.  We discuss the advantages and limitations of small, medium and large-step scaffold hopping.  Finally, we summarize software that is frequently used to facilitate different kinds of scaffold-hopping methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAONaJ8Be0x7Vg90H21EOLACvtfcHk0ljTs6xV7OuYew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D&md5=5f1143cc255c81b88ea4f83ac9f8efc6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DWallqvist%26aufirst%3DA.%26atitle%3DClassification%2520of%2520scaffold%2520hopping%2520approaches%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D310%26epage%3D324%26doi%3D10.1016%2Fj.drudis.2011.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2974</span>â <span class="NLM_lpage">2978</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2013.03.037" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2974-2978&author=Y.+Zhouauthor=X.+Xuauthor=Y.+Sunauthor=H.+Wangauthor=H.+Sunauthor=Q.+You&title=Synthesis%2C+cytotoxicity+and+topoisomerase+II+inhibitory+activity+of+lomefloxacin+derivatives&doi=10.1016%2Fj.bmcl.2013.03.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYou%26aufirst%3DQ.%26atitle%3DSynthesis%252C%2520cytotoxicity%2520and%2520topoisomerase%2520II%2520inhibitory%2520activity%2520of%2520lomefloxacin%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2974%26epage%3D2978%26doi%3D10.1016%2Fj.bmcl.2013.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaquiquzzaman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. M.</span></span> <span> </span><span class="NLM_article-title">Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">487</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26310894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCntrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=487-529&author=M.+Shaquiquzzamanauthor=G.+Vermaauthor=A.+Marellaauthor=M.+Akhterauthor=W.+Akhtarauthor=M.+F.+Khanauthor=S.+Tasneemauthor=M.+M.+Alam&title=Piperazine+scaffold%3A+A+remarkable+tool+in+generation+of+diverse+pharmacological+agents&doi=10.1016%2Fj.ejmech.2015.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents</span></div><div class="casAuthors">Shaquiquzzaman, Mohammad; Verma, Garima; Marella, Akranth; Akhter, Mymoona; Akhtar, Wasim; Khan, Mohemmed Faraz; Tasneem, Sharba; Alam, Mohammad Mumtaz</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">487-529</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Piperazine is one of the most sought heterocyclics for the development of new drug candidates.  This ring can be traced in a no. of well established, com. available drugs.  Wide array of pharmacol. activities exhibited by piperazine derivs. have made them indispensable anchors for the development of novel therapeutic agents.  The review herein highlights the therapeutic significance of piperazine derivs.  Various therapeutically active piperazine derivs. developed by several chemists are reported here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm2iQJFfMCIbVg90H21EOLACvtfcHk0ljTs6xV7OuYew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCntrjP&md5=67bf76f4ae4706a7647c5daff4ca6cd5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DShaquiquzzaman%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DG.%26aulast%3DMarella%26aufirst%3DA.%26aulast%3DAkhter%26aufirst%3DM.%26aulast%3DAkhtar%26aufirst%3DW.%26aulast%3DKhan%26aufirst%3DM.%2BF.%26aulast%3DTasneem%26aufirst%3DS.%26aulast%3DAlam%26aufirst%3DM.%2BM.%26atitle%3DPiperazine%2520scaffold%253A%2520A%2520remarkable%2520tool%2520in%2520generation%2520of%2520diverse%2520pharmacological%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D487%26epage%3D529%26doi%3D10.1016%2Fj.ejmech.2015.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.07.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26291037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=277-287&author=H.+Haoauthor=W.+Chenauthor=J.+Zhuauthor=C.+Luauthor=Y.+Shen&title=Design+and+synthesis+of+2-phenylnaphthalenoids+and+2-phenylbenzofuranoids+as+DNA+topoisomerase+inhibitors+and+antitumor+agents&doi=10.1016%2Fj.ejmech.2015.07.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span></div><div class="casAuthors">Hao, Huilin; Chen, Wang; Zhu, Jing; Lu, Chunhua; Shen, Yuemao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eight 2-phenylnaphthalenoids (2PNs) and twenty four 2-phenylbenzofuranoids (2PBFs) were successfully designed, synthesized and their antiproliferative and in vitro DNA topoisomerase inhibitory activities were evaluated.  Nine compds. (four 2PNs and five 2PBFs) showed either TopoI or TopoIIÎ± inhibitory activities.  Six compds. (four 2PNs and two 2PBFs) exhibited potent cytotoxicity with IC50 values for 72 h exposure ranging from 0.3 to above 20 Î¼M against MDA-MB-231, MDA-MB-435, HepG2 and PC3 cell lines.  The two 2PBFs displayed comparable and even better antiproliferative as well as TopoIIÎ± inhibitory activities than 2PNs.  Interestingly, the active 2PBFs displayed different mechanisms of TopoIIÎ± inhibition from that of 2PNs, suggesting that the chromophore scaffold replacement may result in a change of the binding site of inhibitors to TopoIIÎ±.  Furthermore, the mechanisms of antiproliferation on MDA-MB-231 cells indicate that compds. I and II are promising for further development of anticancer agents.  The results of this study reveal that the evolutionary strategy of medicinal chem. through scaffold hopping is a promising strategy for structure optimization of TopoIIÎ± inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptY9xrEHooKbVg90H21EOLACvtfcHk0ljbqPELnA1cdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO&md5=1ab3a31789c3ac2b7d632d379bb48992</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-phenylnaphthalenoids%2520and%25202-phenylbenzofuranoids%2520as%2520DNA%2520topoisomerase%2520inhibitors%2520and%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D277%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A. F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: an ATP-competitive human topoisomerase IIÎ± catalytic inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1898</span>â <span class="NLM_lpage">1908</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2016.03.017" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1898-1908&author=P.+Ahmadauthor=H.+Wooauthor=K.+Y.+Junauthor=A.+A.+Kadiauthor=H.+A.+Abdel-Azizauthor=Y.+Kwonauthor=A.+F.+Rahman&title=Design%2C+synthesis%2C+topoisomerase+I+%26+II+inhibitory+activity%2C+antiproliferative+activity%2C+and+structure-activity+relationship+study+of+pyrazoline+derivatives%3A+an+ATP-competitive+human+topoisomerase+II%CE%B1+catalytic+inhibitor&doi=10.1016%2Fj.bmc.2016.03.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DP.%26aulast%3DWoo%26aufirst%3DH.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadi%26aufirst%3DA.%2BA.%26aulast%3DAbdel-Aziz%26aufirst%3DH.%2BA.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DRahman%26aufirst%3DA.%2BF.%26atitle%3DDesign%252C%2520synthesis%252C%2520topoisomerase%2520I%2520%2526%2520II%2520inhibitory%2520activity%252C%2520antiproliferative%2520activity%252C%2520and%2520structure-activity%2520relationship%2520study%2520of%2520pyrazoline%2520derivatives%253A%2520an%2520ATP-competitive%2520human%2520topoisomerase%2520II%25CE%25B1%2520catalytic%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1898%26epage%3D1908%26doi%3D10.1016%2Fj.bmc.2016.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and mechanism studies of 1,3-benzoazolyl substituted pyrrolo[2,3-b]pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">238</span>â <span class="NLM_lpage">252</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01284</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01284" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=238-252&author=P.+H.+Liauthor=P.+Zengauthor=S.+B.+Chenauthor=P.+F.+Yaoauthor=Y.+W.+Maiauthor=J.+H.+Tanauthor=T.+M.+Ouauthor=S.+L.+Huangauthor=D.+Liauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Synthesis+and+mechanism+studies+of+1%2C3-benzoazolyl+substituted+pyrrolo%5B2%2C3-b%5Dpyrazine+derivatives+as+nonintercalative+topoisomerase+II+catalytic+inhibitors&doi=10.1021%2Facs.jmedchem.5b01284"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01284%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%2BH.%26aulast%3DZeng%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DMai%26aufirst%3DY.%2BW.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DSynthesis%2520and%2520mechanism%2520studies%2520of%25201%252C3-benzoazolyl%2520substituted%2520pyrrolo%255B2%252C3-b%255Dpyrazine%2520derivatives%2520as%2520nonintercalative%2520topoisomerase%2520II%2520catalytic%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D238%26epage%3D252%26doi%3D10.1021%2Facs.jmedchem.5b01284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagotto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianoncelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capranico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribaudo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, M.</span></span> <span> </span><span class="NLM_article-title">Novel ametantrone-amsacrine related hybrids as topoisomerase IIÎ² poisons and cytotoxic agents</span>. <i>Arch. Pharm. (Weinheim, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">728</span>â <span class="NLM_lpage">737</span>, <span class="refDoi">Â DOI: 10.1002/ardp.201400111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fardp.201400111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25042690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKjs73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2014&pages=728-737&author=G.+Zagottoauthor=A.+Gianoncelliauthor=C.+Sissiauthor=C.+Marzanoauthor=V.+Gandinauthor=R.+Pasqualeauthor=G.+Capranicoauthor=G.+Ribaudoauthor=M.+Palumbo&title=Novel+ametantrone-amsacrine+related+hybrids+as+topoisomerase+II%CE%B2+poisons+and+cytotoxic+agents&doi=10.1002%2Fardp.201400111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Ametantrone-Amsacrine Related Hybrids as Topoisomerase IIÎ² Poisons and Cytotoxic Agents</span></div><div class="casAuthors">Zagotto, Giuseppe; Gianoncelli, Alessandra; Sissi, Claudia; Marzano, Cristina; Gandin, Valentina; Pasquale, Riccardo; Capranico, Giovanni; Ribaudo, Giovanni; Palumbo, Manlio</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">728-737</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The precise definition of the structural requirements for effective topoisomerase II poisoning by drug mols. is still an elusive issue.  In the attempt to better define a pharmacophoric pattern, we prepd. several conjugates combining the chem. features of two well-known topoisomerase II poisons, amsacrine and ametantrone.  Indeed, an appropriate fusion geometry, which entails the anthracenedione moiety of ametantrone appropriately connected to the methanesulfonamidoaniline side chain of amsacrine, elicits DNA-intercalating properties, the capacity to inhibit the human topoisomerase IIÎ² isoform, and cytotoxic activity resembling that of the parent compds.  In addn., the properties of the lateral groups linked to the anthracenedione group play an important role in modulating DNA binding and cell cytotoxicity.  Among the compds. tested, 10, 11, and 19 appear to be promising for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdO_Zu_Qe9LVg90H21EOLACvtfcHk0ljbqPELnA1cdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKjs73F&md5=03266374d96d584d257a980ed3e85868</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fardp.201400111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201400111%26sid%3Dliteratum%253Aachs%26aulast%3DZagotto%26aufirst%3DG.%26aulast%3DGianoncelli%26aufirst%3DA.%26aulast%3DSissi%26aufirst%3DC.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DPasquale%26aufirst%3DR.%26aulast%3DCapranico%26aufirst%3DG.%26aulast%3DRibaudo%26aufirst%3DG.%26aulast%3DPalumbo%26aufirst%3DM.%26atitle%3DNovel%2520ametantrone-amsacrine%2520related%2520hybrids%2520as%2520topoisomerase%2520II%25CE%25B2%2520poisons%2520and%2520cytotoxic%2520agents%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2014%26volume%3D347%26spage%3D728%26epage%3D737%26doi%3D10.1002%2Fardp.201400111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">59</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2016.03.066" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=59-70&author=W.+Zhangauthor=B.+Zhangauthor=W.+Zhangauthor=T.+Yangauthor=N.+Wangauthor=C.+Gaoauthor=C.+Tanauthor=H.+Liuauthor=Y.+Jiang&title=Synthesis+and+antiproliferative+activity+of+9-benzylamino-6-chloro-2-methoxy-acridine+derivatives+as+potent+DNA-binding+ligands+and+topoisomerase+II+inhibitors&doi=10.1016%2Fj.ejmech.2016.03.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%25209-benzylamino-6-chloro-2-methoxy-acridine%2520derivatives%2520as%2520potent%2520DNA-binding%2520ligands%2520and%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D116%26spage%3D59%26epage%3D70%26doi%3D10.1016%2Fj.ejmech.2016.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and biological evaluation of potential prodrugs related to the experimental anticancer agent indotecan (LMP400)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4890</span>â <span class="NLM_lpage">4899</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00220</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00220" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1Cnsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4890-4899&author=P.+C.+Lvauthor=M.+S.+Elsayedauthor=K.+Agamaauthor=C.+Marchandauthor=Y.+Pommierauthor=M.+Cushman&title=Design%2C+Synthesis%2C+and+biological+evaluation+of+potential+prodrugs+related+to+the+experimental+anticancer+agent+indotecan+%28LMP400%29&doi=10.1021%2Facs.jmedchem.6b00220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400)</span></div><div class="casAuthors">Lv, Peng-Cheng; Elsayed, Mohamed S. A.; Agama, Keli; Marchand, Christophe; Pommier, Yves; Cushman, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4890-4899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of anticancer agents with two compds. in clin. trials.  Recent metab. studies of indotecan (LMP400) led to the discovery of the biol. active 2-hydroxylated analog and 3-hydroxylated metabolite, thus providing strategically placed functional groups for the prepn. of a variety of potential ester prodrugs of these two compds.  The current study details the design and synthesis of two series of indenoisoquinoline prodrugs, and it also reveals how substituents on the O-2 and O-3 positions of the A ring, which are next to the cleaved DNA strand in the drug-DNA-Top1 ternary cleavage complex, affect Top1 inhibitory activity and cytotoxicity.  Many of the indenoisoquinoline prodrugs were very potent antiproliferative agents with GI50 values below 10 nM in a variety of human cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraxUKLR9FaWLVg90H21EOLACvtfcHk0lgMYAXQBWac7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1Cnsrg%253D&md5=a1349cde99df9cacac6ded83f5b1e050</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00220%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DP.%2BC.%26aulast%3DElsayed%26aufirst%3DM.%2BS.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DMarchand%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCushman%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520potential%2520prodrugs%2520related%2520to%2520the%2520experimental%2520anticancer%2520agent%2520indotecan%2520%2528LMP400%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4890%26epage%3D4899%26doi%3D10.1021%2Facs.jmedchem.6b00220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham
Thi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Nhat, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo Hanh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luc Quang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham The, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang Thi, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang Thi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nguyen, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and cytotoxic evaluation of novel indenoisoquinoline-substituted triazole hybrids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3652</span>â <span class="NLM_lpage">3657</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2016.05.092" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3652-3657&author=T.+Pham%0AThiauthor=T.+G.+Le+Nhatauthor=T.+Ngo+Hanhauthor=T.+Luc+Quangauthor=C.+Pham+Theauthor=T.+A.+Dang+Thiauthor=H.+T.+Nguyenauthor=T.+H.+Nguyenauthor=P.+Hoang+Thiauthor=T.+Van+Nguyen&title=Synthesis+and+cytotoxic+evaluation+of+novel+indenoisoquinoline-substituted+triazole+hybrids&doi=10.1016%2Fj.bmcl.2016.05.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DPham%2BThi%26aufirst%3DT.%26aulast%3DLe%2BNhat%26aufirst%3DT.%2BG.%26aulast%3DNgo%2BHanh%26aufirst%3DT.%26aulast%3DLuc%2BQuang%26aufirst%3DT.%26aulast%3DPham%2BThe%26aufirst%3DC.%26aulast%3DDang%2BThi%26aufirst%3DT.%2BA.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DNguyen%26aufirst%3DT.%2BH.%26aulast%3DHoang%2BThi%26aufirst%3DP.%26aulast%3DVan%2BNguyen%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520cytotoxic%2520evaluation%2520of%2520novel%2520indenoisoquinoline-substituted%2520triazole%2520hybrids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3652%26epage%3D3657%26doi%3D10.1016%2Fj.bmcl.2016.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VessiÃ¨res, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Top, S.</span></span> <span> </span><span class="NLM_article-title">Ferrocifen type anti cancer drugs</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">8802</span>â <span class="NLM_lpage">8817</span>, <span class="refDoi">Â DOI: 10.1039/C5CS00486A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC5CS00486A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26486993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yktbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=8802-8817&author=G.+Jaouenauthor=A.+Vessi%C3%A8resauthor=S.+Top&title=Ferrocifen+type+anti+cancer+drugs&doi=10.1039%2FC5CS00486A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ferrocifen type anti cancer drugs</span></div><div class="casAuthors">Jaouen, Gerard; Vessieres, Anne; Top, Siden</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8802-8817</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Despite current developments in therapeutics focusing on biotechnol.-oriented species, the unflagging utility of small mols. or peptides in medicine is still producing strong results.  In 2014 for example, of the 41 new medicines authorized for sale, 33 belonged to the category of small mols., while in 2013 they represented 24 of 27, according to the FDA.  This can be explained as the result of recent forays into new or long-neglected areas of chem.  Medicinal organometallic chem. can provide us with an antimalarial against resistant parasitic strains, as attested by the phase II clin. development of ferroquine, with a new framework for conceptual advances based on three-dimensional space-filling, and with redox or indeed catalytic intracellular properties.  In this context, bioferrocene species with antiproliferative potential have for several years been the subject of sustained effort, based on some initial successes and on the nature of ferrocene as a stable arom., with low toxicity, low cost, and possessing reversible redox properties.  We show here the different antitumoral approaches offered by ferrocifen derivs., originally simple derivs. of tamoxifen, which over the course of their development have proved to possess remarkable structural and mechanistic diversity.  These entities act via various targets, some of which have been identified, that are triggered according to the concn. of the products.  They also act according to the nature of the cancer cells and their functionality, by mechanistic pathways that can operate either synergistically or not, in successive, concomitant or sequential ways, depending for example on newly identified signaling pathways inducing senescence or apoptosis.  Here we present a first attempt to rationalize the behavior of these entities with various anticancer targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaB6CyYyApRrVg90H21EOLACvtfcHk0lgMYAXQBWac7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yktbnM&md5=c2a2e22576f6c8ef5dda04ffe9e28ead</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1039%2FC5CS00486A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00486A%26sid%3Dliteratum%253Aachs%26aulast%3DJaouen%26aufirst%3DG.%26aulast%3DVessi%25C3%25A8res%26aufirst%3DA.%26aulast%3DTop%26aufirst%3DS.%26atitle%3DFerrocifen%2520type%2520anti%2520cancer%2520drugs%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D8802%26epage%3D8817%26doi%3D10.1039%2FC5CS00486A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigeon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Top, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span> <span> </span><span class="NLM_article-title">Organometallic antitumor compounds: ferrocifens as precursors to quinone methides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">10230</span>â <span class="NLM_lpage">10233</span>, <span class="refDoi">Â DOI: 10.1002/anie.201503048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fanie.201503048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOrt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=10230-10233&author=Y.+Wangauthor=P.+Pigeonauthor=S.+Topauthor=M.+J.+McGlincheyauthor=G.+Jaouen&title=Organometallic+antitumor+compounds%3A+ferrocifens+as+precursors+to+quinone+methides&doi=10.1002%2Fanie.201503048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Organometallic Antitumor Compounds: Ferrocifens as Precursors to Quinone Methides</span></div><div class="casAuthors">Wang, Yong; Pigeon, Pascal; Top, Siden; McGlinchey, Michael J.; Jaouen, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10230-10233</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The synthesis and chem. oxidn. profile of a new generation of ferrocifen derivs. with strong antiproliferative behavior in vitro is reported.  In particular, the hydroxypropyl deriv. HO(CH2)3C(Fc):C(C6H4OH)2 (3b) exhibited exceptional antiproliferative activity against the cancer cell lines HepG2 and MDA-MB-231 TNBC, with IC50 values of 0.07 and 0.11 Î¼M, resp.  Chem. oxidn. of 3b yielded an unprecedented tetrahydrofuran-substituted quinone methide (QM) via internal cyclization of the hydroxyalkyl chain, whereas the corresponding alkyl analog CH3CH2-C(Fc):C(C6H4OH)2 merely formed a vinyl QM.  The ferrocenyl group in 3b plays a key role, not only as an intramol. reversible redox "antenna", but also as a stabilized carbenium ion "modulator".  The presence of the oxygen heterocycle in 3b-QM enhances its stability and leads to a unique chem. oxidn. profile, thus revealing crucial clues for deciphering its mechanism of action in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvX5qj__CgC7Vg90H21EOLACvtfcHk0lgs0mr0Z1h3cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOrt7jN&md5=8a5b8dd132d5152de45177aec43576c5</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fanie.201503048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201503048%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPigeon%26aufirst%3DP.%26aulast%3DTop%26aufirst%3DS.%26aulast%3DMcGlinchey%26aufirst%3DM.%2BJ.%26aulast%3DJaouen%26aufirst%3DG.%26atitle%3DOrganometallic%2520antitumor%2520compounds%253A%2520ferrocifens%2520as%2520precursors%2520to%2520quinone%2520methides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D10230%26epage%3D10233%26doi%3D10.1002%2Fanie.201503048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Top, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansette, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigeon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VessiÃ¨res, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span> <span> </span><span class="NLM_article-title">Ferrocenyl quinone methide-thiol adducts as new antiproliferative agents: synthesis, metabolic formation from ferrociphenols, and oxidative transformation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10431</span>â <span class="NLM_lpage">10434</span>, <span class="refDoi">Â DOI: 10.1002/anie.201603931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fanie.201603931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFCgtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10431-10434&author=Y.+Wangauthor=M.+A.+Richardauthor=S.+Topauthor=P.+M.+Dansetteauthor=P.+Pigeonauthor=A.+Vessi%C3%A8resauthor=D.+Mansuyauthor=G.+Jaouen&title=Ferrocenyl+quinone+methide-thiol+adducts+as+new+antiproliferative+agents%3A+synthesis%2C+metabolic+formation+from+ferrociphenols%2C+and+oxidative+transformation&doi=10.1002%2Fanie.201603931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Ferrocenyl quinone methide-thiol adducts as new antiproliferative agents: synthesis, metabolic formation from ferrociphenols, and oxidative transformation</span></div><div class="casAuthors">Wang, Yong; Richard, Marie-Aude; Top, Siden; Dansette, Patrick M.; Pigeon, Pascal; Vessieres, Anne; Mansuy, Daniel; Jaouen, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10431-10434</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ferrociphenols (FCs) and their oxidized, electrophilic quinone methide metabolites I [FC-QMs, Fc = ferrocenyl; R1 = H, OH, O(CH2)3NMe2] are organometallic compds. related to tamoxifen that exhibit strong antiproliferative properties.  To evaluate the reactivity of FC-QMs toward cellular nucleophiles, we studied their reaction with selected thiols.  A series of new compds. resulting from the addn. of the nucleophiles RSH, the FC-SR adducts II (RSH = GSH, NACM, ME), were thus synthesized and completely characterized.  Such conjugates are formed upon metab. of FCs by liver microsomes in the presence of NADPH and thiols.  Some of the FC-SR adducts exhibit antiproliferative properties comparable to those of their FC precursors.  Under oxidizing conditions they either revert to their FC-QM precursors or transform into new quinone methides (QMs) contg. the SR moiety, FC-SR-QM.  These results provide interesting data about the reactivity and mechanism of antiproliferative effects of FCs, and also open the way to a new series of organometallic antitumor compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN6sdabCfxmLVg90H21EOLACvtfcHk0lgs0mr0Z1h3cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFCgtL4%253D&md5=cf1f7746f41d6d64820a30aecf6da53b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603931%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRichard%26aufirst%3DM.%2BA.%26aulast%3DTop%26aufirst%3DS.%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DPigeon%26aufirst%3DP.%26aulast%3DVessi%25C3%25A8res%26aufirst%3DA.%26aulast%3DMansuy%26aufirst%3DD.%26aulast%3DJaouen%26aufirst%3DG.%26atitle%3DFerrocenyl%2520quinone%2520methide-thiol%2520adducts%2520as%2520new%2520antiproliferative%2520agents%253A%2520synthesis%252C%2520metabolic%2520formation%2520from%2520ferrociphenols%252C%2520and%2520oxidative%2520transformation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10431%26epage%3D10434%26doi%3D10.1002%2Fanie.201603931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scalcon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciofini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de JÃ©sÃºs
CÃ¡zares-Marinero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigeon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VessiÃ¨res, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigobello, M. P.</span></span> <span> </span><span class="NLM_article-title">Enzymatic oxidation of ansa-ferrocifen leads to strong and selective thioredoxin reductase inhibition</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">146</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2016.08.005" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=146-151&author=V.+Scalconauthor=A.+Cittaauthor=A.+Foldaauthor=A.+Bindoliauthor=M.+Salmainauthor=I.+Ciofiniauthor=S.+Blanchardauthor=J.+de+J%C3%A9s%C3%BAs%0AC%C3%A1zares-Marineroauthor=Y.+Wangauthor=P.+Pigeonauthor=G.+Jaouenauthor=A.+Vessi%C3%A8resauthor=M.+P.+Rigobello&title=Enzymatic+oxidation+of+ansa-ferrocifen+leads+to+strong+and+selective+thioredoxin+reductase+inhibition&doi=10.1016%2Fj.jinorgbio.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DScalcon%26aufirst%3DV.%26aulast%3DCitta%26aufirst%3DA.%26aulast%3DFolda%26aufirst%3DA.%26aulast%3DBindoli%26aufirst%3DA.%26aulast%3DSalmain%26aufirst%3DM.%26aulast%3DCiofini%26aufirst%3DI.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3Dde%2BJ%25C3%25A9s%25C3%25BAs%2BC%25C3%25A1zares-Marinero%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPigeon%26aufirst%3DP.%26aulast%3DJaouen%26aufirst%3DG.%26aulast%3DVessi%25C3%25A8res%26aufirst%3DA.%26aulast%3DRigobello%26aufirst%3DM.%2BP.%26atitle%3DEnzymatic%2520oxidation%2520of%2520ansa-ferrocifen%2520leads%2520to%2520strong%2520and%2520selective%2520thioredoxin%2520reductase%2520inhibition%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2016%26volume%3D165%26spage%3D146%26epage%3D151%26doi%3D10.1016%2Fj.jinorgbio.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wambang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schifano-Faux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aillerie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldeyrou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bal-Mahieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndifon, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meignan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansiaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©linski, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">651</span>â <span class="NLM_lpage">660</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.12.033" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=651-660&author=N.+Wambangauthor=N.+Schifano-Fauxauthor=A.+Aillerieauthor=B.+Baldeyrouauthor=C.+Jacquetauthor=C.+Bal-Mahieuauthor=T.+Bousquetauthor=S.+Pellegriniauthor=P.+T.+Ndifonauthor=S.+Meignanauthor=J.+F.+Goossensauthor=A.+Lansiauxauthor=L.+P%C3%A9linski&title=Synthesis+and+biological+activity+of+ferrocenyl+indeno%5B1%2C2-c%5Disoquinolines+as+topoisomerase+II+inhibitors&doi=10.1016%2Fj.bmc.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DWambang%26aufirst%3DN.%26aulast%3DSchifano-Faux%26aufirst%3DN.%26aulast%3DAillerie%26aufirst%3DA.%26aulast%3DBaldeyrou%26aufirst%3DB.%26aulast%3DJacquet%26aufirst%3DC.%26aulast%3DBal-Mahieu%26aufirst%3DC.%26aulast%3DBousquet%26aufirst%3DT.%26aulast%3DPellegrini%26aufirst%3DS.%26aulast%3DNdifon%26aufirst%3DP.%2BT.%26aulast%3DMeignan%26aufirst%3DS.%26aulast%3DGoossens%26aufirst%3DJ.%2BF.%26aulast%3DLansiaux%26aufirst%3DA.%26aulast%3DP%25C3%25A9linski%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520ferrocenyl%2520indeno%255B1%252C2-c%255Disoquinolines%2520as%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D651%26epage%3D660%26doi%3D10.1016%2Fj.bmc.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Oliveira Figueiredo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdomo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcez, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fatima
Cepa Matos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcez, W. S.</span></span> <span> </span><span class="NLM_article-title">Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIÎ± by its cytotoxic Î²-carboline alkaloids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1358</span>â <span class="NLM_lpage">1361</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2014.01.039" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1358-1361&author=P.+de%0AOliveira+Figueiredoauthor=R.+T.+Perdomoauthor=F.+R.+Garcezauthor=M.+de+Fatima%0ACepa+Matosauthor=J.+E.+de+Carvalhoauthor=W.+S.+Garcez&title=Further+constituents+of+Galianthe+thalictroides+%28Rubiaceae%29+and+inhibition+of+DNA+topoisomerases+I+and+II%CE%B1+by+its+cytotoxic+%CE%B2-carboline+alkaloids&doi=10.1016%2Fj.bmcl.2014.01.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.01.039%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%2BFigueiredo%26aufirst%3DP.%26aulast%3DPerdomo%26aufirst%3DR.%2BT.%26aulast%3DGarcez%26aufirst%3DF.%2BR.%26aulast%3Dde%2BFatima%2BCepa%2BMatos%26aufirst%3DM.%26aulast%3Dde%2BCarvalho%26aufirst%3DJ.%2BE.%26aulast%3DGarcez%26aufirst%3DW.%2BS.%26atitle%3DFurther%2520constituents%2520of%2520Galianthe%2520thalictroides%2520%2528Rubiaceae%2529%2520and%2520inhibition%2520of%2520DNA%2520topoisomerases%2520I%2520and%2520II%25CE%25B1%2520by%2520its%2520cytotoxic%2520%25CE%25B2-carboline%2520alkaloids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D1358%26epage%3D1361%26doi%3D10.1016%2Fj.bmcl.2014.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naithani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmeder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span> <span> </span><span class="NLM_article-title">Cancer chemopreventive activity of sulforamate derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2005.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2005.10.002" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2006&pages=121-124&author=R.+M.+Moriartyauthor=R.+Naithaniauthor=J.+Kosmederauthor=O.+Prakash&title=Cancer+chemopreventive+activity+of+sulforamate+derivatives&doi=10.1016%2Fj.ejmech.2005.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2005.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2005.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26aulast%3DNaithani%26aufirst%3DR.%26aulast%3DKosmeder%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DO.%26atitle%3DCancer%2520chemopreventive%2520activity%2520of%2520sulforamate%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2006%26volume%3D41%26spage%3D121%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2005.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talibov, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LinkuvienÄ, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, U. H.</span></span> <span> </span><span class="NLM_article-title">Kinetically selective inhibitors of human carbonic anhydrase isozymes I, II, VII, IX, XII, and XIII</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2083</span>â <span class="NLM_lpage">2093</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2083-2093&author=V.+O.+Talibovauthor=V.+Linkuvien%C4%97author=D.+Matulisauthor=U.+H.+Danielson&title=Kinetically+selective+inhibitors+of+human+carbonic+anhydrase+isozymes+I%2C+II%2C+VII%2C+IX%2C+XII%2C+and+XIII&doi=10.1021%2Facs.jmedchem.5b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetically Selective Inhibitors of Human Carbonic Anhydrase Isozymes I, II, VII, IX, XII, and XIII</span></div><div class="casAuthors">Talibov, Vladimir O.; Linkuviene, Vaida; Matulis, Daumantas; Danielson, U. Helena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2083-2093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To get a better understanding of the possibility of developing selective carbonic anhydrase (CA) inhibitors, interactions between 17 benzenesulfonamide ligands and 6 human CAs (full-length CA I, II, VII, and XIII and catalytic domains of CA IX and XII) were characterized using surface plasmon resonance and fluorescent-based thermal shift assays.  Kinetics revealed that the strongest binders had subnanomolar affinities with low dissocn. rates (i.e., kd values around 1 Ã 10-3 s-1) or were essentially irreversible.  Chemodynamic anal. of the interactions highlighted an intrinsic mechanism of the CA-sulfonamide interaction kinetics and showed that slow dissocn. rates were mediated by large hydrophobic contacts.  The studied inhibitors demonstrated a high cross-reactivity within the protein family.  However, according to chem. phylogenetic anal. developed for kinetic data, several ligands were found to be selective against certain CA isoenzymes, indicating that it should be possible to develop selective CA inhibitors suitable for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOw1t_w4zwELVg90H21EOLACvtfcHk0lgWPhOC__3lPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWksLo%253D&md5=c861a0cc9afdfea5fd7427d7e9c2ba89</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01723%26sid%3Dliteratum%253Aachs%26aulast%3DTalibov%26aufirst%3DV.%2BO.%26aulast%3DLinkuvien%25C4%2597%26aufirst%3DV.%26aulast%3DMatulis%26aufirst%3DD.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26atitle%3DKinetically%2520selective%2520inhibitors%2520of%2520human%2520carbonic%2520anhydrase%2520isozymes%2520I%252C%2520II%252C%2520VII%252C%2520IX%252C%2520XII%252C%2520and%2520XIII%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2083%26epage%3D2093%26doi%3D10.1021%2Facs.jmedchem.5b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasulu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavitha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangella, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummuri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankaraiah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dithiocarbamate linked Î²-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5511</span>â <span class="NLM_lpage">5526</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26264845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=5511-5526&author=A.+Kamalauthor=M.+Sathishauthor=V.+L.+Nayakauthor=V.+Srinivasuluauthor=B.+Kavithaauthor=Y.+Tangellaauthor=D.+Thummuriauthor=C.+Bagulauthor=N.+Shankaraiahauthor=N.+Nagesh&title=Design+and+synthesis+of+dithiocarbamate+linked+%CE%B2-carboline+derivatives%3A+DNA+topoisomerase+II+inhibition+with+DNA+binding+and+apoptosis+inducing+ability&doi=10.1016%2Fj.bmc.2015.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dithiocarbamate linked Î²-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span></div><div class="casAuthors">Kamal, Ahmed; Sathish, Manda; Nayak, V. Lakshma; Srinivasulu, Vunnam; Kavitha, Botla; Tangella, Yellaiah; Thummuri, Dinesh; Bagul, Chandrakant; Shankaraiah, Nagula; Nagesh, Narayana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5511-5526</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of new Î²-carboline-dithiocarbamate derivs. bearing Ph, dithiocarbamate and H/methyl substitutions at position-1, 3 and 9, resp., were designed and synthesized.  These derivs. 8a-l and 13a-l and their starting precursors (7a-d and 12a-d) have been evaluated for their in vitro cytotoxic activity on selected human cancer cell lines.  Among the derivs. tested, 7c, 12c, 8a, 8d, 8i, 8j, 8k, 8l and 13d-l exhibited considerable cytotoxicity against most of the tested cancer cell lines (IC50 <10 Î¼M).  Interestingly, most of the derivs. (8a-l and 13a-l) exhibited enhanced activity than their precursors (7a-d and 12a-d), which indicates that the combination of dithiocarbamate with Î²-carboline enhances the cytotoxicity of 8a-l and 13a-l.  Moreover, the derivs. 8j and 13g exhibited significant cytotoxic activity with IC50 values of 1.34 Î¼M and 0.79 Î¼M on DU-145 cancer cells, resp.  Further, the induction of apoptosis by these derivs. was confirmed by Annexin V-FITC and Hoechst staining assays.  However, both biophys. as well as mol. docking studies suggested a combilexin-type of interaction between these derivs. and DNA, unlike simple Î²-carbolines.  With a view to understand their mechanism of action, DNA topoisomerase II (topo II) inhibition assay was also performed.  Overall, the present study emphasizes the importance of linking a dithiocarbamate moiety to the Î²-carboline scaffold for exhibiting profound activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2JbzggrG7v7Vg90H21EOLACvtfcHk0lgWPhOC__3lPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ&md5=8b85c9edc23342973d0ee6b5aa08cd5c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DSathish%26aufirst%3DM.%26aulast%3DNayak%26aufirst%3DV.%2BL.%26aulast%3DSrinivasulu%26aufirst%3DV.%26aulast%3DKavitha%26aufirst%3DB.%26aulast%3DTangella%26aufirst%3DY.%26aulast%3DThummuri%26aufirst%3DD.%26aulast%3DBagul%26aufirst%3DC.%26aulast%3DShankaraiah%26aufirst%3DN.%26aulast%3DNagesh%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dithiocarbamate%2520linked%2520%25CE%25B2-carboline%2520derivatives%253A%2520DNA%2520topoisomerase%2520II%2520inhibition%2520with%2520DNA%2520binding%2520and%2520apoptosis%2520inducing%2520ability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5511%26epage%3D5526%26doi%3D10.1016%2Fj.bmc.2015.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of the novel DNA topoisomerase II inhibitors: Esterification and amination substituted 4â-demethylepipodophyllotoxin derivates exhibiting anti-tumor activity by activating ATM/ATR signaling pathways</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">267</span>â <span class="NLM_lpage">277</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.03.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2014.03.082" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=267-277&author=L.+Xiaoauthor=W.+Zhaoauthor=H.+M.+Liauthor=D.+J.+Wanauthor=D.+S.+Liauthor=T.+Chenauthor=Y.+J.+Tang&title=Design+and+synthesis+of+the+novel+DNA+topoisomerase+II+inhibitors%3A+Esterification+and+amination+substituted+4%E2%80%99-demethylepipodophyllotoxin+derivates+exhibiting+anti-tumor+activity+by+activating+ATM%2FATR+signaling+pathways&doi=10.1016%2Fj.ejmech.2014.03.082"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.03.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.03.082%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DWan%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DY.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520the%2520novel%2520DNA%2520topoisomerase%2520II%2520inhibitors%253A%2520Esterification%2520and%2520amination%2520substituted%25204%25E2%2580%2599-demethylepipodophyllotoxin%2520derivates%2520exhibiting%2520anti-tumor%2520activity%2520by%2520activating%2520ATM%252FATR%2520signaling%2520pathways%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D267%26epage%3D277%26doi%3D10.1016%2Fj.ejmech.2014.03.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. J.</span></span> <span> </span><span class="NLM_article-title">A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-<i>O</i>-(2-pyrazinecarboxylic)-4â-demethyl epipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2998</span>â <span class="NLM_lpage">3007</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2014.03.048" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2998-3007&author=W.+Zhaoauthor=L.+Chenauthor=H.+M.+Liauthor=D.+J.+Wangauthor=D.+S.+Liauthor=T.+Chenauthor=Z.+P.+Yuanauthor=Y.+J.+Tang&title=A+rational+design+strategy+of+the+novel+topoisomerase+II+inhibitors+for+the+synthesis+of+the+4-O-%282-pyrazinecarboxylic%29-4%E2%80%99-demethyl+epipodophyllotoxin+with+antitumor+activity+by+diminishing+the+relaxation+reaction+of+topoisomerase+II-DNA+decatenation&doi=10.1016%2Fj.bmc.2014.03.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DWang%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DZ.%2BP.%26aulast%3DTang%26aufirst%3DY.%2BJ.%26atitle%3DA%2520rational%2520design%2520strategy%2520of%2520the%2520novel%2520topoisomerase%2520II%2520inhibitors%2520for%2520the%2520synthesis%2520of%2520the%25204-O-%25282-pyrazinecarboxylic%2529-4%25E2%2580%2599-demethyl%2520epipodophyllotoxin%2520with%2520antitumor%2520activity%2520by%2520diminishing%2520the%2520relaxation%2520reaction%2520of%2520topoisomerase%2520II-DNA%2520decatenation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2998%26epage%3D3007%26doi%3D10.1016%2Fj.bmc.2014.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasinoff, B. B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-<i>N</i>-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5935</span>â <span class="NLM_lpage">5949</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2014.09.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5935-5949&author=A.+A.+Yadavauthor=X.+Wuauthor=D.+Patelauthor=J.+C.+Yalowichauthor=B.+B.+Hasinoff&title=Structure-based+design%2C+synthesis+and+biological+testing+of+etoposide+analog+epipodophyllotoxin-N-mustard+hybrid+compounds+designed+to+covalently+bind+to+topoisomerase+II+and+DNA&doi=10.1016%2Fj.bmc.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DA.%2BA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520testing%2520of%2520etoposide%2520analog%2520epipodophyllotoxin-N-mustard%2520hybrid%2520compounds%2520designed%2520to%2520covalently%2520bind%2520to%2520topoisomerase%2520II%2520and%2520DNA%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5935%26epage%3D5949%26doi%3D10.1016%2Fj.bmc.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. V.</span></span> <span> </span><span class="NLM_article-title">Piperazine derivatives for therapeutic use: a patent review (2010-present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">777</span>â <span class="NLM_lpage">797</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2016.1189902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1080%2F13543776.2016.1189902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27177234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVajtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=777-797&author=A.+K.+Rathiauthor=R.+Syedauthor=H.+S.+Shinauthor=R.+V.+Patel&title=Piperazine+derivatives+for+therapeutic+use%3A+a+patent+review+%282010-present%29&doi=10.1080%2F13543776.2016.1189902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Piperazine derivatives for therapeutic use: a patent review (2010-present)</span></div><div class="casAuthors">Rathi, Anuj K.; Syed, Riyaz; Shin, Han-Seung; Patel, Rahul V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">777-797</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Piperazine, a six membered nitrogen contg. heterocycle, is of great significance to the rational design of drugs.  This moiety can be found in a plethora of well-known drugs with various therapeutic uses, such as antipsychotic, antihistamine, antianginal, antidepressant, anticancer, antiviral, cardio protectors, anti-inflammatory, and imaging agents.  Slight modification to the substitution pattern on the piperazine nucleus facilitates a recognizable difference in the medicinal potential of the resultant mols.  Scifinder was the main source used to search for patents contg. piperazine compds. with therapeutic uses.  The article describes a variety of mol. designs bearing piperazine entity furnishing CNS agents, anticancer, cardio-protective agents, antiviral, anti-tuberculosis, anti-inflammatory, antidiabetic, and antihistamine profiles, as well as agents relieving pain and useful in imaging applications.  The great interest gathered to explore piperazine based mols. in relatively few years reflects the broad potential of the entity.  Earlier, this scaffold was considered to express CNS activity only.  However, a significant increase in research covering studies of several different activities of piperazine ring suggest a successful emergence of the pharmacophore.  Certain patents outlined in the present article recommend that piperazines can be a flexible building block to discover drug-like elements and modification of substituents present on the piperazine ring may have a significant impact on the pharmacokinetic and pharmacodynamics factors of the resulting mols.  This article aims to provide insights to piperazine based mol. fragments that would assist drug discoverers to rationally design mols. for various diseases.  We anticipate, and highly recommend, further therapeutic investigations on this motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIhdjKw214crVg90H21EOLACvtfcHk0lg2wHgxtcDA1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVajtb0%253D&md5=186a0479043f37982b9aa880a4f2791a</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1189902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1189902%26sid%3Dliteratum%253Aachs%26aulast%3DRathi%26aufirst%3DA.%2BK.%26aulast%3DSyed%26aufirst%3DR.%26aulast%3DShin%26aufirst%3DH.%2BS.%26aulast%3DPatel%26aufirst%3DR.%2BV.%26atitle%3DPiperazine%2520derivatives%2520for%2520therapeutic%2520use%253A%2520a%2520patent%2520review%2520%25282010-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D777%26epage%3D797%26doi%3D10.1080%2F13543776.2016.1189902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">11014</span>â <span class="NLM_lpage">11019</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0704002104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.0704002104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=17578914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=11014-11019&author=A.+M.+Azarovaauthor=Y.+L.+Lyuauthor=C.+P.+Linauthor=Y.+C.+Tsaiauthor=J.+Y.+Lauauthor=J.+C.+Wangauthor=L.+F.+Liu&title=Roles+of+DNA+topoisomerase+II+isozymes+in+chemotherapy+and+secondary+malignancies&doi=10.1073%2Fpnas.0704002104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span></div><div class="casAuthors">Azarova, Anna M.; Lyu, Yi Lisa; Lin, Chao-Po; Tsai, Yuan-Chin; Lau, Johnson Yiu-Nam; Wang, James C.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">11014-11019</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clin. use.  However, Top2-based chemotherapy has been assocd. with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients.  This assocn. is suggestive of a link between carcinogenesis and Top2-mediated DNA damage.  We show here that VP-16-induced carcinogenesis involves mainly the Î² rather than the isoenzyme of Top2.  In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is significantly higher in TOP2Î²+ than in skin-specific top2Î²-knockout mice.  Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are Top2Î²-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degrdn. of the Top2Î²-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements.  VP-16 cytotoxicity in transformed cells expressing both Top2 isoenzymes is, however, primarily Top2Î±-dependent.  These results point to the importance of developing Top2-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqEXje8wQTrVg90H21EOLACvtfcHk0lgU-Kr13BfXKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D&md5=f10976e9b0dbb918158916036a0349a7</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0704002104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0704002104%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DLyu%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DTsai%26aufirst%3DY.%2BC.%26aulast%3DLau%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DRoles%2520of%2520DNA%2520topoisomerase%2520II%2520isozymes%2520in%2520chemotherapy%2520and%2520secondary%2520malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D11014%26epage%3D11019%26doi%3D10.1073%2Fpnas.0704002104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10861</span>â <span class="NLM_lpage">10871</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkx742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1093%2Fnar%2Fgkx742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=28977631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=10861-10871&author=Y.+R.+Wangauthor=S.+F.+Chenauthor=C.+C.+Wuauthor=Y.+W.+Liaoauthor=T.+S.+Linauthor=K.+T.+Liuauthor=Y.+S.+Chenauthor=T.+K.+Liauthor=T.+C.+Chienauthor=N.+L.+Chan&title=Producing+irreversible+topoisomerase+II-mediated+DNA+breaks+by+site-specific+Pt%28II%29-methionine+coordination+chemistry&doi=10.1093%2Fnar%2Fgkx742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span></div><div class="casAuthors">Wang, Ying-Ren; Chen, Shin-Fu; Wu, Chyuan-Chuan; Liao, Yi-Wen; Lin, Te-Sheng; Liu, Ko-Ting; Chen, Yi-Song; Li, Tsai-Kun; Chien, Tun-Cheng; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10861-10871</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Human type II topoisomerase (Top2) isoforms, hTop2Î± and hTop2Î², are targeted by some of the most successful anticancer drugs.  These drugs induce Top2-mediated DNA cleavage to trigger cell-death pathways.  The potency of these drugs correlates pos. with their efficacy in stabilizing the enzyme-mediated DNA breaks.  Structural anal. of hTop2Î± and hTop2Î² revealed the presence of methionine residues in the drug binding pocket, we therefore tested whether a tighter Top2-drug assocn. may be accomplished by introducing a methionine-reactive Pt2+ into a drug to further stabilize the DNA break.  Herein, we synthesized an organoplatinum compd., etoplatin-N2Î², by replacing the methioninejuxtaposing group of the drug etoposide with a cis-dichlorodiammineplatinum(II) moiety.  Compared to etoposide, etoplatin-N2Î² more potently inhibits both human Top2s.  While the DNA breaks arrested by etoposide can be rejoined, those captured by etoplatin-N2 are practically irreversible.  Crystallog. analyses of hTop2Î² complexed with DNA and etoplatin-N2Î² demonstrate coordinate bond formation between Pt2+ and a flanking methionine.  Notably, this stable coordinate tether can be loosened by disrupting the structural integrity of drug-binding pocket, suggesting that Pt2+ coordination chem. may allow for the development of potent inhibitors with protein conformation-dependent reversibility.  This approach may be exploited to achieve isoformspecific targeting of human Top2s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_1lsBFMml7Vg90H21EOLACvtfcHk0lgU-Kr13BfXKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D&md5=ddc7d7d51f099dc62d40a04819287178</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx742%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DY.%2BW.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DK.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DChien%26aufirst%3DT.%2BC.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DProducing%2520irreversible%2520topoisomerase%2520II-mediated%2520DNA%2520breaks%2520by%2520site-specific%2520Pt%2528II%2529-methionine%2520coordination%2520chemistry%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2017%26volume%3D45%26spage%3D10861%26epage%3D10871%26doi%3D10.1093%2Fnar%2Fgkx742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, l M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span> <span> </span><span class="NLM_article-title">Differential targeting of human topoisomerase II isoforms with small molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4851</span>â <span class="NLM_lpage">4856</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvV2lsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4851-4856&author=A.+Marianiauthor=A.+Bartoliauthor=l+M.+Atwalauthor=K.+C.+Leeauthor=C.+A.+Austinauthor=R.+Rodriguez&title=Differential+targeting+of+human+topoisomerase+II+isoforms+with+small+molecules&doi=10.1021%2Facs.jmedchem.5b00473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules</span></div><div class="casAuthors">Mariani, Angelica; Bartoli, Alexandra; Atwal, Mandeep; Lee, Ka C.; Austin, Caroline A.; Rodriguez, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4851-4856</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The TOP2 poison etoposide has been implicated in the generation of secondary malignancies during cancer treatment.  Structural similarities between TOP2 isoforms challenge the rational design of isoform-specific poisons to further delineate these processes.  Herein, the authors describe the synthesis and biol. evaluation of a focused library of etoposide analogs, with the identification of two novel small mols. exhibiting TOP2B-dependent toxicity.  The findings pave the way toward studying isoform-specific cellular processes by means of small mol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsJib9B-KeD7Vg90H21EOLACvtfcHk0lgU-Kr13BfXKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvV2lsro%253D&md5=1dd44d728aa9c4c71fb80f6d416b8438</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00473%26sid%3Dliteratum%253Aachs%26aulast%3DMariani%26aufirst%3DA.%26aulast%3DBartoli%26aufirst%3DA.%26aulast%3DAtwal%26aufirst%3Dl%2BM.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DRodriguez%26aufirst%3DR.%26atitle%3DDifferential%2520targeting%2520of%2520human%2520topoisomerase%2520II%2520isoforms%2520with%2520small%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4851%26epage%3D4856%26doi%3D10.1021%2Facs.jmedchem.5b00473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chee, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasinoff, B. B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllo toxin etoposide analogs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3542</span>â <span class="NLM_lpage">3551</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.04.022" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3542-3551&author=A.+A.+Yadavauthor=G.+L.+Cheeauthor=X.+Wuauthor=D.+Patelauthor=J.+C.+Yalowichauthor=B.+B.+Hasinoff&title=Structure-based+design%2C+synthesis+and+biological+testing+of+piperazine-linked+bis-epipodophyllo+toxin+etoposide+analogs&doi=10.1016%2Fj.bmc.2015.04.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DA.%2BA.%26aulast%3DChee%26aufirst%3DG.%2BL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520testing%2520of%2520piperazine-linked%2520bis-epipodophyllo%2520toxin%2520etoposide%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3542%26epage%3D3551%26doi%3D10.1016%2Fj.bmc.2015.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothenborg-Jensen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehested, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, L. H.</span></span> <span> </span><span class="NLM_article-title">Linker length in podophyllotoxin-acridine conjugates determines potency <i>in vivo</i> and <i>in vitro</i> as well as specificity against MDR cell lines</span>. <i>Anti-Cancer Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">305</span>â <span class="NLM_lpage">315</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2001&pages=305-315&author=L.+Rothenborg-Jensenauthor=H.+F.+Hansenauthor=I.+Wesselauthor=J.+L.+Nitissauthor=G.+Schmidtauthor=P.+B.+Jensenauthor=M.+Sehestedauthor=L.+H.+Jensen&title=Linker+length+in+podophyllotoxin-acridine+conjugates+determines+potency+in+vivo+and+in+vitro+as+well+as+specificity+against+MDR+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothenborg-Jensen%26aufirst%3DL.%26aulast%3DHansen%26aufirst%3DH.%2BF.%26aulast%3DWessel%26aufirst%3DI.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DJensen%26aufirst%3DP.%2BB.%26aulast%3DSehested%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DL.%2BH.%26atitle%3DLinker%2520length%2520in%2520podophyllotoxin-acridine%2520conjugates%2520determines%2520potency%2520in%2520vivo%2520and%2520in%2520vitro%2520as%2520well%2520as%2520specificity%2520against%2520MDR%2520cell%2520lines%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D2001%26volume%3D16%26spage%3D305%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nateewattana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeeng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasemsook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jariyawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chairoungdua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suksamrarn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piyachaturawat, P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of topoisomerase IIÎ± activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">320</span>â <span class="NLM_lpage">332</span>, <span class="refDoi">Â DOI: 10.1007/s10637-012-9868-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs10637-012-9868-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=320-332&author=J.+Nateewattanaauthor=R.+Saeengauthor=S.+Kasemsookauthor=K.+Suksenauthor=S.+Duttaauthor=S.+Jariyawatauthor=A.+Chairoungduaauthor=A.+Suksamrarnauthor=P.+Piyachaturawat&title=Inhibition+of+topoisomerase+II%CE%B1+activity+and+induction+of+apoptosis+in+mammalian+cells+by+semi-synthetic+andrographolide+analogues&doi=10.1007%2Fs10637-012-9868-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9868-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9868-9%26sid%3Dliteratum%253Aachs%26aulast%3DNateewattana%26aufirst%3DJ.%26aulast%3DSaeeng%26aufirst%3DR.%26aulast%3DKasemsook%26aufirst%3DS.%26aulast%3DSuksen%26aufirst%3DK.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DJariyawat%26aufirst%3DS.%26aulast%3DChairoungdua%26aufirst%3DA.%26aulast%3DSuksamrarn%26aufirst%3DA.%26aulast%3DPiyachaturawat%26aufirst%3DP.%26atitle%3DInhibition%2520of%2520topoisomerase%2520II%25CE%25B1%2520activity%2520and%2520induction%2520of%2520apoptosis%2520in%2520mammalian%2520cells%2520by%2520semi-synthetic%2520andrographolide%2520analogues%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D320%26epage%3D332%26doi%3D10.1007%2Fs10637-012-9868-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel mansonone E derivatives prepared <i>via</i> CuAAC click chemistry as topoisomerase II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">58</span>â <span class="NLM_lpage">71</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.07.011" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=58-71&author=Z.+H.+Huangauthor=S.+T.+Zhuoauthor=C.+Y.+Liauthor=H.+T.+Xieauthor=D.+Liauthor=J.+H.+Tanauthor=T.+M.+Ouauthor=Z.+S.+Huangauthor=L.+Q.+Guauthor=S.+L.+Huang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+mansonone+E+derivatives+prepared+via+CuAAC+click+chemistry+as+topoisomerase+II+inhibitors&doi=10.1016%2Fj.ejmech.2013.07.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%2BH.%26aulast%3DZhuo%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DXie%26aufirst%3DH.%2BT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520mansonone%2520E%2520derivatives%2520prepared%2520via%2520CuAAC%2520click%2520chemistry%2520as%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D58%26epage%3D71%26doi%3D10.1016%2Fj.ejmech.2013.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">A novel <i>p</i>-terphenyl derivative inducing cell-cycle arrest and apoptosis in MDA-MB-435 cells through topoisomerase inhibition</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">192</span>â <span class="NLM_lpage">202</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.07.020" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=192-202&author=J.+Qiuauthor=B.+Zhaoauthor=Y.+Shenauthor=W.+Chenauthor=Y.+Maauthor=Y.+Shen&title=A+novel+p-terphenyl+derivative+inducing+cell-cycle+arrest+and+apoptosis+in+MDA-MB-435+cells+through+topoisomerase+inhibition&doi=10.1016%2Fj.ejmech.2013.07.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DA%2520novel%2520p-terphenyl%2520derivative%2520inducing%2520cell-cycle%2520arrest%2520and%2520apoptosis%2520in%2520MDA-MB-435%2520cells%2520through%2520topoisomerase%2520inhibition%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D192%26epage%3D202%26doi%3D10.1016%2Fj.ejmech.2013.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sharkawy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel Bar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span> <span> </span><span class="NLM_article-title">Rational design and synthesis of topoisomerase I and II inhibitors based on oleanolic acid moiety for new anti-cancer drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2013.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2013.11.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24326278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7rE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=211-220&author=A.+Ashourauthor=S.+El-Sharkawyauthor=M.+Amerauthor=F.+Abdel+Barauthor=Y.+Katakuraauthor=T.+Miyamotoauthor=N.+Toyotaauthor=T.+H.+Bangauthor=R.+Kondoauthor=K.+Shimizu&title=Rational+design+and+synthesis+of+topoisomerase+I+and+II+inhibitors+based+on+oleanolic+acid+moiety+for+new+anti-cancer+drugs&doi=10.1016%2Fj.bmc.2013.11.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and synthesis of topoisomerase I and II inhibitors based on oleanolic acid moiety for new anti-cancer drugs</span></div><div class="casAuthors">Ashour, Ahmed; El-Sharkawy, Saleh; Amer, Mohamed; Abdel Bar, Fatma; Katakura, Yoshinori; Miyamoto, Tomofumi; Toyota, Nozomi; Bang, Tran Hai; Kondo, Ryuichiro; Shimizu, Kuniyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">211-220</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Semisynthetic reactions were conducted on oleanolic acid, a common plant-derived oleanane-type triterpene.  Ten rationally designed derivs. of oleanolic acid were synthesized based on docking studies and tested for their topoisomerase I and IIÎ± inhibitory activity.  Semisynthetic reactions targeted C-3, C-12, C-13, and C-17.  Nine of the synthesized compds. were identified as new compds.  The structures of these compds. were confirmed by spectroscopic methods (1D, 2D NMR and MS).  Five oleanolic acid analogs (S2, S3, S5, S7 and S9) showed higher activity than camptothecin (CPT) in the topoisomerase I DNA relaxation assay.  Four oleanolic acid analogs (S2, S3, S5 and S6) showed higher activity than etoposide in a topoisomerase II assay.  The results indicated that the C12-C13 double bond of the oleanolic acid skeleton is important for the inhibitory activity against both types of topoisomerases, while insertion of a longer chain at either position 3 or 17 increases the activity against topoisomerases by various degrees.  Some of the synthesized compds. act as dual inhibitors for both topoisomerase I and IIÎ±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAiji539lqZLVg90H21EOLACvtfcHk0ljqM63dDsKbfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7rE&md5=9185e97509d5b813a54756943cec6144</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DAshour%26aufirst%3DA.%26aulast%3DEl-Sharkawy%26aufirst%3DS.%26aulast%3DAmer%26aufirst%3DM.%26aulast%3DAbdel%2BBar%26aufirst%3DF.%26aulast%3DKatakura%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DToyota%26aufirst%3DN.%26aulast%3DBang%26aufirst%3DT.%2BH.%26aulast%3DKondo%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DK.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520topoisomerase%2520I%2520and%2520II%2520inhibitors%2520based%2520on%2520oleanolic%2520acid%2520moiety%2520for%2520new%2520anti-cancer%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D211%26epage%3D220%26doi%3D10.1016%2Fj.bmc.2013.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">The essential medicinal chemistry of curcumin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1620</span>â <span class="NLM_lpage">1637</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00975</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00975" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFKjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1620-1637&author=K.+M.+Nelsonauthor=J.+L.+Dahlinauthor=J.+Bissonauthor=J.+Grahamauthor=G.+F.+Pauliauthor=M.+A.+Walters&title=The+essential+medicinal+chemistry+of+curcumin&doi=10.1021%2Facs.jmedchem.6b00975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The Essential Medicinal Chemistry of Curcumin</span></div><div class="casAuthors">Nelson, Kathryn M.; Dahlin, Jayme L.; Bisson, Jonathan; Graham, James; Pauli, Guido F.; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1620-1637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Curcumin is a constituent (3-5%) of the traditional medicine known as turmeric.  Interest in the therapeutic use of turmeric and the relative ease of isolation of curcuminoids has led to their extensive investigation.  Curcumin has recently been classified as both a PAINS (pan-assay interference compds.) and an IMPS (invalid metabolic panaceas) candidate.  The likely false activity of curcumin in vitro and in vivo has resulted in >120 clin. trials of curcuminoids against several diseases.  No double-blinded, placebo controlled clin. trial of curcumin has been successful.  This Perspective reviews the essential medicinal chem. of curcumin and provides evidence that curcumin is an unstable, reactive, nonbioavailable compd. and, therefore, a highly improbable lead.  Based on this in-depth evaluation, potential new directions for research on curcuminoids are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSvgRUG-0XoLVg90H21EOLACvtfcHk0ljqM63dDsKbfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFKjsA%253D%253D&md5=dfb16371e0ef27d4111628203c6acc09</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00975%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DK.%2BM.%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DBisson%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DPauli%26aufirst%3DG.%2BF.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DThe%2520essential%2520medicinal%2520chemistry%2520of%2520curcumin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1620%26epage%3D1637%26doi%3D10.1021%2Facs.jmedchem.6b00975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span> <span> </span><span class="NLM_article-title">Deceptive curcumin offers cautionary tale for chemists</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>541</i></span>,  <span class="NLM_fpage">144</span>â <span class="NLM_lpage">145</span>, <span class="refDoi">Â DOI: 10.1038/541144a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2F541144a" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=541&publication_year=2017&pages=144-145&author=M.+Baker&title=Deceptive+curcumin+offers+cautionary+tale+for+chemists&doi=10.1038%2F541144a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2F541144a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F541144a%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%26atitle%3DDeceptive%2520curcumin%2520offers%2520cautionary%2520tale%2520for%2520chemists%26jtitle%3DNature%26date%3D2017%26volume%3D541%26spage%3D144%26epage%3D145%26doi%3D10.1038%2F541144a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ness, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravoori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupasinghe, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Curcumin-inspired cytotoxic 3,5-bis(arylmethylene)-1-(<i>N</i>-(<i>ortho</i>-substituted aryl)maleamoyl)- 4-piperidones: A novel group of topoisomerase II alpha inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6404</span>â <span class="NLM_lpage">6417</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.08.023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6404-6417&author=A.+Jhaauthor=K.+M.+Duffieldauthor=M.+R.+Nessauthor=S.+Ravooriauthor=G.+Andrewsauthor=K.+S.+Bhullarauthor=H.+P.+Rupasingheauthor=J.+Balzarini&title=Curcumin-inspired+cytotoxic+3%2C5-bis%28arylmethylene%29-1-%28N-%28ortho-substituted+aryl%29maleamoyl%29-+4-piperidones%3A+A+novel+group+of+topoisomerase+II+alpha+inhibitors&doi=10.1016%2Fj.bmc.2015.08.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DJha%26aufirst%3DA.%26aulast%3DDuffield%26aufirst%3DK.%2BM.%26aulast%3DNess%26aufirst%3DM.%2BR.%26aulast%3DRavoori%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DBhullar%26aufirst%3DK.%2BS.%26aulast%3DRupasinghe%26aufirst%3DH.%2BP.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DCurcumin-inspired%2520cytotoxic%25203%252C5-bis%2528arylmethylene%2529-1-%2528N-%2528ortho-substituted%2520aryl%2529maleamoyl%2529-%25204-piperidones%253A%2520A%2520novel%2520group%2520of%2520topoisomerase%2520II%2520alpha%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6404%26epage%3D6417%26doi%3D10.1016%2Fj.bmc.2015.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeÃ³n-Gonzalez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MuÃ±oz-Mingarro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-LÃ¡zaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n-Cordero, C.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic activity of hirsutanone, a diarylheptanoid isolated from <i>Alnus glutinosa</i> leaves</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">866</span>â <span class="NLM_lpage">870</span>, <span class="refDoi">Â DOI: 10.1016/j.phymed.2014.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.phymed.2014.01.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=866-870&author=A.+J.+Le%C3%B3n-Gonzalezauthor=N.+Aceroauthor=D.+Mu%C3%B1oz-Mingarroauthor=M.+L%C3%B3pez-L%C3%A1zaroauthor=C.+Mart%C3%ADn-Cordero&title=Cytotoxic+activity+of+hirsutanone%2C+a+diarylheptanoid+isolated+from+Alnus+glutinosa+leaves&doi=10.1016%2Fj.phymed.2014.01.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2014.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2014.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DLe%25C3%25B3n-Gonzalez%26aufirst%3DA.%2BJ.%26aulast%3DAcero%26aufirst%3DN.%26aulast%3DMu%25C3%25B1oz-Mingarro%26aufirst%3DD.%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn-Cordero%26aufirst%3DC.%26atitle%3DCytotoxic%2520activity%2520of%2520hirsutanone%252C%2520a%2520diarylheptanoid%2520isolated%2520from%2520Alnus%2520glutinosa%2520leaves%26jtitle%3DPhytomedicine%26date%3D2014%26volume%3D21%26spage%3D866%26epage%3D870%26doi%3D10.1016%2Fj.phymed.2014.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">StiborovÃ¡, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frei, E.</span></span> <span> </span><span class="NLM_article-title">Ellipticines as DNA-targeted chemotherapeutics</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">575</span>â <span class="NLM_lpage">591</span>, <span class="refDoi">Â DOI: 10.2174/09298673113206660272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F09298673113206660272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24059226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFyjt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=575-591&author=M.+Stiborov%C3%A1author=E.+Frei&title=Ellipticines+as+DNA-targeted+chemotherapeutics&doi=10.2174%2F09298673113206660272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ellipticines as DNA-Targeted Chemotherapeutics</span></div><div class="casAuthors">Stiborova, Marie; Frei, Eva</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">575-591</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The anti-tumor therapeutic ellipticine and its derivs. act as potent anticancer agents via a combined mechanism involving cell cycle arrest and induction of apoptosis.  Cell death induced by ellipticine has been shown to engage a p53-dependent pathway, cell cycle arrest, interaction with several kinases and induction of the mitochondrial pathway of apoptotic cell death.  Cell cycle arrest was shown to result from DNA damage caused by a variety of tumor chemotherapeutic agents; this is also the case for ellipticines.  The prevalent DNA-mediated mechanisms of anti-tumor, mutagenic and cytotoxic activities of ellipticine are (i) intercalation into DNA, (ii) inhibition of DNA topoisomerase II activity, and (iii) covalent binding to DNA in vitro and in vivo after enzymic activation by cytochrome P 450 and/or peroxidase enzymes The mechanism leading to apoptosis by ellipticine is thought to also be assocd. with DNA damage, by inhibition of topoisomerase II and the covalent modification of DNA.  In addn., the formation of ellipticine-DNA adducts ultimately can mutate cancer cells or initiate cell death.  The aim of this review is to summarize our knowledge on the mol. mechanisms with the aim to explain the effectiveness of ellipticines as DNA-targeted chemotherapeutics in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZkGZmnzXYLrVg90H21EOLACvtfcHk0lhfCwDy-DNWBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFyjt7k%253D&md5=2617220884efc039658e464f64f0a691</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.2174%2F09298673113206660272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113206660272%26sid%3Dliteratum%253Aachs%26aulast%3DStiborov%25C3%25A1%26aufirst%3DM.%26aulast%3DFrei%26aufirst%3DE.%26atitle%3DEllipticines%2520as%2520DNA-targeted%2520chemotherapeutics%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D575%26epage%3D591%26doi%3D10.2174%2F09298673113206660272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deane, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâSullivan, E.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoff, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel ellipticines as potential anti-cancer agents</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1334</span>â <span class="NLM_lpage">1344</span>, <span class="refDoi">Â DOI: 10.1039/c2ob27186a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc2ob27186a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=23314103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaruro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1334-1344&author=F.+M.+Deaneauthor=E.%0AC.+O%E2%80%99Sullivanauthor=A.+R.+Maguireauthor=J.+Gilbertauthor=J.+A.+Sakoffauthor=A.+McCluskeyauthor=F.+O.+McCarthy&title=Synthesis+and+evaluation+of+novel+ellipticines+as+potential+anti-cancer+agents&doi=10.1039%2Fc2ob27186a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel ellipticines as potential anti-cancer agents</span></div><div class="casAuthors">Deane, Fiona M.; O'Sullivan, Elaine C.; Maguire, Anita R.; Gilbert, Jayne; Sakoff, Jennette A.; McCluskey, Adam; McCarthy, Florence O.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1334-1344</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Drugs that inhibit DNA topoisomerase I and DNA topoisomerase II have been widely used in cancer chemotherapy.  The results of a focused medicinal chem. effort around novel ellipticinium salts which target topoisomerase I and II enzymes with improved soly are reported.  The salts were prepd. by reaction of ellipticine with the required alkyl halide and evaluated for DNA intercalation, topoisomerase inhibition and growth inhibition against 12 cancer cell lines.  Results from the topoisomerase I relaxation assay indicated that all novel ellipticine derivs. behaved as intercalating agents.  At a concn. of 100 Î¼M, specific topoisomerase I inhibition was not obsd.  Two of the derivs. under investigation were found to fully inhibit the DNA decatenation reaction at a concn. of 100 Î¼M, indicative of topoisomerase II inhibition.  N-Alkylation of ellipticine was found to enhance the obsd. growth inhibition across all cell lines and induce growth inhibition comparable to that of Irinotecan (CPT-11; GI50 1-18 Î¼M) and in some cell lines better than Etoposide (VP-16; GI50 = 0.04-5.2 Î¼M).  6-Methylellipticine (I) was the most potent growth inhibitory compd. assessed (GI50 = 0.47-0.9 Î¼M).  N-Alkylation of I was found to reduce this response with GI50 values in the range of 1.3-28 Î¼M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI46Fm5Vc0iLVg90H21EOLACvtfcHk0lhfCwDy-DNWBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaruro%253D&md5=d070dddab77a24b35fdd07120b19eea1</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1039%2Fc2ob27186a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob27186a%26sid%3Dliteratum%253Aachs%26aulast%3DDeane%26aufirst%3DF.%2BM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DE.%2BC.%26aulast%3DMaguire%26aufirst%3DA.%2BR.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DSakoff%26aufirst%3DJ.%2BA.%26aulast%3DMcCluskey%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520ellipticines%2520as%2520potential%2520anti-cancer%2520agents%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1334%26epage%3D1344%26doi%3D10.1039%2Fc2ob27186a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vann, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ErgÃ¼n, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zencir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oncuoglu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topcu, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human DNA topoisomerase IIÎ± by two novel ellipticine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1809</span>â <span class="NLM_lpage">1812</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.02.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2016.02.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26906637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFKjtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1809-1812&author=K.+R.+Vannauthor=Y.+Erg%C3%BCnauthor=S.+Zencirauthor=S.+Oncuogluauthor=N.+Osheroffauthor=Z.+Topcu&title=Inhibition+of+human+DNA+topoisomerase+II%CE%B1+by+two+novel+ellipticine+derivatives&doi=10.1016%2Fj.bmcl.2016.02.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human DNA topoisomerase IIÎ± by two novel ellipticine derivatives</span></div><div class="casAuthors">Vann, Kendra R.; Ergun, Yavuz; Zencir, Sevil; Oncuoglu, Serkan; Osheroff, Neil; Topcu, Zeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1809-1812</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity.  Unfortunately, this compd. displays a no. of adverse properties.  Therefore, to investigate new ellipticine-based compds. for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivs., N-methyl-5-demethyl ellipticine (ET-1, I) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2, II.I-).  As detd. by DNA decatenation and cleavage assays, ET-1 and ET-2 act as catalytic inhibitors of human topoisomerase IIÎ± and are both more potent than the parent compd.  Neither compd. impairs the ability of the type II enzyme to bind its DNA substrate.  Finally, the potency of ET-1 and ET-2 as catalytic inhibitors of topoisomerase IIÎ± appears to be related to their ability to intercalate into the double helix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJqcpTy5LtabVg90H21EOLACvtfcHk0lhfCwDy-DNWBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFKjtL8%253D&md5=ac87bed43d131dc0f274c574430609fe</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.034%26sid%3Dliteratum%253Aachs%26aulast%3DVann%26aufirst%3DK.%2BR.%26aulast%3DErg%25C3%25BCn%26aufirst%3DY.%26aulast%3DZencir%26aufirst%3DS.%26aulast%3DOncuoglu%26aufirst%3DS.%26aulast%3DOsheroff%26aufirst%3DN.%26aulast%3DTopcu%26aufirst%3DZ.%26atitle%3DInhibition%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520by%2520two%2520novel%2520ellipticine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1809%26epage%3D1812%26doi%3D10.1016%2Fj.bmcl.2016.02.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iacopetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puoci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, O. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturnino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceramella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malzert-FrÃ©on, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinicropi, M. S.</span></span> <span> </span><span class="NLM_article-title">Multifaceted properties of 1,4-dimethylcarbazoles: Focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">272</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2016.09.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejps.2016.09.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27702608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1akt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=263-272&author=D.+Iacopettaauthor=C.+Rosanoauthor=F.+Puociauthor=O.+I.+Parisiauthor=C.+Saturninoauthor=A.+Carusoauthor=P.+Longoauthor=J.+Ceramellaauthor=A.+Malzert-Fr%C3%A9onauthor=P.+Dallemagneauthor=S.+Raultauthor=M.+S.+Sinicropi&title=Multifaceted+properties+of+1%2C4-dimethylcarbazoles%3A+Focus+on+trimethoxybenzamide+and+trimethoxyphenylurea+derivatives+as+novel+human+topoisomerase+II+inhibitors&doi=10.1016%2Fj.ejps.2016.09.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted properties of 1,4-dimethylcarbazoles: Focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors</span></div><div class="casAuthors">Iacopetta, Domenico; Rosano, Camillo; Puoci, Francesco; Parisi, Ortensia Ilaria; Saturnino, Carmela; Caruso, Anna; Longo, Pasquale; Ceramella, Jessica; Malzert-Freon, Aurelie; Dallemagne, Patrick; Rault, Sylvain; Sinicropi, Maria Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263-272</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Natural or synthetic carbazole derivs. have recently attracted the attention of the scientific world because of their multiple biol. activity, leading to an increase of designed, synthesized and studied analogs.  In this paper, four 1,4-dimethylcarbazole derivs., analogs of Ellipticine, have been investigated for their ability to block cancer cells growth, with low effects on the proliferation of normal cells.  DNA topoisomerases inhibition assays, docking simulations, stability studies and effects on a membrane model are reported.  Particularly, compds. 2 and 3 have been found thermally stable and able to inhibit, strongly and selectively, the human DNA topoisomerase II.  These properties confer a good and broad antitumoral activity in vitro, with very low cytotoxic effect on the proliferation of normal cell lines and without damaging, in contrast with Ellipticine, the cell membrane model.  The presented outcomes set the most active compds. as good candidates for pre-clin. studies useful in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovndKvg18iarVg90H21EOLACvtfcHk0lgIjfnqn2dEzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1akt7bI&md5=88533ae53ed391ef972ef64e217476e5</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.09.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.09.039%26sid%3Dliteratum%253Aachs%26aulast%3DIacopetta%26aufirst%3DD.%26aulast%3DRosano%26aufirst%3DC.%26aulast%3DPuoci%26aufirst%3DF.%26aulast%3DParisi%26aufirst%3DO.%2BI.%26aulast%3DSaturnino%26aufirst%3DC.%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DLongo%26aufirst%3DP.%26aulast%3DCeramella%26aufirst%3DJ.%26aulast%3DMalzert-Fr%25C3%25A9on%26aufirst%3DA.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DRault%26aufirst%3DS.%26aulast%3DSinicropi%26aufirst%3DM.%2BS.%26atitle%3DMultifaceted%2520properties%2520of%25201%252C4-dimethylcarbazoles%253A%2520Focus%2520on%2520trimethoxybenzamide%2520and%2520trimethoxyphenylurea%2520derivatives%2520as%2520novel%2520human%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D96%26spage%3D263%26epage%3D272%26doi%3D10.1016%2Fj.ejps.2016.09.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Evodiamine and its role in chronic diseases</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1007/978-3-319-41342-6_14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2F978-3-319-41342-6_14" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2016&pages=315-328&author=Q.+Tanauthor=J.+Zhang&title=Evodiamine+and+its+role+in+chronic+diseases&doi=10.1007%2F978-3-319-41342-6_14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-41342-6_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-41342-6_14%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DEvodiamine%2520and%2520its%2520role%2520in%2520chronic%2520diseases%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2016%26volume%3D929%26spage%3D315%26epage%3D328%26doi%3D10.1007%2F978-3-319-41342-6_14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span> <span> </span><span class="NLM_article-title">Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2832</span>â <span class="NLM_lpage">2838</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2016.5575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3892%2Fmmr.2016.5575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27485202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSjurnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=2832-2838&author=L.+Linauthor=L.+Renauthor=L.+Wenauthor=Y.+Wangauthor=J.+Qi&title=Effect+of+evodiamine+on+the+proliferation+and+apoptosis+of+A549+human+lung+cancer+cells&doi=10.3892%2Fmmr.2016.5575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells</span></div><div class="casAuthors">Lin, Li; Ren, Li; Wen, Liujing; Wang, Yu; Qi, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2832-2838</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Evodia rutaecarpa is a plant, which has antitumor activity.  Evodiamine is an alkaloid with antitumor activity present in E. rutaecarpa and has potential to be developed into a therapeutic antitumor agent.  The present study investigated the effect of evodiamine on the proliferation of A549 human lung cancer cells and the mechanism underlying these effects.  The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase 3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor ÎB (NF ÎB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.  In conclusion, the evodiamine induced inhibition of the proliferation of A549 lung cancer cells may be attributable to its ability to promote oxidative injury in the cells, induce apoptosis, arrest the cell cycle and regulate the AKT/NF ÎB and SHH/GLI1 signaling pathways, subsequently controlling the expression of tumor assocd. genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyhYaYNGuufbVg90H21EOLACvtfcHk0lgIjfnqn2dEzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSjurnK&md5=bd1d900edec68f21b888081c1f72034b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.5575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.5575%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520evodiamine%2520on%2520the%2520proliferation%2520and%2520apoptosis%2520of%2520A549%2520human%2520lung%2520cancer%2520cells%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D2832%26epage%3D2838%26doi%3D10.3892%2Fmmr.2016.5575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting Î²-catenin-mediated angiogenesis</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">12791</span>â <span class="NLM_lpage">12803</span>, <span class="refDoi">Â DOI: 10.1007/s13277-016-5251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs13277-016-5251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmsbfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=12791-12803&author=L.+Shiauthor=F.+Yangauthor=F.+Luoauthor=Y.+Liuauthor=F.+Zhangauthor=M.+Zouauthor=Q.+Liu&title=Evodiamine+exerts+anti-tumor+effects+against+hepatocellular+carcinoma+through+inhibiting+%CE%B2-catenin-mediated+angiogenesis&doi=10.1007%2Fs13277-016-5251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting Î²-catenin-mediated angiogenesis</span></div><div class="casAuthors">Shi, Le; Yang, Fan; Luo, Fei; Liu, Yi; Zhang, Feng; Zou, Meijuan; Liu, Qizhan</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">12791-12803</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is a highly vascular tumor with high microvessel d. and high levels of circulating vascular endothelial growth factor (VEGF).  Thus, the angiogenesis pathway is an attractive therapeutic target for HCC.  The anti-tumor effects of evodiamine, a quinolone alkaloid isolated from Euodia rutaecarpa (Juss.) Benth.  (Rutaceae), were investigated in a mouse xenograft model using BALB/c nude mice, various HCC cell lines (HepG2, SMMC-7721, H22), and human umbilical vein endothelial cells (HUVECs).  The effects of evodiamine on tumor vols. and wts., levels of tumor markers, angiogenesis in vivo and in vitro, cell viability, and cell migration and invasion were measured, and the mechanism through which its effects are achieved was investigated.  Transcriptional regulation of VEGFa via interaction with Î²-catenin was established by luciferase activity assays and electrophoretic mobility shift assays.  In a s.c. H22 xenograft model, evodiamine inhibited tumor growth and reduced serum tumor markers and the levels of Î²-catenin and VEGFa.  It also blocked VEGF-induced angiogenesis in a Matrigel plug assay.  Evodiamine suppressed cellular proliferation, invasion, and migration and inhibited tube formation of HUVECs.  Moreover, in a concn.-dependent manner, evodiamine reduced the no. of capillary sprouts from Matrigel-embedded rat thoracic aortic rings.  Also, evodiamine suppressed various biomarkers of angiogenesis and the expression of Î²-catenin.  Evodiamine decreased Î²-catenin levels activated by LiCl, which led to reduced expression of VEGFa.  In addn., Î²-catenin interacted with VEGFa and transcriptionally regulated VEGFa, an effect inhibited by evodiamine in HCCs.  Moreover, in an SMMC-7721 xenograft model, evodiamine suppressed tumor growth, various biomarkers of angiogenesis, and the levels of Î²-catenin and VEGFa.  Evodiamine has anti-tumor effects on HCCs through inhibiting Î²-catenin, which interacts with and reduces VEGFa expression, thus inhibiting angiogenesis.  These results indicate that evodiamine, which inhibits cellular invasion and migration and blocks angiogenesis, is a potential therapeutic agent for HCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobKOTBDYV9pbVg90H21EOLACvtfcHk0lgIjfnqn2dEzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmsbfJ&md5=79676d37c9dd5c5ec4f976502cee3dc0</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs13277-016-5251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-016-5251-3%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DZou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DEvodiamine%2520exerts%2520anti-tumor%2520effects%2520against%2520hepatocellular%2520carcinoma%2520through%2520inhibiting%2520%25CE%25B2-catenin-mediated%2520angiogenesis%26jtitle%3DTumor%2520Biol.%26date%3D2016%26volume%3D37%26spage%3D12791%26epage%3D12803%26doi%3D10.1007%2Fs13277-016-5251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span> <span> </span><span class="NLM_article-title">Evodiamine inhibits PDGF-BB-induced proliferation of rat vascular smooth muscle cells through the suppression of cell cycle progression and oxidative stress</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4551</span>â <span class="NLM_lpage">4558</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2016.5798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3892%2Fmmr.2016.5798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27748810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1ejsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=4551-4558&author=X.+Geauthor=S.+Y.+Chenauthor=M.+Liuauthor=T.+M.+Liangauthor=C.+Liu&title=Evodiamine+inhibits+PDGF-BB-induced+proliferation+of+rat+vascular+smooth+muscle+cells+through+the+suppression+of+cell+cycle+progression+and+oxidative+stress&doi=10.3892%2Fmmr.2016.5798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Evodiamine inhibits PDGF BB induced proliferation of rat vascular smooth muscle cells through the suppression of cell cycle progression and oxidative stress</span></div><div class="casAuthors">Ge, Xie; Chen, Si-Yu; Liu, Mei; Liang, Ting-Ming; Liu, Chang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4551-4558</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Vascular smooth muscle cell (VSMC) proliferation is a key event in the development of in-stent restenosis.  Evodiamine is an indole alkaloid extd. from the Chinese medicine, evodia, and has been shown to inhibit tumor cell proliferation and protect the cardiovascular system.  However, whether evodiamine affects VSMC proliferation remains to be elucidated.  Therefore, the present study examd. the effects and the mechanisms of action of evodiamine on the proliferation of rat VSMCs.  The cells were treated with evodiamine alone or in combination with platelet-derived growth factor-BB (PDGF-BB) stimulation.  It was found that evodiamine inhibited PDGF-BB-induced VSMC proliferation in a dose-dependent manner, without inducing cell death.  Evodiamine also retarded cell cycle progression, evidenced by the suppression of the expression of cell cycle-promoting cyclin proteins and cyclin-dependent kinases.  In addn., evodiamine attenuated the PDGF-BB-induced phosphorylation of mitogen-activated protein kinases p38 and extracellular signal-regulated kinases 1/2, however, it had no effect on the phosphorylation of Akt.  Evodiamine also inhibited the increase of reactive oxygen species generation and upregulated the mRNA expression levels of genes encoding antioxidant enzymes.  These findings provide important insights into the mechanisms underlying the vasoprotective actions of evodiamine and suggest that it may be a useful therapeutic agent for the treatment of vascular occlusive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVTCjGQ3WNNrVg90H21EOLACvtfcHk0lhZI_kZAWBTvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1ejsLo%253D&md5=0800883e06a1209a3e30fbd4497b65d6</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.5798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.5798%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DT.%2BM.%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DEvodiamine%2520inhibits%2520PDGF-BB-induced%2520proliferation%2520of%2520rat%2520vascular%2520smooth%2520muscle%2520cells%2520through%2520the%2520suppression%2520of%2520cell%2520cycle%2520progression%2520and%2520oxidative%2520stress%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D4551%26epage%3D4558%26doi%3D10.3892%2Fmmr.2016.5798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Scaffold diversity inspired by the natural product evodiamine discovery of highly potent and multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6678</span>â <span class="NLM_lpage">6696</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00910</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00910" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6678-6696&author=S.+Wangauthor=K.+Fangauthor=G.+Dongauthor=S.+Chenauthor=N.+Liuauthor=Z.+Miaoauthor=J.+Yaoauthor=J.+Liauthor=W.+Zhangauthor=C.+Sheng&title=Scaffold+diversity+inspired+by+the+natural+product+evodiamine+discovery+of+highly+potent+and+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b00910"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00910%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DScaffold%2520diversity%2520inspired%2520by%2520the%2520natural%2520product%2520evodiamine%2520discovery%2520of%2520highly%2520potent%2520and%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6678%26epage%3D6696%26doi%3D10.1021%2Facs.jmedchem.5b00910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PogorelÄnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brvar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajc, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FilipiÄ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span> <span> </span><span class="NLM_article-title">Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIÎ±</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5762</span>â <span class="NLM_lpage">5768</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2014.10.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25453816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVenur3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5762-5768&author=B.+Pogorel%C4%8Dnikauthor=M.+Brvarauthor=I.+Zajcauthor=M.+Filipi%C4%8Dauthor=T.+Solmajerauthor=A.+Perdih&title=Monocyclic+4-amino-6-%28phenylamino%29-1%2C3%2C5-triazines+as+inhibitors+of+human+DNA+topoisomerase+II%CE%B1&doi=10.1016%2Fj.bmcl.2014.10.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIÎ±</span></div><div class="casAuthors">Pogorelcnik, Barbara; Brvar, Matjaz; Zajc, Irena; Filipic, Metka; Solmajer, Tom; Perdih, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5762-5768</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human DNA topoisomerase IIÎ± (htIIÎ±) is a validated target for the development of anticancer agents.  Starting from the available information about the binding of the purine-based htIIÎ± inhibitors in the ATP binding site the authors designed a virtual screening campaign combining structure-based and ligand-based pharmacophores with a mol. docking calcn. searching for compds. that would contain a monocycle mimetic of the purine moiety.  The authors discovered novel 4-amino-6-(phenylamino)-1,3,5-triazines 6, 7 and 11 as monocyclic htIIÎ± inhibitors targeting the ATP binding site.  Compd. 6 from the 1,3,5-triazine series also displayed cytotoxicity properties in hepatocellular carcinoma (HepG2) cell lines and selectivity against human umbilical vein endothelial (HUVEC) cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWXH0kKOtfdLVg90H21EOLACvtfcHk0lhZI_kZAWBTvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVenur3E&md5=c013837cf454cc3a84be32f3d78ee506</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DPogorel%25C4%258Dnik%26aufirst%3DB.%26aulast%3DBrvar%26aufirst%3DM.%26aulast%3DZajc%26aufirst%3DI.%26aulast%3DFilipi%25C4%258D%26aufirst%3DM.%26aulast%3DSolmajer%26aufirst%3DT.%26aulast%3DPerdih%26aufirst%3DA.%26atitle%3DMonocyclic%25204-amino-6-%2528phenylamino%2529-1%252C3%252C5-triazines%2520as%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5762%26epage%3D5768%26doi%3D10.1016%2Fj.bmcl.2014.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PogorelÄnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brvar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Å½egura, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FilipiÄ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of mono- and disubstituted 1<i>H</i>-pyrazolo[3,4]pyrimidines and 9<i>H</i>-purines as catalytic inhibitors of human DNA topoisomerase IIÎ±</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">345</span>â <span class="NLM_lpage">359</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201402459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fcmdc.201402459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25522133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFShs7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=345-359&author=B.+Pogorel%C4%8Dnikauthor=M.+Brvarauthor=B.+%C5%BDeguraauthor=M.+Filipi%C4%8Dauthor=T.+Solmajerauthor=A.+Perdih&title=Discovery+of+mono-+and+disubstituted+1H-pyrazolo%5B3%2C4%5Dpyrimidines+and+9H-purines+as+catalytic+inhibitors+of+human+DNA+topoisomerase+II%CE%B1&doi=10.1002%2Fcmdc.201402459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mono- and Disubstituted 1H-Pyrazolo[3,4]pyrimidines and 9H-Purines as Catalytic Inhibitors of Human DNA Topoisomerase IIÎ±</span></div><div class="casAuthors">Pogorelcnik, Barbara; Brvar, Matjaz; Zegura, Bojana; Filipic, Metka; Solmajer, Tom; Perdih, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">345-359</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human DNA topoisomerase IIÎ± (htIIÎ±) is a validated target for the development of anticancer agents.  Based on structural data regarding the binding mode of AMP-PNP (5'-adenylyl-Î²,Î³-imidodiphosphate) to htIIÎ±, we designed a two-stage virtual screening campaign that combines structure-based pharmacophores and mol. docking.  In the first stage, we identified several monosubstituted 9H-purine compds. and a novel class of 1H-pyrazolo[3,4]pyrimidines as inhibitors of htIIÎ±.  In the second stage, disubstituted analogs with improved cellular activities were discovered.  Compds. from both classes were shown to inhibit htIIÎ±-mediated DNA decatenation, and surface plasmon resonance (SPR) expts. confirmed binding of these two compds. on the htIIÎ± ATPase domain.  Proposed complexes and interaction patterns between both compds. and htIIÎ± were further analyzed in mol. dynamics simulations.  Two compds. identified in the second stage showed promising anticancer activities in hepatocellular carcinoma (HepG2) and breast cancer (MCF-7) cell lines.  The discovered compds. are suitable starting points for further hit-to-lead development in anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQwpkZhauA7rVg90H21EOLACvtfcHk0lgNItH8UTi1Lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFShs7jP&md5=1f8dab53f316854793616b978591bd79</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402459%26sid%3Dliteratum%253Aachs%26aulast%3DPogorel%25C4%258Dnik%26aufirst%3DB.%26aulast%3DBrvar%26aufirst%3DM.%26aulast%3D%25C5%25BDegura%26aufirst%3DB.%26aulast%3DFilipi%25C4%258D%26aufirst%3DM.%26aulast%3DSolmajer%26aufirst%3DT.%26aulast%3DPerdih%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520mono-%2520and%2520disubstituted%25201H-pyrazolo%255B3%252C4%255Dpyrimidines%2520and%25209H-purines%2520as%2520catalytic%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D345%26epage%3D359%26doi%3D10.1002%2Fcmdc.201402459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span> <span> </span><span class="NLM_article-title">QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase IIÎ±</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S51577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2147%2FDDDT.S51577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24516330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFyjtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=183-195&author=S.+Alamauthor=F.+Khan&title=QSAR+and+docking+studies+on+xanthone+derivatives+for+anticancer+activity+targeting+DNA+topoisomerase+II%CE%B1&doi=10.2147%2FDDDT.S51577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase II Î±</span></div><div class="casAuthors">Alam, Sarfaraz; Khan, Feroz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-195, 13</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Due to the high mortality rate in India, the identification of novel mols. is important in the development of novel and potent anticancer drugs.  Xanthones are natural constituents of plants in the families Bonnetiaceae and Clusiaceae, and comprise oxygenated heterocycles with a variety of biol. activities along with an anticancer effect.  To explore the anticancer compds. from xanthone derivs., a quant. structure activity relationship (QSAR) model was developed by the multiple linear regression method.  The structure-activity relationship represented by the QSAR model yielded a high activity-descriptors relationship accuracy (84%) referred by regression coeff. (r2=0.84) and a high activity prediction accuracy (82%).  Five mol. descriptors - dielec. energy, group count (hydroxyl), LogP (the logarithm of the partition coeff. between n-octanol and water), shape index basic (order 3), and the solvent-accessible surface area - were significantly correlated with anticancer activity.  Using this QSAR model, a set of virtually designed xanthone derivs. was screened out.  A mol. docking study was also carried out to predict the mol. interaction between proposed compds. and DNA (DNA) topoisomerase IIÂ´a.  The pharmacokinetics parameters, such as absorption, distribution, metab., excretion, and toxicity, were also calcd., and later an appraisal of synthetic accessibility of org. compds. was carried out.  The strategy used in this study may provide understanding in designing novel DNA topoisomerase IIÎ± inhibitors, as well as for other cancer targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjn75cri7W07Vg90H21EOLACvtfcHk0lgNItH8UTi1Lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFyjtrY%253D&md5=f329803ad231a4c2ac5f19c365b07a60</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S51577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S51577%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DF.%26atitle%3DQSAR%2520and%2520docking%2520studies%2520on%2520xanthone%2520derivatives%2520for%2520anticancer%2520activity%2520targeting%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D183%26epage%3D195%26doi%3D10.2147%2FDDDT.S51577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuelsson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altera, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrow, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parman, T.</span></span> <span> </span><span class="NLM_article-title">Characterization of batracylin-induced renal and bladder toxicity in rats</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">519</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1177/0192623314548766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1177%2F0192623314548766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25274659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVGjsr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=519-529&author=M.+Davisauthor=D.+I.+Buninauthor=S.+J.+Samuelssonauthor=K.+P.+Alteraauthor=R.+J.+Kindersauthor=S.+M.+Lawrenceauthor=J.+Jiauthor=M.+M.+Amesauthor=S.+A.+Buhrowauthor=C.+Waldenauthor=J.+M.+Reidauthor=L.+L.+Rauschauthor=T.+Parman&title=Characterization+of+batracylin-induced+renal+and+bladder+toxicity+in+rats&doi=10.1177%2F0192623314548766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of batracylin-induced renal and bladder toxicity in rats</span></div><div class="casAuthors">Davis, Myrtle; Bunin, Deborah I.; Samuelsson, Steven J.; Altera, Kenneth P.; Kinders, Robert J.; Lawrence, Scott M.; Ji, Jiuping; Ames, Matthew M.; Buhrow, Sarah A.; Walden, Chad; Reid, Joel M.; Rausch, Linda L.; Parman, Toufan</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-529</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Batracylin (NSC-320846) is a dual inhibitor of DNA topoisomerases I and II.  Batracylin advanced as an anticancer agent to Phase I clin. trials where dose limiting hemorrhagic cystitis (bladder inflammation and bleeding) was obsd.  To further investigate batracylin's mechanism of toxicity, studies were conducted in Fischer 344 rats.  Once daily oral administration of 16 or 32 mg/kg batracylin to rats for 4 days caused overt toxicity.  Abnormal clin. observations and adverse effects on clin. pathol., urinalysis, and histol. indicated acute renal damage and urothelial damage and bone marrow dysfunction.  SEM revealed sloughing of the superficial and intermediate urothelial layers.  DNA damage was evident in kidney and bone marrow as indicated by histone Î³-H2AX immunofluorescence.  After a single oral administration of 16 or 32 mg/ kg, the majority of batracylin was converted to N-acetylbatracylin (NAB) with a half-life of 4 h to 11 h.  Mesna (Mesnex), a drug known to reduce the incidence of hemorrhagic cystitis induced by ifosfamide or cyclophosphamide, was administered to rats prior to batracylin, but did not alleviate batracylin-induced bladder and renal toxicity.  These findings suggest that batracylin results in DNA damage-based mechanisms of toxicity and not an acrolein-based mechanism of toxicity as occurs after ifosfamide or cyclophosphamide administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqTKsO9VUlXbVg90H21EOLACvtfcHk0lgNItH8UTi1Lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVGjsr3F&md5=050d29751f705725119e767657e804f8</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1177%2F0192623314548766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314548766%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DD.%2BI.%26aulast%3DSamuelsson%26aufirst%3DS.%2BJ.%26aulast%3DAltera%26aufirst%3DK.%2BP.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DLawrence%26aufirst%3DS.%2BM.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DBuhrow%26aufirst%3DS.%2BA.%26aulast%3DWalden%26aufirst%3DC.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DRausch%26aufirst%3DL.%2BL.%26aulast%3DParman%26aufirst%3DT.%26atitle%3DCharacterization%2520of%2520batracylin-induced%2520renal%2520and%2520bladder%2520toxicity%2520in%2520rats%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D519%26epage%3D529%26doi%3D10.1177%2F0192623314548766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzeng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of indeno[1,2-<i>b</i>]quinoxaline derivatives as potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">258</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26686931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Kmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=258-273&author=C.+H.+Tsengauthor=Y.+R.+Chenauthor=C.+C.+Tzengauthor=W.+Liuauthor=C.+K.+Chouauthor=C.+C.+Chiuauthor=Y.+L.+Chen&title=Discovery+of+indeno%5B1%2C2-b%5Dquinoxaline+derivatives+as+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2015.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indeno[1,2-b]quinoxaline derivatives as potential anticancer agents</span></div><div class="casAuthors">Tseng, Chih-Hua; Chen, You-Ren; Tzeng, Cherng-Chyi; Liu, Wangta; Chou, Chon-Kit; Chiu, Chien-Chih; Chen, Yeh-Long</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">258-273</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis of certain indeno[1,2-b]quinoxaline derivs. I [R = 3-(dimethylamino)propyl, 2-(dimethylamino)ethyl, 2-(pyrrolidin-1-yl)ethyl, 2-morpholinoethyl] for antiproliferative evaluation was reported.  Among them, I [R = 3-(dimethylamino)propyl] was active against the growth of MDA-MB231, PC-3 and Huh-7 with IC50 values of 0.87 (selectivity index, SI = 36.22), 0.82 (SI = 38.43), and 0.64 Î¼M (SI = 49.23) resp.  Compd. I [R = 3-(dimethylamino)propyl] was inactive against the growth of normal human fetal lung fibroblast cell line (MRC-5) with an IC50 value of 31.51 Î¼M.  Its analogs, I [R = 2-(dimethylamino)ethyl] and I [R = 2-(pyrrolidin-1-yl)ethyl], were also active against the growth of MB231, PC-3, and Huh-7 with IC50 values of <1.0 Î¼M in each case.  Results also indicated compds. I exhibited comparable inhibitory activities against topo I and topo II with the pos. compd. (E)-6-hydroxy-9-methoxy-11H-indeno[1,2-c]quinolin-11-one O-2-(pyrrolidin-1-yl)ethyl oxime at a concn. of 10 Î¼M.  Mechanism studies indicated that compd. I [R = 3-(dimethylamino)propyl] induced cell cycle arrest at S phase via activation of caspase-3, -7 and an increase in the protein expression of Bad and Bax but a decrease in expression of Bcl-2 and PARP, which consequently cause cell death.  In addn., compd. I [R = 3-(dimethylamino)propyl] attenuated the levels of phosphorylated Src, Akt-1, and Akt-2 protein levels but did not affect the total protein expression of Akt.  Human hepatocellular carcinoma cells also implanted into the yolk sac of zebrafish larvae and incubated larvae with various concns. of I [R = 3-(dimethylamino)propyl].  Results of the zebrafish xenograft assay confirmed the anti-tumor effect of I [R = 3-(dimethylamino)propyl] in-vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk_MC1CklJLVg90H21EOLACvtfcHk0lhafqsX2Me3Ow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Kmsw%253D%253D&md5=701f724881ebf8199e32ad335bb85cc5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BR.%26aulast%3DTzeng%26aufirst%3DC.%2BC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DChiu%26aufirst%3DC.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BL.%26atitle%3DDiscovery%2520of%2520indeno%255B1%252C2-b%255Dquinoxaline%2520derivatives%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D258%26epage%3D273%26doi%3D10.1016%2Fj.ejmech.2015.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tabassum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arjmand, F.</span></span> <span> </span><span class="NLM_article-title">New modulated design, docking and synthesis of carbohydrate-conjugate heterobimetallic Cu<sup>II</sup>-Sn<sup>IV</sup> complex as potential topoisomerase II inhibitor: <i>In vitro</i> DNA binding, cleavage and cytotoxicity against human cancer cell lines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">694</span>â <span class="NLM_lpage">702</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.09.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.09.036" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=694-702&author=S.+Tabassumauthor=M.+Afzalauthor=F.+Arjmand&title=New+modulated+design%2C+docking+and+synthesis+of+carbohydrate-conjugate+heterobimetallic+CuII-SnIV+complex+as+potential+topoisomerase+II+inhibitor%3A+In+vitro+DNA+binding%2C+cleavage+and+cytotoxicity+against+human+cancer+cell+lines&doi=10.1016%2Fj.ejmech.2013.09.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.036%26sid%3Dliteratum%253Aachs%26aulast%3DTabassum%26aufirst%3DS.%26aulast%3DAfzal%26aufirst%3DM.%26aulast%3DArjmand%26aufirst%3DF.%26atitle%3DNew%2520modulated%2520design%252C%2520docking%2520and%2520synthesis%2520of%2520carbohydrate-conjugate%2520heterobimetallic%2520CuII-SnIV%2520complex%2520as%2520potential%2520topoisomerase%2520II%2520inhibitor%253A%2520In%2520vitro%2520DNA%2520binding%252C%2520cleavage%2520and%2520cytotoxicity%2520against%2520human%2520cancer%2520cell%2520lines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D694%26epage%3D702%26doi%3D10.1016%2Fj.ejmech.2013.09.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisceglie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musiari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alinovi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menozzi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polverini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasconi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span> <span> </span><span class="NLM_article-title">Quinoline-2-carboxaldehyde thiosemicarbazones and their Cu(II) and Ni(II) complexes as topoisomerase IIÎ± inhibitors</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2015.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2015.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26335598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2lsLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2015&pages=10-19&author=F.+Bisceglieauthor=A.+Musiariauthor=S.+Pinelliauthor=R.+Alinoviauthor=I.+Menozziauthor=E.+Polveriniauthor=P.+Tarasconiauthor=M.+Tavoneauthor=G.+Pelosi&title=Quinoline-2-carboxaldehyde+thiosemicarbazones+and+their+Cu%28II%29+and+Ni%28II%29+complexes+as+topoisomerase+II%CE%B1+inhibitors&doi=10.1016%2Fj.jinorgbio.2015.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Quinoline-2-carboxaldehyde thiosemicarbazones and their Cu(II) and Ni(II) complexes as topoisomerase IIa inhibitors</span></div><div class="casAuthors">Bisceglie, Franco; Musiari, Anastasia; Pinelli, Silvana; Alinovi, Rossella; Menozzi, Ilaria; Polverini, Eugenia; Tarasconi, Pieralberto; Tavone, Matteo; Pelosi, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-19</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of quinoline-2-carboxaldehyde thiosemicarbazones and their copper(II) and nickel(II) complexes were synthesized and characterized.  In all complexes the ligands are in the E configuration with respect to the imino bond and behave as tridentate binding ligands.  The copper(II) complexes form square planar derivs. with one mol. of terdentate ligand and chloride ion.  A further non-coordinated chloride ion compensates the overall charge.  Nickel(II) ions form instead octahedral complexes with two ligands for each metal ion, independently from the stoichiometric metal:ligand ratio used in the synthesis.  Ligands and complexes were tested for their antiproliferative properties on histiocytic lymphoma cell line U937.  Copper(II) derivs. are systematically more active than the ligands and the nickel complexes.  All copper derivs. result in inhibiting topoisomerase IIa in vitro.  Computational methods were used to propose a model to explain the different extent of inhibition presented by these compds.  The pos. charge of the dissocd. form of the copper complexes may play a key role in their action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN4G9akpb26bVg90H21EOLACvtfcHk0lhafqsX2Me3Ow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2lsLzJ&md5=f388c698f63dce138a613317861b8881</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2015.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2015.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DBisceglie%26aufirst%3DF.%26aulast%3DMusiari%26aufirst%3DA.%26aulast%3DPinelli%26aufirst%3DS.%26aulast%3DAlinovi%26aufirst%3DR.%26aulast%3DMenozzi%26aufirst%3DI.%26aulast%3DPolverini%26aufirst%3DE.%26aulast%3DTarasconi%26aufirst%3DP.%26aulast%3DTavone%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DG.%26atitle%3DQuinoline-2-carboxaldehyde%2520thiosemicarbazones%2520and%2520their%2520Cu%2528II%2529%2520and%2520Ni%2528II%2529%2520complexes%2520as%2520topoisomerase%2520II%25CE%25B1%2520inhibitors%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2015%26volume%3D152%26spage%3D10%26epage%3D19%26doi%3D10.1016%2Fj.jinorgbio.2015.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGill, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisic, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deweese, J. E.</span></span> <span> </span><span class="NLM_article-title">Examination of the impact of copper(II) Î±(<i>N</i>)-heterocyclic thiosemicarbazone complexes on DNA topoisomerase IIÎ±</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">649</span>â <span class="NLM_lpage">658</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.5b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=649-658&author=J.+T.+Wilsonauthor=X.+Jiangauthor=B.+C.+McGillauthor=E.+C.+Lisicauthor=J.+E.+Deweese&title=Examination+of+the+impact+of+copper%28II%29+%CE%B1%28N%29-heterocyclic+thiosemicarbazone+complexes+on+DNA+topoisomerase+II%CE%B1&doi=10.1021%2Facs.chemrestox.5b00471"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00471%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DMcGill%26aufirst%3DB.%2BC.%26aulast%3DLisic%26aufirst%3DE.%2BC.%26aulast%3DDeweese%26aufirst%3DJ.%2BE.%26atitle%3DExamination%2520of%2520the%2520impact%2520of%2520copper%2528II%2529%2520%25CE%25B1%2528N%2529-heterocyclic%2520thiosemicarbazone%2520complexes%2520on%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D649%26epage%3D658%26doi%3D10.1021%2Facs.chemrestox.5b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barra, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manente, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, I. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauro, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netto, A. V.</span></span> <span> </span><span class="NLM_article-title">Cationic Pd(II) complexes acting as topoisomerase II inhibitors: Synthesis, characterization, DNA interaction and cytotoxicity</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">168</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2016.02.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2016.02.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27045995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVWkt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2016&pages=165-168&author=F.+V.+Rochaauthor=C.+V.+Barraauthor=S.+S.+Garridoauthor=F.+A.+Manenteauthor=I.+Z.+Carlosauthor=J.+Ellenaauthor=A.+S.+Fuentesauthor=A.+Gautierauthor=L.+Morelauthor=A.+E.+Mauroauthor=A.+V.+Netto&title=Cationic+Pd%28II%29+complexes+acting+as+topoisomerase+II+inhibitors%3A+Synthesis%2C+characterization%2C+DNA+interaction+and+cytotoxicity&doi=10.1016%2Fj.jinorgbio.2016.02.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Cationic Pd(II) complexes acting as topoisomerase II inhibitors: Synthesis, characterization, DNA interaction and cytotoxicity</span></div><div class="casAuthors">Rocha, Fillipe V.; Barra, Carolina V.; Garrido, Saulo S.; Manente, Francine A.; Carlos, Iracilda Z.; Ellena, Javier; Fuentes, Andrea S. C.; Gautier, Arnaud; Morel, Laurent; Mauro, Antonio E.; Netto, Adelino V. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-168</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pd(II) 4-methyl-3-thiosemicarbazide complexes with interesting in vitro antitumor activity were synthesized.  These compds. are unable to interact to the DNA in low concn., but are capable of inhibiting human topoisomerase II and cathepsin B in the same range of concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomyX_JTIaqpbVg90H21EOLACvtfcHk0lgM6FwDsgr5mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVWkt7s%253D&md5=a68bb81e9c646e640e60a225e16e42fe</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2016.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2016.02.039%26sid%3Dliteratum%253Aachs%26aulast%3DRocha%26aufirst%3DF.%2BV.%26aulast%3DBarra%26aufirst%3DC.%2BV.%26aulast%3DGarrido%26aufirst%3DS.%2BS.%26aulast%3DManente%26aufirst%3DF.%2BA.%26aulast%3DCarlos%26aufirst%3DI.%2BZ.%26aulast%3DEllena%26aufirst%3DJ.%26aulast%3DFuentes%26aufirst%3DA.%2BS.%26aulast%3DGautier%26aufirst%3DA.%26aulast%3DMorel%26aufirst%3DL.%26aulast%3DMauro%26aufirst%3DA.%2BE.%26aulast%3DNetto%26aufirst%3DA.%2BV.%26atitle%3DCationic%2520Pd%2528II%2529%2520complexes%2520acting%2520as%2520topoisomerase%2520II%2520inhibitors%253A%2520Synthesis%252C%2520characterization%252C%2520DNA%2520interaction%2520and%2520cytotoxicity%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2016%26volume%3D159%26spage%3D165%26epage%3D168%26doi%3D10.1016%2Fj.jinorgbio.2016.02.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MitroviÄ, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SosiÄ, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span> <span> </span><span class="NLM_article-title">Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">16913</span>â <span class="NLM_lpage">16921</span>, <span class="refDoi">Â DOI: 10.1039/C6DT02369J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC6DT02369J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27711842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWlsbrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=16913-16921&author=A.+Mitrovi%C4%87author=J.+Kljunauthor=I.+Sosi%C4%8Dauthor=S.+Gobecauthor=I.+Turelauthor=J.+Kos&title=Clioquinol-ruthenium+complex+impairs+tumour+cell+invasion+by+inhibiting+cathepsin+B+activity&doi=10.1039%2FC6DT02369J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity</span></div><div class="casAuthors">Mitrovic, Ana; Kljun, Jakob; Sosic, Izidor; Gobec, Stanislav; Turel, Iztok; Kos, Janko</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">16913-16921</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Over the past few years, the organometalled compds., including ruthenium, gained a lot of attention as anticancer agents.  We report on the clioquinol-ruthenium complex [Ru(Î·6-p-cymene)(Cq)Cl] as a potent inhibitor of cathepsin B, a lysosomal cysteine peptidase, involved in tumor cell invasion and metastasis.  In the low micromolar concn. range, the clioquinol-ruthenium complex did not exhibit cytotoxic effects on MCF-10A neoT and U-87 MG cells; it did, however, significantly reduce their ability for extracellular matrix degrdn. and invasiveness in two independent cell-based models, measuring either elec. impedance in real time or the growth of multicellular tumor spheroids implanted in Matrigel, a model representing the extracellular matrix.  These results establish ruthenium based organometallic compds. as promising candidates for further pre-clin. studies as anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2u9JSigLoF7Vg90H21EOLACvtfcHk0lgM6FwDsgr5mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWlsbrK&md5=d738041691cff1b992272d50118f0186</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1039%2FC6DT02369J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT02369J%26sid%3Dliteratum%253Aachs%26aulast%3DMitrovi%25C4%2587%26aufirst%3DA.%26aulast%3DKljun%26aufirst%3DJ.%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DS.%26aulast%3DTurel%26aufirst%3DI.%26aulast%3DKos%26aufirst%3DJ.%26atitle%3DClioquinol-ruthenium%2520complex%2520impairs%2520tumour%2520cell%2520invasion%2520by%2520inhibiting%2520cathepsin%2520B%2520activity%26jtitle%3DDalton.%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D16913%26epage%3D16921%26doi%3D10.1039%2FC6DT02369J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G.</span></span> <span> </span><span class="NLM_article-title">Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">7817</span>â <span class="NLM_lpage">7823</span>, <span class="refDoi">Â DOI: 10.1039/c0dt01816c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc0dt01816c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=21629963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptleqs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=7817-7823&author=A.+Bergamoauthor=G.+Sava&title=Ruthenium+anticancer+compounds%3A+myths+and+realities+of+the+emerging+metal-based+drugs&doi=10.1039%2Fc0dt01816c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs</span></div><div class="casAuthors">Bergamo, Alberta; Sava, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">7817-7823</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Ru anticancer drugs have attracted an increasing interest in the last 20 years and 2 of them have entered clin. trials.  Compared to Pt drugs, the complexes based on Ru are often identified as less toxic and capable of overcoming the resistance induced by platinum drugs in cancer cells.  These activities were attributed to the transportation to tumor cells by transferrin and to the selective activation to more reactive species by the reducing environment of solid tumors as compared to healthy tissues.  Ru anticancer drugs were almost always designed to mimic platinum drugs, particularly for targeting DNA.  Indeed, none of the above properties has never been clearly demonstrated even for the Ru drugs that entered clin. trials.  The suggestion for the future is to change the perspective when designing new chem. entities, abandoning the philosophy that guided the actual panel of Ru drugs and to look further into the fine mechanism by which the most relevant ruthenium complexes available kill the target tumor cells, then focusing on targets selective of tumor cells and responsible for cell growth and malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo6uOiHOBkJLVg90H21EOLACvtfcHk0lgM6FwDsgr5mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptleqs7c%253D&md5=834f2ebd83602caa4abfc34b9376cba3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2Fc0dt01816c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt01816c%26sid%3Dliteratum%253Aachs%26aulast%3DBergamo%26aufirst%3DA.%26aulast%3DSava%26aufirst%3DG.%26atitle%3DRuthenium%2520anticancer%2520compounds%253A%2520myths%2520and%2520realities%2520of%2520the%2520emerging%2520metal-based%2520drugs%26jtitle%3DDalton.%2520Trans.%26date%3D2011%26volume%3D40%26spage%3D7817%26epage%3D7823%26doi%3D10.1039%2Fc0dt01816c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-Loncella, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purazo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorchak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shriver, C. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cancer cell growth by ruthenium complexes</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">48</span>, <span class="refDoi">Â DOI: 10.1186/s12967-016-0797-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1186%2Fs12967-016-0797-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26867596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1ehsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=48&author=J.+Iidaauthor=E.+T.+Bell-Loncellaauthor=M.+L.+Purazoauthor=Y.+Luauthor=J.+Dorchakauthor=R.+Clancyauthor=J.+Slavikauthor=M.+L.+Cutlerauthor=C.+D.+Shriver&title=Inhibition+of+cancer+cell+growth+by+ruthenium+complexes&doi=10.1186%2Fs12967-016-0797-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cancer cell growth by ruthenium complexes</span></div><div class="casAuthors">Iida, Joji; Bell-Loncella, Elisabeth T.; Purazo, Marc L.; Lu, Yifeng; Dorchak, Jesse; Clancy, Rebecca; Slavik, Julianna; Cutler, Mary Lou; Shriver, Craig D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48/1-48/10</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Previous studies suggest that certain transition metal complexes, such as cisplatin, are efficacious for treating various cancer types, including ovarian, lung, and breast.  Methods: In order to further evaluate ruthenium (Ru) complexes as potential anti-cancer agents, we synthesized and evaluated Ru-arene complexes.  Two complexes with the general formula [Ru (Î·6-p-cym) (N-N) Cl]+ were tested for their abilities to inhibit cancer cells.  Results: The complex with o-phenylenediamine as the N-N ligand (o-PDA) significantly inhibited growth of breast (MDA-MB-231, MCF-7, SKBR-3, and SUM149), lymphoma (Raji), melanoma (Bowes), and osteosarcoma (HT1080); however, the complex with o-benzoquinonediimine (o-BQDI) was ineffective except for SUM149.  In contrast, o-PDA failed to inhibit growth of human breast epithelial cells, MCF-10A.  Treatment of MDA-MBA-231 cells with o-PDA resulted in a significant redn. of productions of PDGF-AA, GM-CSF, and VEGF-A proteins at the transcriptional levels.  Finally, we demonstrated that o-PDA synergistically inhibited MDA-MB-231 cell growth with cyclophosphamide but not doxorubicin or paclitaxel.  Conclusion: These results suggest that Ru-arene complexes are promising anti-cancer drugs that inhibit progression and metastasis by blocking multiple processes for breast and other types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GEM4VtJ0jrVg90H21EOLACvtfcHk0lhAO-kNUF2KZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1ehsb8%253D&md5=b8d1aeb4e6d7d26deee78860b1886119</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1186%2Fs12967-016-0797-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-016-0797-9%26sid%3Dliteratum%253Aachs%26aulast%3DIida%26aufirst%3DJ.%26aulast%3DBell-Loncella%26aufirst%3DE.%2BT.%26aulast%3DPurazo%26aufirst%3DM.%2BL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDorchak%26aufirst%3DJ.%26aulast%3DClancy%26aufirst%3DR.%26aulast%3DSlavik%26aufirst%3DJ.%26aulast%3DCutler%26aufirst%3DM.%2BL.%26aulast%3DShriver%26aufirst%3DC.%2BD.%26atitle%3DInhibition%2520of%2520cancer%2520cell%2520growth%2520by%2520ruthenium%2520complexes%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2016%26volume%3D14%26spage%3D48%26doi%3D10.1186%2Fs12967-016-0797-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eble, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamo, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of adhesion, migration and of Î±5Î²1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">225</span>â <span class="NLM_lpage">235</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2016.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2016.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26961176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVGhtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=225-235&author=C.+Pelilloauthor=H.+Mollicaauthor=J.+A.+Ebleauthor=J.+Groscheauthor=L.+Herzogauthor=B.+Codanauthor=G.+Savaauthor=A.+Bergamo&title=Inhibition+of+adhesion%2C+migration+and+of+%CE%B15%CE%B21+integrin+in+the+HCT-116+colorectal+cancer+cells+treated+with+the+ruthenium+drug+NAMI-A&doi=10.1016%2Fj.jinorgbio.2016.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of adhesion, migration and of Î±5Î²1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A</span></div><div class="casAuthors">Pelillo, Chiara; Mollica, Hilaria; Eble, Johannes A.; Grosche, Julius; Herzog, Lea; Codan, Barbara; Sava, Gianni; Bergamo, Alberta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-235</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NAMI-A, imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate, is a ruthenium-based drug characterised by the selective activity against tumor metastases.  Previously we have shown the influence of the hepatic microenvironment to direct the arrest of the metastatic cells of colorectal cancer.  Here we used the exptl. model of HCT-116 colorectal cancer cells in vitro to explore whether the interference with Î±5Î²1 integrin may mechanistically explain the anti-metastatic effect of NAMI-A.  NAMI-A inhibits two important steps of the tumor metastatic progression of colorectal cancer, i.e. the adhesion and migration of the tumor cells on the extracellular matrix proteins.  The fibronectin receptor Î±5Î²1 integrin is likely involved in the anti-adhesive effects of NAMI-A on the HCT-116 colorectal cancer cells during their interaction with the extracellular matrix.  Mechanistically, NAMI-A decreases the Î±5Î²1 integrin expression, and reduces FAK (Focal Adhesion Kinase) auto-phosphorylation on Tyr397, an important signalling event, involved in Î±5Î²1 integrin activation.  These effects were validated by siRNA-induced knock down of the Î±5 integrin subunit and/or by the use of specific blocking mAbs against the active site of the integrin.  Our results demonstrate the relevance of Î±5Î²1 integrin for colorectal cancer.  We also show that the anti-metastatic effect of NAMI-A depends on the modulation of this integrin.  Thus, our data on NAMI-A support the new concept that metal-based drugs can inhibit tumor metastases through targeting of integrins and of other proteins which mediate tumor progression-related cell functions such as adhesion and migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbFwTSmGQ-I7Vg90H21EOLACvtfcHk0lhAO-kNUF2KZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVGhtbg%253D&md5=5e6745e2a1335e276db5132381e3ad43</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2016.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2016.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DPelillo%26aufirst%3DC.%26aulast%3DMollica%26aufirst%3DH.%26aulast%3DEble%26aufirst%3DJ.%2BA.%26aulast%3DGrosche%26aufirst%3DJ.%26aulast%3DHerzog%26aufirst%3DL.%26aulast%3DCodan%26aufirst%3DB.%26aulast%3DSava%26aufirst%3DG.%26aulast%3DBergamo%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520adhesion%252C%2520migration%2520and%2520of%2520%25CE%25B15%25CE%25B21%2520integrin%2520in%2520the%2520HCT-116%2520colorectal%2520cancer%2520cells%2520treated%2520with%2520the%2520ruthenium%2520drug%2520NAMI-A%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2016%26volume%3D160%26spage%3D225%26epage%3D235%26doi%3D10.1016%2Fj.jinorgbio.2016.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunden, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenzel, M. H.</span></span> <span> </span><span class="NLM_article-title">Anti-metastatic effects of RAPTA-C conjuated polymeric micelles on two-dimensional (2D) breast tumor cells and three-dimensional (3D) multicellular tumor spheroids</span>. <i>Acta Biomater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">68</span>â <span class="NLM_lpage">76</span>, <span class="refDoi">Â DOI: 10.1016/j.actbio.2015.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.actbio.2015.12.020" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=68-76&author=H.+Luauthor=B.+M.+Blundenauthor=W.+Scaranoauthor=M.+Luauthor=M.+H.+Stenzel&title=Anti-metastatic+effects+of+RAPTA-C+conjuated+polymeric+micelles+on+two-dimensional+%282D%29+breast+tumor+cells+and+three-dimensional+%283D%29+multicellular+tumor+spheroids&doi=10.1016%2Fj.actbio.2015.12.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.actbio.2015.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.actbio.2015.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DBlunden%26aufirst%3DB.%2BM.%26aulast%3DScarano%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DStenzel%26aufirst%3DM.%2BH.%26atitle%3DAnti-metastatic%2520effects%2520of%2520RAPTA-C%2520conjuated%2520polymeric%2520micelles%2520on%2520two-dimensional%2520%25282D%2529%2520breast%2520tumor%2520cells%2520and%2520three-dimensional%2520%25283D%2529%2520multicellular%2520tumor%2520spheroids%26jtitle%3DActa%2520Biomater.%26date%3D2016%26volume%3D32%26spage%3D68%26epage%3D76%26doi%3D10.1016%2Fj.actbio.2015.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G.</span></span> <span> </span><span class="NLM_article-title">In vivo tumour and metastasis reduction and <i>in vitro</i> effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">79</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2009.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2009.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=19906432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=79-86&author=A.+Bergamoauthor=A.+Masiauthor=A.+F.+Peacockauthor=A.+Habtemariamauthor=P.+J.+Sadlerauthor=G.+Sava&title=In+vivo+tumour+and+metastasis+reduction+and+in+vitro+effects+on+invasion+assays+of+the+ruthenium+RM175+and+osmium+AFAP51+organometallics+in+the+mammary+cancer+model&doi=10.1016%2Fj.jinorgbio.2009.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo tumor and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model</span></div><div class="casAuthors">Bergamo, A.; Masi, A.; Peacock, A. F. A.; Habtemariam, A.; Sadler, P. J.; Sava, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-86</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have compared the organometallic arene complexes [(Î·6-biphenyl)M(ethylenediamine)Cl]+ RM175 (M = RuII) and its isostructural osmium(II) analog AFAP51 (M = OsII) for their ability to induce cell detachment resistance from fibronectin, collagen IV and poly--lysine, and cell re-adhesion after treatment, their effects on cell migration and cell viability, on matrix metalloproteinases prodn., and on primary tumor growth of MCa mammary carcinoma, the effect of human serum albumin on their cytotoxicity.  There are differences between ruthenium and osmium.  The Os complex is up to 6Ã more potent than RM175 towards highly-invasive breast MDA-MB-231, human breast MCF-7 and human epithelial HBL-100 cancer cells, but whereas RM175 was active against MCa mammary carcinoma in vivo and caused metastasis redn., AFAP51 was not.  Intriguingly the presence of human serum albumin in the growth medium enhanced the cytotoxicity of both compds.  RM175 increased the resistance of MDA-MB-231 cells to detachment from substrates and both compds. inhibited the prodn. of MMP-2.  These data confirm the key role of ruthenium itself in anti-metastatic activity.  It will be interesting to explore the activity of osmium arene complexes in other tumor models and the possibility of changing the non-arene ligands to tune the anticancer activity of osmium in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6s0C91SLLYrVg90H21EOLACvtfcHk0ljF_XYTr_gm0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhurnN&md5=0f04eebc507085087f8f8612b95553e0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2009.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2009.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DBergamo%26aufirst%3DA.%26aulast%3DMasi%26aufirst%3DA.%26aulast%3DPeacock%26aufirst%3DA.%2BF.%26aulast%3DHabtemariam%26aufirst%3DA.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26aulast%3DSava%26aufirst%3DG.%26atitle%3DIn%2520vivo%2520tumour%2520and%2520metastasis%2520reduction%2520and%2520in%2520vitro%2520effects%2520on%2520invasion%2520assays%2520of%2520the%2520ruthenium%2520RM175%2520and%2520osmium%2520AFAP51%2520organometallics%2520in%2520the%2520mammary%2520cancer%2520model%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2010%26volume%3D104%26spage%3D79%26epage%3D86%26doi%3D10.1016%2Fj.jinorgbio.2009.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase IIÎ± poisoning and DNA double-strand breaking by chiral ruthenium(II) complexes containing 2-furanyl-imidazo[4,5-<i>f</i>][1,10] phenanthroline derivatives</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10546</span>â <span class="NLM_lpage">10555</span>, <span class="refDoi">Â DOI: 10.1039/C6DT01422D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC6DT01422D" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=10546-10555&author=C.+Qianauthor=J.+Wuauthor=L.+Jiauthor=H.+Chao&title=Topoisomerase+II%CE%B1+poisoning+and+DNA+double-strand+breaking+by+chiral+ruthenium%28II%29+complexes+containing+2-furanyl-imidazo%5B4%2C5-f%5D%5B1%2C10%5D+phenanthroline+derivatives&doi=10.1039%2FC6DT01422D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1039%2FC6DT01422D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01422D%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DTopoisomerase%2520II%25CE%25B1%2520poisoning%2520and%2520DNA%2520double-strand%2520breaking%2520by%2520chiral%2520ruthenium%2528II%2529%2520complexes%2520containing%25202-furanyl-imidazo%255B4%252C5-f%255D%255B1%252C10%255D%2520phenanthroline%2520derivatives%26jtitle%3DDalton.%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D10546%26epage%3D10555%26doi%3D10.1039%2FC6DT01422D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of polypyridyl ruthenium(II) complexes as DNA intercalators, DNA photocleavage reagents, and DNA topoisomerase and RNA polymerase inhibitors</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">367</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1002/cbdv.201100414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fcbdv.201100414" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=367-384&author=X.+Chenauthor=F.+Gaoauthor=W.+Y.+Yangauthor=Z.+X.+Zhouauthor=J.+Q.+Linauthor=L.+N.+Ji&title=Structure-activity+relationship+of+polypyridyl+ruthenium%28II%29+complexes+as+DNA+intercalators%2C+DNA+photocleavage+reagents%2C+and+DNA+topoisomerase+and+RNA+polymerase+inhibitors&doi=10.1002%2Fcbdv.201100414"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201100414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201100414%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DW.%2BY.%26aulast%3DZhou%26aufirst%3DZ.%2BX.%26aulast%3DLin%26aufirst%3DJ.%2BQ.%26aulast%3DJi%26aufirst%3DL.%2BN.%26atitle%3DStructure-activity%2520relationship%2520of%2520polypyridyl%2520ruthenium%2528II%2529%2520complexes%2520as%2520DNA%2520intercalators%252C%2520DNA%2520photocleavage%2520reagents%252C%2520and%2520DNA%2520topoisomerase%2520and%2520RNA%2520polymerase%2520inhibitors%26jtitle%3DChem.%2520Biodiversity%26date%3D2013%26volume%3D10%26spage%3D367%26epage%3D384%26doi%3D10.1002%2Fcbdv.201100414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">DNA-binding, topoisomerases I and II inhibition and in vitro cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)<sub>2</sub>L]<sup>2+</sup> (L = dppz-11-CO<sub>2</sub>Me and dppz)</span>. <i>Spectrochim. Acta, Part A</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.saa.2014.06.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.saa.2014.06.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25062055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=101-109&author=X.+Heauthor=L.+Jinauthor=L.+Tan&title=DNA-binding%2C+topoisomerases+I+and+II+inhibition+and+in+vitro+cytotoxicity+of+ruthenium%28II%29+polypyridyl+complexes%3A+%5BRu%28dppz%292L%5D2%2B+%28L+%3D+dppz-11-CO2Me+and+dppz%29&doi=10.1016%2Fj.saa.2014.06.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-binding, topoisomerases I and II inhibition and in vitro cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)2L]2+ (L = dppz-11-CO2Me and dppz)</span></div><div class="casAuthors">He, Xiaojun; Jin, Lianhe; Tan, Lifeng</div><div class="citationInfo"><span class="NLM_cas:title">Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101-109</span>CODEN:
                <span class="NLM_cas:coden">SAMCAS</span>;
        ISSN:<span class="NLM_cas:issn">1386-1425</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two ruthenium(II) polypyridyl complexes, [Ru(dppz)2dppz-11-CO2Me](ClO4)2 (Ru1) and [Ru(dppz)3](ClO4)2 (Ru2), have been synthesized and characterized (dppz = dipyrido[3,2-a:2',3'-c]phenazine; dppz-11-CO2Me = Me dipyrido[3,2-a:2',3'-c]phenazine-11-carboxylate).  The spectral characteristics of Ru1 and Ru2 were investigated by fluorescence spectroscopy and revealed that both complexes were sensitive to solvent polarity.  The binding properties of the two complexes towards calf-thymus DNA (CT-DNA) have been investigated by different spectrophotometric methods and viscosity measurements, indicating that both complexes bind to CT-DNA by intercalation, but with different binding affinities.  Topoisomerase inhibition and DNA strand passage assay demonstrates that the two complexes are dual inhibitors of topoisomerases I and IIa.  However, the cytotoxicity of both complexes has been evaluated by MTT assays and Giemsa staining expts.  The main results reveal that the ester functional group has a significant effect on the DNA-binding affinities and topoisomerases inhibition effects of Ru1 and Ru2, and further advance the authors' knowledge on the DNA-binding and topoisomerase inhibition by Ru(II) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppit6q12DgL7Vg90H21EOLACvtfcHk0ljF_XYTr_gm0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL&md5=8e0cc6e987cdf93432132daa43790600</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.saa.2014.06.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.saa.2014.06.147%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26atitle%3DDNA-binding%252C%2520topoisomerases%2520I%2520and%2520II%2520inhibition%2520and%2520in%2520vitro%2520cytotoxicity%2520of%2520ruthenium%2528II%2529%2520polypyridyl%2520complexes%253A%2520%255BRu%2528dppz%25292L%255D2%252B%2520%2528L%2520%253D%2520dppz-11-CO2Me%2520and%2520dppz%2529%26jtitle%3DSpectrochim.%2520Acta%252C%2520Part%2520A%26date%3D2015%26volume%3D135%26spage%3D101%26epage%3D109%26doi%3D10.1016%2Fj.saa.2014.06.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of topoisomerases I and IIÎ± by ruthenium(II) complexes containing asymmetric tridentate ligands</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">17303</span>â <span class="NLM_lpage">17316</span>, <span class="refDoi">Â DOI: 10.1039/C4DT02142H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC4DT02142H" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=17303-17316&author=K.+Duauthor=J.+Liangauthor=Y.+Wangauthor=J.+Kouauthor=C.+Qianauthor=L.+Jiauthor=H.+Chao&title=Dual+inhibition+of+topoisomerases+I+and+II%CE%B1+by+ruthenium%28II%29+complexes+containing+asymmetric+tridentate+ligands&doi=10.1039%2FC4DT02142H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2FC4DT02142H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT02142H%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKou%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DDual%2520inhibition%2520of%2520topoisomerases%2520I%2520and%2520II%25CE%25B1%2520by%2520ruthenium%2528II%2529%2520complexes%2520containing%2520asymmetric%2520tridentate%2520ligands%26jtitle%3DDalton.%2520Trans.%26date%3D2014%26volume%3D43%26spage%3D17303%26epage%3D17316%26doi%3D10.1039%2FC4DT02142H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MuthnÃ¡, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TomÅ¡Ã­k, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havelek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¶hlerovÃ¡, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasilingam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ÄermÃ¡kovÃ¡, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StÃ­bal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ÅezÃ¡ÄovÃ¡, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¼ss-Fink, G.</span></span> <span> </span><span class="NLM_article-title">In-vitro and in-vivo evaluation of the anticancer activity of diruthenium-2, a new trithiolato arene ruthenium complex [(Î·<sup>6</sup>-<i>p</i>-MeC<sub>6</sub>H<sub>4</sub>Pr<sup><i>i</i></sup>)<sub>2</sub>Ru<sub>2</sub>(Î¼-S- <i>p</i>-C<sub>6</sub>H<sub>4</sub>OH)<sub>3</sub>]Cl</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">643</span>â <span class="NLM_lpage">650</span>, <span class="refDoi">Â DOI: 10.1097/CAD.0000000000000374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1097%2FCAD.0000000000000374" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=643-650&author=D.+Muthn%C3%A1author=P.+Tom%C5%A1%C3%ADkauthor=R.+Havelekauthor=R.+K%C3%B6hlerov%C3%A1author=V.+Kasilingamauthor=E.+%C4%8Cerm%C3%A1kov%C3%A1author=D.+St%C3%ADbalauthor=M.+%C5%98ez%C3%A1%C4%8Dov%C3%A1author=G.+S%C3%BCss-Fink&title=In-vitro+and+in-vivo+evaluation+of+the+anticancer+activity+of+diruthenium-2%2C+a+new+trithiolato+arene+ruthenium+complex+%5B%28%CE%B76-p-MeC6H4Pri%292Ru2%28%CE%BC-S-+p-C6H4OH%293%5DCl&doi=10.1097%2FCAD.0000000000000374"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000374%26sid%3Dliteratum%253Aachs%26aulast%3DMuthn%25C3%25A1%26aufirst%3DD.%26aulast%3DTom%25C5%25A1%25C3%25ADk%26aufirst%3DP.%26aulast%3DHavelek%26aufirst%3DR.%26aulast%3DK%25C3%25B6hlerov%25C3%25A1%26aufirst%3DR.%26aulast%3DKasilingam%26aufirst%3DV.%26aulast%3D%25C4%258Cerm%25C3%25A1kov%25C3%25A1%26aufirst%3DE.%26aulast%3DSt%25C3%25ADbal%26aufirst%3DD.%26aulast%3D%25C5%2598ez%25C3%25A1%25C4%258Dov%25C3%25A1%26aufirst%3DM.%26aulast%3DS%25C3%25BCss-Fink%26aufirst%3DG.%26atitle%3DIn-vitro%2520and%2520in-vivo%2520evaluation%2520of%2520the%2520anticancer%2520activity%2520of%2520diruthenium-2%252C%2520a%2520new%2520trithiolato%2520arene%2520ruthenium%2520complex%2520%255B%2528%25CE%25B76-p-MeC6H4Pri%25292Ru2%2528%25CE%25BC-S-%2520p-C6H4OH%25293%255DCl%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2016%26volume%3D27%26spage%3D643%26epage%3D650%26doi%3D10.1097%2FCAD.0000000000000374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilruba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalayda, G. V.</span></span> <span> </span><span class="NLM_article-title">Platinum-based drugs: past, present and future</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1103</span>â <span class="NLM_lpage">1124</span>, <span class="refDoi">Â DOI: 10.1007/s00280-016-2976-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs00280-016-2976-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26886018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2016&pages=1103-1124&author=S.+Dilrubaauthor=G.+V.+Kalayda&title=Platinum-based+drugs%3A+past%2C+present+and+future&doi=10.1007%2Fs00280-016-2976-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum-based drugs: past, present and future</span></div><div class="casAuthors">Dilruba, Shahana; Kalayda, Ganna V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1103-1124</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms.  Their clin. success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment.  Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clin. application so far.  Nedaplatin, lobaplatin and heptaplatin received only regional approval.  Some new platinum complexes and platinum drug formulations are undergoing clin. trials.  Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biol. active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems.  For each class of compds., a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clin. used platinum drugs, and the clin. perspectives are discussed.  A crit. anal. of lessons to be learned is presented.  Finally, a general outlook regarding future directions in the field of new platinum drugs is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfV4v-5JjduLVg90H21EOLACvtfcHk0lhN4FnfhVnLeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D&md5=1e1882f631ad56ef1a07b2075b1faa5e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-2976-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-2976-z%26sid%3Dliteratum%253Aachs%26aulast%3DDilruba%26aufirst%3DS.%26aulast%3DKalayda%26aufirst%3DG.%2BV.%26atitle%3DPlatinum-based%2520drugs%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D77%26spage%3D1103%26epage%3D1124%26doi%3D10.1007%2Fs00280-016-2976-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Chiral ruthenium(II) complexes with phenolic hydroxyl groups as dual poisons of topoisomerases I and IIÎ±</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">8907</span>â <span class="NLM_lpage">8917</span>, <span class="refDoi">Â DOI: 10.1039/c3dt50472g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc3dt50472g" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=8907-8917&author=P.+Zhangauthor=J.+Wangauthor=H.+Huangauthor=L.+Qiaoauthor=L.+Jiauthor=H.+Chao&title=Chiral+ruthenium%28II%29+complexes+with+phenolic+hydroxyl+groups+as+dual+poisons+of+topoisomerases+I+and+II%CE%B1&doi=10.1039%2Fc3dt50472g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1039%2Fc3dt50472g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3dt50472g%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DChiral%2520ruthenium%2528II%2529%2520complexes%2520with%2520phenolic%2520hydroxyl%2520groups%2520as%2520dual%2520poisons%2520of%2520topoisomerases%2520I%2520and%2520II%25CE%25B1%26jtitle%3DDalton.%2520Trans.%26date%3D2013%26volume%3D42%26spage%3D8907%26epage%3D8917%26doi%3D10.1039%2Fc3dt50472g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagenson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruangpradit, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, O. Q.</span></span> <span> </span><span class="NLM_article-title">Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7889</span>â <span class="NLM_lpage">7906</span>, <span class="refDoi">Â DOI: 10.1021/ic400339z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic400339z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=7889-7906&author=C.+R.+Wilsonauthor=A.+M.+Fagensonauthor=W.+Ruangpraditauthor=M.+T.+Mullerauthor=O.+Q.+Munro&title=Gold%28III%29+complexes+of+pyridyl-+and+isoquinolylamido+ligands%3A+structural%2C+spectroscopic%2C+and+biological+studies+of+a+new+class+of+dual+topoisomerase+I+and+II+inhibitors&doi=10.1021%2Fic400339z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fic400339z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic400339z%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BR.%26aulast%3DFagenson%26aufirst%3DA.%2BM.%26aulast%3DRuangpradit%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DM.%2BT.%26aulast%3DMunro%26aufirst%3DO.%2BQ.%26atitle%3DGold%2528III%2529%2520complexes%2520of%2520pyridyl-%2520and%2520isoquinolylamido%2520ligands%253A%2520structural%252C%2520spectroscopic%252C%2520and%2520biological%2520studies%2520of%2520a%2520new%2520class%2520of%2520dual%2520topoisomerase%2520I%2520and%2520II%2520inhibitors%26jtitle%3DInorg.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D7889%26epage%3D7906%26doi%3D10.1021%2Fic400339z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BornhÃ¤user, M.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin in acute myeloid leukaemia</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1000</span>â <span class="NLM_lpage">1001</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00165-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS1470-2045%2815%2900165-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26234173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fos1Kjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1000-1001&author=M.+Bornh%C3%A4user&title=Vosaroxin+in+acute+myeloid+leukaemia&doi=10.1016%2FS1470-2045%2815%2900165-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Vosaroxin in acute myeloid leukaemia</span></div><div class="casAuthors">Bornhauser Martin</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1000-1001</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2wvxYycAgy_6xYuD7tu2XfW6udTcc2eYeKqLhcATbDrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fos1Kjsg%253D%253D&md5=908d575de72d30b7ec27b71d062acc22</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900165-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900165-5%26sid%3Dliteratum%253Aachs%26aulast%3DBornh%25C3%25A4user%26aufirst%3DM.%26atitle%3DVosaroxin%2520in%2520acute%2520myeloid%2520leukaemia%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1000%26epage%3D1001%26doi%3D10.1016%2FS1470-2045%2815%2900165-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Short, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia â a critical review</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">529</span>â <span class="NLM_lpage">534</span>, <span class="refDoi">Â DOI: 10.1080/17474086.2016.1187063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1080%2F17474086.2016.1187063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27158854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFejur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=529-534&author=N.+J.+Shortauthor=F.+Ravandi&title=The+safety+and+efficacy+of+vosaroxin+in+patients+with+first+relapsed+or+refractory+acute+myeloid+leukemia+%E2%80%93+a+critical+review&doi=10.1080%2F17474086.2016.1187063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review</span></div><div class="casAuthors">Short, Nicholas J.; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">529-534</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) are dismal, and effective treatment options in this patient population are therefore desperately needed.  Vosaroxin is a first-in-class anticancer quinolone deriv. that has shown promising activity in patients with relapsed or refractory AML.  Areas Covered: Studies in relapsed/refractory AML, including a large randomized phase III trial, have shown improved response rates when vosaroxin was combined with cytarabine, which translated to prolonged survival in certain subsets of patients, including older patients.  Given the encouraging results of vosaroxin in the relapsed/refractory setting, several studies are also evaluating vosaroxin in older patients with untreated AML who are not candidates for intensive chemotherapy.  The results from clin. trials evaluating vosaroxin in both treatment naive and relapsed/refractory AML will be reviewed.  Expert Commentary: Vosaroxin has shown significant promise in the management of AML, esp. in older patients with relapsed/refractory disease.  As vosaroxin has been assocd. with increased toxicity in some studies, appropriate dosing and patient selection will be crucial to det. the future role of vosaroxin in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOE5EmlFsbVg90H21EOLACvtfcHk0lhWWqyM53RkWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFejur8%253D&md5=fd9edad09939672351dc48b6237e1124</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1080%2F17474086.2016.1187063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2016.1187063%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DN.%2BJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520vosaroxin%2520in%2520patients%2520with%2520first%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%2520%25E2%2580%2593%2520a%2520critical%2520review%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2016%26volume%3D9%26spage%3D529%26epage%3D534%26doi%3D10.1080%2F17474086.2016.1187063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 40 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jose Antonio Ortega, Jose M. Arencibia, Elirosa Minniti, Jo Ann W. Byl, Sebastian Franco-Ulloa, Marco Borgogno, Vito Genna, Maria Summa, Sine Mandrup Bertozzi, Rosalia Bertorelli, Andrea Armirotti, Anna Minarini, Claudia Sissi, Neil Osheroff, <span class="NLM_string-name hlFld-ContribAuthor">Marco De Vivo</span>. </span><span class="cited-content_cbyCitation_article-title">Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II Î± over Î². </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12873-12886. <a href="https://doi.org/10.1021/acs.jmedchem.0c00774" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00774</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00774%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%25252C%252BPotent%25252C%252Band%252BDruglike%252BTetrahydroquinazoline%252BInhibitor%252BThat%252BIs%252BHighly%252BSelective%252Bfor%252BHuman%252BTopoisomerase%252BII%252B%2525CE%2525B1%252Bover%252B%2525CE%2525B2%26aulast%3DOrtega%26aufirst%3DJose%2BAntonio%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20072020%26date%3D20102020%26volume%3D63%26issue%3D21%26spage%3D12873%26epage%3D12886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kaja Bergant Loboda, Matej JaneÅ¾iÄ, Martina Å tampar, Bojana Å½egura, Metka FilipiÄ, <span class="NLM_string-name hlFld-ContribAuthor">Andrej Perdih</span>. </span><span class="cited-content_cbyCitation_article-title">Substituted 4,5â²-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIÎ±. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (7)
                                     , 3662-3678. <a href="https://doi.org/10.1021/acs.jcim.0c00202" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00202</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00202%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSubstituted%252B4%25252C5%2525E2%252580%2525B2-Bithiazoles%252Bas%252BCatalytic%252BInhibitors%252Bof%252BHuman%252BDNA%252BTopoisomerase%252BII%2525CE%2525B1%26aulast%3DBergant%2BLoboda%26aufirst%3DKaja%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27022020%26date%3D22062020%26date%3D02062020%26volume%3D60%26issue%3D7%26spage%3D3662%26epage%3D3678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jose M. Arencibia, Nicoletta Brindani, Sebastian Franco-Ulloa, Michela Nigro, Jissy Akkarapattiakal Kuriappan, Giuliana Ottonello, Sine Mandrup Bertozzi, Maria Summa, Stefania Girotto, Rosalia Bertorelli, Andrea Armirotti, <span class="NLM_string-name hlFld-ContribAuthor">Marco De Vivo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Dynamic Docking, Biochemical Characterization, and in Vivo Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (7)
                                     , 3508-3521. <a href="https://doi.org/10.1021/acs.jmedchem.9b01760" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01760</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01760%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BDynamic%252BDocking%25252C%252BBiochemical%252BCharacterization%25252C%252Band%252Bin%252BVivo%252BPharmacokinetics%252BStudies%252Bof%252BNovel%252BTopoisomerase%252BII%252BPoisons%252Bwith%252BPromising%252BAntiproliferative%252BActivity%26aulast%3DArencibia%26aufirst%3DJose%2BM.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D30102019%26date%3D30032020%26date%3D20032020%26volume%3D63%26issue%3D7%26spage%3D3508%26epage%3D3521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Å½iga Skok, Nace Zidar, Danijel Kikelj, <span class="NLM_string-name hlFld-ContribAuthor">Janez IlaÅ¡</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 884-904. <a href="https://doi.org/10.1021/acs.jmedchem.9b00726" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00726</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00726%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BInhibitors%252Bof%252BHuman%252BDNA%252BTopoisomerase%252BII%252Band%252BOther%252BCancer-Related%252BTargets%26aulast%3DSkok%26aufirst%3D%25C5%25BDiga%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D03052019%26date%3D21102019%26date%3D08102019%26volume%3D63%26issue%3D3%26spage%3D884%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Simone Di Micco, Milena Masullo, Afif F. Bandak, James M. Berger, Raffaele Riccio, Sonia Piacente, <span class="NLM_string-name hlFld-ContribAuthor">Giuseppe Bifulco</span>. </span><span class="cited-content_cbyCitation_article-title">Garcinol and Related Polyisoprenylated Benzophenones as Topoisomerase II Inhibitors: Biochemical and Molecular Modeling Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2019,</strong> <em>82 </em>
                                    (10)
                                     , 2768-2779. <a href="https://doi.org/10.1021/acs.jnatprod.9b00382" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.9b00382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.9b00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.9b00382%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DGarcinol%252Band%252BRelated%252BPolyisoprenylated%252BBenzophenones%252Bas%252BTopoisomerase%252BII%252BInhibitors%25253A%252BBiochemical%252Band%252BMolecular%252BModeling%252BStudies%26aulast%3DDi%2BMicco%26aufirst%3DSimone%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26042019%26date%3D16102019%26volume%3D82%26issue%3D10%26spage%3D2768%26epage%3D2779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jissy A. Kuriappan, Neil Osheroff, <span class="NLM_string-name hlFld-ContribAuthor">Marco De Vivo</span>. </span><span class="cited-content_cbyCitation_article-title">Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (9)
                                     , 4007-4017. <a href="https://doi.org/10.1021/acs.jcim.9b00605" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00605%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSmoothed%252BPotential%252BMD%252BSimulations%252Bfor%252BDissociation%252BKinetics%252Bof%252BEtoposide%252BTo%252BUnravel%252BIsoform%252BSpecificity%252Bin%252BTargeting%252BHuman%252BTopoisomerase%252BII%26aulast%3DKuriappan%26aufirst%3DJissy%2BA.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23072019%26date%3D09092019%26date%3D26082019%26volume%3D59%26issue%3D9%26spage%3D4007%26epage%3D4017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tara Man Kadayat, Seojeong Park, Aarajana Shrestha, Hyunji Jo, Soo-Yeon Hwang, Pramila Katila, Ritina Shrestha, Mahesh Raj Nepal, Keumhan Noh, Sang Kyoon Kim, Woo-Suk Koh, Kil Soo Kim, Yong Hyun Jeon, Tae Cheon Jeong, Youngjoo Kwon, <span class="NLM_string-name hlFld-ContribAuthor">Eung-Seok Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase IIÎ±-Targeted Chemotherapeutic Agents for Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (17)
                                     , 8194-8234. <a href="https://doi.org/10.1021/acs.jmedchem.9b00970" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00970</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00970%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252BEvaluations%252Bof%252BHalogenated%252B2%25252C4-Diphenyl%252BIndeno%25255B1%25252C2-b%25255Dpyridinol%252BDerivatives%252Bas%252BPotent%252BTopoisomerase%252BII%2525CE%2525B1-Targeted%252BChemotherapeutic%252BAgents%252Bfor%252BBreast%252BCancer%26aulast%3DKadayat%26aufirst%3DTara%2BMan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18062019%26date%3D22082019%26date%3D09082019%26volume%3D62%26issue%3D17%26spage%3D8194%26epage%3D8234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulei  Wu</span>, <span class="hlFld-ContribAuthor ">Zaoduan  Wu</span>, <span class="hlFld-ContribAuthor ">Qianyi  Ge</span>, <span class="hlFld-ContribAuthor ">Xing  Zheng</span>, <span class="hlFld-ContribAuthor ">Zehua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor activity of tridentate pincer and related metal complexes. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (24)
                                     , 5254-5273. <a href="https://doi.org/10.1039/D1OB00577D" title="DOI URL">https://doi.org/10.1039/D1OB00577D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00577D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00577D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DAntitumor%252Bactivity%252Bof%252Btridentate%252Bpincer%252Band%252Brelated%252Bmetal%252Bcomplexes%26aulast%3DWu%26aufirst%3DShulei%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D24%26spage%3D5254%26epage%3D5273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sudesh  Rani</span>, <span class="hlFld-ContribAuthor ">Vijay  Luxami</span>, <span class="hlFld-ContribAuthor ">Kamaldeep  Paul</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of TriphenylethyleneâNaphthalimide Conjugates as topoisomeraseâIIÎ± inhibitor and HSA binder. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (11)
                                     , 1822-1832. <a href="https://doi.org/10.1002/cmdc.202100034" title="DOI URL">https://doi.org/10.1002/cmdc.202100034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100034%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%252Bof%252BTriphenylethylene%2525E2%252580%252590Naphthalimide%252BConjugates%252Bas%252Btopoisomerase%2525E2%252580%252590II%2525CE%2525B1%252Binhibitor%252Band%252BHSA%252Bbinder%26aulast%3DRani%26aufirst%3DSudesh%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D11%26spage%3D1822%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Basak  TurkâErbul</span>, <span class="hlFld-ContribAuthor ">Ecem F.  Karaman</span>, <span class="hlFld-ContribAuthor ">Gizem N.  Duran</span>, <span class="hlFld-ContribAuthor ">Mehmet  Ozbil</span>, <span class="hlFld-ContribAuthor ">Sibel  Ozden</span>, <span class="hlFld-ContribAuthor ">Fusun  Goktas</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, in vitro cytotoxic and apoptotic effects, and molecular docking study of novel adamantane derivatives. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>354 </em>
                                    (5)
                                     , 2000256. <a href="https://doi.org/10.1002/ardp.202000256" title="DOI URL">https://doi.org/10.1002/ardp.202000256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000256%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%25252C%252Bin%252Bvitro%252Bcytotoxic%252Band%252Bapoptotic%252Beffects%25252C%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnovel%252Badamantane%252Bderivatives%26aulast%3DTurk%25E2%2580%2590Erbul%26aufirst%3DBasak%26date%3D2021%26date%3D2021%26volume%3D354%26issue%3D5%26spage%3D2000256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Dong  Wu</span>, <span class="hlFld-ContribAuthor ">Jie-Tong  Ye</span>, <span class="hlFld-ContribAuthor ">Bei-Lei  Zhu</span>, <span class="hlFld-ContribAuthor ">Fang-Min  Ye</span>, <span class="hlFld-ContribAuthor ">Wang-Yue  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Effect and mechanisms of LINC00152 knockdown on chemotherapy resistance in mitomycin-resistant gastric cancer NCI-N87/MMC cells. </span><span class="cited-content_cbyCitation_journal-name">World Chinese Journal of Digestology</span><span> <strong>2021,</strong> <em>29 </em>
                                    (7)
                                     , 332-339. <a href="https://doi.org/10.11569/wcjd.v29.i7.332" title="DOI URL">https://doi.org/10.11569/wcjd.v29.i7.332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.11569/wcjd.v29.i7.332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.11569%2Fwcjd.v29.i7.332%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Chinese%2520Journal%2520of%2520Digestology%26atitle%3DEffect%252Band%252Bmechanisms%252Bof%252BLINC00152%252Bknockdown%252Bon%252Bchemotherapy%252Bresistance%252Bin%252Bmitomycin-resistant%252Bgastric%252Bcancer%252BNCI-N87%25252FMMC%252Bcells%26aulast%3DWu%26aufirst%3DMing-Dong%26date%3D2021%26volume%3D29%26issue%3D7%26spage%3D332%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ezzat  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridine Derivatives as Biologically Active Precursors; Organics and Selected Coordination Complexes. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (13)
                                     , 3041-3064. <a href="https://doi.org/10.1002/slct.202100332" title="DOI URL">https://doi.org/10.1002/slct.202100332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DPyridine%252BDerivatives%252Bas%252BBiologically%252BActive%252BPrecursors%25253B%252BOrganics%252Band%252BSelected%252BCoordination%252BComplexes%26aulast%3DKhan%26aufirst%3DEzzat%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D13%26spage%3D3041%26epage%3D3064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pei  Yan</span>, <span class="hlFld-ContribAuthor ">Qingfu  Lai</span>, <span class="hlFld-ContribAuthor ">Ming  Li</span>, <span class="hlFld-ContribAuthor ">Xiaobao  Jin</span>, <span class="hlFld-ContribAuthor ">Gao  Wie</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Chen</span>, <span class="hlFld-ContribAuthor ">Lianbao  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">New Anticancer Agents: Design, Synthesis, Biological Activity, and Molecular Docking of Bicyclic Phloroglucinol Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (7)
                                     , 1453-1457. <a href="https://doi.org/10.1002/slct.202004442" title="DOI URL">https://doi.org/10.1002/slct.202004442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202004442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202004442%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DNew%252BAnticancer%252BAgents%25253A%252BDesign%25252C%252BSynthesis%25252C%252BBiological%252BActivity%25252C%252Band%252BMolecular%252BDocking%252Bof%252BBicyclic%252BPhloroglucinol%252BDerivatives%26aulast%3DYan%26aufirst%3DPei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D7%26spage%3D1453%26epage%3D1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Spallarossa</span>, <span class="hlFld-ContribAuthor ">Matteo  Lusardi</span>, <span class="hlFld-ContribAuthor ">Chiara  Caneva</span>, <span class="hlFld-ContribAuthor ">Aldo  Profumo</span>, <span class="hlFld-ContribAuthor ">Camillo  Rosano</span>, <span class="hlFld-ContribAuthor ">Marco  Ponassi</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic Basic Merbarone Analogues as Antiproliferative Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (3)
                                     , 557. <a href="https://doi.org/10.3390/molecules26030557" title="DOI URL">https://doi.org/10.3390/molecules26030557</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26030557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26030557%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBicyclic%252BBasic%252BMerbarone%252BAnalogues%252Bas%252BAntiproliferative%252BAgents%26aulast%3DSpallarossa%26aufirst%3DAndrea%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D3%26spage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhamad  Mustafa</span>, <span class="hlFld-ContribAuthor ">Ahmed  El-Kardocy</span>, <span class="hlFld-ContribAuthor ">Yaser A  Mostafa</span>. </span><span class="cited-content_cbyCitation_article-title">Development of new hetero-steroid hybrids with antiproliferative activity against MCF-7 breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte fÃ¼r Chemie - Chemical Monthly</span><span> <strong>2021,</strong> <em>152 </em>
                                    (1)
                                     , 137-149. <a href="https://doi.org/10.1007/s00706-020-02716-0" title="DOI URL">https://doi.org/10.1007/s00706-020-02716-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-020-02716-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-020-02716-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DDevelopment%252Bof%252Bnew%252Bhetero-steroid%252Bhybrids%252Bwith%252Bantiproliferative%252Bactivity%252Bagainst%252BMCF-7%252Bbreast%252Bcancer%252Bcells%26aulast%3DMustafa%26aufirst%3DMuhamad%26date%3D2021%26date%3D2021%26volume%3D152%26issue%3D1%26spage%3D137%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arindam  Talukdar</span>, <span class="hlFld-ContribAuthor ">Sourav  Pal</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Approaches Toward Development of Topoisomerase I Inhibitor: A Clinically Validated Target. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 441-462. <a href="https://doi.org/10.1016/B978-0-12-822312-3.00018-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-822312-3.00018-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-822312-3.00018-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-822312-3.00018-7%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BApproaches%252BToward%252BDevelopment%252Bof%252BTopoisomerase%252BI%252BInhibitor%25253A%252BA%252BClinically%252BValidated%252BTarget%26aulast%3DTalukdar%26aufirst%3DArindam%26date%3D2021%26spage%3D441%26epage%3D462%26pub%3DElsevier%26atitle%3DMolecular%252BDocking%252Bfor%252BComputer-Aided%252BDrug%252BDesign%26date%3D2021%26volume%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Surbhi  Mahajan</span>, <span class="hlFld-ContribAuthor ">Gaddam  Kiranmai</span>, <span class="hlFld-ContribAuthor ">Dilep Kumar  Sigalapalli</span>, <span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Stephy Elza  John</span>, <span class="hlFld-ContribAuthor ">Narayana  Nagesh</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Î²-carboline-benzothiazole hybrids via carboxamide formation as cytotoxic agents: DNA intercalative topoisomerase IIÎ± inhibition and apoptosis induction. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>106 </em>, 104481. <a href="https://doi.org/10.1016/j.bioorg.2020.104481" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104481</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104481%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDevelopment%252Bof%252B%2525CE%2525B2-carboline-benzothiazole%252Bhybrids%252Bvia%252Bcarboxamide%252Bformation%252Bas%252Bcytotoxic%252Bagents%25253A%252BDNA%252Bintercalative%252Btopoisomerase%252BII%2525CE%2525B1%252Binhibition%252Band%252Bapoptosis%252Binduction%26aulast%3DTokala%26aufirst%3DRamya%26date%3D2021%26volume%3D106%26spage%3D104481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji-Ning  Chen</span>, <span class="hlFld-ContribAuthor ">Xing-Kang  Wu</span>, <span class="hlFld-ContribAuthor ">Chun-Hua  Lu</span>, <span class="hlFld-ContribAuthor ">Xun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship of novel acridone derivatives as antiproliferative agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115868. <a href="https://doi.org/10.1016/j.bmc.2020.115868" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115868</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115868%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Bof%252Bnovel%252Bacridone%252Bderivatives%252Bas%252Bantiproliferative%252Bagents%26aulast%3DChen%26aufirst%3DJi-Ning%26date%3D2021%26volume%3D29%26spage%3D115868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Uppu Jaya  Lakshmi</span>, <span class="hlFld-ContribAuthor ">Prasanthi  Sankarana</span>, <span class="hlFld-ContribAuthor ">Dilep Kumar  Sigalapalli</span>, <span class="hlFld-ContribAuthor ">Nikhil  Gadewal</span>, <span class="hlFld-ContribAuthor ">Jyoti  Kode</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of thiadiazolo-carboxamide bridged Î²-carboline-indole hybrids: DNA intercalative topo-IIÎ± inhibition with promising antiproliferative activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>105 </em>, 104357. <a href="https://doi.org/10.1016/j.bioorg.2020.104357" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104357%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bthiadiazolo-carboxamide%252Bbridged%252B%2525CE%2525B2-carboline-indole%252Bhybrids%25253A%252BDNA%252Bintercalative%252Btopo-II%2525CE%2525B1%252Binhibition%252Bwith%252Bpromising%252Bantiproliferative%252Bactivity%26aulast%3DTokala%26aufirst%3DRamya%26date%3D2020%26volume%3D105%26spage%3D104357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maryam  Gholampour</span>, <span class="hlFld-ContribAuthor ">Hassan  Seradj</span>, <span class="hlFld-ContribAuthor ">Somayeh  Pirhadi</span>, <span class="hlFld-ContribAuthor ">Mehdi  Khoshneviszadeh</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2-amino-1,4-naphthoquinone hybrids: Design, synthesis, cytotoxicity evaluation and in silico studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (21)
                                     , 115718. <a href="https://doi.org/10.1016/j.bmc.2020.115718" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115718</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115718%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B2-amino-1%25252C4-naphthoquinone%252Bhybrids%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bcytotoxicity%252Bevaluation%252Band%252Bin%252Bsilico%252Bstudies%26aulast%3DGholampour%26aufirst%3DMaryam%26date%3D2020%26volume%3D28%26issue%3D21%26spage%3D115718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ozum  Ozturk</span>, <span class="hlFld-ContribAuthor ">Esin  Aki-Yalcin</span>, <span class="hlFld-ContribAuthor ">Ismail  Yalcin</span>, <span class="hlFld-ContribAuthor ">Renate  Grifitth</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into Mechanism of Action of Anticancer Benzazoles. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (23)
                                     , 2056-2069. <a href="https://doi.org/10.2174/1568026620666200819152108" title="DOI URL">https://doi.org/10.2174/1568026620666200819152108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200819152108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200819152108%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DInsight%252Binto%252BMechanism%252Bof%252BAction%252Bof%252BAnticancer%252BBenzazoles%26aulast%3DOzturk%26aufirst%3DOzum%26date%3D2020%26volume%3D20%26issue%3D23%26spage%3D2056%26epage%3D2069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline  Molinaro</span>, <span class="hlFld-ContribAuthor ">Alain  Martoriati</span>, <span class="hlFld-ContribAuthor ">Lydie  Pelinski</span>, <span class="hlFld-ContribAuthor ">Katia  Cailliau</span>. </span><span class="cited-content_cbyCitation_article-title">Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 2863. <a href="https://doi.org/10.3390/cancers12102863" title="DOI URL">https://doi.org/10.3390/cancers12102863</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12102863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12102863%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCopper%252BComplexes%252Bas%252BAnticancer%252BAgents%252BTargeting%252BTopoisomerases%252BI%252Band%252BII%26aulast%3DMolinaro%26aufirst%3DCaroline%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D2863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Catanzaro</span>, <span class="hlFld-ContribAuthor ">Nibal  Betari</span>, <span class="hlFld-ContribAuthor ">Jose M.  Arencibia</span>, <span class="hlFld-ContribAuthor ">Serena  Montanari</span>, <span class="hlFld-ContribAuthor ">Claudia  Sissi</span>, <span class="hlFld-ContribAuthor ">Angela  De Simone</span>, <span class="hlFld-ContribAuthor ">Ivano  Vassura</span>, <span class="hlFld-ContribAuthor ">Alan  Santini</span>, <span class="hlFld-ContribAuthor ">Vincenza  Andrisano</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Tumiatti</span>, <span class="hlFld-ContribAuthor ">Marco  De Vivo</span>, <span class="hlFld-ContribAuthor ">Dmitri V.  Krysko</span>, <span class="hlFld-ContribAuthor ">Marco B.L.  Rocchi</span>, <span class="hlFld-ContribAuthor ">Carmela  Fimognari</span>, <span class="hlFld-ContribAuthor ">Andrea  Milelli</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112504. <a href="https://doi.org/10.1016/j.ejmech.2020.112504" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112504%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Btopoisomerase%252BII%252Bwith%252Btrypthantrin%252Bderivatives%25253A%252BDiscovery%252Bof%252B7-%252528%2525282-%252528dimethylamino%252529ethyl%252529amino%252529indolo%25255B2%25252C1-b%25255Dquinazoline-6%25252C12-dione%252Bas%252Ban%252Bantiproliferative%252Bagent%252Band%252Bto%252Btreat%252Bcancer%26aulast%3DCatanzaro%26aufirst%3DElena%26date%3D2020%26volume%3D202%26spage%3D112504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Wen  Xie</span>, <span class="hlFld-ContribAuthor ">Zhao-Peng  Liu</span>, <span class="hlFld-ContribAuthor ">Xun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, bioevaluation of LFC- and PA-tethered anthraquinone analogues of mitoxantrone. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 104005. <a href="https://doi.org/10.1016/j.bioorg.2020.104005" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104005%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbioevaluation%252Bof%252BLFC-%252Band%252BPA-tethered%252Banthraquinone%252Banalogues%252Bof%252Bmitoxantrone%26aulast%3DXie%26aufirst%3DXin-Wen%26date%3D2020%26volume%3D101%26spage%3D104005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Song</span>, <span class="hlFld-ContribAuthor ">Siran  Feng</span>, <span class="hlFld-ContribAuthor ">Jiajia  Feng</span>, <span class="hlFld-ContribAuthor ">Jinjiao  Dong</span>, <span class="hlFld-ContribAuthor ">Kan  Yang</span>, <span class="hlFld-ContribAuthor ">Zhenming  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoqiang  Qiao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel pyrazoline derivatives containing indole skeleton as anti-cancer agents targeting topoisomerase II. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112459. <a href="https://doi.org/10.1016/j.ejmech.2020.112459" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112459%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrazoline%252Bderivatives%252Bcontaining%252Bindole%252Bskeleton%252Bas%252Banti-cancer%252Bagents%252Btargeting%252Btopoisomerase%252BII%26aulast%3DSong%26aufirst%3DYali%26date%3D2020%26volume%3D200%26spage%3D112459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Junhong  Zhang</span>, <span class="hlFld-ContribAuthor ">Kaili  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Han</span>, <span class="hlFld-ContribAuthor ">Xinying  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Gao</span>, <span class="hlFld-ContribAuthor ">Zihan  Wang</span>, <span class="hlFld-ContribAuthor ">Yaxin  Sun</span>, <span class="hlFld-ContribAuthor ">Hao  Yan</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xia  Xu</span>, <span class="hlFld-ContribAuthor ">Dong-Hua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Quercetin overcomes colon cancer cells resistance to chemotherapy by inhibiting solute carrier family 1, member 5 transporter. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2020,</strong> <em>881 </em>, 173185. <a href="https://doi.org/10.1016/j.ejphar.2020.173185" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173185%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DQuercetin%252Bovercomes%252Bcolon%252Bcancer%252Bcells%252Bresistance%252Bto%252Bchemotherapy%252Bby%252Binhibiting%252Bsolute%252Bcarrier%252Bfamily%252B1%25252C%252Bmember%252B5%252Btransporter%26aulast%3DZhou%26aufirst%3DYuanyuan%26date%3D2020%26volume%3D881%26spage%3D173185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenjin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Peng</span>, <span class="hlFld-ContribAuthor ">Zhi-Hong  Jiang</span>, <span class="hlFld-ContribAuthor ">Lanyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiyun  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (14)
                                     , 3180. <a href="https://doi.org/10.3390/molecules25143180" title="DOI URL">https://doi.org/10.3390/molecules25143180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25143180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25143180%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BAnti-Tumor%252BActivity%252Bof%252BNovel%252BBenzimidazole-Chalcone%252BHybrids%252Bas%252BNon-Intercalative%252BTopoisomerase%252BII%252BCatalytic%252BInhibitors%26aulast%3DZhou%26aufirst%3DWei%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D14%26spage%3D3180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvana  Pedatella</span>, <span class="hlFld-ContribAuthor ">Carmen  Cerchia</span>, <span class="hlFld-ContribAuthor ">Michele  Manfra</span>, <span class="hlFld-ContribAuthor ">Anna  Cioce</span>, <span class="hlFld-ContribAuthor ">Adele  Bolognese</span>, <span class="hlFld-ContribAuthor ">Antonio  Lavecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIÎ± inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111960. <a href="https://doi.org/10.1016/j.ejmech.2019.111960" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111960</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111960%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAntitumor%252Bagents%252B7.%252BSynthesis%25252C%252Bantiproliferative%252Bactivity%252Band%252Bmolecular%252Bmodeling%252Bof%252Bnew%252Bl-lysine-conjugated%252Bpyridophenoxazinones%252Bas%252Bpotent%252BDNA-binding%252Bligands%252Band%252Btopoisomerase%252BII%2525CE%2525B1%252Binhibitors%26aulast%3DPedatella%26aufirst%3DSilvana%26date%3D2020%26volume%3D187%26spage%3D111960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">AmÃ©lia Galdino  Ribeiro</span>, <span class="hlFld-ContribAuthor ">Sinara MÃ´nica Vitalino de  Almeida</span>, <span class="hlFld-ContribAuthor ">Jamerson Ferreira  de Oliveira</span>, <span class="hlFld-ContribAuthor ">Tulio Ricardo Couto de Lima  Souza</span>, <span class="hlFld-ContribAuthor ">Keriolaine Lima dos  Santos</span>, <span class="hlFld-ContribAuthor ">Amanda Pinheiro de Barros  Albuquerque</span>, <span class="hlFld-ContribAuthor ">Mariane Cajuba de Britto Lira  Nogueira</span>, <span class="hlFld-ContribAuthor ">Luiz Bezerra de  Carvalho Junior</span>, <span class="hlFld-ContribAuthor ">Ricardo OlÃ­mpio de  Moura</span>, <span class="hlFld-ContribAuthor ">Aline Caroline  da Silva</span>, <span class="hlFld-ContribAuthor ">ValÃ©ria RÃªgo Alves  Pereira</span>, <span class="hlFld-ContribAuthor ">Maria Carolina Accioly Brelaz de  Castro</span>, <span class="hlFld-ContribAuthor ">Maria do Carmo Alves de  Lima</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, inÂ vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111592. <a href="https://doi.org/10.1016/j.ejmech.2019.111592" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111592</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111592%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B4-quinoline-thiosemicarbazone%252Bderivatives%25253A%252BSynthesis%25252C%252Bantiproliferative%252Bactivity%25252C%252Bin%2525C2%2525A0vitro%252Band%252Bin%252Bsilico%252Bbiomacromolecule%252Binteraction%252Bstudies%252Band%252Btopoisomerase%252Binhibition%26aulast%3DRibeiro%26aufirst%3DAm%25C3%25A9lia%2BGaldino%26date%3D2019%26volume%3D182%26spage%3D111592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minji  Bang</span>, <span class="hlFld-ContribAuthor ">Do Gyeong  Kim</span>, <span class="hlFld-ContribAuthor ">Edson Luck  Gonzales</span>, <span class="hlFld-ContribAuthor ">Kyoung Ja  Kwon</span>, <span class="hlFld-ContribAuthor ">Chan Young  Shin</span>. </span><span class="cited-content_cbyCitation_article-title">Etoposide Induces Mitochondrial Dysfunction and Cellular Senescence in Primary Cultured Rat Astrocytes. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules & Therapeutics</span><span> <strong>2019,</strong> <em>27 </em>
                                    (6)
                                     , 530-539. <a href="https://doi.org/10.4062/biomolther.2019.151" title="DOI URL">https://doi.org/10.4062/biomolther.2019.151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4062/biomolther.2019.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4062%2Fbiomolther.2019.151%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%2520%2526%2520Therapeutics%26atitle%3DEtoposide%252BInduces%252BMitochondrial%252BDysfunction%252Band%252BCellular%252BSenescence%252Bin%252BPrimary%252BCultured%252BRat%252BAstrocytes%26aulast%3DBang%26aufirst%3DMinji%26date%3D2019%26volume%3D27%26issue%3D6%26spage%3D530%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Syed Moiz  Ahmed</span>, <span class="hlFld-ContribAuthor ">Peter  DrÃ¶ge</span>. </span><span class="cited-content_cbyCitation_article-title">Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2019,</strong> <em>13 </em>
                                    (10)
                                     , 2062-2078. <a href="https://doi.org/10.1002/1878-0261.12541" title="DOI URL">https://doi.org/10.1002/1878-0261.12541</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/1878-0261.12541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F1878-0261.12541%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DOncofetal%252BHMGA2%252Battenuates%252Bgenotoxic%252Bdamage%252Binduced%252Bby%252Btopoisomerase%252BII%252Btarget%252Bcompounds%252Bthrough%252Bthe%252Bregulation%252Bof%252Blocal%252BDNA%252Btopology%26aulast%3DAhmed%26aufirst%3DSyed%2BMoiz%26date%3D2019%26date%3D2019%26volume%3D13%26issue%3D10%26spage%3D2062%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang-Liang  Wang</span>, <span class="hlFld-ContribAuthor ">Narsaiah  Battini</span>, <span class="hlFld-ContribAuthor ">Rammohan R. Yadav  Bheemanaboina</span>, <span class="hlFld-ContribAuthor ">Mohammad Fawad  Ansari</span>, <span class="hlFld-ContribAuthor ">Jin-Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Yun-Peng  Xie</span>, <span class="hlFld-ContribAuthor ">Gui-Xin  Cai</span>, <span class="hlFld-ContribAuthor ">Shao-Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">A new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antibacterial agents: Design, synthesis and evaluation acting on microbes, DNA, HSA and topoisomerase IV. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 166-181. <a href="https://doi.org/10.1016/j.ejmech.2019.06.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnew%252Bexploration%252Btowards%252Baminothiazolquinolone%252Boximes%252Bas%252Bpotentially%252Bmulti-targeting%252Bantibacterial%252Bagents%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bacting%252Bon%252Bmicrobes%25252C%252BDNA%25252C%252BHSA%252Band%252Btopoisomerase%252BIV%26aulast%3DWang%26aufirst%3DLiang-Liang%26date%3D2019%26volume%3D179%26spage%3D166%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francivaldo AraÃºjo  da Silva Filho</span>, <span class="hlFld-ContribAuthor ">Thais  de Freitas Souza</span>, <span class="hlFld-ContribAuthor ">AmÃ©lia Galdino  Ribeiro</span>, <span class="hlFld-ContribAuthor ">Josival Emanuel Ferreira  Alves</span>, <span class="hlFld-ContribAuthor ">Jamerson Ferreira  de Oliveira</span>, <span class="hlFld-ContribAuthor ">TÃºlio Ricardo Couto  de Lima Souza</span>, <span class="hlFld-ContribAuthor ">Ricardo OlÃ­mpio  de Moura</span>, <span class="hlFld-ContribAuthor ">Maria  do Carmo Alves de Lima</span>, <span class="hlFld-ContribAuthor ">Luiz Bezerra  de Carvalho Junior</span>, <span class="hlFld-ContribAuthor ">Sinara MÃ´nica Vitalino  de Almeida</span>. </span><span class="cited-content_cbyCitation_article-title">Topoisomerase inhibition and albumin interaction studies of acridine-thiosemicarbazone derivatives. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2019,</strong> <em>138 </em>, 582-589. <a href="https://doi.org/10.1016/j.ijbiomac.2019.07.097" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2019.07.097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2019.07.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2019.07.097%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DTopoisomerase%252Binhibition%252Band%252Balbumin%252Binteraction%252Bstudies%252Bof%252Bacridine-thiosemicarbazone%252Bderivatives%26aulast%3Dda%2BSilva%2BFilho%26aufirst%3DFrancivaldo%2BAra%25C3%25BAjo%26date%3D2019%26volume%3D138%26spage%3D582%26epage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keisuke  Otake</span>, <span class="hlFld-ContribAuthor ">Kana  Yamada</span>, <span class="hlFld-ContribAuthor ">Kazuki  Miura</span>, <span class="hlFld-ContribAuthor ">Yukiko  Sasazawa</span>, <span class="hlFld-ContribAuthor ">So  Miyazaki</span>, <span class="hlFld-ContribAuthor ">Yuki  Niwa</span>, <span class="hlFld-ContribAuthor ">Akihiro  Ogura</span>, <span class="hlFld-ContribAuthor ">Ken-ichi  Takao</span>, <span class="hlFld-ContribAuthor ">Siro  Simizu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of topoisomerases as molecular targets of cytosporolide C and its analog. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3334-3338. <a href="https://doi.org/10.1016/j.bmc.2019.06.014" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.06.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.06.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Btopoisomerases%252Bas%252Bmolecular%252Btargets%252Bof%252Bcytosporolide%252BC%252Band%252Bits%252Banalog%26aulast%3DOtake%26aufirst%3DKeisuke%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3334%26epage%3D3338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaja  Bergant</span>, <span class="hlFld-ContribAuthor ">Matej  JaneÅ¾iÄ</span>, <span class="hlFld-ContribAuthor ">Katja  Valjavec</span>, <span class="hlFld-ContribAuthor ">Izidor  SosiÄ</span>, <span class="hlFld-ContribAuthor ">Stane  Pajk</span>, <span class="hlFld-ContribAuthor ">Martina  Å tampar</span>, <span class="hlFld-ContribAuthor ">Bojana  Å½egura</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>, <span class="hlFld-ContribAuthor ">Metka  FilipiÄ</span>, <span class="hlFld-ContribAuthor ">Andrej  Perdih</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIÎ±. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>175 </em>, 330-348. <a href="https://doi.org/10.1016/j.ejmech.2019.04.055" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.055%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-guided%252Boptimization%252Bof%252B4%25252C6-substituted-1%25252C3%25252C5-triazin-2%2525281H%252529-ones%252Bas%252Bcatalytic%252Binhibitors%252Bof%252Bhuman%252BDNA%252Btopoisomerase%252BII%2525CE%2525B1%26aulast%3DBergant%26aufirst%3DKaja%26date%3D2019%26volume%3D175%26spage%3D330%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Qiang  Wu</span>, <span class="hlFld-ContribAuthor ">Shangxian  Luan</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Zhixiang  Yuan</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Min  He</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>171 </em>, 129-168. <a href="https://doi.org/10.1016/j.ejmech.2019.03.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Breview%252Bof%252Btopoisomerase%252Binhibitors%252Bas%252Banticancer%252Bagents%252Bin%252Bthe%252Bpast%252Bdecade%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2019%26volume%3D171%26spage%3D129%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji-Ning  Chen</span>, <span class="hlFld-ContribAuthor ">Xing-Kang  Wu</span>, <span class="hlFld-ContribAuthor ">Chun-Hua  Lu</span>, <span class="hlFld-ContribAuthor ">Xun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">E17 exerts anti-tumor activity through inhibiting topo II-mediated chromosomes condensation in CRC cells. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2019,</strong> <em>513 </em>
                                    (2)
                                     , 313-318. <a href="https://doi.org/10.1016/j.bbrc.2019.04.002" title="DOI URL">https://doi.org/10.1016/j.bbrc.2019.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2019.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2019.04.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DE17%252Bexerts%252Banti-tumor%252Bactivity%252Bthrough%252Binhibiting%252Btopo%252BII-mediated%252Bchromosomes%252Bcondensation%252Bin%252BCRC%252Bcells%26aulast%3DChen%26aufirst%3DJi-Ning%26date%3D2019%26volume%3D513%26issue%3D2%26spage%3D313%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Murugavel</span>, <span class="hlFld-ContribAuthor ">C.  Ravikumar</span>, <span class="hlFld-ContribAuthor ">G.  Jaabil</span>, <span class="hlFld-ContribAuthor ">Ponnuswamy  Alagusundaram</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIÎ± inhibiting anticancer agent. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>79 </em>, 73-82. <a href="https://doi.org/10.1016/j.compbiolchem.2019.01.013" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2019.01.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2019.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2019.01.013%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DSynthesis%25252C%252Bcomputational%252Bquantum%252Bchemical%252Bstudy%25252C%252Bin%252Bsilico%252BADMET%252Band%252Bmolecular%252Bdocking%252Banalysis%25252C%252Bin%252Bvitro%252Bbiological%252Bevaluation%252Bof%252Ba%252Bnovel%252Bsulfur%252Bheterocyclic%252Bthiophene%252Bderivative%252Bcontaining%252B1%25252C2%25252C3-triazole%252Band%252Bpyridine%252Bmoieties%252Bas%252Ba%252Bpotential%252Bhuman%252Btopoisomerase%252BII%2525CE%2525B1%252Binhibiting%252Banticancer%252Bagent%26aulast%3DMurugavel%26aufirst%3DS.%26date%3D2019%26volume%3D79%26spage%3D73%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang-Liang  Wang</span>, <span class="hlFld-ContribAuthor ">Narsaiah  Battini</span>, <span class="hlFld-ContribAuthor ">Rammohan R.Yadav  Bheemanaboina</span>, <span class="hlFld-ContribAuthor ">Shao-Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 105-123. <a href="https://doi.org/10.1016/j.ejmech.2019.01.072" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.072%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Baminothiazolyl%252Bnorfloxacin%252Banalogues%252Bas%252Bpotential%252Bantimicrobial%252Bagents%252Band%252Btheir%252Bbiological%252Bevaluation%26aulast%3DWang%26aufirst%3DLiang-Liang%26date%3D2019%26volume%3D167%26spage%3D105%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Belluti</span>, <span class="hlFld-ContribAuthor ">Giulia  Orteca</span>, <span class="hlFld-ContribAuthor ">Valentina  Semeghini</span>, <span class="hlFld-ContribAuthor ">Giovanna  Rigillo</span>, <span class="hlFld-ContribAuthor ">Francesca  Parenti</span>, <span class="hlFld-ContribAuthor ">Erika  Ferrari</span>, <span class="hlFld-ContribAuthor ">Carol  Imbriano</span>. </span><span class="cited-content_cbyCitation_article-title">Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (1)
                                     , 28. <a href="https://doi.org/10.3390/ijms20010028" title="DOI URL">https://doi.org/10.3390/ijms20010028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20010028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20010028%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPotent%252BAnti-Cancer%252BProperties%252Bof%252BPhthalimide-Based%252BCurcumin%252BDerivatives%252Bon%252BProstate%252BTumor%252BCells%26aulast%3DBelluti%26aufirst%3DSilvia%26date%3D2019%26date%3D2018%26volume%3D20%26issue%3D1%26spage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0037.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. ATP binding domain of topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) complexed with an ATP analogue AMPPNP (left) and the major H-bonding interactions between topo IIÎ± and AMPPNP (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structures of ternary âdrug-enzyme-DNAâ complexes (A: etoposide, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3">3QX3</a>; B: MTZ, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0V">4G0V</a>), and the binding contacts are also schematized in a simplified form (C: DNA nonintercalating agent etoposide; D: DNA intercalating agent MTZ).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Illustrative examples of representative topo II inhibitors that have been used in clinical trials or are at various stages of development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. 2,4,6-Triarylpyridine (Î±-terpyridine) is a promising backbone for exploring dual topo inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR investigation of the Î±-terpyridine motif led to a series of diphenyl-6-thiophen-2-yl-pyridine derivatives (<b>18</b>) with high selectivity against topo II over topo I and the X-ray crystallographic structure of <b>18a</b> complexed with human topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of naphthalimide-bearing topo II inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Naphthalimide-based derivatives <b>22</b> were designed as multifunctional molecules by targeting both topo II and receptor tyrosine kinases (RTKs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. SAR exploration of 2-phenylnaphthalene-based derivatives (<b>23</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Modification of the 1,3,4-thiadiazole core with 2,5-disubstituted groups led to a series of derivatives (<b>24</b>) with different topo II-interacting patterns.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Discovery of the novel spiro-acridines <b>26a</b> and <b>26b</b> as topo IIÎ±-mediated poisons derived from the acridine and TSC chemotypes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Benzo[<i>a</i>]phenazine heterocycle has been shown as a promising backbone for exploring dual topo I and II inhibitors (e.g., <b>30</b> and <b>31</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Discovery of terpyridine-based libraries <b>32</b>â<b>36</b> through a conformational restriction approach and methylation modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Systematic optimization of CPT led to a range of lomefloxacin derivatives (<b>38</b>) with potent topo II inhibitory potencies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. An illustrative example of 2-phenylbenzofuranoid <b>40</b> designed from 2-phenylnaphthalenoids <b>39</b> using a scaffold-hopping strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Application of a molecular hybridization strategy led to new chemotypes with equipotent or more potent topo II inhibitory efficacies owing to the synergistic effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures of the ametantrone-amsacrine-related hybrid (<b>43</b>) as topo II-induced poisons. The binding mode of compound <b>43b</b> in complex with topo II (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) was also shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Design of acridine <b>44</b> and indeno[1,2-<i>c</i>]isoquinoline-5,11(6<i>H</i>)-dione derivatives <b>46</b>â<b>49</b> involves the combination of several topo II-oriented fragments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Optimization of the pharmacophoric Î²-carboline ring by incorporating the biologically active DTC and trifluoromethylphenyl moieties, which are spatially adaptive to the active binding domain of topo II, led to the hybrid Î²-carboline derivatives (<b>50a</b>, <b>50b</b>, <b>50d</b>, <b>50e</b>) with selective cytotoxicity toward DU-145 prostate cancer cell.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical modification of the 9-hydroxyl group of the DMEP prototype led to the DMEP esters <b>51</b> and amides <b>52</b> by means of prodrug principles combined with bioisosteric manipulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Combination of naturally available topo II inhibitor DMEP backbone with nitrogen mustard alkylating agents led to several DMEP analogues (<b>56</b>â<b>64</b>) with strong topo II inhibitory activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Design and SAR for topo IIÎ²-specific DMEP analogues <b>65</b> and <b>66</b> that involved replacing the prototype sugar motif with 1,2,3-triazole-bridging segments, which highlights the importance of effective interaction with the polar topo IIÎ² Q778 residue, a position that is different between topo IIÎ± and Î² subtypes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Design of mono- and bis-epipodophyllotoxin derivatives <b>67a</b>â<b>c</b> and <b>68a</b>â<b>e</b> involved replacement of the glycosidic part of archetype <b>1</b> with methylene-linked piperazines to enhance activity by allowing more effective interactions with the topo II active binding area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Semisynthetic processes for the desired ether intermediates (<b>71</b> and <b>73</b>) and silyl ethers (<b>70</b>, <b>72</b>, and <b>74</b>) from naturally available <b>69</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Combination of a sesquiterpene ME ring and a 1,2,3-triazole motif led to novel ME derivatives <b>77</b> with decent antitumoral efficacies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. <i>p</i>-Terphenyl derivatives <b>78</b> with phenolic hydroxyl groups at different positions gave differing selectivity of inhibition toward topo IIÎ± and Î² isoforms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structures of several oleanane-type triterpenoids (<b>79</b>â<b>82</b>) and oleanolic acid-based analogues <b>83</b> and <b>84a</b>â<b>i</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structural modification of naturally occurring keto-type curcumin led to a myriad of curcumin-inspired analogues <b>85</b> with significantly elevated cytotoxicity compared with curcumin and melphalan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structures of ellipticine-derived analogues <b>89</b>â<b>92</b> and the binding mode of <b>92a</b> with topo IIÎ± (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>). Some of these compounds, exemplified by <b>90b</b> and <b>92</b>, presented significant antineoplastic improvements compared with the parent ellipticine for targeting topo IIÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Natural product evodiamine (EVO) inspired scaffold diversity and led to a large variety of derivatives <b>93</b>â<b>105</b> via multiple design protocols. Among them, the 3-chloro-10-hydroxyl derivatives <b>98d</b>â<b>h</b> showed particularly excellent potencies, highlighting their promise as leads for further exploitation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. (A) Schematic flowchart for the discovery of potent topo IIÎ± inhibitors possessing the skeletons of triazines (<b>106</b>), triazoles (<b>107</b>), pyrimidines (<b>108</b>), 9<i>H</i>-purines (<b>109</b>), and 1<i>H</i>-pyrazolo[3,4]pyrimidines (<b>110</b>) via an in silico protocol. (B) Binding modes of the two representative examples <b>109a</b> and <b>110a</b> with human topo IIÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. (A) A hierarchical computational screening used for the discovery of xanthone derivatives <b>111a</b>â<b>d</b> with potent topo IIÎ± inhibitory potencies from a 50-member xanthone combinatorial library; the X-ray structures of <b>111a</b> and <b>111b</b> complexed with topo IIÎ± (PBD ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM">1ZXM</a>) are also presented. (B) Putative binding modes of xanthone derivatives <b>111a</b>â<b>d</b> with topo IIÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Design of indeno[1,2-<i>b</i>]quinoxaline analogues <b>113</b> and <b>114</b> via bioisosteric modification protocol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Formation of complexes provided more potent DNA binding affinities with an affinity order of heterobimetallic complexes > monometallic counterparts > free ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Pd(II)-based thiol-reactive complex has great potential to be developed as potent topo IIÎ± inhibitor <b>121</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. For the Ru-based complexes, coplanar aromatic conjugation and hydrophobicity are fundamental elements for achieving both notable DNA binding affinities and topo IIÎ± inhibitory profiles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/medium/jm-2017-01202e_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Ru(II)-chelated compounds <b>140</b> and <b>141</b> are topo I/IIÎ± poisons, note that the mode of action of Au(III) complex <b>142</b> changes with the concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-20/acs.jmedchem.7b01202/20181019/images/large/jm-2017-01202e_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01202&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 125 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, D.</span></span> <span> </span><span class="NLM_article-title">Global cancer transitions according to the Human Development Index (2008â2030): a population-based study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">790</span>â <span class="NLM_lpage">801</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(12)70211-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS1470-2045%2812%2970211-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=22658655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A280%3ADC%252BC38notlaktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=790-801&author=F.+Brayauthor=A.+Jemalauthor=N.+Greyauthor=J.+Ferlayauthor=D.+Forman&title=Global+cancer+transitions+according+to+the+Human+Development+Index+%282008%E2%80%932030%29%3A+a+population-based+study&doi=10.1016%2FS1470-2045%2812%2970211-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer transitions according to the Human Development Index (2008-2030): a population-based study</span></div><div class="casAuthors">Bray Freddie; Jemal Ahmedin; Grey Nathan; Ferlay Jacques; Forman David</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">790-801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cancer is set to become a major cause of morbidity and mortality in the coming decades in every region of the world.  We aimed to assess the changing patterns of cancer according to varying levels of human development.  METHODS:  We used four levels (low, medium, high, and very high) of the Human Development Index (HDI), a composite indicator of life expectancy, education, and gross domestic product per head, to highlight cancer-specific patterns in 2008 (on the basis of GLOBOCAN estimates) and trends 1988-2002 (on the basis of the series in Cancer Incidence in Five Continents), and to produce future burden scenario for 2030 according to projected demographic changes alone and trends-based changes for selected cancer sites.  FINDINGS:  In the highest HDI regions in 2008, cancers of the female breast, lung, colorectum, and prostate accounted for half the overall cancer burden, whereas in medium HDI regions, cancers of the oesophagus, stomach, and liver were also common, and together these seven cancers comprised 62% of the total cancer burden in medium to very high HDI areas.  In low HDI regions, cervical cancer was more common than both breast cancer and liver cancer.  Nine different cancers were the most commonly diagnosed in men across 184 countries, with cancers of the prostate, lung, and liver being the most common.  Breast and cervical cancers were the most common in women.  In medium HDI and high HDI settings, decreases in cervical and stomach cancer incidence seem to be offset by increases in the incidence of cancers of the female breast, prostate, and colorectum.  If the cancer-specific and sex-specific trends estimated in this study continue, we predict an increase in the incidence of all-cancer cases from 12Â·7 million new cases in 2008 to 22Â·2 million by 2030.  INTERPRETATION:  Our findings suggest that rapid societal and economic transition in many countries means that any reductions in infection-related cancers are offset by an increasing number of new cases that are more associated with reproductive, dietary, and hormonal factors.  Targeted interventions can lead to a decrease in the projected increases in cancer burden through effective primary prevention strategies, alongside the implementation of vaccination, early detection, and effective treatment programmes.  FUNDING:  None.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4RsIpOg2j3kNoizSOkG_FfW6udTcc2eaRA3fsm3z7ILntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38notlaktA%253D%253D&md5=e4d8ab5b9b8c2e6bd1387ceaf9458f35</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970211-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970211-5%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DGrey%26aufirst%3DN.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DForman%26aufirst%3DD.%26atitle%3DGlobal%2520cancer%2520transitions%2520according%2520to%2520the%2520Human%2520Development%2520Index%2520%25282008%25E2%2580%25932030%2529%253A%2520a%2520population-based%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D790%26epage%3D801%26doi%3D10.1016%2FS1470-2045%2812%2970211-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-methyl-10-hydroxyhomocamptothecins with 1,2,3-triazole moiety as potent topoisomerase I inhibitors</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">398</span>â <span class="NLM_lpage">403</span>, <span class="refDoi">Â DOI: 10.1111/cbdd.12767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1111%2Fcbdd.12767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27062430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt1Oiurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2016&pages=398-403&author=X.+Xuauthor=Y.+Wuauthor=W.+Liuauthor=C.+Shengauthor=J.+Yaoauthor=G.+Dongauthor=K.+Fangauthor=J.+Liauthor=Z.+Yuauthor=X.+Minauthor=H.+Zhangauthor=Z.+Miaoauthor=W.+Zhang&title=Discovery+of+7-methyl-10-hydroxyhomocamptothecins+with+1%2C2%2C3-triazole+moiety+as+potent+topoisomerase+I+inhibitors&doi=10.1111%2Fcbdd.12767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-Methyl-10-Hydroxyhomocamptothecins with 1,2,3-Triazole Moiety as Potent Topoisomerase I Inhibitors</span></div><div class="casAuthors">Xu, Xiguo; Wu, Yuelin; Liu, Wenfeng; Sheng, Chuanquan; Yao, Jianzhong; Dong, Guoqiang; Fang, Kun; Li, Jin; Yu, Zhiliang; Min, Xiao; Zhang, Huojun; Miao, Zhenyuan; Zhang, Wannian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">398-403</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Homocamptothecin is emerging as an important topoisomerase I inhibitor originating in natural product camptothecin.  We report the modifications and SAR of homocamptothecin on position C10 to develop potent topoisomerase I inhibitors for anticancer drug discovery.  Based on click chem., twenty-one 1,2,3-triazole-substituted homocamptothecin derivs. were readily synthesized in two steps.  For A549, cycloalkyl- and alkyl-substituted compds. 6j, 6l, and 6o revealed highly antiproliferative inhibitory activities with IC50 value of 30, 30, and 50 nm, resp.  In addn., cyclopropyl 6j exhibited greater Topo I inhibitory activity than 20(S)-Camptothecin, which indicated suitability for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplUX2aW_CMILVg90H21EOLACvtfcHk0lgBwNjYUuKEXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt1Oiurc%253D&md5=9564084132e83d833dc4cf3c71a6723e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12767%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25207-methyl-10-hydroxyhomocamptothecins%2520with%25201%252C2%252C3-triazole%2520moiety%2520as%2520potent%2520topoisomerase%2520I%2520inhibitors%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2016%26volume%3D88%26spage%3D398%26epage%3D403%26doi%3D10.1111%2Fcbdd.12767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Cellular roles of DNA topoisomerases: A molecular perspective</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">430</span>â <span class="NLM_lpage">440</span>, <span class="refDoi">Â DOI: 10.1038/nrm831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2Fnrm831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=12042765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=430-440&author=J.+C.+Wang&title=Cellular+roles+of+DNA+topoisomerases%3A+A+molecular+perspective&doi=10.1038%2Fnrm831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular roles of DNA topoisomerases: a molecular perspective</span></div><div class="casAuthors">Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the magicians of the DNA world , by allowing DNA strands or double helixes to pass through each other, they can solve all of the topol. problems of DNA in replication, transcription and other cellular transactions.  Extensive biochem. and structural studies over the past three decades have provided mol. models of how the various subfamilies of DNA topoisomerase manipulate DNA.  In this review, the cellular roles of these enzymes are examd. from a mol. point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ptPGi1NWFLVg90H21EOLACvtfcHk0lgBwNjYUuKEXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D&md5=5b9641a6d78a019ebad9307c854a7f7e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm831%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCellular%2520roles%2520of%2520DNA%2520topoisomerases%253A%2520A%2520molecular%2520perspective%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fnrm831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase II and its growing repertoire of biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">327</span>â <span class="NLM_lpage">333</span>, <span class="refDoi">Â DOI: 10.1038/nrc2608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2Fnrc2608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=19377505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=327-333&author=J.+L.+Nitiss&title=DNA+topoisomerase+II+and+its+growing+repertoire+of+biological+functions&doi=10.1038%2Fnrc2608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerase II and its growing repertoire of biological functions</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are enzymes that disentangle the topol. problems that arise in double-stranded DNA.  Many of these can be solved by the generation of either DNA single- or double-strand breaks.  However, where there is a clear requirement to alter DNA topol. by introducing transient double-strand breaks, only DNA topoisomerase II (I) can carry out this reaction.  Extensive biochem. and structural studies have provided detailed models of how I alters DNA structure, and recent mol. studies have greatly expanded knowledge of the biol. contexts in which I functions, such as DNA replication, transcription, and chromosome segregation, processes that are essential for preventing tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAj0wiBApAc7Vg90H21EOLACvtfcHk0lgBwNjYUuKEXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12ktLo%253D&md5=4be33ccf2701425ef3933b894b31e7fd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2608%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DDNA%2520topoisomerase%2520II%2520and%2520its%2520growing%2520repertoire%2520of%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D327%26epage%3D333%26doi%3D10.1038%2Fnrc2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2894</span>â <span class="NLM_lpage">2902</span>, <span class="refDoi">Â DOI: 10.1021/cr900097c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900097c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFals7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2894-2902&author=Y.+Pommier&title=DNA+topoisomerase+I+inhibitors%3A+chemistry%2C+biology%2C+and+interfacial+inhibition&doi=10.1021%2Fcr900097c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition</span></div><div class="casAuthors">Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2894-2902</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on DNA topoisomerase I inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8qSNXYdDat7Vg90H21EOLACvtfcHk0li3HmGD_MU30g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFals7o%253D&md5=438bcf21b446a6b87634dd362d9467e4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fcr900097c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900097c%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DDNA%2520topoisomerase%2520I%2520inhibitors%253A%2520chemistry%252C%2520biology%252C%2520and%2520interfacial%2520inhibition%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2894%26epage%3D2902%26doi%3D10.1021%2Fcr900097c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vann, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedgeman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golan-Goldhirsh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Effects of olive metabolites on DNA cleavage mediated by human type II topoisomerases</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4531</span>â <span class="NLM_lpage">4541</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.5b00162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2is7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=4531-4541&author=K.+R.+Vannauthor=C.+A.+Sedgemanauthor=J.+Gopasauthor=A.+Golan-Goldhirshauthor=N.+Osheroff&title=Effects+of+olive+metabolites+on+DNA+cleavage+mediated+by+human+type+II+topoisomerases&doi=10.1021%2Facs.biochem.5b00162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases</span></div><div class="casAuthors">Vann, Kendra R.; Sedgeman, Carl A.; Gopas, Jacob; Golan-Goldhirsh, Avi; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4531-4541</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several naturally occurring dietary polyphenols with chemopreventive or anticancer properties are topoisomerase II poisons.  To identify addnl. phytochems. that enhance topoisomerase II-mediated DNA cleavage, a library of 341 Mediterranean plant exts. was screened for activity against human topoisomerase IIÎ±.  An ext. from Phillyrea latifolia L., a member of the olive tree family, displayed high activity against the human enzyme.  On the basis of previous metabolomics studies, we identified several polyphenols (hydroxytyrosol, oleuropein, verbascoside, tyrosol, and caffeic acid) as potential candidates for topoisomerase II poisons.  Of these, hydroxytyrosol, oleuropein, and verbascoside enhanced topoisomerase II-mediated DNA cleavage.  The potency of these olive metabolites increased 10-100-fold in the presence of an oxidant.  Hydroxytyrosol, oleuropein, and verbascoside displayed hallmark characteristics of covalent topoisomerase II poisons.  (1) The activity of the metabolites was abrogated by a reducing agent.  (2) Compds. inhibited topoisomerase II activity when they were incubated with the enzyme prior to the addn. of DNA.  (3) Compds. were unable to poison a topoisomerase IIÎ± construct that lacked the N-terminal domain.  Because hydroxytyrosol, oleuropein, and verbascoside are broadly distributed across the olive family, exts. from the leaves, bark, and fruit of 11 olive tree species were tested for activity against human topoisomerase IIÎ±.  Several of the exts. enhanced enzyme-mediated DNA cleavage.  Finally, a com. olive leaf supplement and extra virgin olive oils pressed from a variety of Olea europea subspecies enhanced DNA cleavage mediated by topoisomerase IIÎ±.  Thus, olive metabolites appear to act as topoisomerase II poisons in complex formulations intended for human dietary consumption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxFrk851aHGbVg90H21EOLACvtfcHk0li3HmGD_MU30g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2is7nN&md5=f440917b0a12e90e1d44d77f381a3b45</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00162%26sid%3Dliteratum%253Aachs%26aulast%3DVann%26aufirst%3DK.%2BR.%26aulast%3DSedgeman%26aufirst%3DC.%2BA.%26aulast%3DGopas%26aufirst%3DJ.%26aulast%3DGolan-Goldhirsh%26aufirst%3DA.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DEffects%2520of%2520olive%2520metabolites%2520on%2520DNA%2520cleavage%2520mediated%2520by%2520human%2520type%2520II%2520topoisomerases%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D4531%26epage%3D4541%26doi%3D10.1021%2Facs.biochem.5b00162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA topoisomerase II in cancer chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">338</span>â <span class="NLM_lpage">350</span>, <span class="refDoi">Â DOI: 10.1038/nrc2607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2Fnrc2607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=19377506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=338-350&author=J.+L.+Nitiss&title=Targeting+DNA+topoisomerase+II+in+cancer+chemotherapy&doi=10.1038%2Fnrc2607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA topoisomerase II in cancer chemotherapy</span></div><div class="casAuthors">Nitiss, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">338-350</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent mol. studies have expanded the biol. contexts in which topoisomerase II (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation.  Although the biol. functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy.  The mol. tools that have allowed an understanding of the biol. functions of TOP2 are also being applied to understanding the details of drug action.  These studies promise refined targeting of TOP2 as an effective anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_7Nq6nIe1RbVg90H21EOLACvtfcHk0li3HmGD_MU30g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12kur0%253D&md5=a787de602687580188cda6a2af7b6a07</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2607%26sid%3Dliteratum%253Aachs%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26atitle%3DTargeting%2520DNA%2520topoisomerase%2520II%2520in%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D338%26epage%3D350%26doi%3D10.1038%2Fnrc2607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escargueil, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skladanowski, A.</span></span> <span> </span><span class="NLM_article-title">Catalytic topoisomerase II inhibitors in cancer therapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1016/S0163-7258(03)00058-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS0163-7258%2803%2900058-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=12888111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=167-181&author=A.+K.+Larsenauthor=A.+E.+Escargueilauthor=A.+Skladanowski&title=Catalytic+topoisomerase+II+inhibitors+in+cancer+therapy&doi=10.1016%2FS0163-7258%2803%2900058-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic topoisomerase II inhibitors in cancer therapy</span></div><div class="casAuthors">Larsen, Annette K.; Escargueil, Alexandre E.; Skladanowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The nuclear enzyme DNA topoisomerase II is a major target for antineoplastic agents.  All topoisomerase II-directed agents are able to interfere with at least one step of the catalytic cycle.  Agents able to stabilize the covalent DNA topoisomerase II complex (also known as the cleavable complex) are traditionally called topoisomerase II poisons, while agents acting on any of the other steps in the catalytic cycle are called catalytic inhibitors.  Thus, catalytic topoisomerase II inhibitors are a heterogeneous group of compds. that might interfere with the binding between DNA and topoisomerase II (aclarubicin and suramin), stabilize noncovalent DNA topoisomerase II complexes (merbarone, ICRF-187, and structurally related bisdioxopiperazine derivs.), or inhibit ATP binding (novobiocin).  Some, such as fostriecin, may also have alternative biol. targets.  Whereas topoisomerase II poisons are used solely for their antitumor activities, catalytic inhibitors are utilized for a variety of reasons, including their activity as antineoplastic agents (aclarubicin and MST-16), cardioprotectors (ICRF-187), or modulators in order to increase the efficacy of other agents (suramin and novobiocin).  In this review, the mechanism and biol. activity of different catalytic inhibitors is described, with emphasis on therapeutically used compds.  We will then discuss future development and applications of this interesting class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGote2bOTWP17bVg90H21EOLACvtfcHk0ljhV7p9zY3dfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D&md5=4207fb899e2b98345f97e91983514913</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900058-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900058-5%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DEscargueil%26aufirst%3DA.%2BE.%26aulast%3DSkladanowski%26aufirst%3DA.%26atitle%3DCatalytic%2520topoisomerase%2520II%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26spage%3D167%26epage%3D181%26doi%3D10.1016%2FS0163-7258%2803%2900058-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoniou-Kourounioti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimmack, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, A. C.</span></span> <span> </span><span class="NLM_article-title">The Î± isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4414</span>â <span class="NLM_lpage">4426</span>, <span class="refDoi">Â DOI: 10.1093/nar/gku076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1093%2Fnar%2Fgku076" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=4414-4426&author=C.+J.+Farrauthor=M.+Antoniou-Kourouniotiauthor=M.+L.+Mimmackauthor=A.+Volkovauthor=A.+C.+Porter&title=The+%CE%B1+isoform+of+topoisomerase+II+is+required+for+hypercompaction+of+mitotic+chromosomes+in+human+cells&doi=10.1093%2Fnar%2Fgku076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgku076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgku076%26sid%3Dliteratum%253Aachs%26aulast%3DFarr%26aufirst%3DC.%2BJ.%26aulast%3DAntoniou-Kourounioti%26aufirst%3DM.%26aulast%3DMimmack%26aufirst%3DM.%2BL.%26aulast%3DVolkov%26aufirst%3DA.%26aulast%3DPorter%26aufirst%3DA.%2BC.%26atitle%3DThe%2520%25CE%25B1%2520isoform%2520of%2520topoisomerase%2520II%2520is%2520required%2520for%2520hypercompaction%2520of%2520mitotic%2520chromosomes%2520in%2520human%2520cells%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3D4414%26epage%3D4426%26doi%3D10.1093%2Fnar%2Fgku076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikoletopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deogracias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakurela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirbelauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoerner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boege, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barde, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼beler, D.</span></span> <span> </span><span class="NLM_article-title">Target genes of topoisomerase IIÎ² regulate neuronal survival and are defined by their chromatin state</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">E934</span>â <span class="NLM_lpage">943</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1119798109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.1119798109" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E934-943&author=V.+K.+Tiwariauthor=L.+Burgerauthor=V.+Nikoletopoulouauthor=R.+Deograciasauthor=S.+Thakurelaauthor=C.+Wirbelauerauthor=J.+Kautauthor=R.+Terranovaauthor=L.+Hoernerauthor=C.+Mielkeauthor=F.+Boegeauthor=R.+Murrauthor=A.+H.+Petersauthor=Y.+A.+Bardeauthor=D.+Sch%C3%BCbeler&title=Target+genes+of+topoisomerase+II%CE%B2+regulate+neuronal+survival+and+are+defined+by+their+chromatin+state&doi=10.1073%2Fpnas.1119798109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1119798109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1119798109%26sid%3Dliteratum%253Aachs%26aulast%3DTiwari%26aufirst%3DV.%2BK.%26aulast%3DBurger%26aufirst%3DL.%26aulast%3DNikoletopoulou%26aufirst%3DV.%26aulast%3DDeogracias%26aufirst%3DR.%26aulast%3DThakurela%26aufirst%3DS.%26aulast%3DWirbelauer%26aufirst%3DC.%26aulast%3DKaut%26aufirst%3DJ.%26aulast%3DTerranova%26aufirst%3DR.%26aulast%3DHoerner%26aufirst%3DL.%26aulast%3DMielke%26aufirst%3DC.%26aulast%3DBoege%26aufirst%3DF.%26aulast%3DMurr%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DA.%2BH.%26aulast%3DBarde%26aufirst%3DY.%2BA.%26aulast%3DSch%25C3%25BCbeler%26aufirst%3DD.%26atitle%3DTarget%2520genes%2520of%2520topoisomerase%2520II%25CE%25B2%2520regulate%2520neuronal%2520survival%2520and%2520are%2520defined%2520by%2520their%2520chromatin%2520state%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3DE934%26epage%3D943%26doi%3D10.1073%2Fpnas.1119798109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClendon, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">39337</span>â <span class="NLM_lpage">39345</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M503320200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1074%2Fjbc.M503320200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=39337-39345&author=A.+K.+McClendonauthor=A.+C.+Rodriguezauthor=N.+Osheroff&title=Human+topoisomerase+IIalpha+rapidly+relaxes+positively+supercoiled+DNA%3A+implications+for+enzyme+action+ahead+of+replication+forks&doi=10.1074%2Fjbc.M503320200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M503320200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M503320200%26sid%3Dliteratum%253Aachs%26aulast%3DMcClendon%26aufirst%3DA.%2BK.%26aulast%3DRodriguez%26aufirst%3DA.%2BC.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DHuman%2520topoisomerase%2520IIalpha%2520rapidly%2520relaxes%2520positively%2520supercoiled%2520DNA%253A%2520implications%2520for%2520enzyme%2520action%2520ahead%2520of%2520replication%2520forks%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D39337%26epage%3D39345%26doi%3D10.1074%2Fjbc.M503320200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondka, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manville, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidorczuk-Lesthuruge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span> <span> </span><span class="NLM_article-title">Model for MLL translocations in therapy-related leukemia involving topoisomerase IIÎ²-mediated DNA strand breaks and gene proximity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">8989</span>â <span class="NLM_lpage">8994</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1204406109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.1204406109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=22615413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC38XovF2gtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=8989-8994&author=I.+G.+Cowellauthor=Z.+Sondkaauthor=K.+Smithauthor=K.+C.+Leeauthor=C.+M.+Manvilleauthor=M.+Sidorczuk-Lesthurugeauthor=H.+A.+Ranceauthor=K.+Padgetauthor=G.+H.+Jacksonauthor=N.+Adachiauthor=C.+A.+Austin&title=Model+for+MLL+translocations+in+therapy-related+leukemia+involving+topoisomerase+II%CE%B2-mediated+DNA+strand+breaks+and+gene+proximity&doi=10.1073%2Fpnas.1204406109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Model for MLL translocations in therapy-related leukemia involving topoisomerase IIÎ²-mediated DNA strand breaks and gene proximity</span></div><div class="casAuthors">Cowell, Ian G.; Sondka, Zbyslaw; Smith, Kayleigh; Lee, Ka Cheong; Manville, Catriona M.; Sidorczuk-Lesthuruge, Malgorzata; Rance, Holly Ashlene; Padget, Kay; Jackson, Graham Hunter; Adachi, Noritaka; Austin, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8989-8994, S8989/1-S8989/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Topoisomerase poisons such as the epipodophyllotoxin etoposide are widely used effective cytotoxic anticancer agents.  However, they are assocd. with the development of therapy-related acute myeloid leukemias (t-AMLs), which display characteristic balanced chromosome translocations, most often involving the mixed lineage leukemia (MLL) locus at 11q23.  MLL translocation break-points in t-AMLs cluster in a DNase I hypersensitive region, which possesses cryptic promoter activity, implicating transcription as well as topoisomerase II activity in the translocation mechanism.  We find that 2-3% of MLL alleles undergoing transcription do so in dose proximity to one of its recurrent translocation partner genes, AF9 or AF4, consistent with their sharing transcription factories.  We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIÎ², but that topoisomerase IIÎ± and -Î² occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concn. det. specific clustering of MLL translocation breakpoints in t-AML.  We propose a model where DNA double-strand breaks (DSBs) introduced by topoisomerase lip into pairs of genes undergoing transcription within a common transcription factory become stabilized by antitopoisomerase II drugs such as etoposide, providing the opportunity for illegitimate end joining and translocation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriLDB2Aoa_ibVg90H21EOLACvtfcHk0ljWFHmLGkvJnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovF2gtb8%253D&md5=1ad16dec579b37ef08da76e6520e7222</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1204406109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1204406109%26sid%3Dliteratum%253Aachs%26aulast%3DCowell%26aufirst%3DI.%2BG.%26aulast%3DSondka%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DManville%26aufirst%3DC.%2BM.%26aulast%3DSidorczuk-Lesthuruge%26aufirst%3DM.%26aulast%3DRance%26aufirst%3DH.%2BA.%26aulast%3DPadget%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DAdachi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26atitle%3DModel%2520for%2520MLL%2520translocations%2520in%2520therapy-related%2520leukemia%2520involving%2520topoisomerase%2520II%25CE%25B2-mediated%2520DNA%2520strand%2520breaks%2520and%2520gene%2520proximity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D8989%26epage%3D8994%26doi%3D10.1073%2Fpnas.1204406109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendorff, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heslop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">The structure of DNA-bound human topoisomerase IIalpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>424</i></span>,  <span class="NLM_fpage">109</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2012.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jmb.2012.07.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2012&pages=109-124&author=T.+J.+Wendorffauthor=B.+H.+Schmidtauthor=P.+Heslopauthor=C.+A.+Austinauthor=J.+M.+Berger&title=The+structure+of+DNA-bound+human+topoisomerase+IIalpha%3A+conformational+mechanisms+for+coordinating+inter-subunit+interactions+with+DNA+cleavage&doi=10.1016%2Fj.jmb.2012.07.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2012.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2012.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWendorff%26aufirst%3DT.%2BJ.%26aulast%3DSchmidt%26aufirst%3DB.%2BH.%26aulast%3DHeslop%26aufirst%3DP.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520structure%2520of%2520DNA-bound%2520human%2520topoisomerase%2520IIalpha%253A%2520conformational%2520mechanisms%2520for%2520coordinating%2520inter-subunit%2520interactions%2520with%2520DNA%2520cleavage%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D424%26spage%3D109%26epage%3D124%26doi%3D10.1016%2Fj.jmb.2012.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Champoux, J. J.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerases: structure, function, and mechanism</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">369</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1146/annurev.biochem.70.1.369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1146%2Fannurev.biochem.70.1.369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=11395412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=369-413&author=J.+J.+Champoux&title=DNA+topoisomerases%3A+structure%2C+function%2C+and+mechanism&doi=10.1146%2Fannurev.biochem.70.1.369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerases: structure, function, and mechanism</span></div><div class="casAuthors">Champoux, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">369-413</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 196 refs.  DNA topoisomerases solve the topol. problems assocd. with DNA replication, transcription, recombination, and chromatin remodeling by introducing temporary single- or double-strand breaks in the DNA.  In addn., these enzymes fine-tune the steady-state level of DNA supercoiling both to facilitate protein interactions with the DNA and to prevent excessive supercoiling that is deleterious.  In recent years, the crystal structures of a no. of topoisomerase fragments, representing nearly all of the known classes of enzymes, have been solved.  These structures provide remarkable insights into the mechanisms of these enzymes and complement previous conclusions based on biochem. analyses.  Surprisingly, despite little or no sequence homol., both type IA and type IIA topoisomerases from prokaryotes and the type IIA enzymes from eukaryotes share structural folds that appear to reflect functional motifs within crit. regions of the enzymes.  The type IB enzymes are structurally distinct from all other known topoisomerases but are similar to a class of enzymes referred to as tyrosine recombinases.  The structural themes common to all topoisomerases include hinged clamps that open and close to bind DNA, the presence of DNA binding cavities for temporary storage of DNA segments, and the coupling of protein conformational changes to DNA rotation or DNA movement.  For the type II topoisomerases, the binding and hydrolysis of ATP further modulate conformational changes in the enzymes to effect changes in DNA topol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Y4rDyIYy17Vg90H21EOLACvtfcHk0ljWFHmLGkvJnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D&md5=67c3e38eb4fcb85527b33d7077309482</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.369%26sid%3Dliteratum%253Aachs%26aulast%3DChampoux%26aufirst%3DJ.%2BJ.%26atitle%3DDNA%2520topoisomerases%253A%2520structure%252C%2520function%252C%2520and%2520mechanism%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D369%26epage%3D413%26doi%3D10.1146%2Fannurev.biochem.70.1.369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruthenburg, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechis, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdine, G. L.</span></span> <span> </span><span class="NLM_article-title">Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">37041</span>â <span class="NLM_lpage">37047</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M506520200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1074%2Fjbc.M506520200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=16100112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=37041-37047&author=H.+Weiauthor=A.+J.+Ruthenburgauthor=S.+K.+Bechisauthor=G.+L.+Verdine&title=Nucleotide-dependent+domain+movement+in+the+ATPase+domain+of+a+human+type+IIA+DNA+topoisomerase&doi=10.1074%2Fjbc.M506520200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide-dependent Domain Movement in the ATPase Domain of a Human Type IIA DNA Topoisomerase</span></div><div class="casAuthors">Wei, Hua; Ruthenburg, Alexander J.; Bechis, Seth K.; Verdine, Gregory L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37041-37047</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topol. state, chromosome segregation, and chromatin condensation.  These diverse physiol. functions are all accomplished through a common mol. mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex (the G-segment) to yield a double-stranded gap through which another duplex (the T-segment) is passed.  The overall process is orchestrated by the opening and closing of mol. "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorg. phosphate.  Here, we present two crystal structures of the ATPase domain of human DNA topoisomerase IIÎ± in different nucleotide-bound states.  Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a mol. gate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp657jcFw3OM7Vg90H21EOLACvtfcHk0ljWFHmLGkvJnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKhtLrO&md5=e2672f1ac3605c57f10031edcd5c4584</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M506520200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M506520200%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DH.%26aulast%3DRuthenburg%26aufirst%3DA.%2BJ.%26aulast%3DBechis%26aufirst%3DS.%2BK.%26aulast%3DVerdine%26aufirst%3DG.%2BL.%26atitle%3DNucleotide-dependent%2520domain%2520movement%2520in%2520the%2520ATPase%2520domain%2520of%2520a%2520human%2520type%2520IIA%2520DNA%2520topoisomerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D37041%26epage%3D37047%26doi%3D10.1074%2Fjbc.M506520200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">Enhancing protein backbone binding-a fruitful concept for combating drug-resistant HIV</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1778</span>â <span class="NLM_lpage">1802</span>, <span class="refDoi">Â DOI: 10.1002/anie.201102762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fanie.201102762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOru7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=1778-1802&author=A.+K.+Ghoshauthor=D.+D.+Andersonauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Enhancing+protein+backbone+binding-a+fruitful+concept+for+combating+drug-resistant+HIV&doi=10.1002%2Fanie.201102762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing Protein Backbone Binding-A Fruitful Concept for Combating Drug-Resistant HIV</span></div><div class="casAuthors">Ghosh, Arun K.; Anderson, David D.; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1778-1802</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The evolution of drug resistance is one of the most fundamental problems in medicine.  In HIV/AIDS, the rapid emergence of drug-resistant HIV-1 variants is a major obstacle to current treatments.  HIV-1 protease inhibitors are essential components of present antiretroviral therapies.  However, with these protease inhibitors, resistance occurs through viral mutations that alter inhibitor binding, resulting in a loss of efficacy.  This loss of potency has raised serious questions with regard to effective long-term antiretroviral therapy for HIV/AIDS.  In this context, our research has focused on designing inhibitors that form extensive hydrogen-bonding interactions with the enzyme's backbone in the active site.  In doing so, we limit the protease's ability to acquire drug resistance as the geometry of the catalytic site must be conserved to maintain functionality.  In this Review, we examine the underlying principles of enzyme structure that support our backbone-binding concept as an effective means to combat drug resistance and highlight their application in our recent work on antiviral HIV-1 protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UjK1GY9jV7Vg90H21EOLACvtfcHk0lgHcctubHYb9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOru7k%253D&md5=0751c1ccc5d043f76fe53f7470e7b47e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fanie.201102762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201102762%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DAnderson%26aufirst%3DD.%2BD.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DEnhancing%2520protein%2520backbone%2520binding-a%2520fruitful%2520concept%2520for%2520combating%2520drug-resistant%2520HIV%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D1778%26epage%3D1802%26doi%3D10.1002%2Fanie.201102762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Her, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1652</span>â <span class="NLM_lpage">1670</span>, <span class="refDoi">Â DOI: 10.3390/biom5031652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3390%2Fbiom5031652" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1652-1670&author=Y.+Xuauthor=C.+Her&title=Inhibition+of+topoisomerase+%28DNA%29+I+%28TOP1%29%3A+DNA+damage+repair+and+anticancer+therapy&doi=10.3390%2Fbiom5031652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3390%2Fbiom5031652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom5031652%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHer%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520topoisomerase%2520%2528DNA%2529%2520I%2520%2528TOP1%2529%253A%2520DNA%2520damage%2520repair%2520and%2520anticancer%2520therapy%26jtitle%3DBiomolecules%26date%3D2015%26volume%3D5%26spage%3D1652%26epage%3D1670%26doi%3D10.3390%2Fbiom5031652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zubovych, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M. G.</span></span> <span> </span><span class="NLM_article-title">A novel inhibitor of topoisomerase I is selectively toxic for a subset of non-small cell lung cancer cell lines</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-15-0458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1158%2F1535-7163.MCT-15-0458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26668189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsleruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=23-36&author=I.+O.+Zubovychauthor=A.+Sethiauthor=A.+Kulkarniauthor=V.+Tagalauthor=M.+G.+Roth&title=A+novel+inhibitor+of+topoisomerase+I+is+selectively+toxic+for+a+subset+of+non-small+cell+lung+cancer+cell+lines&doi=10.1158%2F1535-7163.MCT-15-0458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines</span></div><div class="casAuthors">Zubovych, Iryna O.; Sethi, Anirudh; Kulkarni, Aditya; Tagal, Vural; Roth, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">SW044248, identified through a screen for chems. that are selectively toxic for non-small cell lung cancer (NSCLC) cell lines, was found to rapidly inhibit macromol. synthesis in sensitive, but not in insensitive, cells.  SW044248 killed approx. 15% of a panel of 74 NSCLC cell lines and was nontoxic to immortalized human bronchial cell lines.  The acute transcriptional response to SW044248 in sensitive HCC4017 cells correlated significantly with inhibitors of topoisomerases and SW044248 inhibited topoisomerase 1 (Top1) but not topoisomerase 2.  SW044248 inhibited Top1 differently from camptothecin and camptothecin did not show the same selective toxicity as SW044248.  Elimination of Top1 by siRNA partially protected cells from SW044248, although removing Top1 was itself eventually toxic.  Cells resistant to SW044248 responded to the compd. by upregulating CDKN1A and siRNA to CDKN1A sensitized those cells to SW044248.  Thus, at least part of the differential sensitivity of NSCLC cells to SW044248 is the ability to upregulate CDKN1A.  Mol Cancer Ther; 15(1); 23-36. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsSkmg18AaYrVg90H21EOLACvtfcHk0lgHcctubHYb9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsleruw%253D%253D&md5=b6e46a1257e99484d3459611634ab9d8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0458%26sid%3Dliteratum%253Aachs%26aulast%3DZubovych%26aufirst%3DI.%2BO.%26aulast%3DSethi%26aufirst%3DA.%26aulast%3DKulkarni%26aufirst%3DA.%26aulast%3DTagal%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DM.%2BG.%26atitle%3DA%2520novel%2520inhibitor%2520of%2520topoisomerase%2520I%2520is%2520selectively%2520toxic%2520for%2520a%2520subset%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D23%26epage%3D36%26doi%3D10.1158%2F1535-7163.MCT-15-0458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerases and their poisoning by anticancer and antibacterial drugs</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">433</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2010.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.chembiol.2010.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=20534341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslCjsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=421-433&author=Y.+Pommierauthor=E.+Leoauthor=H.+Zhangauthor=C.+Marchand&title=DNA+topoisomerases+and+their+poisoning+by+anticancer+and+antibacterial+drugs&doi=10.1016%2Fj.chembiol.2010.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs</span></div><div class="casAuthors">Pommier, Yves; Leo, Elisabetta; Zhang, Hong-Liang; Marchand, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-433</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the targets of important anticancer and antibacterial drugs.  Camptothecins and novel noncamptothecins in clin. development (indenoisoquinolines and ARC-111) target eukaryotic type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2Î± and Top2Î²) are the targets of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxantrone.  Bacterial type II topoisomerases (gyrase and Topo IV) are the targets of quinolones and aminocoumarin antibiotics.  This review focuses on the mol. and biochem. characteristics of topoisomerases and their inhibitors.  We also discuss the common mechanism of action of topoisomerase poisons by interfacial inhibition and trapping of topoisomerase cleavage complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr6m1st3bchbVg90H21EOLACvtfcHk0lgHcctubHYb9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslCjsLY%253D&md5=ab00ffa6d0e8bf0c433b154e2a4b484a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DLeo%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarchand%26aufirst%3DC.%26atitle%3DDNA%2520topoisomerases%2520and%2520their%2520poisoning%2520by%2520anticancer%2520and%2520antibacterial%2520drugs%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D421%26epage%3D433%26doi%3D10.1016%2Fj.chembiol.2010.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">459</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1126/science.1204117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1126%2Fscience.1204117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=21778401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2011&pages=459-462&author=C.+C.+Wuauthor=T.+K.+Liauthor=L.+Farhauthor=L.+Y.+Linauthor=T.+S.+Linauthor=Y.+J.+Yuauthor=T.+J.+Yenauthor=C.+W.+Chiangauthor=N.+L.+Chan&title=Structural+basis+of+type+II+topoisomerase+inhibition+by+the+anticancer+drug+etoposide&doi=10.1126%2Fscience.1204117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide</span></div><div class="casAuthors">Wu, Chyuan-Chuan; Li, Tsai-Kun; Farh, Lynn; Lin, Li-Ying; Lin, Te-Sheng; Yu, Yu-Jen; Yen, Tien-Jui; Chiang, Chia-Wang; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">6041</span>),
    <span class="NLM_cas:pages">459-462</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Type II topoisomerases (TOP2s) resolve the topol. problems of DNA by transiently cleaving both strands of a DNA duplex to form a cleavage complex through which another DNA segment can be transported.  Several widely prescribed anticancer drugs increase the population of TOP2 cleavage complex, which leads to TOP2-mediated chromosome DNA breakage and death of cancer cells.  We present the crystal structure of a large fragment of human TOP2Î² complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex.  The interplay between the protein, the DNA, and the drug explains the structure-activity relations of etoposide derivs. and the mol. basis of drug-resistant mutations.  The anal. of protein-drug interactions provides information applicable for developing an isoform-specific TOP2-targeting strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBC6vqPeyB-bVg90H21EOLACvtfcHk0lhuGCR-cHr4PA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovF2mur0%253D&md5=c2eab1b2e9b8a75322b88e76c62c4b74</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.1204117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1204117%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DFarh%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DL.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DT.%2BJ.%26aulast%3DChiang%26aufirst%3DC.%2BW.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DStructural%2520basis%2520of%2520type%2520II%2520topoisomerase%2520inhibition%2520by%2520the%2520anticancer%2520drug%2520etoposide%26jtitle%3DScience%26date%3D2011%26volume%3D333%26spage%3D459%26epage%3D462%26doi%3D10.1126%2Fscience.1204117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">10630</span>â <span class="NLM_lpage">10640</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkt828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1093%2Fnar%2Fgkt828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24038465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2lsbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=10630-10640&author=C.+C.+Wuauthor=Y.+C.+Liauthor=Y.+R.+Wangauthor=T.+K.+Liauthor=N.+L.+Chan&title=On+the+structural+basis+and+design+guidelines+for+type+II+topoisomerase-targeting+anticancer+drugs&doi=10.1093%2Fnar%2Fgkt828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs</span></div><div class="casAuthors">Wu, Chyuan-Chuan; Li, Yi-Ching; Wang, Ying-Ren; Li, Tsai-Kun; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10630-10640</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Type II topoisomerases (Top2s) alter DNA topol. via the formation of an enzyme-DNA adduct termed cleavage complex, which harbors a transient double-strand break in one DNA to allow the passage of another.  Agents targeting human Top2s are clin. active anticancer drugs whose trapping of Top2-mediated DNA breakage effectively induces genome fragmentation and cell death.  To understand the structural basis of this drug action, we previously detd. the structure of human Top2 Î²-isoform forming a cleavage complex with the drug etoposide and DNA, and described the insertion of drug into DNA cleavage site and drug-induced decoupling of catalytic groups.  By developing a post-crystn. drug replacement procedure that simplifies structural characterization of drug-stabilized cleavage complexes, we have extended the anal. toward other structurally distinct drugs, m-AMSA and mitoxantrone.  Besides the expected drug intercalation, a switch in ribose puckering in the 3'-nucleotide of the cleavage site was robustly obsd. in the new structures, representing a new mechanism for trapping the Top2 cleavage complex.  Anal. of drug-binding modes and the conformational landscapes of the drug-binding pockets provide rationalization of the drugs' structural-activity relationships and explain why Top2 mutants exhibit differential effects toward each drug.  Drug design guidelines were proposed to facilitate the development of isoform-specific Top2-targeting anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMHX9ZEqN2nbVg90H21EOLACvtfcHk0lhuGCR-cHr4PA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2lsbjJ&md5=7a94c43460176f7a2bcc65406fd28f34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt828%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLi%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DOn%2520the%2520structural%2520basis%2520and%2520design%2520guidelines%2520for%2520type%2520II%2520topoisomerase-targeting%2520anticancer%2520drugs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2013%26volume%3D41%26spage%3D10630%26epage%3D10640%26doi%3D10.1093%2Fnar%2Fgkt828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">11014</span>â <span class="NLM_lpage">11019</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0704002104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.0704002104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=17578914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=11014-11019&author=A.+M.+Azarovaauthor=Y.+L.+Lyuauthor=C.+P.+Linauthor=Y.+C.+Tsaiauthor=J.+Y.+Lauauthor=J.+C.+Wangauthor=L.+F.+Liu&title=Roles+of+DNA+topoisomerase+II+isozymes+in+chemotherapy+and+secondary+malignancies&doi=10.1073%2Fpnas.0704002104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span></div><div class="casAuthors">Azarova, Anna M.; Lyu, Yi Lisa; Lin, Chao-Po; Tsai, Yuan-Chin; Lau, Johnson Yiu-Nam; Wang, James C.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">11014-11019</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clin. use.  However, Top2-based chemotherapy has been assocd. with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients.  This assocn. is suggestive of a link between carcinogenesis and Top2-mediated DNA damage.  We show here that VP-16-induced carcinogenesis involves mainly the Î² rather than the isoenzyme of Top2.  In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is significantly higher in TOP2Î²+ than in skin-specific top2Î²-knockout mice.  Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are Top2Î²-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degrdn. of the Top2Î²-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements.  VP-16 cytotoxicity in transformed cells expressing both Top2 isoenzymes is, however, primarily Top2Î±-dependent.  These results point to the importance of developing Top2-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqEXje8wQTrVg90H21EOLACvtfcHk0lhuGCR-cHr4PA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D&md5=f10976e9b0dbb918158916036a0349a7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0704002104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0704002104%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DLyu%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DTsai%26aufirst%3DY.%2BC.%26aulast%3DLau%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DRoles%2520of%2520DNA%2520topoisomerase%2520II%2520isozymes%2520in%2520chemotherapy%2520and%2520secondary%2520malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D11014%26epage%3D11019%26doi%3D10.1073%2Fpnas.0704002104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurosawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iiizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, N.</span></span> <span> </span><span class="NLM_article-title">NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">23711</span>â <span class="NLM_lpage">23720</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M803936200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1074%2Fjbc.M803936200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=18596031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWktr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=23711-23720&author=E.+Toyodaauthor=S.+Kagayaauthor=I.+G.+Cowellauthor=A.+Kurosawaauthor=K.+Kamoshitaauthor=K.+Nishikawaauthor=S.+Iiizumiauthor=H.+Koyamaauthor=C.+A.+Austinauthor=N.+Adachi&title=NK314%2C+a+topoisomerase+II+inhibitor+that+specifically+targets+the+alpha+isoform&doi=10.1074%2Fjbc.M803936200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">NK314, a Topoisomerase II Inhibitor That Specifically Targets the Î± Isoform</span></div><div class="casAuthors">Toyoda, Eriko; Kagaya, Shigehide; Cowell, Ian G.; Kurosawa, Aya; Kamoshita, Keiichi; Nishikawa, Kiyohiro; Iiizumi, Susumu; Koyama, Hideki; Austin, Caroline A.; Adachi, Noritaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">23711-23720</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Topoisomerase II (Top2) is a ubiquitous nuclear enzyme that relieves torsional stress in chromosomal DNA during various cellular processes.  Agents that target Top2, involving etoposide, doxorubicin, and mitoxantrone, are among the most effective anticancer drugs used in the clinic.  Mammalian cells possess two genetically distinct Top2 isoforms, both of which are the target of these agents.  Top2Î± is essential for cell proliferation and is highly expressed in vigorously growing cells, whereas Top2Î² is nonessential for growth and has recently been implicated in treatment-assocd. secondary malignancies, highlighting the validity of a Top2Î±-specific drug for future cancer treatment; however, no such agent has been hitherto reported.  Here we show that NK314, a novel synthetic benzo[c]phenanthridine alkaloid, targets Top2Î± and not Top2Î² in vivo.  Unlike other Top2 inhibitors, NK314 induces Top2-DNA complexes and double-strand breaks (DSBs) in an Î± isoform-specific manner.  Heterozygous disruption of the human TOP2Î± gene confers increased NK314 resistance, whereas TOP2Î² homozygous knock-out cells display increased NK314 sensitivity, indicating that the Î± isoform is the cellular target.  We further show that the absence of Top2Î² does not alleviate NK314 hypersensitivity of cells deficient in non-homologous end-joining, a crit. pathway for repairing Top2-mediated DSBs.  Our results indicate that NK314 acts as a Top2Î±-specific poison in mammalian cells, with excellent potential as an efficacious and safe chemotherapeutic agent.  We also suggest that a series of human knock-out cell lines are useful in assessing DNA damage and repair induced by potential topoisomerase-targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoipLdMB1ovO7Vg90H21EOLACvtfcHk0ljSFCtqKbn0dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWktr%252FK&md5=ce9e60205b62f04c65e33b31721ad95d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M803936200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M803936200%26sid%3Dliteratum%253Aachs%26aulast%3DToyoda%26aufirst%3DE.%26aulast%3DKagaya%26aufirst%3DS.%26aulast%3DCowell%26aufirst%3DI.%2BG.%26aulast%3DKurosawa%26aufirst%3DA.%26aulast%3DKamoshita%26aufirst%3DK.%26aulast%3DNishikawa%26aufirst%3DK.%26aulast%3DIiizumi%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DH.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DAdachi%26aufirst%3DN.%26atitle%3DNK314%252C%2520a%2520topoisomerase%2520II%2520inhibitor%2520that%2520specifically%2520targets%2520the%2520alpha%2520isoform%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D23711%26epage%3D23720%26doi%3D10.1074%2Fjbc.M803936200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isambert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbouloux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drouin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loadman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capizzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieshaber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumoleau, P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">729</span>â <span class="NLM_lpage">734</span>, <span class="refDoi">Â DOI: 10.1016/j.ejca.2009.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejca.2009.12.005" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=729-734&author=N.+Isambertauthor=M.+Camponeauthor=E.+Bourboulouxauthor=M.+Drouinauthor=A.+Majorauthor=W.+Yinauthor=P.+Loadmanauthor=R.+Capizziauthor=C.+Grieshaberauthor=P.+Fumoleau&title=Evaluation+of+the+safety+of+C-1311+%28SYMADEX%29+administered+in+a+phase+1+dose+escalation+trial+as+a+weekly+infusion+for+3+consecutive+weeks+in+patients+with+advanced+solid+tumours&doi=10.1016%2Fj.ejca.2009.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DIsambert%26aufirst%3DN.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DBourbouloux%26aufirst%3DE.%26aulast%3DDrouin%26aufirst%3DM.%26aulast%3DMajor%26aufirst%3DA.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DLoadman%26aufirst%3DP.%26aulast%3DCapizzi%26aufirst%3DR.%26aulast%3DGrieshaber%26aufirst%3DC.%26aulast%3DFumoleau%26aufirst%3DP.%26atitle%3DEvaluation%2520of%2520the%2520safety%2520of%2520C-1311%2520%2528SYMADEX%2529%2520administered%2520in%2520a%2520phase%25201%2520dose%2520escalation%2520trial%2520as%2520a%2520weekly%2520infusion%2520for%25203%2520consecutive%2520weeks%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D729%26epage%3D734%26doi%3D10.1016%2Fj.ejca.2009.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laskowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SowiÅski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazerski, J.</span></span> <span> </span><span class="NLM_article-title">Intercalation complex of imidazoacridinone C-1311, a potential anticancer drug, with DNA helix d(CGATCG)2: stereostructural studies by 2D NMR spectroscopy</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">653</span>â <span class="NLM_lpage">663</span>, <span class="refDoi">Â DOI: 10.1080/07391102.2015.1049552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1080%2F07391102.2015.1049552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26211888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFals7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=653-663&author=T.+Laskowskiauthor=J.+Czubauthor=P.+Sowi%C5%84skiauthor=J.+Mazerski&title=Intercalation+complex+of+imidazoacridinone+C-1311%2C+a+potential+anticancer+drug%2C+with+DNA+helix+d%28CGATCG%292%3A+stereostructural+studies+by+2D+NMR+spectroscopy&doi=10.1080%2F07391102.2015.1049552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Intercalation complex of imidazoacridinone C-1311, a potential anticancer drug, with DNA helix d(CGATCG)2: stereostructural studies by 2D NMR spectroscopy</span></div><div class="casAuthors">Laskowski, Tomasz; Czub, Jacek; Sowinski, Pawel; Mazerski, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-663</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Imidazoacridinone C-1311 (Symadex) is a powerful antitumor agent, which successfully made its way through the Phase I clin. trials and has been recommended for Phase II few a years ago.  It has been shown exptl. that during the initial stage of its action C-1311 forms a relatively stable intercalation complex with DNA, yet it has shown no base-sequence specificity while binding to DNA.  In this paper, the d(CGATCG)2:C-1311 intercalation complex has been studied by means of two-dimensional NMR spectroscopy, yielding a full assignment of the resonance lines obsd. in 1H NMR spectra.  The observation of the intermol. NOE contacts between C-1311 and DNA allowed locating the ligand between the guanine and adenine moieties.  Formation of a sym. complex was pointed out on the basis of the lack of a second set of the 1H resonances.  The resulting stereostructure of the complex was then improved by means of mol. dynamics, using the CHARMM force field and GROMACS software.  To this end, distance restraints derived from the NOESY cross-peak vols. were applied to the atomistic model of the d(CGATCG)2:C-1311 complex.  Obtained results are in full agreement with biochem. data on the mechanism of action of C-1311, in particular with the previously postulated post-intercalation enzymic activation of the studied drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9pG4gmpCT87Vg90H21EOLACvtfcHk0ljSFCtqKbn0dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFals7vF&md5=cfa97e43853f199b51f57dc3f2b68a23</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1080%2F07391102.2015.1049552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2015.1049552%26sid%3Dliteratum%253Aachs%26aulast%3DLaskowski%26aufirst%3DT.%26aulast%3DCzub%26aufirst%3DJ.%26aulast%3DSowi%25C5%2584ski%26aufirst%3DP.%26aulast%3DMazerski%26aufirst%3DJ.%26atitle%3DIntercalation%2520complex%2520of%2520imidazoacridinone%2520C-1311%252C%2520a%2520potential%2520anticancer%2520drug%252C%2520with%2520DNA%2520helix%2520d%2528CGATCG%25292%253A%2520stereostructural%2520studies%2520by%25202D%2520NMR%2520spectroscopy%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2016%26volume%3D34%26spage%3D653%26epage%3D663%26doi%3D10.1080%2F07391102.2015.1049552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimek, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havelange, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derigs, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carella, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1025</span>â <span class="NLM_lpage">1036</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00201-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS1470-2045%2815%2900201-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26234174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OgsrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1025-1036&author=F.+Ravandiauthor=E.+K.+Ritchieauthor=H.+Sayarauthor=J.+E.+Lancetauthor=M.+D.+Craigauthor=N.+Veyauthor=S.+A.+Stricklandauthor=G.+J.+Schillerauthor=E.+Jabbourauthor=H.+P.+Erbaauthor=A.+Pigneuxauthor=H.+A.+Horstauthor=C.+Recherauthor=V.+M.+Klimekauthor=J.+Cortesauthor=G.+J.+Robozauthor=O.+Odenikeauthor=X.+Thomasauthor=V.+Havelangeauthor=J.+Maertensauthor=H.+G.+Derigsauthor=M.+Heuserauthor=L.+Damonauthor=B.+L.+Powellauthor=G.+Gaidanoauthor=A.+M.+Carellaauthor=A.+Weiauthor=D.+Hoggeauthor=A.+R.+Craigauthor=J.+A.+Foxauthor=R.+Wardauthor=J.+A.+Smithauthor=G.+Actonauthor=C.+Mehtaauthor=R.+K.+Stuartauthor=H.+M.+Kantarjian&title=Vosaroxin+plus+cytarabine+versus+placebo+plus+cytarabine+in+patients+with+first+relapsed+or+refractory+acute+myeloid+leukaemia+%28VALOR%29%3A+a+randomised%2C+controlled%2C+double-blind%2C+multinational%2C+phase+3+study&doi=10.1016%2FS1470-2045%2815%2900201-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study</span></div><div class="casAuthors">Ravandi, Farhad; Ritchie, Ellen K.; Sayar, Hamid; Lancet, Jeffrey E.; Craig, Michael D.; Vey, Norbert; Strickland, Stephen A.; Schiller, Gary J.; Jabbour, Elias; Erba, Harry P.; Pigneux, Arnaud; Horst, Heinz-August; Recher, Christian; Klimek, Virginia M.; Cortes, Jorge; Roboz, Gail J.; Odenike, Olatoyosi; Thomas, Xavier; Havelange, Violaine; Maertens, Johan; Derigs, Hans-Gunter; Heuser, Michael; Damon, Lloyd; Powell, Bayard L.; Gaidano, Gianluca; Carella, Angelo-Michele; Wei, Andrew; Hogge, Donna; Craig, Adam R.; Fox, Judith A.; Ward, Renee; Smith, Jennifer A.; Acton, Gary; Mehta, Cyrus; Stuart, Robert K.; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1025-1036</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Safe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukemia.  We investigated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone deriv., plus cytarabine in patients with relapsed or refractory acute myeloid leukemia.  This phase 3, double-blind, placebo-controlled trial was undertaken at 101 international sites.  Eligible patients with acute myeloid leukemia were aged 18 years of age or older and had refractory disease or were in first relapse after one or two cycles of previous induction chemotherapy, including at least one cycle of anthracycline (or anthracenedione) plus cytarabine.  Patients were randomly assigned 1:1 to vosaroxin (90 mg/m2 i.v. on days 1 and 4 in a first cycle; 70 mg/m2 in subsequent cycles) plus cytarabine (1 g/m2 i.v. on days 1-5) or placebo plus cytarabine through a central interactive voice system with a permuted block procedure stratified by disease status, age, and geog. location.  All participants were masked to treatment assignment.  The primary efficacy endpoint was overall survival and the primary safety endpoint was 30-day and 60-day all-cause mortality.  Efficacy analyses were done by intention to treat; safety analyses included all treated patients.  This study is registered with ClinicalTrials.gov, no. NCT01191801.  Between Dec 17, 2010, and Sept 25, 2013, 711 patients were randomly assigned to vosaroxin plus cytarabine (n=356) or placebo plus cytarabine (n=355).  At the final anal., median overall survival was 7Â·5 mo (95% CI 6Â·4-8Â·5) in the vosaroxin plus cytarabine group and 6Â·1 mo (5Â·2-7Â·1) in the placebo plus cytarabine group (hazard ratio 0Â·87, 95% CI 0Â·73-1Â·02; unstratified log-rank p=0Â·061; stratified p=0Â·024).  A higher proportion of patients achieved complete remission in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group (107 [30%] of 356 patients vs 58 [16%] of 355 patients, p<0Â·0001).  Early mortality was similar between treatment groups (30-day: 28 [8%] of 355 patients in the vosaroxin plus cytarabine group vs 23 [7%] of 350 in the placebo plus cytarabine group; 60-day: 70 [20%] vs 68 [19%]).  Treatment-related deaths occurred at any time in 20 (6%) of 355 patients given vosaroxin plus cytarabine and in eight (2%) of 350 patients given placebo plus cytarabine.  Treatment-related serious adverse events occurred in 116 (33%) and 58 (17%) patients in each group, resp.  Grade 3 or worse adverse events that were more frequent in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group included febrile neutropenia (167 [47%] vs 117 [33%]), neutropenia (66 [19%] vs 49 [14%]), stomatitis (54 [15%] vs 10 [3%]), hypokalemia (52 [15%] vs 21 [6%]), bacteremia (43 [12%] vs 16 [5%]), sepsis (42 [12%] vs 18 [5%]), and pneumonia (39 [11%] vs 26 [7%]).  Although there was no significant difference in the primary endpoint between groups, the prespecified secondary anal. stratified by randomization factors suggests that the addn. of vosaroxin to cytarabine might be of clin. benefit to some patients with relapsed or refractory acute myeloid leukemia.Sunesis Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ivy3DpaLubVg90H21EOLACvtfcHk0ljOOVV2wGZJTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OgsrrP&md5=5287a03ea15d5dc2f9cb44aa8522ef2d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900201-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900201-6%26sid%3Dliteratum%253Aachs%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DRitchie%26aufirst%3DE.%2BK.%26aulast%3DSayar%26aufirst%3DH.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DCraig%26aufirst%3DM.%2BD.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DSchiller%26aufirst%3DG.%2BJ.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DKlimek%26aufirst%3DV.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DHavelange%26aufirst%3DV.%26aulast%3DMaertens%26aufirst%3DJ.%26aulast%3DDerigs%26aufirst%3DH.%2BG.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DPowell%26aufirst%3DB.%2BL.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DCarella%26aufirst%3DA.%2BM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DCraig%26aufirst%3DA.%2BR.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DWard%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DActon%26aufirst%3DG.%26aulast%3DMehta%26aufirst%3DC.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DVosaroxin%2520plus%2520cytarabine%2520versus%2520placebo%2520plus%2520cytarabine%2520in%2520patients%2520with%2520first%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukaemia%2520%2528VALOR%2529%253A%2520a%2520randomised%252C%2520controlled%252C%2520double-blind%252C%2520multinational%252C%2520phase%25203%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1025%26epage%3D1036%26doi%3D10.1016%2FS1470-2045%2815%2900201-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hotinski, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. M.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1395</span>â <span class="NLM_lpage">1402</span>, <span class="refDoi">Â DOI: 10.1517/14656566.2015.1044437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1517%2F14656566.2015.1044437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25958926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFaitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1395-1402&author=A.+K.+Hotinskiauthor=I.+D.+Lewisauthor=D.+M.+Ross&title=Vosaroxin+is+a+novel+topoisomerase-II+inhibitor+with+efficacy+in+relapsed+and+refractory+acute+myeloid+leukaemia&doi=10.1517%2F14656566.2015.1044437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia</span></div><div class="casAuthors">Hotinski, Anya K.; Lewis, Ian D.; Ross, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1395-1402</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Vosaroxin is a first-in-class anti-cancer quinolone that inhibits topoisomerase-II leading to cell cycle arrest and apoptosis.  It has shown efficacy in a range of solid organ and haematopoietic tumors in vitro, and several clin. trials are underway or completed in the field of Acute Myeloid Leukemia (AML).  The treatment of relapsed and refractory AML is a clin. challenge, where long-term survival is rare without allogeneic haematopoietic stem cell transplantation.  Areas covered: We review the data from the published clin. trials of vosaroxin, including the recently presented Phase III VALOR study.  In combination with intermediate dose cytarabine, vosaroxin almost doubled complete response (CR) rates in relapsed and refractory AML compared with cytarabine alone, and prolonged median survival by 1.4 mo.  Expert opinion: Vosaroxin is a promising new agent in the treatment of AML, with the potential to improve CR rates in a high-risk group of patients with relapsed and refractory AML.  However, higher CR rates have been assocd. with higher rates of treatment-related morbidity and mortality, esp. in elderly/unfit patients.  Maximising the potential of vosaroxin will therefore require the identification of patients most likely to benefit from vosaroxin-contg. combination regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolne5lUqdZYbVg90H21EOLACvtfcHk0ljOOVV2wGZJTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFaitr0%253D&md5=0cfd1fd4a9b8ab22a43c01bf338c117f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1044437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1044437%26sid%3Dliteratum%253Aachs%26aulast%3DHotinski%26aufirst%3DA.%2BK.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DRoss%26aufirst%3DD.%2BM.%26atitle%3DVosaroxin%2520is%2520a%2520novel%2520topoisomerase-II%2520inhibitor%2520with%2520efficacy%2520in%2520relapsed%2520and%2520refractory%2520acute%2520myeloid%2520leukaemia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D1395%26epage%3D1402%26doi%3D10.1517%2F14656566.2015.1044437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin: a novel antineoplastic quinolone</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1223</span>â <span class="NLM_lpage">1233</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2012.699038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1517%2F13543784.2012.699038" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1223-1233&author=J.+A.+Abbasauthor=R.+K.+Stuart&title=Vosaroxin%3A+a+novel+antineoplastic+quinolone&doi=10.1517%2F13543784.2012.699038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.699038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.699038%26sid%3Dliteratum%253Aachs%26aulast%3DAbbas%26aufirst%3DJ.%2BA.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26atitle%3DVosaroxin%253A%2520a%2520novel%2520antineoplastic%2520quinolone%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1223%26epage%3D1233%26doi%3D10.1517%2F13543784.2012.699038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ­rez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirkov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owzar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulkey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamazon, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Undevia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M. J.</span></span> <span> </span><span class="NLM_article-title">A pharmacogenetic study of aldehyde oxidase I in patients treated withXK469</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">129</span>â <span class="NLM_lpage">132</span>, <span class="refDoi">Â DOI: 10.1097/FPC.0000000000000023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1097%2FFPC.0000000000000023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24300566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislyjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=129-132&author=J.+Ram%C3%ADrezauthor=T.+W.+Kimauthor=W.+Liuauthor=J.+L.+Myersauthor=S.+Mirkovauthor=K.+Owzarauthor=D.+Watsonauthor=F.+Mulkeyauthor=E.+R.+Gamazonauthor=W.+Stockauthor=S.+Undeviaauthor=F.+Innocentiauthor=M.+J.+Ratain&title=A+pharmacogenetic+study+of+aldehyde+oxidase+I+in+patients+treated+withXK469&doi=10.1097%2FFPC.0000000000000023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469</span></div><div class="casAuthors">Ramirez, Jacqueline; Kim, Tae Won; Liu, Wanqing; Myers, Jamie L.; Mirkov, Snezana; Owzar, Kouros; Watson, Dorothy; Mulkey, Flora; Gamazon, Eric R.; Stock, Wendy; Undevia, Samir; Innocenti, Federico; Ratain, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">XK469 (NSC 697887) is a selective topoisomerase II Î² inhibitor eliminated mainly by aldehyde oxidase I (AOX1).  We performed a candidate gene study to investigate whether AOX1 genetic variation contributes to interindividual variability in XK469 clearance.  Forty-one AOX1 single nucleotide polymorphisms (SNPs) and seven liver expression quant. trait loci were genotyped in White patients with advanced refractory solid tumors (n=59) and leukemia (n=33).  We found a significant decrease in clearance (Ï=-0.32, P=0.003) in solid tumor patients with rs10931910, although it failed to replicate in the leukemia cohort (Ï=0.18, P=0.20).  Four other AOX1 SNPs were assocd. with clearance (P=0.01-0.02) in only one of the two cohorts.  Our study provides a starting point for future investigations on the functionality of AOX1 SNPs.  However, variability in XK469 clearance cannot be attributed to polymorphisms in AOX1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqg-LaRfV57Vg90H21EOLACvtfcHk0liACUryhtJFRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislyjtQ%253D%253D&md5=2c77da326aa1c796ea297849671bdea7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2FFPC.0000000000000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0000000000000023%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25ADrez%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMyers%26aufirst%3DJ.%2BL.%26aulast%3DMirkov%26aufirst%3DS.%26aulast%3DOwzar%26aufirst%3DK.%26aulast%3DWatson%26aufirst%3DD.%26aulast%3DMulkey%26aufirst%3DF.%26aulast%3DGamazon%26aufirst%3DE.%2BR.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DUndevia%26aufirst%3DS.%26aulast%3DInnocenti%26aufirst%3DF.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26atitle%3DA%2520pharmacogenetic%2520study%2520of%2520aldehyde%2520oxidase%2520I%2520in%2520patients%2520treated%2520withXK469%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2014%26volume%3D24%26spage%3D129%26epage%3D132%26doi%3D10.1097%2FFPC.0000000000000023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouw, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">243</span>â <span class="NLM_lpage">252</span>, <span class="refDoi">Â DOI: 10.1007/s10637-016-0333-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs10637-016-0333-z" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=243-252&author=S.+Guptaauthor=L.+Gouwauthor=J.+Wrightauthor=S.+Chawlaauthor=D.+Pittauthor=M.+Wadeauthor=K.+Boucherauthor=S.+Sharma&title=Phase+II+study+of+amrubicin+%28SM-5887%29%2C+a+synthetic+9-aminoanthracycline%2C+as+first+line+treatment+in+patients+with+metastatic+or+unresectable+soft+tissue+sarcoma%3A+durable+response+in+myxoid+liposarcoma+with+TLS-CHOP+translocation&doi=10.1007%2Fs10637-016-0333-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0333-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0333-z%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGouw%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DChawla%26aufirst%3DS.%26aulast%3DPitt%26aufirst%3DD.%26aulast%3DWade%26aufirst%3DM.%26aulast%3DBoucher%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DPhase%2520II%2520study%2520of%2520amrubicin%2520%2528SM-5887%2529%252C%2520a%2520synthetic%25209-aminoanthracycline%252C%2520as%2520first%2520line%2520treatment%2520in%2520patients%2520with%2520metastatic%2520or%2520unresectable%2520soft%2520tissue%2520sarcoma%253A%2520durable%2520response%2520in%2520myxoid%2520liposarcoma%2520with%2520TLS-CHOP%2520translocation%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26spage%3D243%26epage%3D252%26doi%3D10.1007%2Fs10637-016-0333-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokosza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, D. G.</span></span> <span> </span><span class="NLM_article-title">Design, antiviral and cytostatic properties of isoxazolidine-containing amonafideanalogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3135</span>â <span class="NLM_lpage">3146</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.04.079" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3135-3146&author=K.+Kokoszaauthor=G.+Andreiauthor=D.+Scholsauthor=R.+Snoeckauthor=D.+G.+Piotrowska&title=Design%2C+antiviral+and+cytostatic+properties+of+isoxazolidine-containing+amonafideanalogues&doi=10.1016%2Fj.bmc.2015.04.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DKokosza%26aufirst%3DK.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DPiotrowska%26aufirst%3DD.%2BG.%26atitle%3DDesign%252C%2520antiviral%2520and%2520cytostatic%2520properties%2520of%2520isoxazolidine-containing%2520amonafideanalogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3135%26epage%3D3146%26doi%3D10.1016%2Fj.bmc.2015.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warzocha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egyed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span> <span> </span><span class="NLM_article-title">Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1252</span>â <span class="NLM_lpage">1257</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2014.57.0952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1200%2FJCO.2014.57.0952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25732165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlWhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1252-1257&author=R.+M.+Stoneauthor=E.+Mazzolaauthor=D.+Neubergauthor=S.+L.+Allenauthor=A.+Pigneuxauthor=R.+K.+Stuartauthor=M.+Wetzlerauthor=D.+Rizzieriauthor=H.+P.+Erbaauthor=L.+Damonauthor=J.+H.+Jangauthor=M.+S.+Tallmanauthor=K.+Warzochaauthor=T.+Massziauthor=M.+A.+Sekeresauthor=M.+Egyedauthor=H.+A.+Horstauthor=D.+Selleslagauthor=S.+R.+Solomonauthor=P.+Venugopalauthor=A.+S.+Lundbergauthor=B.+Powell&title=Phase+III+open-label+randomized+study+of+cytarabine+in+combination+with+amonafide+L-malate+or+daunorubicin+as+induction+therapy+for+patients+with+secondary+acute+myeloid+leukemia&doi=10.1200%2FJCO.2014.57.0952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia</span></div><div class="casAuthors">Stone, Richard M.; Mazzola, Emanuele; Neuberg, Donna; Allen, Steven L.; Pigneux, Arnaud; Stuart, Robert K.; Wetzler, Meir; Rizzieri, David; Erba, Harry P.; Damon, Lloyd; Jang, Jun-Ho; Talhnan, Martin S.; Warzocha, Krzysztof; Masszi, Tamas; Sekeres, Mikkael A.; Egyed, Miklos; Horst, Heinz-August; Selleslag, Dominik; Solomon, Scott R.; Venugopal, Parameswaran; Lundberg, Ante S.; Powell, Bayard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1252-1257</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodys-plastic syndrome or after antineoplastic therapy, responds poorly to current therapies.  It is often assocd. with adverse karyotypic abnormalities and overexpression of proteins that mediate drug resistance.  We performed a phase III trial to det. whether induction therapy with cytarabine and amonafide L-malate, a DNA intercalator and non-ATP-dependent topoisomerase II inhibitor that evades drug resistance mechanisms, yielded a superior complete remission rate than std. therapy with cytarabine and daunorubicin in sAML.  Patients and Methods: Patients with previously untreated sAML were randomly assigned at a one-to-one ratio to cytarabine 200 mg/m2 continuous i.v. (IV) infusion once per day on days 1 to 7 plus either amonafide 600 mg/m2 IV over 4 h on days 1 to 5 (A + C arm) or daunorubicin 45 mg/m2 IV over 30 min once per day on days 1 to 3 (D + C arm).  Results: The complete remission (CR) rate was 46% (99 of 216 patients) in A + C arm and 45% (97 of 217 patients) in D + C arm (P = .81).  The 30- and 60-day mortality rates were 19% and 28% in A + C arm and 13% and 21% in D + C arm, resp.  Conclusion: Induction treatment with A + C did not improve the CR rate compared with D + C in patients with sAML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVAceiK2zCfbVg90H21EOLACvtfcHk0li6prZG2d3Cpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlWhu70%253D&md5=1412b402499ecf8fc747ea8de90e6b38</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.57.0952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.57.0952%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DMazzola%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DS.%2BL.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DWetzler%26aufirst%3DM.%26aulast%3DRizzieri%26aufirst%3DD.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DWarzocha%26aufirst%3DK.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DEgyed%26aufirst%3DM.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DSelleslag%26aufirst%3DD.%26aulast%3DSolomon%26aufirst%3DS.%2BR.%26aulast%3DVenugopal%26aufirst%3DP.%26aulast%3DLundberg%26aufirst%3DA.%2BS.%26aulast%3DPowell%26aufirst%3DB.%26atitle%3DPhase%2520III%2520open-label%2520randomized%2520study%2520of%2520cytarabine%2520in%2520combination%2520with%2520amonafide%2520L-malate%2520or%2520daunorubicin%2520as%2520induction%2520therapy%2520for%2520patients%2520with%2520secondary%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1252%26epage%3D1257%26doi%3D10.1200%2FJCO.2014.57.0952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S. F.</span></span> <span> </span><span class="NLM_article-title">Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">439</span>â <span class="NLM_lpage">481</span>, <span class="refDoi">Â DOI: 10.2174/092986711794839197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F092986711794839197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=21143116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=439-481&author=S.+M.+Heauthor=R.+Liauthor=J.+R.+Kanwarauthor=S.+F.+Zhou&title=Structural+and+functional+properties+of+human+multidrug+resistance+protein+1+%28MRP1%2FABCC1%29&doi=10.2174%2F092986711794839197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)</span></div><div class="casAuthors">He, S.-M.; Li, R.; Kanwar, J. R.; Zhou, S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-481</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Multidrug ABC transporters such as P-glycoprotein (P-gp/MDR1/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1) play an important role in the extrusion of drugs from the cell and their overexpression can be a cause of failure of anticancer and antimicrobial chemotherapy.  Recently, the mouse P-gp/Abcb1a structure has been detd. and this has significantly enhanced our understanding of the structure-activity relationship (SAR) of mammalian ABC transporters.  This paper highlights our current knowledge on the structural and functional properties and the SAR of human MRP1/ABCC1.  Although the crystal structure of MRP1/ABCC1 has yet to be resolved, the current topol. model of MRP1/ABCC1 contains two transmembrane domains (TMD1 and TMD2) each followed by a nucleotide binding domain (NBD) plus a third NH2-terminal TMD0.  MRP1/ABCC1 is expressed in the liver, kidney, intestine, brain and other tissues.  MRP1/ABCC1 transports a structurally diverse array of important endogenous substances (e.g. leukotrienes and estrogen conjugates) and xenobiotics and their metabolites, including various conjugates, anticancer drugs, heavy metals, org. anions and lipids.  Cells that highly express MRP1/ABCC1 confer resistance to a variety of natural product anticancer drugs such as vinca alkaloids (e.g. vincristine), anthracyclines (e.g. etoposide) and epipodophyllotoxins (e.g. doxorubicin and mitoxantrone).  MRP1/ABCC1 is assocd. with tumor resistance which is often caused by an increased efflux and decreased intracellular accumulation of natural product anticancer drugs and other anticancer agents.  However, most compds. that efficiently reverse P-gp/ABCB1-mediated multidrug resistance have only low affinity for MRP1/ABCC1 and there are only a few effective and relatively specific MRP1/ABCC1 inhibitors available.  A no. of site-directed mutagenesis studies, biophys. and photolabeling studies, SAR and QSAR, mol. docking and homol. modeling studies have documented the role of multiple residues in detg. the substrate specificity and inhibitor selectivity of MRP1/ABCC1.  Most of these residues are located in the TMs of TMD1 and TMD2, in particular TMs 4, 6, 7, 8, 10, 11, 14, 16, and 17, or in close proximity to the membrane/cytosol interface of MRP1/ABCC1.  The exact transporting mechanism of MRP1/ABCC1 is unclear.  MRP1/ABCC1 and other multidrug transporters are front-line mediators of drug resistance in cancers and represent important therapeutic targets in future chemotherapy.  The crystal structure of human MRP1/ABCC1 is expected to be resolved in the near future and this will provide an insight into the SAR of MRP1/ABCC1 and allow for rational design of anticancer drugs and potent and selective MRP1/ABCC1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7slbZ6tZ2rVg90H21EOLACvtfcHk0li6prZG2d3Cpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtrs%253D&md5=ef2c7f9b64948ef9dd5b3e8b7c4d7837</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2174%2F092986711794839197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839197%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DKanwar%26aufirst%3DJ.%2BR.%26aulast%3DZhou%26aufirst%3DS.%2BF.%26atitle%3DStructural%2520and%2520functional%2520properties%2520of%2520human%2520multidrug%2520resistance%2520protein%25201%2520%2528MRP1%252FABCC1%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D439%26epage%3D481%26doi%3D10.2174%2F092986711794839197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase II and leukemia</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1310</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">110</span>, <span class="refDoi">Â DOI: 10.1111/nyas.12358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1111%2Fnyas.12358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24495080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1310&publication_year=2014&pages=98-110&author=M.+Pendletonauthor=R.+H.+Lindseyauthor=C.+A.+Felixauthor=D.+Grimwadeauthor=N.+Osheroff&title=Topoisomerase+II+and+leukemia&doi=10.1111%2Fnyas.12358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerase II and leukemia</span></div><div class="casAuthors">Pendleton, MaryJean; Lindsey, R. Hunter Jr.; Felix, Carolyn A.; Grimwade, David; Osheroff, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1310</span>
        (<span class="NLM_cas:issue">y</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Type II topoisomerases are essential enzymes that modulate DNA under- and overwinding, knotting, and tangling.  Beyond their crit. physiol. functions, these enzymes are the targets for some of the most widely prescribed anticancer drugs (topoisomerase II poisons) in clin. use.  Topoisomerase II poisons kill cells by increasing levels of covalent enzyme-cleaved DNA complexes that are normal reaction intermediates.  Drugs such as etoposide, doxorubicin, and mitoxantrone are frontline therapies for a variety of solid tumors and hematol. malignancies.  Unfortunately, their use also is assocd. with the development of specific leukemias.  Regimens that include etoposide or doxorubicin are linked to the occurrence of acute myeloid leukemias that feature rearrangements at chromosomal band 11q23.  Similar rearrangements are seen in infant leukemias and are assocd. with gestational diets that are high in naturally occurring topoisomerase II-active compds.  Finally, regimens that include mitoxantrone and epirubicin are linked to acute promyelocytic leukemias that feature t(15;17) rearrangements.  The first part of this article will focus on type II topoisomerases and describe the mechanism of enzyme and drug action.  The second part will discuss how topoisomerase II poisons trigger chromosomal breaks that lead to leukemia and potential approaches for dissocg. the actions of drugs from their leukemogenic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiALYgvTJB7LVg90H21EOLACvtfcHk0ljDsvvsUr7i5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslyltr8%253D&md5=9bb86013f9a010450587baa0c924bfec</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12358%26sid%3Dliteratum%253Aachs%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DLindsey%26aufirst%3DR.%2BH.%26aulast%3DFelix%26aufirst%3DC.%2BA.%26aulast%3DGrimwade%26aufirst%3DD.%26aulast%3DOsheroff%26aufirst%3DN.%26atitle%3DTopoisomerase%2520II%2520and%2520leukemia%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1310%26spage%3D98%26epage%3D110%26doi%3D10.1111%2Fnyas.12358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">228</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2016.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26945111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=228-245&author=R.+Karkiauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=S.+Shinauthor=T.+B.+Thapa+Magarauthor=G.+Bistauthor=A.+Shresthaauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=A+new+series+of+2-phenol-4-aryl-6-chlorophenyl+pyridine+derivatives+as+dual+topoisomerase+I%2FII+inhibitors%3A+Synthesis%2C+biological+evaluation+and+3D-QSAR+study&doi=10.1016%2Fj.ejmech.2016.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study</span></div><div class="casAuthors">Karki, Radha; Jun, Kyu-Yeon; Kadayat, Tara Man; Shin, Somin; Thapa Magar, Til Bahadur; Bist, Ganesh; Shrestha, Aarajana; Na, Younghwa; Kwon, Youngjoo; Lee, Eung-Seok</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a continuous effort to develop novel antitumor agents, a new series of forty-five 2-phenol-4-aryl-6-chlorophenyl pyridine compds. I (R1 = 2-HOC6H4, 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) were synthesized and evaluated for cytotoxicity against four different human cancer cell lines (DU145, HCT15, T47D, and HeLa), and topoisomerase I and II inhibitory activity.  Several compds. I (R1 = 3-HOC6H4, 4-HOC6H4; R2 = Ph, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl; R3 = 2-ClC6H4, 3-ClC6H4, 4-ClC6H4) displayed strong to moderate dual topoisomerase I and II inhibitory activity at 100 Î¼M.  It was obsd. that hydroxyl and chlorine moiety at meta or para position of Ph ring is favorable for dual topoisomerase inhibitory activity and cytotoxicity.  Most of the compds. I displayed stronger cytotoxicities than those of all pos. controls against the HCT15 and T47D cell lines.  For investigation of the structure-activity relationships, a 3D-QSAR anal. using the method of comparative mol. field anal. (CoMFA) was performed.  The generated 3D contour maps can be used for further rational design of novel terpyridine derivs. I as highly selective and potent cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeg-6-GpSiTrVg90H21EOLACvtfcHk0ljDsvvsUr7i5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1egu70%253D&md5=1d85da38e23e3c8d9e35188d189c64d8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DA%2520new%2520series%2520of%25202-phenol-4-aryl-6-chlorophenyl%2520pyridine%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%253A%2520Synthesis%252C%2520biological%2520evaluation%2520and%25203D-QSAR%2520study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D113%26spage%3D228%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">428</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.04.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2014.04.066" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=428-438&author=K.+Y.+Junauthor=H.+Kwonauthor=S.+E.+Parkauthor=E.+Leeauthor=R.+Karkiauthor=P.+Thapaauthor=J.+H.+Leeauthor=E.+S.+Leeauthor=Y.+Kwon&title=Discovery+of+dihydroxylated+2%2C4-diphenyl-6-thiophen-2-yl-pyridine+as+a+non-intercalative+DNA-binding+topoisomerase+II-specific+catalytic+inhibitor&doi=10.1016%2Fj.ejmech.2014.04.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.066%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520dihydroxylated%25202%252C4-diphenyl-6-thiophen-2-yl-pyridine%2520as%2520a%2520non-intercalative%2520DNA-binding%2520topoisomerase%2520II-specific%2520catalytic%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D428%26epage%3D438%26doi%3D10.1016%2Fj.ejmech.2014.04.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa
Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 2-aryl-4-(4â-hydroxyphenyl)-5<i>H</i>-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">14</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2016.09.019" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=14-28&author=S.+Parkauthor=T.+M.+Kadayatauthor=K.+Y.+Junauthor=T.+B.+Thapa%0AMagarauthor=G.+Bistauthor=A.+Shresthaauthor=E.+S.+Leeauthor=Y.+Kwon&title=Novel+2-aryl-4-%284%E2%80%99-hydroxyphenyl%29-5H-indeno%5B1%2C2-b%5Dpyridines+as+potent+DNA+non-intercalative+topoisomerase+catalytic+inhibitors&doi=10.1016%2Fj.ejmech.2016.09.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DNovel%25202-aryl-4-%25284%25E2%2580%2599-hydroxyphenyl%2529-5H-indeno%255B1%252C2-b%255Dpyridines%2520as%2520potent%2520DNA%2520non-intercalative%2520topoisomerase%2520catalytic%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D14%26epage%3D28%26doi%3D10.1016%2Fj.ejmech.2016.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span> <span> </span><span class="NLM_article-title">R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">484</span>â <span class="NLM_lpage">495</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-06-0584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1158%2F1535-7163.MCT-06-0584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=17308047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=484-495&author=H.+Zhuauthor=M.+Huangauthor=F.+Yangauthor=Y.+Chenauthor=Z.+H.+Miaoauthor=X.+H.+Qianauthor=Y.+F.+Xuauthor=Y.+X.+Qinauthor=H.+B.+Luoauthor=X.+Shenauthor=M.+Y.+Gengauthor=Y.+J.+Caiauthor=J.+Ding&title=R16%2C+a+novel+amonafide+analogue%2C+induces+apoptosis+and+G2-M+arrest+via+poisoning+topoisomerase+II&doi=10.1158%2F1535-7163.MCT-06-0584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II</span></div><div class="casAuthors">Zhu, Hong; Huang, Min; Yang, Fan; Chen, Yi; Miao, Ze-Hong; Qian, Xu-Hong; Xu, Yu-Fang; Qin, Yu-Xin; Luo, Hai-Bin; Shen, Xu; Geng, Mei-Yu; Cai, Yu-Jun; Ding, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">484-495</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amonafide, a naphthalimide deriv., although selected for exploratory clin. trials for its potent anticancer activity, has long been challenged by its unpredictable side effects.  In the present study, a novel amonafide analog (R16, I) was synthesized by substituting 5'-NH2 of the naphthyl with a heterocyclic group to amonafide, with addnl. introduction of a thiol group.  In a panel of various human tumor cell lines, R16 was more cytotoxic than its parent compd. amonafide.  It was also effective against multidrug-resistant cells.  Importantly, the i.p. administration of R16 inhibited tumor growth in mice implanted with S-180 sarcoma and H22 hepatoma.  The mol. and cellular machinery studies showed that the R16 functions as a topoisomerase II (topo II) poison via binding to the ATPase domain of human topo IIÎ±.  The superior cytotoxicity of R16 to amonafide was ascribed to its potent effects on trapping topo II-DNA cleavage complexes.  Moreover, using a topo II catalytic inhibitor aclarubicin, ataxia-telangiectasia-mutated (ATM)/ATM- and Rad3-related (ATR) kinase inhibitor caffeine and topo II-deficient HL-60/MX2 cells, the authors further showed that R16-triggered DNA double-strand breaks, tumor cell cycle arrest, and apoptosis were in a topo II-dependent manner.  Taken together, R16 stood out by its improved anticancer activity, appreciable antimultidrug resistance activities, and well-defined topo II poisoning mechanisms, as comparable with the parent compd. amonafide.  All these collectively promise the potential value of R16 as an anticancer drug candidate, which deserves further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZVr76EHH9i7Vg90H21EOLACvtfcHk0lgnd6_hJ9012g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWku7k%253D&md5=f70d0c13743f421fc9857b6bce9fb384</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0584%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DQian%26aufirst%3DX.%2BH.%26aulast%3DXu%26aufirst%3DY.%2BF.%26aulast%3DQin%26aufirst%3DY.%2BX.%26aulast%3DLuo%26aufirst%3DH.%2BB.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DCai%26aufirst%3DY.%2BJ.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DR16%252C%2520a%2520novel%2520amonafide%2520analogue%252C%2520induces%2520apoptosis%2520and%2520G2-M%2520arrest%2520via%2520poisoning%2520topoisomerase%2520II%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D484%26epage%3D495%26doi%3D10.1158%2F1535-7163.MCT-06-0584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BraÃ±a, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pascual-Teresa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DomÃ­nguez, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozuelo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abradelo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-Stolle, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuste, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡Ã±ez-Coronel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacal, J. C.</span></span> <span> </span><span class="NLM_article-title">New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1391</span>â <span class="NLM_lpage">1399</span>, <span class="refDoi">Â DOI: 10.1021/jm0308850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0308850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1391-1399&author=M.+F.+Bra%C3%B1aauthor=M.+Cachoauthor=M.+A.+Garc%C3%ADaauthor=B.+de+Pascual-Teresaauthor=A.+Ramosauthor=M.+T.+Dom%C3%ADnguezauthor=J.+M.+Pozueloauthor=C.+Abradeloauthor=M.+F.+Rey-Stolleauthor=M.+Yusteauthor=M.+B%C3%A1%C3%B1ez-Coronelauthor=J.+C.+Lacal&title=New+analogues+of+amonafide+and+elinafide%2C+containing+aromatic+heterocycles%3A+synthesis%2C+antitumor+activity%2C+molecular+modeling%2C+and+DNA+binding+properties&doi=10.1021%2Fjm0308850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">New Analogues of Amonafide and Elinafide, Containing Aromatic Heterocycles: Synthesis, Antitumor Activity, Molecular Modeling, and DNA Binding Properties</span></div><div class="casAuthors">Brana, Miguel F.; Cacho, Monica; Garcia, Mario A.; de Pascual-Teresa, Beatriz; Ramos, Ana; Dominguez, M. Teresa; Pozuelo, Jose M.; Abradelo, Cristina; Rey-Stolle, Maria Fernanda; Yuste, Mercedes; Banez-Coronel, Monica; Lacal, Juan Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1391-1399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amonafide- and elinafide-related mono and bisintercalators, e.g. I and II (X = O, S) modified by the introduction of a Ï-excedent furan or thiophene ring fused to the naphthalimide moiety, have been synthesized.  These compds. have shown an interesting antitumor profile.  The best compd., II (X = O), was 2.5-fold more potent than elinafide against human colon carcinoma cells (HT-29).  Mol. dynamic simulations and physicochem. expts. have demonstrated that these compds. are capable of forming stable DNA complexes.  These results, together with those previously reported by us for imidazo- and pyrazinonaphthalimide analogs, have prompted us to propose that the DNA binding process does not depend on the electronic nature of the fused heterocycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghczuS0ltzbVg90H21EOLACvtfcHk0lgnd6_hJ9012g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL0%253D&md5=6f0509a3b7984835b5cf5f42f0da6d7e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0308850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0308850%26sid%3Dliteratum%253Aachs%26aulast%3DBra%25C3%25B1a%26aufirst%3DM.%2BF.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%2BA.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DM.%2BT.%26aulast%3DPozuelo%26aufirst%3DJ.%2BM.%26aulast%3DAbradelo%26aufirst%3DC.%26aulast%3DRey-Stolle%26aufirst%3DM.%2BF.%26aulast%3DYuste%26aufirst%3DM.%26aulast%3DB%25C3%25A1%25C3%25B1ez-Coronel%26aufirst%3DM.%26aulast%3DLacal%26aufirst%3DJ.%2BC.%26atitle%3DNew%2520analogues%2520of%2520amonafide%2520and%2520elinafide%252C%2520containing%2520aromatic%2520heterocycles%253A%2520synthesis%252C%2520antitumor%2520activity%252C%2520molecular%2520modeling%252C%2520and%2520DNA%2520binding%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1391%26epage%3D1399%26doi%3D10.1021%2Fjm0308850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolla, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srikanth, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. K.</span></span> <span> </span><span class="NLM_article-title">Naphthalimide derivatives with therapeutic characteristics: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">299</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1517/13543776.2013.746313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1517%2F13543776.2013.746313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=23369185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Sqsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=299-317&author=A.+Kamalauthor=N.+R.+Bollaauthor=P.+S.+Srikanthauthor=A.+K.+Srivastava&title=Naphthalimide+derivatives+with+therapeutic+characteristics%3A+a+patent+review&doi=10.1517%2F13543776.2013.746313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Naphthalimide derivatives with therapeutic characteristics: a patent review</span></div><div class="casAuthors">Kamal, Ahmed; Bolla, Narasimha Rao; Srikanth, Pandala Sindayla; Srivastava, Ajay Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-317</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Naphthalimides are important arom. heterocycles with immense pharmacol. significance as they serve as core scaffold for many antitumor, anti-inflammatory, antidepressant, antiprotozoal and antiviral agents, etc.  The tricyclic planar ring system of naphthalimide is primarily responsible for its intercalation with DNA to perturb the cellular events and the substitution pattern of the mol. leads to several other applications.  The promising pharmacol. activity profile and ease of synthesis have been attractive in design and development of new class of naphthalimides and their conjugates as various potential therapeutic agents.  Few of such mols. are currently under preclin. and clin. evaluations.Areas covered: Important patents focusing on naphthalimides as potential class of therapeutics, published between the period of 2006 - 2011 have been covered.  The reports are presented together with a review of the related structural chem. space.  This review mainly focuses on the therapeutic applications, structural modifications of naphthalimide scaffold, their conjugates and heterocyclics bearing naphthalimide moiety.Expert opinion: The tricyclic planar ring system of naphthalimide restrains important pharmaceutical properties along with excellent fluorescent after proper substitution pattern.  Linking these active naphthalimide derivs. with other active pharmacophore has become an interesting area of research.  The utility of naphthalimide derivs. as novel pharmaceutical and photochem. agents can be further enhanced by introducing polar side chains and fusing functionalized heterocyclic rings with naphthalimide cores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiCS3WT7YqRLVg90H21EOLACvtfcHk0lgfA3gTqWOwlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Sqsr0%253D&md5=a04f5f79fd0176e6f2e940f62268648b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.746313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.746313%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DBolla%26aufirst%3DN.%2BR.%26aulast%3DSrikanth%26aufirst%3DP.%2BS.%26aulast%3DSrivastava%26aufirst%3DA.%2BK.%26atitle%3DNaphthalimide%2520derivatives%2520with%2520therapeutic%2520characteristics%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D299%26epage%3D317%26doi%3D10.1517%2F13543776.2013.746313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Naphthalimides exhibit <i>in vitro</i> antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinase (RTKs)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">477</span>â <span class="NLM_lpage">486</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.05.002" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=477-486&author=X.+Wangauthor=Z.+Chenauthor=L.+Tongauthor=S.+Tanauthor=W.+Zhouauthor=T.+Pengauthor=K.+Hanauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xu&title=Naphthalimides+exhibit+in+vitro+antiproliferative+and+antiangiogenic+activities+by+inhibiting+both+topoisomerase+II+%28topo+II%29+and+receptor+tyrosine+kinase+%28RTKs%29&doi=10.1016%2Fj.ejmech.2013.05.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DNaphthalimides%2520exhibit%2520in%2520vitro%2520antiproliferative%2520and%2520antiangiogenic%2520activities%2520by%2520inhibiting%2520both%2520topoisomerase%2520II%2520%2528topo%2520II%2529%2520and%2520receptor%2520tyrosine%2520kinase%2520%2528RTKs%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D477%26epage%3D486%26doi%3D10.1016%2Fj.ejmech.2013.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Quinoxalinone (Part II). Discovery of (<i>Z</i>)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1840</span>â <span class="NLM_lpage">1852</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2016.03.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1840-1852&author=L.+Shiauthor=J.+Zhouauthor=J.+Wuauthor=J.+Caoauthor=Y.+Shenauthor=H.+Zhouauthor=X.+Li&title=Quinoxalinone+%28Part+II%29.+Discovery+of+%28Z%29-3-%282-%28pyridin-4-yl%29vinyl%29quinoxalinone+derivates+as+potent+VEGFR-2+kinase+inhibitors&doi=10.1016%2Fj.bmc.2016.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DQuinoxalinone%2520%2528Part%2520II%2529.%2520Discovery%2520of%2520%2528Z%2529-3-%25282-%2528pyridin-4-yl%2529vinyl%2529quinoxalinone%2520derivates%2520as%2520potent%2520VEGFR-2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1840%26epage%3D1852%26doi%3D10.1016%2Fj.bmc.2016.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Anti-angiogenic therapy: strategies to develop potent VEGFR-2 tyrosine kinase inhibitors and future prospect</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1000</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.2174/0929867323666160210130426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F0929867323666160210130426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26860998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOku70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1000-1040&author=L.+Shiauthor=J.+Zhouauthor=J.+Wuauthor=Y.+Shenauthor=X.+Li&title=Anti-angiogenic+therapy%3A+strategies+to+develop+potent+VEGFR-2+tyrosine+kinase+inhibitors+and+future+prospect&doi=10.2174%2F0929867323666160210130426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect</span></div><div class="casAuthors">Shi, Leilei; Zhou, Jianfeng; Wu, Jifeng; Shen, Yuemao; Li, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1000-1040</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Tumor angiogenesis has always been a major gap for effective cancer therapy.  Interruption of aberrant angiogenesis by specific inhibitors targeting receptor tyrosine kinases (RTKs) has been of great interests to medicinal chemists.  Among the factors that are involved in tumor angiogenesis, vascular endothelial growth factor receptor-2 (VEGFR-2) is validated as the most closely related factor which can drive angiogenesis through binding with its natural ligand VEGF.  The well-validated VEGF-driven VEGFR-2 signaling pathway can stimulate many endothelial responses, including increasing vessel permeability and enhancing endothelial cell proliferation, migration and differentiation.  Consequently, circumventing angiogenesis by VEGFR-2 inhibitors represents a promising strategy for counteracting various VEGFR-2-mediated disorders as well as drug resistance.  Over the past decades, a considerable no. of novel small mol. VEGFR-2 inhibitors have been exploited with diverse chem. scaffolds.  Esp., recent frequently launched inhibitors have declared their research values and therapeutic potentials in oncol.  Still, the antiangiogenesis based treatment remains an ongoing challenge.  In this review, a comprehensive retrospective of newly emerged VEGFR-2 inhibitors have been summarized, with the emphasis on the structure-activity relationship (SAR) investigation, and also binding patterns of representative inhibitors with biotargets.  On the basis of all of this information, varied strategies for developing potent VEGFR-2 inhibitors and the future prospect of the clin. application of antiangiogenic inhibitors are discussed hereby.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohrFu9JNyl1LVg90H21EOLACvtfcHk0lgnXNzUgUgxTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOku70%253D&md5=3ac7107ac9eaf3657caf83649aea6abf</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160210130426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160210130426%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DAnti-angiogenic%2520therapy%253A%2520strategies%2520to%2520develop%2520potent%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitors%2520and%2520future%2520prospect%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D1000%26epage%3D1040%26doi%3D10.2174%2F0929867323666160210130426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomerase IIÎ± and antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">782</span>â <span class="NLM_lpage">796</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.08.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2014.08.073" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=782-796&author=W.+Chenauthor=Y.+Shenauthor=Z.+Liauthor=M.+Zhangauthor=C.+Luauthor=Y.+Shen&title=Design+and+synthesis+of+2-phenylnaphthalenoids+as+inhibitors+of+DNA+topoisomerase+II%CE%B1+and+antitumor+agents&doi=10.1016%2Fj.ejmech.2014.08.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-phenylnaphthalenoids%2520as%2520inhibitors%2520of%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520and%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D782%26epage%3D796%26doi%3D10.1016%2Fj.ejmech.2014.08.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plech, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KaproÅ, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wujec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotsko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KuÅmierz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneth, P.</span></span> <span> </span><span class="NLM_article-title">Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1021</span>â <span class="NLM_lpage">1026</span>, <span class="refDoi">Â DOI: 10.3109/14756366.2014.995179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3109%2F14756366.2014.995179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25792499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKks73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=1021-1026&author=T.+Plechauthor=B.+Kapro%C5%84author=A.+Panethauthor=M.+Wujecauthor=R.+Czarnomysyauthor=A.+Bielawskaauthor=K.+Bielawskiauthor=N.+Trotskoauthor=E.+Ku%C5%9Bmierzauthor=P.+Paneth&title=Search+for+human+DNA+topoisomerase+II+poisons+in+the+group+of+2%2C5-disubstituted-1%2C3%2C4-thiadiazoles&doi=10.3109%2F14756366.2014.995179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles</span></div><div class="casAuthors">Plech, Tomasz; Kapron, Barbara; Paneth, Agata; Wujec, Monika; Czarnomysy, Robert; Bielawska, Anna; Bielawski, Krzysztof; Trotsko, Nazar; Kusmierz, Edyta; Paneth, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1021-1026</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A series of six 2,5-disubstituted 1,3,4-thiadiazole derivs. was synthesized and examd. for cytotoxic activity in MCF-7 and MDA-MB-231 breast cancer cells.  MTT assay confirmed that 2-(3-fluorophenylamino)-5-(3-hydroxyphenyl)-1,3,4-thiadiazole (I), 2-(4-bromophenylamino)-5-(2,4-dichlorophenyl)-1,3,4-thiadiazole, 2-(4-fluorophenylamino)-5-(2,4-dichlorophenyl)-1,3,4-thiadiazole, had ability to inhibit MCF-7 and MDA-MB-231 cells proliferation.  The IC50 values for the mentioned compds. ranged between 120 and 160 Î¼M (with respect to MCF-7 cells) and from 70 to 170 Î¼M (with respect to MDA-MB-231 cells).  It turned out, moreover, that compd. I is a human topoisomerase II (topoII) catalytic inhibitor whereas the two other compds. (i.e. and ) are capable of stabilizing DNA-topoII cleavage complex and thus are topoII poisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAL7s6ity1XrVg90H21EOLACvtfcHk0lgnXNzUgUgxTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKks73N&md5=50361e633f5b062395e1e94ae315ae6d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3109%2F14756366.2014.995179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756366.2014.995179%26sid%3Dliteratum%253Aachs%26aulast%3DPlech%26aufirst%3DT.%26aulast%3DKapro%25C5%2584%26aufirst%3DB.%26aulast%3DPaneth%26aufirst%3DA.%26aulast%3DWujec%26aufirst%3DM.%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DK.%26aulast%3DTrotsko%26aufirst%3DN.%26aulast%3DKu%25C5%259Bmierz%26aufirst%3DE.%26aulast%3DPaneth%26aufirst%3DP.%26atitle%3DSearch%2520for%2520human%2520DNA%2520topoisomerase%2520II%2520poisons%2520in%2520the%2520group%2520of%25202%252C5-disubstituted-1%252C3%252C4-thiadiazoles%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2015%26volume%3D30%26spage%3D1021%26epage%3D1026%26doi%3D10.3109%2F14756366.2014.995179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porwal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleinick, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dealwis, C. G.</span></span> <span> </span><span class="NLM_article-title">Identification of non-nucleoside human ribonucleotide reductase modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9498</span>â <span class="NLM_lpage">9509</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00929</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00929" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9498-9509&author=M.+F.+Ahmadauthor=S.+E.+Huffauthor=J.+Pinkauthor=I.+Alamauthor=A.+Zhangauthor=K.+Perryauthor=M.+E.+Harrisauthor=T.+Miskoauthor=S.+K.+Porwalauthor=N.+L.+Oleinickauthor=M.+Miyagiauthor=R.+Viswanathanauthor=C.+G.+Dealwis&title=Identification+of+non-nucleoside+human+ribonucleotide+reductase+modulators&doi=10.1021%2Facs.jmedchem.5b00929"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00929%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DM.%2BF.%26aulast%3DHuff%26aufirst%3DS.%2BE.%26aulast%3DPink%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DPerry%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DM.%2BE.%26aulast%3DMisko%26aufirst%3DT.%26aulast%3DPorwal%26aufirst%3DS.%2BK.%26aulast%3DOleinick%26aufirst%3DN.%2BL.%26aulast%3DMiyagi%26aufirst%3DM.%26aulast%3DViswanathan%26aufirst%3DR.%26aulast%3DDealwis%26aufirst%3DC.%2BG.%26atitle%3DIdentification%2520of%2520non-nucleoside%2520human%2520ribonucleotide%2520reductase%2520modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9498%26epage%3D9509%26doi%3D10.1021%2Facs.jmedchem.5b00929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gumienna-Kontecka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrkosz-Bulska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szebesczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowska, M.</span></span> <span> </span><span class="NLM_article-title">Iron chelating strategies in systemic metal overload, neurodegeneration and cancer</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3741</span>â <span class="NLM_lpage">3767</span>, <span class="refDoi">Â DOI: 10.2174/0929867321666140706143402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F0929867321666140706143402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25005181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=3741-3767&author=E.+Gumienna-Konteckaauthor=M.+Pyrkosz-Bulskaauthor=A.+Szebesczykauthor=M.+Ostrowska&title=Iron+chelating+strategies+in+systemic+metal+overload%2C+neurodegeneration+and+cancer&doi=10.2174%2F0929867321666140706143402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer</span></div><div class="casAuthors">Gumienna-Kontecka, Elzbieta; Pyrkosz-Bulska, Monika; Szebesczyk, Agnieszka; Ostrowska, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3741-3767</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Iron is a trace element required for normal performance of cellular processes.  Because both the deficiency and excess of this metal are dangerous, its absorption, distribution and accumulation must be tightly regulated.  Disturbances of iron homeostasis and an increase in its level may lead to overload and neurodegenerative diseases.  Phlebotomy was for a long time the only way of removing excess iron.  But since there are many possible disadvantages of this method, chelation therapy seems to be a logical approach to remove toxic levels of iron.  In clin. use, there are three drugs: desferrioxamine, deferiprone and deferasirox.  FBS0701, a novel oral iron chelator, is under clin. trials with very promising results.  Developing novel iron-binding chelators is an urgent matter, not only for systemic iron overload, but also for neurodegenerative disorders, such as Parkinson's disease.  Deferiprone is also used in clin. trials in Parkinson's disease.  In neurodegenerative disorders the main goal is not only to remove iron from brain tissues, but also its redistribution in system.  Few chelators are tested for their potential use in neurodegeneration, such as nonhalogeneted derivs. of clioquinol.  Such compds. gave promising results in animal models of neurodegenerative diseases.  Drugs of possible use in neurodegeneration must meet certain criteria.  Their development includes the improvement in blood brain barrier permeability, low toxicity and the ability to prevent lipid peroxidn.  One of the compds. satisfying these requirements is VK28.  In rat models it was able to protect neurons in very low doses without significantly changing the iron level in liver or serum.  Also iron chelators able to regulate activity of monoamine oxidase were tested.  Polyphenols and flavonoids are able to prevent lipid peroxidn. and demonstrate neuroprotective activity.  While cancer does not involve true iron overload, neoplastic cells have a higher iron requirement and are esp. prone to its depletion.  It was shown, that desferrioxamine and deferasirox are antiproliferative agents active in several types of cancer.  Very potent compds. with possible use as anticancer drugs are thiosemicarbazones.  They are able to inhibit ribonucleotide reductase, an enzyme involved in DNA synthesis.  Because the relationship between the development of overload / neurodegenerative disorders, or cancer, and iron are very complex, comprehension of the mechanisms involved in the regulation of iron homeostasis is a crucial factor in the development of new pharmacol. strategies based on iron chelation.  In view of various factors closely involved in pathogenesis of such diseases, designing multifunctional metal-chelators seems to be the most promising approach, but it requires a lot of effort.  In this perspective, the review summarizes systemic iron homeostasis, and in brain and cancer cells, iron dysregulation in neurodegenerative disease and possible chelation strategies in the treatment of metal systemic overload, neurodegeneration and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJpjzfymaGbVg90H21EOLACvtfcHk0lhQNze3-N32fQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3E&md5=a631de27f34e736bcc55bd82c5646180</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140706143402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140706143402%26sid%3Dliteratum%253Aachs%26aulast%3DGumienna-Kontecka%26aufirst%3DE.%26aulast%3DPyrkosz-Bulska%26aufirst%3DM.%26aulast%3DSzebesczyk%26aufirst%3DA.%26aulast%3DOstrowska%26aufirst%3DM.%26atitle%3DIron%2520chelating%2520strategies%2520in%2520systemic%2520metal%2520overload%252C%2520neurodegeneration%2520and%2520cancer%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D3741%26epage%3D3767%26doi%3D10.2174%2F0929867321666140706143402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafayette, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima Serafim, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neves, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BeltrÃ£o, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho JÃºnior, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, M. D.</span></span> <span> </span><span class="NLM_article-title">New spiro-acridines: DNA interaction, antiproliferative activity and inhibition of human DNA topoisomerases</span>. <i>Int. J. Biol. Macromol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">467</span>â <span class="NLM_lpage">475</span>, <span class="refDoi">Â DOI: 10.1016/j.ijbiomac.2016.07.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ijbiomac.2016.07.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27435006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A280%3ADC%252BC2s3isVOquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=467-475&author=S.+M.+Almeidaauthor=E.+A.+Lafayetteauthor=W.+L.+Silvaauthor=V.+Lima+Serafimauthor=T.+M.+Menezesauthor=J.+L.+Nevesauthor=A.+L.+Ruizauthor=J.+E.+Carvalhoauthor=R.+O.+Mouraauthor=E.+I.+Beltr%C3%A3oauthor=L.+B.+Carvalho+J%C3%BAniorauthor=M.+D.+Lima&title=New+spiro-acridines%3A+DNA+interaction%2C+antiproliferative+activity+and+inhibition+of+human+DNA+topoisomerases&doi=10.1016%2Fj.ijbiomac.2016.07.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">New spiro-acridines: DNA interaction, antiproliferative activity and inhibition of human DNA topoisomerases</span></div><div class="casAuthors">Almeida Sinara Monica Vitalino de; Lafayette Elizabeth Almeida; Silva Willams Leal; Lima Maria do Carmo Alves de; Lima Serafim Vanessa de; Menezes Thais Meira; Neves Jorge Luiz; Ruiz Ana Lucia Tasca Gois; Carvalho Joao Ernesto de; Moura Ricardo Olimpio de; Beltrao Eduardo Isidoro Carneiro; Carvalho Junior Luiz Bezerra de</div><div class="citationInfo"><span class="NLM_cas:title">International journal of biological macromolecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">467-475</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Two new spiro-acridines were synthesized by introducing cyano-N-acylhydrazone between the acridine and phenyl rings followed by spontaneous cyclization.  The final compounds (E)-1'-(benzylideneamino)-5'-oxo-1',5'-dihydro-10H-spiro[acridine-9,2'-pyrrole]-4'-carbonitrile (AMTAC-01) and (E)-1'-((4-methoxybenzylidene)amino)-5'-oxo-1',5'-dihydro-10H-spiro[acridine-9,2'-pyrrole]-4'-carbonitrile (AMTAC-02) were evaluated for their interactions with calf thymus DNA, antiproliferative and human topoisomerase I and IIÎ± inhibitory activities.  Both compounds presented ability to bind DNA.  The binding constant determined by UV-vis spectroscopy was found to be 10(4)M(-1).  Antiproliferative assay demonstrated that AMTAC-01 and AMTAC-02 were most active against prostate and melanoma tumor cell lines, respectively.  The compound did not present Topo I inhibitory activity.  However, both derivatives displayed topoisomerase IIÎ± inhibitory activity comparable to amsacrine, and AMTAC-02 was more potent than AMTAC-01 with methoxy substituent group on phenyl ring.  This study demonstrates that the new derivatives are promising molecules with topoisomerase IIÎ± inhibitory and antiproliferative activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS90vbHMeE_Ksve_zCu79I8fW6udTcc2eYUhPbI5fYaw7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3isVOquw%253D%253D&md5=14e854cb4d574c616e0df91ecbc501da</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ijbiomac.2016.07.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijbiomac.2016.07.057%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%26aufirst%3DS.%2BM.%26aulast%3DLafayette%26aufirst%3DE.%2BA.%26aulast%3DSilva%26aufirst%3DW.%2BL.%26aulast%3DLima%2BSerafim%26aufirst%3DV.%26aulast%3DMenezes%26aufirst%3DT.%2BM.%26aulast%3DNeves%26aufirst%3DJ.%2BL.%26aulast%3DRuiz%26aufirst%3DA.%2BL.%26aulast%3DCarvalho%26aufirst%3DJ.%2BE.%26aulast%3DMoura%26aufirst%3DR.%2BO.%26aulast%3DBeltr%25C3%25A3o%26aufirst%3DE.%2BI.%26aulast%3DCarvalho%2BJ%25C3%25BAnior%26aufirst%3DL.%2BB.%26aulast%3DLima%26aufirst%3DM.%2BD.%26atitle%3DNew%2520spiro-acridines%253A%2520DNA%2520interaction%252C%2520antiproliferative%2520activity%2520and%2520inhibition%2520of%2520human%2520DNA%2520topoisomerases%26jtitle%3DInt.%2520J.%2520Biol.%2520Macromol.%26date%3D2016%26volume%3D92%26spage%3D467%26epage%3D475%26doi%3D10.1016%2Fj.ijbiomac.2016.07.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jobson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilby, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span> <span> </span><span class="NLM_article-title">Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">889</span>â <span class="NLM_lpage">901</span>, <span class="refDoi">Â DOI: 10.1007/s00280-008-0812-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs00280-008-0812-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=18679685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlWhtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2009&pages=889-901&author=A.+G.+Jobsonauthor=E.+Willmoreauthor=M.+J.+Tilbyauthor=P.+Mistryauthor=P.+Charltonauthor=C.+A.+Austin&title=Effect+of+phenazine+compounds+XR11576+and+XR5944+on+DNA+topoisomerases&doi=10.1007%2Fs00280-008-0812-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases</span></div><div class="casAuthors">Jobson, Andrew G.; Willmore, Elaine; Tilby, Michael J.; Mistry, Prakash; Charlton, Peter; Austin, Caroline A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">889-901</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Previous in vitro cleavage data showed that XR11576 and XR5944 stabilized topoisomerase I and topoisomerase II complexes on DNA in a dose-dependent fashion.  However, some studies indicated a possible topoisomerase-independent mechanism of action for these drugs.  Methods: Three methods, the TARDIS assay, immunoband depletion and the K+/SDS assay have been used to assess topoisomerase complex formation induced by XR11576 or XR5944 in human leukemic K562 cells.  Results: TARDIS and immunoband depletion assays demonstrated that XR11576 and XR5944 induced complex formation for both topoisomerase I and topoisomerase II (alpha and beta) in a dose- and time-dependent manner, following exposure times of 24 and 48 h at concns. of 1 or 10 Î¼M.  The K+/SDS assay showed the formation of protein/DNA complexes after a 1 h exposure to 1 or 10 Î¼M XR11576.  Conclusion: Our data confirm that XR11576 or XR5944 can form topoisomerase complexes, after long periods of exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsTcFhvBTpqrVg90H21EOLACvtfcHk0ljmNks2oxZ6zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlWhtrg%253D&md5=bf3ae39fa7a616150f66b069bdd57ad5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00280-008-0812-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-008-0812-9%26sid%3Dliteratum%253Aachs%26aulast%3DJobson%26aufirst%3DA.%2BG.%26aulast%3DWillmore%26aufirst%3DE.%26aulast%3DTilby%26aufirst%3DM.%2BJ.%26aulast%3DMistry%26aufirst%3DP.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26atitle%3DEffect%2520of%2520phenazine%2520compounds%2520XR11576%2520and%2520XR5944%2520on%2520DNA%2520topoisomerases%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D63%26spage%3D889%26epage%3D901%26doi%3D10.1007%2Fs00280-008-0812-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of benzo[<i>a</i>]phenazine derivatives as a dual inhibitor of topoisomerase I and II</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3989</span>â <span class="NLM_lpage">4005</span>, <span class="refDoi">Â DOI: 10.1039/c3ob40325d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc3ob40325d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=23657605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVegu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=3989-4005&author=S.+T.+Zhuoauthor=C.+Y.+Liauthor=M.+H.+Huauthor=S.+B.+Chenauthor=P.+F.+Yaoauthor=S.+L.+Huangauthor=T.+M.+Ouauthor=J.+H.+Tanauthor=L.+K.+Anauthor=D.+Liauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Synthesis+and+biological+evaluation+of+benzo%5Ba%5Dphenazine+derivatives+as+a+dual+inhibitor+of+topoisomerase+I+and+II&doi=10.1039%2Fc3ob40325d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II</span></div><div class="casAuthors">Zhuo, Shi-Tian; Li, Chun-Yan; Hu, Ming-Hao; Chen, Shuo-Bin; Yao, Pei-Fen; Huang, Shi-Liang; Ou, Tian-Miao; Tan, Jia-Heng; An, Lin-Kun; Li, Ding; Gu, Lian-Quan; Huang, Zhi-Shu</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3989-4005</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Topoisomerases (Topo I and Topo II) are very important players in DNA replication, repair, and transcription, and are a promising class of antitumor target.  In the present study, a series of benzo[a]phenazine derivs. with alkylamino side chains at C-5 were designed, synthesized, and their biol. activities were evaluated.  Most of the derivs. showed good antiproliferative activity with a range of IC50 values of 1-10 Î¼M on the four cancer cell lines HeLa, A549, MCF-7, and HL-60.  Topoisomerase-mediated DNA relaxation assay results showed that the derivs. could effectively inhibit the activity of both Topo I and Topo II, and the structure-activity relationship studies indicated the importance of introducing an alkylamino side chain.  Further mechanism studies revealed that the compds. could stabilize the Topo I-DNA cleavage complexes and inhibit the ATPase activity of hTopo II, indicating that they are a rare class of dual topoisomerase inhibitors by acting as Topo I poisons and Topo II catalytic inhibitors.  Moreover, flow cytometric anal. and caspase-3/7 activation assay showed that this class of compds. could induce apoptosis of HL-60 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBGsS12CM8LVg90H21EOLACvtfcHk0ljmNks2oxZ6zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVegu70%253D&md5=60df539bb99986e58ce8e85a5d9e141e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1039%2Fc3ob40325d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob40325d%26sid%3Dliteratum%253Aachs%26aulast%3DZhuo%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DHu%26aufirst%3DM.%2BH.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DAn%26aufirst%3DL.%2BK.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520benzo%255Ba%255Dphenazine%2520derivatives%2520as%2520a%2520dual%2520inhibitor%2520of%2520topoisomerase%2520I%2520and%2520II%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D3989%26epage%3D4005%26doi%3D10.1039%2Fc3ob40325d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">553</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25599951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=540-553&author=B.+L.+Yaoauthor=Y.+W.+Maiauthor=S.+B.+Chenauthor=H.+T.+Xieauthor=P.+F.+Yaoauthor=T.+M.+Ouauthor=J.+H.+Tanauthor=H.+G.+Wangauthor=D.+Liauthor=S.+L.+Huangauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+7-alkylamino+substituted+benzo%5Ba%5Dphenazin+derivatives+as+dual+topoisomerase+I%2FII+inhibitors&doi=10.1016%2Fj.ejmech.2015.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors</span></div><div class="casAuthors">Yao, Bing-Lei; Mai, Yan-Wen; Chen, Shuo-Bin; Xie, Hua-Ting; Yao, Pei-Fen; Ou, Tian-Miao; Tan, Jia-Heng; Wang, Hong-Gen; Li, Ding; Huang, Shi-Liang; Gu, Lian-Quan; Huang, Zhi-Shu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-553</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of benzo[a]phenazine derivs. (e.g. I) bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerase inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549).  These compds. were found to be dual inhibitors of topoisomerase (Topo) I and Topo II, and exhibited excellent antiproliferative activity, in particular against HL-60 cells with submicromolar IC50 values.  Further mechanistic studies showed that this class of compds. acted as Topo I poisons by stabilizing the Topo I-DNA cleavage complexes and Topo II catalytic inhibitors by inhibiting the ATPase activity of hTopo II.  Mol. docking studies revealed the binding modes of these compds. for Topo I and Topo II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxjnEG72_zALVg90H21EOLACvtfcHk0ljmNks2oxZ6zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFeqsQ%253D%253D&md5=01e94691b81dc1185eb5109930b0d41d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BL.%26aulast%3DMai%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DXie%26aufirst%3DH.%2BT.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25207-alkylamino%2520substituted%2520benzo%255Ba%255Dphenazin%2520derivatives%2520as%2520dual%2520topoisomerase%2520I%252FII%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D540%26epage%3D553%26doi%3D10.1016%2Fj.ejmech.2015.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span> <span> </span><span class="NLM_article-title">A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1100</span>â <span class="NLM_lpage">1122</span>, <span class="refDoi">Â DOI: 10.1021/jm501023q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501023q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVChsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1100-1122&author=H.+B.+Kwonauthor=C.+Parkauthor=K.+H.+Jeonauthor=E.+Leeauthor=S.+E.+Parkauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=P.+Thapaauthor=R.+Karkiauthor=Y.+Naauthor=M.+S.+Parkauthor=S.+B.+Rhoauthor=E.+S.+Leeauthor=Y.+Kwon&title=A+series+of+novel+terpyridine-skeleton+molecule+derivants+inhibit+tumor+growth+and+metastasis+by+targeting+topoisomerases&doi=10.1021%2Fjm501023q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Novel Terpyridine-Skeleton Molecule Derivants Inhibit Tumor Growth and Metastasis by Targeting Topoisomerases</span></div><div class="casAuthors">Kwon, Han-Byeol; Park, Chanmi; Jeon, Kyung-Hwa; Lee, Eunyoung; Park, So-Eun; Jun, Kyu-Yeon; Kadayat, Tara Man; Thapa, Pritam; Karki, Radha; Na, Younghwa; Park, Mi Sun; Rho, Seung Bae; Lee, Eung-Seok; Kwon, Youngjoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1100-1122</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel terpyridine-skeleton mols. contg. conformational rigidity, 14 contg. benzo[4,5]furo[3,2-b]pyridine core and 15 comprising chromeno[4,3-b]pyridine core, were synthesized, and their biol. activities were evaluated. 3-(4-Phenylbenzo[4,5]furo[3,2-b]pyridin-2-yl)phenol (8, I) was detd. to be a nonintercalative topo I and II dual catalytic inhibitor and 3-(4-phenylchromeno[4,3-b]pyridine-2-yl)phenol (22, II) was detd. to be a nonintercalative topo IIÎ± specific catalytic inhibitor by various assays.  These two catalytic inhibitors induced apoptosis in addn. to G1 arrest in T47D human breast cancer cells with much less DNA toxicity than etoposide.  Compds. 8 and 22 significantly inhibited tumor growth in HCT15 s.c. implanted xenografted mice.  The modification of compds. 8 and 22 with the introduction of a methoxy instead of a hydroxy group enhanced endogenous topo inhibitory activity, metabolic stability in diverse types of liver microsomes and improved pharmacokinetic parameters in rat plasma such as augmentation of bioavailability (41.3% and 33.2% for 2-(3-methoxyphenyl)-4-phenylbenzofuro[3,2-b]pyridine and 3-(4-phenylchromeno[4,3-b]pyridine-2-yl)methoxybenzene, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJTC8jRnzzdLVg90H21EOLACvtfcHk0ljkszVNUDiJcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVChsLw%253D&md5=fa7655031fde52c3ca4eee622c3be203</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm501023q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501023q%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DH.%2BB.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJeon%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DS.%2BE.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DKarki%26aufirst%3DR.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DM.%2BS.%26aulast%3DRho%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DKwon%26aufirst%3DY.%26atitle%3DA%2520series%2520of%2520novel%2520terpyridine-skeleton%2520molecule%2520derivants%2520inhibit%2520tumor%2520growth%2520and%2520metastasis%2520by%2520targeting%2520topoisomerases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1100%26epage%3D1122%26doi%3D10.1021%2Fjm501023q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6454</span>â <span class="NLM_lpage">6466</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.08.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6454-6466&author=P.+Thapaauthor=K.+Y.+Junauthor=T.+M.+Kadayatauthor=C.+Parkauthor=Z.+Zhengauthor=T.+B.+Thapa+Magarauthor=G.+Bistauthor=A.+Shresthaauthor=Y.+Naauthor=Y.+Kwonauthor=E.+S.+Lee&title=Design+and+synthesis+of+conformationally+constrained+hydroxylated+4-phenyl-2-aryl+chromenopyridines+as+novel+and+selective+topoisomerase+II-targeted+antiproliferative+agents&doi=10.1016%2Fj.bmc.2015.08.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DThapa%2BMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DShrestha%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520conformationally%2520constrained%2520hydroxylated%25204-phenyl-2-aryl%2520chromenopyridines%2520as%2520novel%2520and%2520selective%2520topoisomerase%2520II-targeted%2520antiproliferative%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6454%26epage%3D6466%26doi%3D10.1016%2Fj.bmc.2015.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadayat, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magar, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bist, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel 2,4-diaryl-5<i>H</i>-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">160</span>â <span class="NLM_lpage">173</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2014.11.010" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=160-173&author=T.+M.+Kadayatauthor=C.+Parkauthor=K.+Y.+Junauthor=T.+B.+Magarauthor=G.+Bistauthor=H.+Y.+Yooauthor=Y.+Kwonauthor=E.+S.+Lee&title=Design+and+synthesis+of+novel+2%2C4-diaryl-5H-indeno%5B1%2C2-b%5Dpyridine+derivatives%2C+and+their+evaluation+of+topoisomerase+inhibitory+activity+and+cytotoxicity&doi=10.1016%2Fj.bmc.2014.11.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DKadayat%26aufirst%3DT.%2BM.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DMagar%26aufirst%3DT.%2BB.%26aulast%3DBist%26aufirst%3DG.%26aulast%3DYoo%26aufirst%3DH.%2BY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%25202%252C4-diaryl-5H-indeno%255B1%252C2-b%255Dpyridine%2520derivatives%252C%2520and%2520their%2520evaluation%2520of%2520topoisomerase%2520inhibitory%2520activity%2520and%2520cytotoxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D160%26epage%3D173%26doi%3D10.1016%2Fj.bmc.2014.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallqvist, A.</span></span> <span> </span><span class="NLM_article-title">Classification of scaffold hopping approaches</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">310</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2011.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.drudis.2011.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=22056715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=310-324&author=H.+Sunauthor=G.+Tawaauthor=A.+Wallqvist&title=Classification+of+scaffold+hopping+approaches&doi=10.1016%2Fj.drudis.2011.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of scaffold-hopping approaches</span></div><div class="casAuthors">Sun, Hongmao; Tawa, Gregory; Wallqvist, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">310-324</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The general goal of drug discovery is to identify novel compds. that are active against a preselected biol. target with acceptable pharmacol. properties defined by marketed drugs.  Scaffold hopping has been widely applied by medicinal chemists to discover equipotent compds. with novel backbones that have improved properties.  In this article we classify scaffold hopping into four major categories, namely heterocycle replacements, ring opening or closure, peptidomimetics and topol.-based hopping.  We review the structural diversity of original and final scaffolds with respect to each category.  We discuss the advantages and limitations of small, medium and large-step scaffold hopping.  Finally, we summarize software that is frequently used to facilitate different kinds of scaffold-hopping methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAONaJ8Be0x7Vg90H21EOLACvtfcHk0liwzSVb0DgozQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D&md5=5f1143cc255c81b88ea4f83ac9f8efc6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DWallqvist%26aufirst%3DA.%26atitle%3DClassification%2520of%2520scaffold%2520hopping%2520approaches%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D310%26epage%3D324%26doi%3D10.1016%2Fj.drudis.2011.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2974</span>â <span class="NLM_lpage">2978</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2013.03.037" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2974-2978&author=Y.+Zhouauthor=X.+Xuauthor=Y.+Sunauthor=H.+Wangauthor=H.+Sunauthor=Q.+You&title=Synthesis%2C+cytotoxicity+and+topoisomerase+II+inhibitory+activity+of+lomefloxacin+derivatives&doi=10.1016%2Fj.bmcl.2013.03.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYou%26aufirst%3DQ.%26atitle%3DSynthesis%252C%2520cytotoxicity%2520and%2520topoisomerase%2520II%2520inhibitory%2520activity%2520of%2520lomefloxacin%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2974%26epage%3D2978%26doi%3D10.1016%2Fj.bmcl.2013.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaquiquzzaman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasneem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. M.</span></span> <span> </span><span class="NLM_article-title">Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">487</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26310894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCntrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=487-529&author=M.+Shaquiquzzamanauthor=G.+Vermaauthor=A.+Marellaauthor=M.+Akhterauthor=W.+Akhtarauthor=M.+F.+Khanauthor=S.+Tasneemauthor=M.+M.+Alam&title=Piperazine+scaffold%3A+A+remarkable+tool+in+generation+of+diverse+pharmacological+agents&doi=10.1016%2Fj.ejmech.2015.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents</span></div><div class="casAuthors">Shaquiquzzaman, Mohammad; Verma, Garima; Marella, Akranth; Akhter, Mymoona; Akhtar, Wasim; Khan, Mohemmed Faraz; Tasneem, Sharba; Alam, Mohammad Mumtaz</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">487-529</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Piperazine is one of the most sought heterocyclics for the development of new drug candidates.  This ring can be traced in a no. of well established, com. available drugs.  Wide array of pharmacol. activities exhibited by piperazine derivs. have made them indispensable anchors for the development of novel therapeutic agents.  The review herein highlights the therapeutic significance of piperazine derivs.  Various therapeutically active piperazine derivs. developed by several chemists are reported here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm2iQJFfMCIbVg90H21EOLACvtfcHk0liwzSVb0DgozQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCntrjP&md5=67bf76f4ae4706a7647c5daff4ca6cd5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DShaquiquzzaman%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DG.%26aulast%3DMarella%26aufirst%3DA.%26aulast%3DAkhter%26aufirst%3DM.%26aulast%3DAkhtar%26aufirst%3DW.%26aulast%3DKhan%26aufirst%3DM.%2BF.%26aulast%3DTasneem%26aufirst%3DS.%26aulast%3DAlam%26aufirst%3DM.%2BM.%26atitle%3DPiperazine%2520scaffold%253A%2520A%2520remarkable%2520tool%2520in%2520generation%2520of%2520diverse%2520pharmacological%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D487%26epage%3D529%26doi%3D10.1016%2Fj.ejmech.2015.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.07.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26291037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=277-287&author=H.+Haoauthor=W.+Chenauthor=J.+Zhuauthor=C.+Luauthor=Y.+Shen&title=Design+and+synthesis+of+2-phenylnaphthalenoids+and+2-phenylbenzofuranoids+as+DNA+topoisomerase+inhibitors+and+antitumor+agents&doi=10.1016%2Fj.ejmech.2015.07.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents</span></div><div class="casAuthors">Hao, Huilin; Chen, Wang; Zhu, Jing; Lu, Chunhua; Shen, Yuemao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eight 2-phenylnaphthalenoids (2PNs) and twenty four 2-phenylbenzofuranoids (2PBFs) were successfully designed, synthesized and their antiproliferative and in vitro DNA topoisomerase inhibitory activities were evaluated.  Nine compds. (four 2PNs and five 2PBFs) showed either TopoI or TopoIIÎ± inhibitory activities.  Six compds. (four 2PNs and two 2PBFs) exhibited potent cytotoxicity with IC50 values for 72 h exposure ranging from 0.3 to above 20 Î¼M against MDA-MB-231, MDA-MB-435, HepG2 and PC3 cell lines.  The two 2PBFs displayed comparable and even better antiproliferative as well as TopoIIÎ± inhibitory activities than 2PNs.  Interestingly, the active 2PBFs displayed different mechanisms of TopoIIÎ± inhibition from that of 2PNs, suggesting that the chromophore scaffold replacement may result in a change of the binding site of inhibitors to TopoIIÎ±.  Furthermore, the mechanisms of antiproliferation on MDA-MB-231 cells indicate that compds. I and II are promising for further development of anticancer agents.  The results of this study reveal that the evolutionary strategy of medicinal chem. through scaffold hopping is a promising strategy for structure optimization of TopoIIÎ± inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptY9xrEHooKbVg90H21EOLACvtfcHk0lh0mKsfV1zu2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegtb%252FO&md5=1ab3a31789c3ac2b7d632d379bb48992</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-phenylnaphthalenoids%2520and%25202-phenylbenzofuranoids%2520as%2520DNA%2520topoisomerase%2520inhibitors%2520and%2520antitumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D102%26spage%3D277%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Aziz, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A. F.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: an ATP-competitive human topoisomerase IIÎ± catalytic inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1898</span>â <span class="NLM_lpage">1908</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2016.03.017" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1898-1908&author=P.+Ahmadauthor=H.+Wooauthor=K.+Y.+Junauthor=A.+A.+Kadiauthor=H.+A.+Abdel-Azizauthor=Y.+Kwonauthor=A.+F.+Rahman&title=Design%2C+synthesis%2C+topoisomerase+I+%26+II+inhibitory+activity%2C+antiproliferative+activity%2C+and+structure-activity+relationship+study+of+pyrazoline+derivatives%3A+an+ATP-competitive+human+topoisomerase+II%CE%B1+catalytic+inhibitor&doi=10.1016%2Fj.bmc.2016.03.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DP.%26aulast%3DWoo%26aufirst%3DH.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKadi%26aufirst%3DA.%2BA.%26aulast%3DAbdel-Aziz%26aufirst%3DH.%2BA.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DRahman%26aufirst%3DA.%2BF.%26atitle%3DDesign%252C%2520synthesis%252C%2520topoisomerase%2520I%2520%2526%2520II%2520inhibitory%2520activity%252C%2520antiproliferative%2520activity%252C%2520and%2520structure-activity%2520relationship%2520study%2520of%2520pyrazoline%2520derivatives%253A%2520an%2520ATP-competitive%2520human%2520topoisomerase%2520II%25CE%25B1%2520catalytic%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1898%26epage%3D1908%26doi%3D10.1016%2Fj.bmc.2016.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and mechanism studies of 1,3-benzoazolyl substituted pyrrolo[2,3-b]pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">238</span>â <span class="NLM_lpage">252</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01284</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01284" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=238-252&author=P.+H.+Liauthor=P.+Zengauthor=S.+B.+Chenauthor=P.+F.+Yaoauthor=Y.+W.+Maiauthor=J.+H.+Tanauthor=T.+M.+Ouauthor=S.+L.+Huangauthor=D.+Liauthor=L.+Q.+Guauthor=Z.+S.+Huang&title=Synthesis+and+mechanism+studies+of+1%2C3-benzoazolyl+substituted+pyrrolo%5B2%2C3-b%5Dpyrazine+derivatives+as+nonintercalative+topoisomerase+II+catalytic+inhibitors&doi=10.1021%2Facs.jmedchem.5b01284"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01284%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%2BH.%26aulast%3DZeng%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DS.%2BB.%26aulast%3DYao%26aufirst%3DP.%2BF.%26aulast%3DMai%26aufirst%3DY.%2BW.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26atitle%3DSynthesis%2520and%2520mechanism%2520studies%2520of%25201%252C3-benzoazolyl%2520substituted%2520pyrrolo%255B2%252C3-b%255Dpyrazine%2520derivatives%2520as%2520nonintercalative%2520topoisomerase%2520II%2520catalytic%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D238%26epage%3D252%26doi%3D10.1021%2Facs.jmedchem.5b01284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagotto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianoncelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capranico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribaudo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, M.</span></span> <span> </span><span class="NLM_article-title">Novel ametantrone-amsacrine related hybrids as topoisomerase IIÎ² poisons and cytotoxic agents</span>. <i>Arch. Pharm. (Weinheim, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">728</span>â <span class="NLM_lpage">737</span>, <span class="refDoi">Â DOI: 10.1002/ardp.201400111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fardp.201400111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25042690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKjs73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2014&pages=728-737&author=G.+Zagottoauthor=A.+Gianoncelliauthor=C.+Sissiauthor=C.+Marzanoauthor=V.+Gandinauthor=R.+Pasqualeauthor=G.+Capranicoauthor=G.+Ribaudoauthor=M.+Palumbo&title=Novel+ametantrone-amsacrine+related+hybrids+as+topoisomerase+II%CE%B2+poisons+and+cytotoxic+agents&doi=10.1002%2Fardp.201400111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Ametantrone-Amsacrine Related Hybrids as Topoisomerase IIÎ² Poisons and Cytotoxic Agents</span></div><div class="casAuthors">Zagotto, Giuseppe; Gianoncelli, Alessandra; Sissi, Claudia; Marzano, Cristina; Gandin, Valentina; Pasquale, Riccardo; Capranico, Giovanni; Ribaudo, Giovanni; Palumbo, Manlio</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">728-737</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The precise definition of the structural requirements for effective topoisomerase II poisoning by drug mols. is still an elusive issue.  In the attempt to better define a pharmacophoric pattern, we prepd. several conjugates combining the chem. features of two well-known topoisomerase II poisons, amsacrine and ametantrone.  Indeed, an appropriate fusion geometry, which entails the anthracenedione moiety of ametantrone appropriately connected to the methanesulfonamidoaniline side chain of amsacrine, elicits DNA-intercalating properties, the capacity to inhibit the human topoisomerase IIÎ² isoform, and cytotoxic activity resembling that of the parent compds.  In addn., the properties of the lateral groups linked to the anthracenedione group play an important role in modulating DNA binding and cell cytotoxicity.  Among the compds. tested, 10, 11, and 19 appear to be promising for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdO_Zu_Qe9LVg90H21EOLACvtfcHk0lh0mKsfV1zu2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKjs73F&md5=03266374d96d584d257a980ed3e85868</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fardp.201400111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201400111%26sid%3Dliteratum%253Aachs%26aulast%3DZagotto%26aufirst%3DG.%26aulast%3DGianoncelli%26aufirst%3DA.%26aulast%3DSissi%26aufirst%3DC.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DPasquale%26aufirst%3DR.%26aulast%3DCapranico%26aufirst%3DG.%26aulast%3DRibaudo%26aufirst%3DG.%26aulast%3DPalumbo%26aufirst%3DM.%26atitle%3DNovel%2520ametantrone-amsacrine%2520related%2520hybrids%2520as%2520topoisomerase%2520II%25CE%25B2%2520poisons%2520and%2520cytotoxic%2520agents%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2014%26volume%3D347%26spage%3D728%26epage%3D737%26doi%3D10.1002%2Fardp.201400111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">59</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2016.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2016.03.066" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=59-70&author=W.+Zhangauthor=B.+Zhangauthor=W.+Zhangauthor=T.+Yangauthor=N.+Wangauthor=C.+Gaoauthor=C.+Tanauthor=H.+Liuauthor=Y.+Jiang&title=Synthesis+and+antiproliferative+activity+of+9-benzylamino-6-chloro-2-methoxy-acridine+derivatives+as+potent+DNA-binding+ligands+and+topoisomerase+II+inhibitors&doi=10.1016%2Fj.ejmech.2016.03.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%25209-benzylamino-6-chloro-2-methoxy-acridine%2520derivatives%2520as%2520potent%2520DNA-binding%2520ligands%2520and%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D116%26spage%3D59%26epage%3D70%26doi%3D10.1016%2Fj.ejmech.2016.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and biological evaluation of potential prodrugs related to the experimental anticancer agent indotecan (LMP400)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4890</span>â <span class="NLM_lpage">4899</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00220</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00220" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1Cnsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4890-4899&author=P.+C.+Lvauthor=M.+S.+Elsayedauthor=K.+Agamaauthor=C.+Marchandauthor=Y.+Pommierauthor=M.+Cushman&title=Design%2C+Synthesis%2C+and+biological+evaluation+of+potential+prodrugs+related+to+the+experimental+anticancer+agent+indotecan+%28LMP400%29&doi=10.1021%2Facs.jmedchem.6b00220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400)</span></div><div class="casAuthors">Lv, Peng-Cheng; Elsayed, Mohamed S. A.; Agama, Keli; Marchand, Christophe; Pommier, Yves; Cushman, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4890-4899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of anticancer agents with two compds. in clin. trials.  Recent metab. studies of indotecan (LMP400) led to the discovery of the biol. active 2-hydroxylated analog and 3-hydroxylated metabolite, thus providing strategically placed functional groups for the prepn. of a variety of potential ester prodrugs of these two compds.  The current study details the design and synthesis of two series of indenoisoquinoline prodrugs, and it also reveals how substituents on the O-2 and O-3 positions of the A ring, which are next to the cleaved DNA strand in the drug-DNA-Top1 ternary cleavage complex, affect Top1 inhibitory activity and cytotoxicity.  Many of the indenoisoquinoline prodrugs were very potent antiproliferative agents with GI50 values below 10 nM in a variety of human cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraxUKLR9FaWLVg90H21EOLACvtfcHk0ljyG4UG0CmjfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1Cnsrg%253D&md5=a1349cde99df9cacac6ded83f5b1e050</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00220%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DP.%2BC.%26aulast%3DElsayed%26aufirst%3DM.%2BS.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DMarchand%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DCushman%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520potential%2520prodrugs%2520related%2520to%2520the%2520experimental%2520anticancer%2520agent%2520indotecan%2520%2528LMP400%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4890%26epage%3D4899%26doi%3D10.1021%2Facs.jmedchem.6b00220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham
Thi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Nhat, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo Hanh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luc Quang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham The, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang Thi, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang Thi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nguyen, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and cytotoxic evaluation of novel indenoisoquinoline-substituted triazole hybrids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3652</span>â <span class="NLM_lpage">3657</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2016.05.092" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3652-3657&author=T.+Pham%0AThiauthor=T.+G.+Le+Nhatauthor=T.+Ngo+Hanhauthor=T.+Luc+Quangauthor=C.+Pham+Theauthor=T.+A.+Dang+Thiauthor=H.+T.+Nguyenauthor=T.+H.+Nguyenauthor=P.+Hoang+Thiauthor=T.+Van+Nguyen&title=Synthesis+and+cytotoxic+evaluation+of+novel+indenoisoquinoline-substituted+triazole+hybrids&doi=10.1016%2Fj.bmcl.2016.05.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DPham%2BThi%26aufirst%3DT.%26aulast%3DLe%2BNhat%26aufirst%3DT.%2BG.%26aulast%3DNgo%2BHanh%26aufirst%3DT.%26aulast%3DLuc%2BQuang%26aufirst%3DT.%26aulast%3DPham%2BThe%26aufirst%3DC.%26aulast%3DDang%2BThi%26aufirst%3DT.%2BA.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DNguyen%26aufirst%3DT.%2BH.%26aulast%3DHoang%2BThi%26aufirst%3DP.%26aulast%3DVan%2BNguyen%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520cytotoxic%2520evaluation%2520of%2520novel%2520indenoisoquinoline-substituted%2520triazole%2520hybrids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3652%26epage%3D3657%26doi%3D10.1016%2Fj.bmcl.2016.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VessiÃ¨res, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Top, S.</span></span> <span> </span><span class="NLM_article-title">Ferrocifen type anti cancer drugs</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">8802</span>â <span class="NLM_lpage">8817</span>, <span class="refDoi">Â DOI: 10.1039/C5CS00486A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC5CS00486A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26486993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yktbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=8802-8817&author=G.+Jaouenauthor=A.+Vessi%C3%A8resauthor=S.+Top&title=Ferrocifen+type+anti+cancer+drugs&doi=10.1039%2FC5CS00486A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ferrocifen type anti cancer drugs</span></div><div class="casAuthors">Jaouen, Gerard; Vessieres, Anne; Top, Siden</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8802-8817</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Despite current developments in therapeutics focusing on biotechnol.-oriented species, the unflagging utility of small mols. or peptides in medicine is still producing strong results.  In 2014 for example, of the 41 new medicines authorized for sale, 33 belonged to the category of small mols., while in 2013 they represented 24 of 27, according to the FDA.  This can be explained as the result of recent forays into new or long-neglected areas of chem.  Medicinal organometallic chem. can provide us with an antimalarial against resistant parasitic strains, as attested by the phase II clin. development of ferroquine, with a new framework for conceptual advances based on three-dimensional space-filling, and with redox or indeed catalytic intracellular properties.  In this context, bioferrocene species with antiproliferative potential have for several years been the subject of sustained effort, based on some initial successes and on the nature of ferrocene as a stable arom., with low toxicity, low cost, and possessing reversible redox properties.  We show here the different antitumoral approaches offered by ferrocifen derivs., originally simple derivs. of tamoxifen, which over the course of their development have proved to possess remarkable structural and mechanistic diversity.  These entities act via various targets, some of which have been identified, that are triggered according to the concn. of the products.  They also act according to the nature of the cancer cells and their functionality, by mechanistic pathways that can operate either synergistically or not, in successive, concomitant or sequential ways, depending for example on newly identified signaling pathways inducing senescence or apoptosis.  Here we present a first attempt to rationalize the behavior of these entities with various anticancer targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaB6CyYyApRrVg90H21EOLACvtfcHk0ljyG4UG0CmjfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yktbnM&md5=c2a2e22576f6c8ef5dda04ffe9e28ead</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1039%2FC5CS00486A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00486A%26sid%3Dliteratum%253Aachs%26aulast%3DJaouen%26aufirst%3DG.%26aulast%3DVessi%25C3%25A8res%26aufirst%3DA.%26aulast%3DTop%26aufirst%3DS.%26atitle%3DFerrocifen%2520type%2520anti%2520cancer%2520drugs%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D8802%26epage%3D8817%26doi%3D10.1039%2FC5CS00486A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigeon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Top, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span> <span> </span><span class="NLM_article-title">Organometallic antitumor compounds: ferrocifens as precursors to quinone methides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">10230</span>â <span class="NLM_lpage">10233</span>, <span class="refDoi">Â DOI: 10.1002/anie.201503048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fanie.201503048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOrt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=10230-10233&author=Y.+Wangauthor=P.+Pigeonauthor=S.+Topauthor=M.+J.+McGlincheyauthor=G.+Jaouen&title=Organometallic+antitumor+compounds%3A+ferrocifens+as+precursors+to+quinone+methides&doi=10.1002%2Fanie.201503048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Organometallic Antitumor Compounds: Ferrocifens as Precursors to Quinone Methides</span></div><div class="casAuthors">Wang, Yong; Pigeon, Pascal; Top, Siden; McGlinchey, Michael J.; Jaouen, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10230-10233</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The synthesis and chem. oxidn. profile of a new generation of ferrocifen derivs. with strong antiproliferative behavior in vitro is reported.  In particular, the hydroxypropyl deriv. HO(CH2)3C(Fc):C(C6H4OH)2 (3b) exhibited exceptional antiproliferative activity against the cancer cell lines HepG2 and MDA-MB-231 TNBC, with IC50 values of 0.07 and 0.11 Î¼M, resp.  Chem. oxidn. of 3b yielded an unprecedented tetrahydrofuran-substituted quinone methide (QM) via internal cyclization of the hydroxyalkyl chain, whereas the corresponding alkyl analog CH3CH2-C(Fc):C(C6H4OH)2 merely formed a vinyl QM.  The ferrocenyl group in 3b plays a key role, not only as an intramol. reversible redox "antenna", but also as a stabilized carbenium ion "modulator".  The presence of the oxygen heterocycle in 3b-QM enhances its stability and leads to a unique chem. oxidn. profile, thus revealing crucial clues for deciphering its mechanism of action in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvX5qj__CgC7Vg90H21EOLACvtfcHk0lhkVxhB-p_pFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOrt7jN&md5=8a5b8dd132d5152de45177aec43576c5</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fanie.201503048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201503048%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPigeon%26aufirst%3DP.%26aulast%3DTop%26aufirst%3DS.%26aulast%3DMcGlinchey%26aufirst%3DM.%2BJ.%26aulast%3DJaouen%26aufirst%3DG.%26atitle%3DOrganometallic%2520antitumor%2520compounds%253A%2520ferrocifens%2520as%2520precursors%2520to%2520quinone%2520methides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D10230%26epage%3D10233%26doi%3D10.1002%2Fanie.201503048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Top, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansette, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigeon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VessiÃ¨res, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span> <span> </span><span class="NLM_article-title">Ferrocenyl quinone methide-thiol adducts as new antiproliferative agents: synthesis, metabolic formation from ferrociphenols, and oxidative transformation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10431</span>â <span class="NLM_lpage">10434</span>, <span class="refDoi">Â DOI: 10.1002/anie.201603931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fanie.201603931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFCgtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10431-10434&author=Y.+Wangauthor=M.+A.+Richardauthor=S.+Topauthor=P.+M.+Dansetteauthor=P.+Pigeonauthor=A.+Vessi%C3%A8resauthor=D.+Mansuyauthor=G.+Jaouen&title=Ferrocenyl+quinone+methide-thiol+adducts+as+new+antiproliferative+agents%3A+synthesis%2C+metabolic+formation+from+ferrociphenols%2C+and+oxidative+transformation&doi=10.1002%2Fanie.201603931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Ferrocenyl quinone methide-thiol adducts as new antiproliferative agents: synthesis, metabolic formation from ferrociphenols, and oxidative transformation</span></div><div class="casAuthors">Wang, Yong; Richard, Marie-Aude; Top, Siden; Dansette, Patrick M.; Pigeon, Pascal; Vessieres, Anne; Mansuy, Daniel; Jaouen, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10431-10434</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ferrociphenols (FCs) and their oxidized, electrophilic quinone methide metabolites I [FC-QMs, Fc = ferrocenyl; R1 = H, OH, O(CH2)3NMe2] are organometallic compds. related to tamoxifen that exhibit strong antiproliferative properties.  To evaluate the reactivity of FC-QMs toward cellular nucleophiles, we studied their reaction with selected thiols.  A series of new compds. resulting from the addn. of the nucleophiles RSH, the FC-SR adducts II (RSH = GSH, NACM, ME), were thus synthesized and completely characterized.  Such conjugates are formed upon metab. of FCs by liver microsomes in the presence of NADPH and thiols.  Some of the FC-SR adducts exhibit antiproliferative properties comparable to those of their FC precursors.  Under oxidizing conditions they either revert to their FC-QM precursors or transform into new quinone methides (QMs) contg. the SR moiety, FC-SR-QM.  These results provide interesting data about the reactivity and mechanism of antiproliferative effects of FCs, and also open the way to a new series of organometallic antitumor compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN6sdabCfxmLVg90H21EOLACvtfcHk0lhkVxhB-p_pFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFCgtL4%253D&md5=cf1f7746f41d6d64820a30aecf6da53b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603931%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRichard%26aufirst%3DM.%2BA.%26aulast%3DTop%26aufirst%3DS.%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DPigeon%26aufirst%3DP.%26aulast%3DVessi%25C3%25A8res%26aufirst%3DA.%26aulast%3DMansuy%26aufirst%3DD.%26aulast%3DJaouen%26aufirst%3DG.%26atitle%3DFerrocenyl%2520quinone%2520methide-thiol%2520adducts%2520as%2520new%2520antiproliferative%2520agents%253A%2520synthesis%252C%2520metabolic%2520formation%2520from%2520ferrociphenols%252C%2520and%2520oxidative%2520transformation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10431%26epage%3D10434%26doi%3D10.1002%2Fanie.201603931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scalcon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciofini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de JÃ©sÃºs
CÃ¡zares-Marinero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigeon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaouen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VessiÃ¨res, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigobello, M. P.</span></span> <span> </span><span class="NLM_article-title">Enzymatic oxidation of ansa-ferrocifen leads to strong and selective thioredoxin reductase inhibition</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">146</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2016.08.005" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=146-151&author=V.+Scalconauthor=A.+Cittaauthor=A.+Foldaauthor=A.+Bindoliauthor=M.+Salmainauthor=I.+Ciofiniauthor=S.+Blanchardauthor=J.+de+J%C3%A9s%C3%BAs%0AC%C3%A1zares-Marineroauthor=Y.+Wangauthor=P.+Pigeonauthor=G.+Jaouenauthor=A.+Vessi%C3%A8resauthor=M.+P.+Rigobello&title=Enzymatic+oxidation+of+ansa-ferrocifen+leads+to+strong+and+selective+thioredoxin+reductase+inhibition&doi=10.1016%2Fj.jinorgbio.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DScalcon%26aufirst%3DV.%26aulast%3DCitta%26aufirst%3DA.%26aulast%3DFolda%26aufirst%3DA.%26aulast%3DBindoli%26aufirst%3DA.%26aulast%3DSalmain%26aufirst%3DM.%26aulast%3DCiofini%26aufirst%3DI.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3Dde%2BJ%25C3%25A9s%25C3%25BAs%2BC%25C3%25A1zares-Marinero%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPigeon%26aufirst%3DP.%26aulast%3DJaouen%26aufirst%3DG.%26aulast%3DVessi%25C3%25A8res%26aufirst%3DA.%26aulast%3DRigobello%26aufirst%3DM.%2BP.%26atitle%3DEnzymatic%2520oxidation%2520of%2520ansa-ferrocifen%2520leads%2520to%2520strong%2520and%2520selective%2520thioredoxin%2520reductase%2520inhibition%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2016%26volume%3D165%26spage%3D146%26epage%3D151%26doi%3D10.1016%2Fj.jinorgbio.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wambang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schifano-Faux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aillerie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldeyrou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bal-Mahieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndifon, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meignan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansiaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©linski, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">651</span>â <span class="NLM_lpage">660</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.12.033" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=651-660&author=N.+Wambangauthor=N.+Schifano-Fauxauthor=A.+Aillerieauthor=B.+Baldeyrouauthor=C.+Jacquetauthor=C.+Bal-Mahieuauthor=T.+Bousquetauthor=S.+Pellegriniauthor=P.+T.+Ndifonauthor=S.+Meignanauthor=J.+F.+Goossensauthor=A.+Lansiauxauthor=L.+P%C3%A9linski&title=Synthesis+and+biological+activity+of+ferrocenyl+indeno%5B1%2C2-c%5Disoquinolines+as+topoisomerase+II+inhibitors&doi=10.1016%2Fj.bmc.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DWambang%26aufirst%3DN.%26aulast%3DSchifano-Faux%26aufirst%3DN.%26aulast%3DAillerie%26aufirst%3DA.%26aulast%3DBaldeyrou%26aufirst%3DB.%26aulast%3DJacquet%26aufirst%3DC.%26aulast%3DBal-Mahieu%26aufirst%3DC.%26aulast%3DBousquet%26aufirst%3DT.%26aulast%3DPellegrini%26aufirst%3DS.%26aulast%3DNdifon%26aufirst%3DP.%2BT.%26aulast%3DMeignan%26aufirst%3DS.%26aulast%3DGoossens%26aufirst%3DJ.%2BF.%26aulast%3DLansiaux%26aufirst%3DA.%26aulast%3DP%25C3%25A9linski%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520ferrocenyl%2520indeno%255B1%252C2-c%255Disoquinolines%2520as%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D651%26epage%3D660%26doi%3D10.1016%2Fj.bmc.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Oliveira Figueiredo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdomo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcez, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fatima
Cepa Matos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcez, W. S.</span></span> <span> </span><span class="NLM_article-title">Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIÎ± by its cytotoxic Î²-carboline alkaloids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1358</span>â <span class="NLM_lpage">1361</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2014.01.039" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1358-1361&author=P.+de%0AOliveira+Figueiredoauthor=R.+T.+Perdomoauthor=F.+R.+Garcezauthor=M.+de+Fatima%0ACepa+Matosauthor=J.+E.+de+Carvalhoauthor=W.+S.+Garcez&title=Further+constituents+of+Galianthe+thalictroides+%28Rubiaceae%29+and+inhibition+of+DNA+topoisomerases+I+and+II%CE%B1+by+its+cytotoxic+%CE%B2-carboline+alkaloids&doi=10.1016%2Fj.bmcl.2014.01.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.01.039%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%2BFigueiredo%26aufirst%3DP.%26aulast%3DPerdomo%26aufirst%3DR.%2BT.%26aulast%3DGarcez%26aufirst%3DF.%2BR.%26aulast%3Dde%2BFatima%2BCepa%2BMatos%26aufirst%3DM.%26aulast%3Dde%2BCarvalho%26aufirst%3DJ.%2BE.%26aulast%3DGarcez%26aufirst%3DW.%2BS.%26atitle%3DFurther%2520constituents%2520of%2520Galianthe%2520thalictroides%2520%2528Rubiaceae%2529%2520and%2520inhibition%2520of%2520DNA%2520topoisomerases%2520I%2520and%2520II%25CE%25B1%2520by%2520its%2520cytotoxic%2520%25CE%25B2-carboline%2520alkaloids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D1358%26epage%3D1361%26doi%3D10.1016%2Fj.bmcl.2014.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naithani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmeder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span> <span> </span><span class="NLM_article-title">Cancer chemopreventive activity of sulforamate derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2005.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2005.10.002" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2006&pages=121-124&author=R.+M.+Moriartyauthor=R.+Naithaniauthor=J.+Kosmederauthor=O.+Prakash&title=Cancer+chemopreventive+activity+of+sulforamate+derivatives&doi=10.1016%2Fj.ejmech.2005.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2005.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2005.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26aulast%3DNaithani%26aufirst%3DR.%26aulast%3DKosmeder%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DO.%26atitle%3DCancer%2520chemopreventive%2520activity%2520of%2520sulforamate%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2006%26volume%3D41%26spage%3D121%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2005.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talibov, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LinkuvienÄ, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, U. H.</span></span> <span> </span><span class="NLM_article-title">Kinetically selective inhibitors of human carbonic anhydrase isozymes I, II, VII, IX, XII, and XIII</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2083</span>â <span class="NLM_lpage">2093</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2083-2093&author=V.+O.+Talibovauthor=V.+Linkuvien%C4%97author=D.+Matulisauthor=U.+H.+Danielson&title=Kinetically+selective+inhibitors+of+human+carbonic+anhydrase+isozymes+I%2C+II%2C+VII%2C+IX%2C+XII%2C+and+XIII&doi=10.1021%2Facs.jmedchem.5b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetically Selective Inhibitors of Human Carbonic Anhydrase Isozymes I, II, VII, IX, XII, and XIII</span></div><div class="casAuthors">Talibov, Vladimir O.; Linkuviene, Vaida; Matulis, Daumantas; Danielson, U. Helena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2083-2093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To get a better understanding of the possibility of developing selective carbonic anhydrase (CA) inhibitors, interactions between 17 benzenesulfonamide ligands and 6 human CAs (full-length CA I, II, VII, and XIII and catalytic domains of CA IX and XII) were characterized using surface plasmon resonance and fluorescent-based thermal shift assays.  Kinetics revealed that the strongest binders had subnanomolar affinities with low dissocn. rates (i.e., kd values around 1 Ã 10-3 s-1) or were essentially irreversible.  Chemodynamic anal. of the interactions highlighted an intrinsic mechanism of the CA-sulfonamide interaction kinetics and showed that slow dissocn. rates were mediated by large hydrophobic contacts.  The studied inhibitors demonstrated a high cross-reactivity within the protein family.  However, according to chem. phylogenetic anal. developed for kinetic data, several ligands were found to be selective against certain CA isoenzymes, indicating that it should be possible to develop selective CA inhibitors suitable for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOw1t_w4zwELVg90H21EOLACvtfcHk0lipvAYyM-Ji3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWksLo%253D&md5=c861a0cc9afdfea5fd7427d7e9c2ba89</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01723%26sid%3Dliteratum%253Aachs%26aulast%3DTalibov%26aufirst%3DV.%2BO.%26aulast%3DLinkuvien%25C4%2597%26aufirst%3DV.%26aulast%3DMatulis%26aufirst%3DD.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26atitle%3DKinetically%2520selective%2520inhibitors%2520of%2520human%2520carbonic%2520anhydrase%2520isozymes%2520I%252C%2520II%252C%2520VII%252C%2520IX%252C%2520XII%252C%2520and%2520XIII%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2083%26epage%3D2093%26doi%3D10.1021%2Facs.jmedchem.5b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasulu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavitha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangella, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummuri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankaraiah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dithiocarbamate linked Î²-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5511</span>â <span class="NLM_lpage">5526</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26264845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=5511-5526&author=A.+Kamalauthor=M.+Sathishauthor=V.+L.+Nayakauthor=V.+Srinivasuluauthor=B.+Kavithaauthor=Y.+Tangellaauthor=D.+Thummuriauthor=C.+Bagulauthor=N.+Shankaraiahauthor=N.+Nagesh&title=Design+and+synthesis+of+dithiocarbamate+linked+%CE%B2-carboline+derivatives%3A+DNA+topoisomerase+II+inhibition+with+DNA+binding+and+apoptosis+inducing+ability&doi=10.1016%2Fj.bmc.2015.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dithiocarbamate linked Î²-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span></div><div class="casAuthors">Kamal, Ahmed; Sathish, Manda; Nayak, V. Lakshma; Srinivasulu, Vunnam; Kavitha, Botla; Tangella, Yellaiah; Thummuri, Dinesh; Bagul, Chandrakant; Shankaraiah, Nagula; Nagesh, Narayana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5511-5526</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of new Î²-carboline-dithiocarbamate derivs. bearing Ph, dithiocarbamate and H/methyl substitutions at position-1, 3 and 9, resp., were designed and synthesized.  These derivs. 8a-l and 13a-l and their starting precursors (7a-d and 12a-d) have been evaluated for their in vitro cytotoxic activity on selected human cancer cell lines.  Among the derivs. tested, 7c, 12c, 8a, 8d, 8i, 8j, 8k, 8l and 13d-l exhibited considerable cytotoxicity against most of the tested cancer cell lines (IC50 <10 Î¼M).  Interestingly, most of the derivs. (8a-l and 13a-l) exhibited enhanced activity than their precursors (7a-d and 12a-d), which indicates that the combination of dithiocarbamate with Î²-carboline enhances the cytotoxicity of 8a-l and 13a-l.  Moreover, the derivs. 8j and 13g exhibited significant cytotoxic activity with IC50 values of 1.34 Î¼M and 0.79 Î¼M on DU-145 cancer cells, resp.  Further, the induction of apoptosis by these derivs. was confirmed by Annexin V-FITC and Hoechst staining assays.  However, both biophys. as well as mol. docking studies suggested a combilexin-type of interaction between these derivs. and DNA, unlike simple Î²-carbolines.  With a view to understand their mechanism of action, DNA topoisomerase II (topo II) inhibition assay was also performed.  Overall, the present study emphasizes the importance of linking a dithiocarbamate moiety to the Î²-carboline scaffold for exhibiting profound activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2JbzggrG7v7Vg90H21EOLACvtfcHk0lj_1_ACPCZp6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ&md5=8b85c9edc23342973d0ee6b5aa08cd5c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DSathish%26aufirst%3DM.%26aulast%3DNayak%26aufirst%3DV.%2BL.%26aulast%3DSrinivasulu%26aufirst%3DV.%26aulast%3DKavitha%26aufirst%3DB.%26aulast%3DTangella%26aufirst%3DY.%26aulast%3DThummuri%26aufirst%3DD.%26aulast%3DBagul%26aufirst%3DC.%26aulast%3DShankaraiah%26aufirst%3DN.%26aulast%3DNagesh%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dithiocarbamate%2520linked%2520%25CE%25B2-carboline%2520derivatives%253A%2520DNA%2520topoisomerase%2520II%2520inhibition%2520with%2520DNA%2520binding%2520and%2520apoptosis%2520inducing%2520ability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5511%26epage%3D5526%26doi%3D10.1016%2Fj.bmc.2015.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of the novel DNA topoisomerase II inhibitors: Esterification and amination substituted 4â-demethylepipodophyllotoxin derivates exhibiting anti-tumor activity by activating ATM/ATR signaling pathways</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">267</span>â <span class="NLM_lpage">277</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.03.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2014.03.082" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=267-277&author=L.+Xiaoauthor=W.+Zhaoauthor=H.+M.+Liauthor=D.+J.+Wanauthor=D.+S.+Liauthor=T.+Chenauthor=Y.+J.+Tang&title=Design+and+synthesis+of+the+novel+DNA+topoisomerase+II+inhibitors%3A+Esterification+and+amination+substituted+4%E2%80%99-demethylepipodophyllotoxin+derivates+exhibiting+anti-tumor+activity+by+activating+ATM%2FATR+signaling+pathways&doi=10.1016%2Fj.ejmech.2014.03.082"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.03.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.03.082%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DWan%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DY.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520the%2520novel%2520DNA%2520topoisomerase%2520II%2520inhibitors%253A%2520Esterification%2520and%2520amination%2520substituted%25204%25E2%2580%2599-demethylepipodophyllotoxin%2520derivates%2520exhibiting%2520anti-tumor%2520activity%2520by%2520activating%2520ATM%252FATR%2520signaling%2520pathways%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D267%26epage%3D277%26doi%3D10.1016%2Fj.ejmech.2014.03.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. J.</span></span> <span> </span><span class="NLM_article-title">A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-<i>O</i>-(2-pyrazinecarboxylic)-4â-demethyl epipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2998</span>â <span class="NLM_lpage">3007</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2014.03.048" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2998-3007&author=W.+Zhaoauthor=L.+Chenauthor=H.+M.+Liauthor=D.+J.+Wangauthor=D.+S.+Liauthor=T.+Chenauthor=Z.+P.+Yuanauthor=Y.+J.+Tang&title=A+rational+design+strategy+of+the+novel+topoisomerase+II+inhibitors+for+the+synthesis+of+the+4-O-%282-pyrazinecarboxylic%29-4%E2%80%99-demethyl+epipodophyllotoxin+with+antitumor+activity+by+diminishing+the+relaxation+reaction+of+topoisomerase+II-DNA+decatenation&doi=10.1016%2Fj.bmc.2014.03.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DWang%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DZ.%2BP.%26aulast%3DTang%26aufirst%3DY.%2BJ.%26atitle%3DA%2520rational%2520design%2520strategy%2520of%2520the%2520novel%2520topoisomerase%2520II%2520inhibitors%2520for%2520the%2520synthesis%2520of%2520the%25204-O-%25282-pyrazinecarboxylic%2529-4%25E2%2580%2599-demethyl%2520epipodophyllotoxin%2520with%2520antitumor%2520activity%2520by%2520diminishing%2520the%2520relaxation%2520reaction%2520of%2520topoisomerase%2520II-DNA%2520decatenation%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2998%26epage%3D3007%26doi%3D10.1016%2Fj.bmc.2014.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasinoff, B. B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-<i>N</i>-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5935</span>â <span class="NLM_lpage">5949</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2014.09.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5935-5949&author=A.+A.+Yadavauthor=X.+Wuauthor=D.+Patelauthor=J.+C.+Yalowichauthor=B.+B.+Hasinoff&title=Structure-based+design%2C+synthesis+and+biological+testing+of+etoposide+analog+epipodophyllotoxin-N-mustard+hybrid+compounds+designed+to+covalently+bind+to+topoisomerase+II+and+DNA&doi=10.1016%2Fj.bmc.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DA.%2BA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520testing%2520of%2520etoposide%2520analog%2520epipodophyllotoxin-N-mustard%2520hybrid%2520compounds%2520designed%2520to%2520covalently%2520bind%2520to%2520topoisomerase%2520II%2520and%2520DNA%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5935%26epage%3D5949%26doi%3D10.1016%2Fj.bmc.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. V.</span></span> <span> </span><span class="NLM_article-title">Piperazine derivatives for therapeutic use: a patent review (2010-present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">777</span>â <span class="NLM_lpage">797</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2016.1189902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1080%2F13543776.2016.1189902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27177234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVajtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=777-797&author=A.+K.+Rathiauthor=R.+Syedauthor=H.+S.+Shinauthor=R.+V.+Patel&title=Piperazine+derivatives+for+therapeutic+use%3A+a+patent+review+%282010-present%29&doi=10.1080%2F13543776.2016.1189902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Piperazine derivatives for therapeutic use: a patent review (2010-present)</span></div><div class="casAuthors">Rathi, Anuj K.; Syed, Riyaz; Shin, Han-Seung; Patel, Rahul V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">777-797</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Piperazine, a six membered nitrogen contg. heterocycle, is of great significance to the rational design of drugs.  This moiety can be found in a plethora of well-known drugs with various therapeutic uses, such as antipsychotic, antihistamine, antianginal, antidepressant, anticancer, antiviral, cardio protectors, anti-inflammatory, and imaging agents.  Slight modification to the substitution pattern on the piperazine nucleus facilitates a recognizable difference in the medicinal potential of the resultant mols.  Scifinder was the main source used to search for patents contg. piperazine compds. with therapeutic uses.  The article describes a variety of mol. designs bearing piperazine entity furnishing CNS agents, anticancer, cardio-protective agents, antiviral, anti-tuberculosis, anti-inflammatory, antidiabetic, and antihistamine profiles, as well as agents relieving pain and useful in imaging applications.  The great interest gathered to explore piperazine based mols. in relatively few years reflects the broad potential of the entity.  Earlier, this scaffold was considered to express CNS activity only.  However, a significant increase in research covering studies of several different activities of piperazine ring suggest a successful emergence of the pharmacophore.  Certain patents outlined in the present article recommend that piperazines can be a flexible building block to discover drug-like elements and modification of substituents present on the piperazine ring may have a significant impact on the pharmacokinetic and pharmacodynamics factors of the resulting mols.  This article aims to provide insights to piperazine based mol. fragments that would assist drug discoverers to rationally design mols. for various diseases.  We anticipate, and highly recommend, further therapeutic investigations on this motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIhdjKw214crVg90H21EOLACvtfcHk0lgnsmwO4BJGvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVajtb0%253D&md5=186a0479043f37982b9aa880a4f2791a</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1189902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1189902%26sid%3Dliteratum%253Aachs%26aulast%3DRathi%26aufirst%3DA.%2BK.%26aulast%3DSyed%26aufirst%3DR.%26aulast%3DShin%26aufirst%3DH.%2BS.%26aulast%3DPatel%26aufirst%3DR.%2BV.%26atitle%3DPiperazine%2520derivatives%2520for%2520therapeutic%2520use%253A%2520a%2520patent%2520review%2520%25282010-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D777%26epage%3D797%26doi%3D10.1080%2F13543776.2016.1189902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">11014</span>â <span class="NLM_lpage">11019</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0704002104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1073%2Fpnas.0704002104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=17578914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=11014-11019&author=A.+M.+Azarovaauthor=Y.+L.+Lyuauthor=C.+P.+Linauthor=Y.+C.+Tsaiauthor=J.+Y.+Lauauthor=J.+C.+Wangauthor=L.+F.+Liu&title=Roles+of+DNA+topoisomerase+II+isozymes+in+chemotherapy+and+secondary+malignancies&doi=10.1073%2Fpnas.0704002104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span></div><div class="casAuthors">Azarova, Anna M.; Lyu, Yi Lisa; Lin, Chao-Po; Tsai, Yuan-Chin; Lau, Johnson Yiu-Nam; Wang, James C.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">11014-11019</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clin. use.  However, Top2-based chemotherapy has been assocd. with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients.  This assocn. is suggestive of a link between carcinogenesis and Top2-mediated DNA damage.  We show here that VP-16-induced carcinogenesis involves mainly the Î² rather than the isoenzyme of Top2.  In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is significantly higher in TOP2Î²+ than in skin-specific top2Î²-knockout mice.  Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are Top2Î²-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degrdn. of the Top2Î²-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements.  VP-16 cytotoxicity in transformed cells expressing both Top2 isoenzymes is, however, primarily Top2Î±-dependent.  These results point to the importance of developing Top2-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqEXje8wQTrVg90H21EOLACvtfcHk0lgnsmwO4BJGvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D&md5=f10976e9b0dbb918158916036a0349a7</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0704002104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0704002104%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DLyu%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DTsai%26aufirst%3DY.%2BC.%26aulast%3DLau%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DRoles%2520of%2520DNA%2520topoisomerase%2520II%2520isozymes%2520in%2520chemotherapy%2520and%2520secondary%2520malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D11014%26epage%3D11019%26doi%3D10.1073%2Fpnas.0704002104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, N. L.</span></span> <span> </span><span class="NLM_article-title">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10861</span>â <span class="NLM_lpage">10871</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkx742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1093%2Fnar%2Fgkx742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=28977631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=10861-10871&author=Y.+R.+Wangauthor=S.+F.+Chenauthor=C.+C.+Wuauthor=Y.+W.+Liaoauthor=T.+S.+Linauthor=K.+T.+Liuauthor=Y.+S.+Chenauthor=T.+K.+Liauthor=T.+C.+Chienauthor=N.+L.+Chan&title=Producing+irreversible+topoisomerase+II-mediated+DNA+breaks+by+site-specific+Pt%28II%29-methionine+coordination+chemistry&doi=10.1093%2Fnar%2Fgkx742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry</span></div><div class="casAuthors">Wang, Ying-Ren; Chen, Shin-Fu; Wu, Chyuan-Chuan; Liao, Yi-Wen; Lin, Te-Sheng; Liu, Ko-Ting; Chen, Yi-Song; Li, Tsai-Kun; Chien, Tun-Cheng; Chan, Nei-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10861-10871</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Human type II topoisomerase (Top2) isoforms, hTop2Î± and hTop2Î², are targeted by some of the most successful anticancer drugs.  These drugs induce Top2-mediated DNA cleavage to trigger cell-death pathways.  The potency of these drugs correlates pos. with their efficacy in stabilizing the enzyme-mediated DNA breaks.  Structural anal. of hTop2Î± and hTop2Î² revealed the presence of methionine residues in the drug binding pocket, we therefore tested whether a tighter Top2-drug assocn. may be accomplished by introducing a methionine-reactive Pt2+ into a drug to further stabilize the DNA break.  Herein, we synthesized an organoplatinum compd., etoplatin-N2Î², by replacing the methioninejuxtaposing group of the drug etoposide with a cis-dichlorodiammineplatinum(II) moiety.  Compared to etoposide, etoplatin-N2Î² more potently inhibits both human Top2s.  While the DNA breaks arrested by etoposide can be rejoined, those captured by etoplatin-N2 are practically irreversible.  Crystallog. analyses of hTop2Î² complexed with DNA and etoplatin-N2Î² demonstrate coordinate bond formation between Pt2+ and a flanking methionine.  Notably, this stable coordinate tether can be loosened by disrupting the structural integrity of drug-binding pocket, suggesting that Pt2+ coordination chem. may allow for the development of potent inhibitors with protein conformation-dependent reversibility.  This approach may be exploited to achieve isoformspecific targeting of human Top2s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_1lsBFMml7Vg90H21EOLACvtfcHk0lgnsmwO4BJGvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Kit7k%253D&md5=ddc7d7d51f099dc62d40a04819287178</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx742%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BR.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DLiao%26aufirst%3DY.%2BW.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DK.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DChien%26aufirst%3DT.%2BC.%26aulast%3DChan%26aufirst%3DN.%2BL.%26atitle%3DProducing%2520irreversible%2520topoisomerase%2520II-mediated%2520DNA%2520breaks%2520by%2520site-specific%2520Pt%2528II%2529-methionine%2520coordination%2520chemistry%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2017%26volume%3D45%26spage%3D10861%26epage%3D10871%26doi%3D10.1093%2Fnar%2Fgkx742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, l M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span> <span> </span><span class="NLM_article-title">Differential targeting of human topoisomerase II isoforms with small molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4851</span>â <span class="NLM_lpage">4856</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvV2lsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4851-4856&author=A.+Marianiauthor=A.+Bartoliauthor=l+M.+Atwalauthor=K.+C.+Leeauthor=C.+A.+Austinauthor=R.+Rodriguez&title=Differential+targeting+of+human+topoisomerase+II+isoforms+with+small+molecules&doi=10.1021%2Facs.jmedchem.5b00473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules</span></div><div class="casAuthors">Mariani, Angelica; Bartoli, Alexandra; Atwal, Mandeep; Lee, Ka C.; Austin, Caroline A.; Rodriguez, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4851-4856</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The TOP2 poison etoposide has been implicated in the generation of secondary malignancies during cancer treatment.  Structural similarities between TOP2 isoforms challenge the rational design of isoform-specific poisons to further delineate these processes.  Herein, the authors describe the synthesis and biol. evaluation of a focused library of etoposide analogs, with the identification of two novel small mols. exhibiting TOP2B-dependent toxicity.  The findings pave the way toward studying isoform-specific cellular processes by means of small mol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsJib9B-KeD7Vg90H21EOLACvtfcHk0liUO3ySgT3rUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvV2lsro%253D&md5=1dd44d728aa9c4c71fb80f6d416b8438</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00473%26sid%3Dliteratum%253Aachs%26aulast%3DMariani%26aufirst%3DA.%26aulast%3DBartoli%26aufirst%3DA.%26aulast%3DAtwal%26aufirst%3Dl%2BM.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DRodriguez%26aufirst%3DR.%26atitle%3DDifferential%2520targeting%2520of%2520human%2520topoisomerase%2520II%2520isoforms%2520with%2520small%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4851%26epage%3D4856%26doi%3D10.1021%2Facs.jmedchem.5b00473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chee, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalowich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasinoff, B. B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllo toxin etoposide analogs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3542</span>â <span class="NLM_lpage">3551</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.04.022" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3542-3551&author=A.+A.+Yadavauthor=G.+L.+Cheeauthor=X.+Wuauthor=D.+Patelauthor=J.+C.+Yalowichauthor=B.+B.+Hasinoff&title=Structure-based+design%2C+synthesis+and+biological+testing+of+piperazine-linked+bis-epipodophyllo+toxin+etoposide+analogs&doi=10.1016%2Fj.bmc.2015.04.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DA.%2BA.%26aulast%3DChee%26aufirst%3DG.%2BL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DYalowich%26aufirst%3DJ.%2BC.%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520testing%2520of%2520piperazine-linked%2520bis-epipodophyllo%2520toxin%2520etoposide%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3542%26epage%3D3551%26doi%3D10.1016%2Fj.bmc.2015.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothenborg-Jensen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitiss, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehested, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, L. H.</span></span> <span> </span><span class="NLM_article-title">Linker length in podophyllotoxin-acridine conjugates determines potency <i>in vivo</i> and <i>in vitro</i> as well as specificity against MDR cell lines</span>. <i>Anti-Cancer Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">305</span>â <span class="NLM_lpage">315</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2001&pages=305-315&author=L.+Rothenborg-Jensenauthor=H.+F.+Hansenauthor=I.+Wesselauthor=J.+L.+Nitissauthor=G.+Schmidtauthor=P.+B.+Jensenauthor=M.+Sehestedauthor=L.+H.+Jensen&title=Linker+length+in+podophyllotoxin-acridine+conjugates+determines+potency+in+vivo+and+in+vitro+as+well+as+specificity+against+MDR+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothenborg-Jensen%26aufirst%3DL.%26aulast%3DHansen%26aufirst%3DH.%2BF.%26aulast%3DWessel%26aufirst%3DI.%26aulast%3DNitiss%26aufirst%3DJ.%2BL.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DJensen%26aufirst%3DP.%2BB.%26aulast%3DSehested%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DL.%2BH.%26atitle%3DLinker%2520length%2520in%2520podophyllotoxin-acridine%2520conjugates%2520determines%2520potency%2520in%2520vivo%2520and%2520in%2520vitro%2520as%2520well%2520as%2520specificity%2520against%2520MDR%2520cell%2520lines%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D2001%26volume%3D16%26spage%3D305%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nateewattana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeeng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasemsook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jariyawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chairoungdua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suksamrarn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piyachaturawat, P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of topoisomerase IIÎ± activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">320</span>â <span class="NLM_lpage">332</span>, <span class="refDoi">Â DOI: 10.1007/s10637-012-9868-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs10637-012-9868-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=320-332&author=J.+Nateewattanaauthor=R.+Saeengauthor=S.+Kasemsookauthor=K.+Suksenauthor=S.+Duttaauthor=S.+Jariyawatauthor=A.+Chairoungduaauthor=A.+Suksamrarnauthor=P.+Piyachaturawat&title=Inhibition+of+topoisomerase+II%CE%B1+activity+and+induction+of+apoptosis+in+mammalian+cells+by+semi-synthetic+andrographolide+analogues&doi=10.1007%2Fs10637-012-9868-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9868-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9868-9%26sid%3Dliteratum%253Aachs%26aulast%3DNateewattana%26aufirst%3DJ.%26aulast%3DSaeeng%26aufirst%3DR.%26aulast%3DKasemsook%26aufirst%3DS.%26aulast%3DSuksen%26aufirst%3DK.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DJariyawat%26aufirst%3DS.%26aulast%3DChairoungdua%26aufirst%3DA.%26aulast%3DSuksamrarn%26aufirst%3DA.%26aulast%3DPiyachaturawat%26aufirst%3DP.%26atitle%3DInhibition%2520of%2520topoisomerase%2520II%25CE%25B1%2520activity%2520and%2520induction%2520of%2520apoptosis%2520in%2520mammalian%2520cells%2520by%2520semi-synthetic%2520andrographolide%2520analogues%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D320%26epage%3D332%26doi%3D10.1007%2Fs10637-012-9868-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel mansonone E derivatives prepared <i>via</i> CuAAC click chemistry as topoisomerase II inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">58</span>â <span class="NLM_lpage">71</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.07.011" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=58-71&author=Z.+H.+Huangauthor=S.+T.+Zhuoauthor=C.+Y.+Liauthor=H.+T.+Xieauthor=D.+Liauthor=J.+H.+Tanauthor=T.+M.+Ouauthor=Z.+S.+Huangauthor=L.+Q.+Guauthor=S.+L.+Huang&title=Design%2C+synthesis+and+biological+evaluation+of+novel+mansonone+E+derivatives+prepared+via+CuAAC+click+chemistry+as+topoisomerase+II+inhibitors&doi=10.1016%2Fj.ejmech.2013.07.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%2BH.%26aulast%3DZhuo%26aufirst%3DS.%2BT.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DXie%26aufirst%3DH.%2BT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DJ.%2BH.%26aulast%3DOu%26aufirst%3DT.%2BM.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DS.%2BL.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520mansonone%2520E%2520derivatives%2520prepared%2520via%2520CuAAC%2520click%2520chemistry%2520as%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D58%26epage%3D71%26doi%3D10.1016%2Fj.ejmech.2013.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">A novel <i>p</i>-terphenyl derivative inducing cell-cycle arrest and apoptosis in MDA-MB-435 cells through topoisomerase inhibition</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">192</span>â <span class="NLM_lpage">202</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.07.020" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=192-202&author=J.+Qiuauthor=B.+Zhaoauthor=Y.+Shenauthor=W.+Chenauthor=Y.+Maauthor=Y.+Shen&title=A+novel+p-terphenyl+derivative+inducing+cell-cycle+arrest+and+apoptosis+in+MDA-MB-435+cells+through+topoisomerase+inhibition&doi=10.1016%2Fj.ejmech.2013.07.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DA%2520novel%2520p-terphenyl%2520derivative%2520inducing%2520cell-cycle%2520arrest%2520and%2520apoptosis%2520in%2520MDA-MB-435%2520cells%2520through%2520topoisomerase%2520inhibition%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D192%26epage%3D202%26doi%3D10.1016%2Fj.ejmech.2013.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sharkawy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel Bar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span> <span> </span><span class="NLM_article-title">Rational design and synthesis of topoisomerase I and II inhibitors based on oleanolic acid moiety for new anti-cancer drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2013.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2013.11.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24326278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7rE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=211-220&author=A.+Ashourauthor=S.+El-Sharkawyauthor=M.+Amerauthor=F.+Abdel+Barauthor=Y.+Katakuraauthor=T.+Miyamotoauthor=N.+Toyotaauthor=T.+H.+Bangauthor=R.+Kondoauthor=K.+Shimizu&title=Rational+design+and+synthesis+of+topoisomerase+I+and+II+inhibitors+based+on+oleanolic+acid+moiety+for+new+anti-cancer+drugs&doi=10.1016%2Fj.bmc.2013.11.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and synthesis of topoisomerase I and II inhibitors based on oleanolic acid moiety for new anti-cancer drugs</span></div><div class="casAuthors">Ashour, Ahmed; El-Sharkawy, Saleh; Amer, Mohamed; Abdel Bar, Fatma; Katakura, Yoshinori; Miyamoto, Tomofumi; Toyota, Nozomi; Bang, Tran Hai; Kondo, Ryuichiro; Shimizu, Kuniyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">211-220</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Semisynthetic reactions were conducted on oleanolic acid, a common plant-derived oleanane-type triterpene.  Ten rationally designed derivs. of oleanolic acid were synthesized based on docking studies and tested for their topoisomerase I and IIÎ± inhibitory activity.  Semisynthetic reactions targeted C-3, C-12, C-13, and C-17.  Nine of the synthesized compds. were identified as new compds.  The structures of these compds. were confirmed by spectroscopic methods (1D, 2D NMR and MS).  Five oleanolic acid analogs (S2, S3, S5, S7 and S9) showed higher activity than camptothecin (CPT) in the topoisomerase I DNA relaxation assay.  Four oleanolic acid analogs (S2, S3, S5 and S6) showed higher activity than etoposide in a topoisomerase II assay.  The results indicated that the C12-C13 double bond of the oleanolic acid skeleton is important for the inhibitory activity against both types of topoisomerases, while insertion of a longer chain at either position 3 or 17 increases the activity against topoisomerases by various degrees.  Some of the synthesized compds. act as dual inhibitors for both topoisomerase I and IIÎ±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAiji539lqZLVg90H21EOLACvtfcHk0lh_BkJpkhW5Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOht7rE&md5=9185e97509d5b813a54756943cec6144</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DAshour%26aufirst%3DA.%26aulast%3DEl-Sharkawy%26aufirst%3DS.%26aulast%3DAmer%26aufirst%3DM.%26aulast%3DAbdel%2BBar%26aufirst%3DF.%26aulast%3DKatakura%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DToyota%26aufirst%3DN.%26aulast%3DBang%26aufirst%3DT.%2BH.%26aulast%3DKondo%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DK.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520topoisomerase%2520I%2520and%2520II%2520inhibitors%2520based%2520on%2520oleanolic%2520acid%2520moiety%2520for%2520new%2520anti-cancer%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D211%26epage%3D220%26doi%3D10.1016%2Fj.bmc.2013.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">The essential medicinal chemistry of curcumin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1620</span>â <span class="NLM_lpage">1637</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00975</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00975" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFKjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1620-1637&author=K.+M.+Nelsonauthor=J.+L.+Dahlinauthor=J.+Bissonauthor=J.+Grahamauthor=G.+F.+Pauliauthor=M.+A.+Walters&title=The+essential+medicinal+chemistry+of+curcumin&doi=10.1021%2Facs.jmedchem.6b00975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The Essential Medicinal Chemistry of Curcumin</span></div><div class="casAuthors">Nelson, Kathryn M.; Dahlin, Jayme L.; Bisson, Jonathan; Graham, James; Pauli, Guido F.; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1620-1637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Curcumin is a constituent (3-5%) of the traditional medicine known as turmeric.  Interest in the therapeutic use of turmeric and the relative ease of isolation of curcuminoids has led to their extensive investigation.  Curcumin has recently been classified as both a PAINS (pan-assay interference compds.) and an IMPS (invalid metabolic panaceas) candidate.  The likely false activity of curcumin in vitro and in vivo has resulted in >120 clin. trials of curcuminoids against several diseases.  No double-blinded, placebo controlled clin. trial of curcumin has been successful.  This Perspective reviews the essential medicinal chem. of curcumin and provides evidence that curcumin is an unstable, reactive, nonbioavailable compd. and, therefore, a highly improbable lead.  Based on this in-depth evaluation, potential new directions for research on curcuminoids are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSvgRUG-0XoLVg90H21EOLACvtfcHk0lh_BkJpkhW5Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFKjsA%253D%253D&md5=dfb16371e0ef27d4111628203c6acc09</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00975%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DK.%2BM.%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DBisson%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DPauli%26aufirst%3DG.%2BF.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DThe%2520essential%2520medicinal%2520chemistry%2520of%2520curcumin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1620%26epage%3D1637%26doi%3D10.1021%2Facs.jmedchem.6b00975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span> <span> </span><span class="NLM_article-title">Deceptive curcumin offers cautionary tale for chemists</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>541</i></span>,  <span class="NLM_fpage">144</span>â <span class="NLM_lpage">145</span>, <span class="refDoi">Â DOI: 10.1038/541144a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1038%2F541144a" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=541&publication_year=2017&pages=144-145&author=M.+Baker&title=Deceptive+curcumin+offers+cautionary+tale+for+chemists&doi=10.1038%2F541144a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2F541144a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F541144a%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%26atitle%3DDeceptive%2520curcumin%2520offers%2520cautionary%2520tale%2520for%2520chemists%26jtitle%3DNature%26date%3D2017%26volume%3D541%26spage%3D144%26epage%3D145%26doi%3D10.1038%2F541144a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ness, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravoori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupasinghe, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Curcumin-inspired cytotoxic 3,5-bis(arylmethylene)-1-(<i>N</i>-(<i>ortho</i>-substituted aryl)maleamoyl)- 4-piperidones: A novel group of topoisomerase II alpha inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6404</span>â <span class="NLM_lpage">6417</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmc.2015.08.023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6404-6417&author=A.+Jhaauthor=K.+M.+Duffieldauthor=M.+R.+Nessauthor=S.+Ravooriauthor=G.+Andrewsauthor=K.+S.+Bhullarauthor=H.+P.+Rupasingheauthor=J.+Balzarini&title=Curcumin-inspired+cytotoxic+3%2C5-bis%28arylmethylene%29-1-%28N-%28ortho-substituted+aryl%29maleamoyl%29-+4-piperidones%3A+A+novel+group+of+topoisomerase+II+alpha+inhibitors&doi=10.1016%2Fj.bmc.2015.08.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DJha%26aufirst%3DA.%26aulast%3DDuffield%26aufirst%3DK.%2BM.%26aulast%3DNess%26aufirst%3DM.%2BR.%26aulast%3DRavoori%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DBhullar%26aufirst%3DK.%2BS.%26aulast%3DRupasinghe%26aufirst%3DH.%2BP.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DCurcumin-inspired%2520cytotoxic%25203%252C5-bis%2528arylmethylene%2529-1-%2528N-%2528ortho-substituted%2520aryl%2529maleamoyl%2529-%25204-piperidones%253A%2520A%2520novel%2520group%2520of%2520topoisomerase%2520II%2520alpha%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6404%26epage%3D6417%26doi%3D10.1016%2Fj.bmc.2015.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeÃ³n-Gonzalez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MuÃ±oz-Mingarro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-LÃ¡zaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n-Cordero, C.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic activity of hirsutanone, a diarylheptanoid isolated from <i>Alnus glutinosa</i> leaves</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">866</span>â <span class="NLM_lpage">870</span>, <span class="refDoi">Â DOI: 10.1016/j.phymed.2014.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.phymed.2014.01.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=866-870&author=A.+J.+Le%C3%B3n-Gonzalezauthor=N.+Aceroauthor=D.+Mu%C3%B1oz-Mingarroauthor=M.+L%C3%B3pez-L%C3%A1zaroauthor=C.+Mart%C3%ADn-Cordero&title=Cytotoxic+activity+of+hirsutanone%2C+a+diarylheptanoid+isolated+from+Alnus+glutinosa+leaves&doi=10.1016%2Fj.phymed.2014.01.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2014.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2014.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DLe%25C3%25B3n-Gonzalez%26aufirst%3DA.%2BJ.%26aulast%3DAcero%26aufirst%3DN.%26aulast%3DMu%25C3%25B1oz-Mingarro%26aufirst%3DD.%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn-Cordero%26aufirst%3DC.%26atitle%3DCytotoxic%2520activity%2520of%2520hirsutanone%252C%2520a%2520diarylheptanoid%2520isolated%2520from%2520Alnus%2520glutinosa%2520leaves%26jtitle%3DPhytomedicine%26date%3D2014%26volume%3D21%26spage%3D866%26epage%3D870%26doi%3D10.1016%2Fj.phymed.2014.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">StiborovÃ¡, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frei, E.</span></span> <span> </span><span class="NLM_article-title">Ellipticines as DNA-targeted chemotherapeutics</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">575</span>â <span class="NLM_lpage">591</span>, <span class="refDoi">Â DOI: 10.2174/09298673113206660272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2174%2F09298673113206660272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24059226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFyjt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=575-591&author=M.+Stiborov%C3%A1author=E.+Frei&title=Ellipticines+as+DNA-targeted+chemotherapeutics&doi=10.2174%2F09298673113206660272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ellipticines as DNA-Targeted Chemotherapeutics</span></div><div class="casAuthors">Stiborova, Marie; Frei, Eva</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">575-591</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The anti-tumor therapeutic ellipticine and its derivs. act as potent anticancer agents via a combined mechanism involving cell cycle arrest and induction of apoptosis.  Cell death induced by ellipticine has been shown to engage a p53-dependent pathway, cell cycle arrest, interaction with several kinases and induction of the mitochondrial pathway of apoptotic cell death.  Cell cycle arrest was shown to result from DNA damage caused by a variety of tumor chemotherapeutic agents; this is also the case for ellipticines.  The prevalent DNA-mediated mechanisms of anti-tumor, mutagenic and cytotoxic activities of ellipticine are (i) intercalation into DNA, (ii) inhibition of DNA topoisomerase II activity, and (iii) covalent binding to DNA in vitro and in vivo after enzymic activation by cytochrome P 450 and/or peroxidase enzymes The mechanism leading to apoptosis by ellipticine is thought to also be assocd. with DNA damage, by inhibition of topoisomerase II and the covalent modification of DNA.  In addn., the formation of ellipticine-DNA adducts ultimately can mutate cancer cells or initiate cell death.  The aim of this review is to summarize our knowledge on the mol. mechanisms with the aim to explain the effectiveness of ellipticines as DNA-targeted chemotherapeutics in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZkGZmnzXYLrVg90H21EOLACvtfcHk0liPAa5wJ3kucg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFyjt7k%253D&md5=2617220884efc039658e464f64f0a691</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.2174%2F09298673113206660272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113206660272%26sid%3Dliteratum%253Aachs%26aulast%3DStiborov%25C3%25A1%26aufirst%3DM.%26aulast%3DFrei%26aufirst%3DE.%26atitle%3DEllipticines%2520as%2520DNA-targeted%2520chemotherapeutics%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D575%26epage%3D591%26doi%3D10.2174%2F09298673113206660272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deane, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâSullivan, E.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoff, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel ellipticines as potential anti-cancer agents</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1334</span>â <span class="NLM_lpage">1344</span>, <span class="refDoi">Â DOI: 10.1039/c2ob27186a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc2ob27186a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=23314103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaruro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1334-1344&author=F.+M.+Deaneauthor=E.%0AC.+O%E2%80%99Sullivanauthor=A.+R.+Maguireauthor=J.+Gilbertauthor=J.+A.+Sakoffauthor=A.+McCluskeyauthor=F.+O.+McCarthy&title=Synthesis+and+evaluation+of+novel+ellipticines+as+potential+anti-cancer+agents&doi=10.1039%2Fc2ob27186a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel ellipticines as potential anti-cancer agents</span></div><div class="casAuthors">Deane, Fiona M.; O'Sullivan, Elaine C.; Maguire, Anita R.; Gilbert, Jayne; Sakoff, Jennette A.; McCluskey, Adam; McCarthy, Florence O.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1334-1344</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Drugs that inhibit DNA topoisomerase I and DNA topoisomerase II have been widely used in cancer chemotherapy.  The results of a focused medicinal chem. effort around novel ellipticinium salts which target topoisomerase I and II enzymes with improved soly are reported.  The salts were prepd. by reaction of ellipticine with the required alkyl halide and evaluated for DNA intercalation, topoisomerase inhibition and growth inhibition against 12 cancer cell lines.  Results from the topoisomerase I relaxation assay indicated that all novel ellipticine derivs. behaved as intercalating agents.  At a concn. of 100 Î¼M, specific topoisomerase I inhibition was not obsd.  Two of the derivs. under investigation were found to fully inhibit the DNA decatenation reaction at a concn. of 100 Î¼M, indicative of topoisomerase II inhibition.  N-Alkylation of ellipticine was found to enhance the obsd. growth inhibition across all cell lines and induce growth inhibition comparable to that of Irinotecan (CPT-11; GI50 1-18 Î¼M) and in some cell lines better than Etoposide (VP-16; GI50 = 0.04-5.2 Î¼M).  6-Methylellipticine (I) was the most potent growth inhibitory compd. assessed (GI50 = 0.47-0.9 Î¼M).  N-Alkylation of I was found to reduce this response with GI50 values in the range of 1.3-28 Î¼M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI46Fm5Vc0iLVg90H21EOLACvtfcHk0liPAa5wJ3kucg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaruro%253D&md5=d070dddab77a24b35fdd07120b19eea1</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1039%2Fc2ob27186a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob27186a%26sid%3Dliteratum%253Aachs%26aulast%3DDeane%26aufirst%3DF.%2BM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DE.%2BC.%26aulast%3DMaguire%26aufirst%3DA.%2BR.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DSakoff%26aufirst%3DJ.%2BA.%26aulast%3DMcCluskey%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520ellipticines%2520as%2520potential%2520anti-cancer%2520agents%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1334%26epage%3D1344%26doi%3D10.1039%2Fc2ob27186a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vann, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ErgÃ¼n, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zencir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oncuoglu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osheroff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topcu, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human DNA topoisomerase IIÎ± by two novel ellipticine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1809</span>â <span class="NLM_lpage">1812</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.02.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2016.02.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26906637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFKjtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1809-1812&author=K.+R.+Vannauthor=Y.+Erg%C3%BCnauthor=S.+Zencirauthor=S.+Oncuogluauthor=N.+Osheroffauthor=Z.+Topcu&title=Inhibition+of+human+DNA+topoisomerase+II%CE%B1+by+two+novel+ellipticine+derivatives&doi=10.1016%2Fj.bmcl.2016.02.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human DNA topoisomerase IIÎ± by two novel ellipticine derivatives</span></div><div class="casAuthors">Vann, Kendra R.; Ergun, Yavuz; Zencir, Sevil; Oncuoglu, Serkan; Osheroff, Neil; Topcu, Zeki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1809-1812</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity.  Unfortunately, this compd. displays a no. of adverse properties.  Therefore, to investigate new ellipticine-based compds. for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivs., N-methyl-5-demethyl ellipticine (ET-1, I) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2, II.I-).  As detd. by DNA decatenation and cleavage assays, ET-1 and ET-2 act as catalytic inhibitors of human topoisomerase IIÎ± and are both more potent than the parent compd.  Neither compd. impairs the ability of the type II enzyme to bind its DNA substrate.  Finally, the potency of ET-1 and ET-2 as catalytic inhibitors of topoisomerase IIÎ± appears to be related to their ability to intercalate into the double helix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJqcpTy5LtabVg90H21EOLACvtfcHk0lgKBic1utWDsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFKjtL8%253D&md5=ac87bed43d131dc0f274c574430609fe</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.034%26sid%3Dliteratum%253Aachs%26aulast%3DVann%26aufirst%3DK.%2BR.%26aulast%3DErg%25C3%25BCn%26aufirst%3DY.%26aulast%3DZencir%26aufirst%3DS.%26aulast%3DOncuoglu%26aufirst%3DS.%26aulast%3DOsheroff%26aufirst%3DN.%26aulast%3DTopcu%26aufirst%3DZ.%26atitle%3DInhibition%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%2520by%2520two%2520novel%2520ellipticine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1809%26epage%3D1812%26doi%3D10.1016%2Fj.bmcl.2016.02.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iacopetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puoci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, O. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturnino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceramella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malzert-FrÃ©on, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinicropi, M. S.</span></span> <span> </span><span class="NLM_article-title">Multifaceted properties of 1,4-dimethylcarbazoles: Focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">272</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2016.09.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejps.2016.09.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27702608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1akt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=263-272&author=D.+Iacopettaauthor=C.+Rosanoauthor=F.+Puociauthor=O.+I.+Parisiauthor=C.+Saturninoauthor=A.+Carusoauthor=P.+Longoauthor=J.+Ceramellaauthor=A.+Malzert-Fr%C3%A9onauthor=P.+Dallemagneauthor=S.+Raultauthor=M.+S.+Sinicropi&title=Multifaceted+properties+of+1%2C4-dimethylcarbazoles%3A+Focus+on+trimethoxybenzamide+and+trimethoxyphenylurea+derivatives+as+novel+human+topoisomerase+II+inhibitors&doi=10.1016%2Fj.ejps.2016.09.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted properties of 1,4-dimethylcarbazoles: Focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors</span></div><div class="casAuthors">Iacopetta, Domenico; Rosano, Camillo; Puoci, Francesco; Parisi, Ortensia Ilaria; Saturnino, Carmela; Caruso, Anna; Longo, Pasquale; Ceramella, Jessica; Malzert-Freon, Aurelie; Dallemagne, Patrick; Rault, Sylvain; Sinicropi, Maria Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263-272</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Natural or synthetic carbazole derivs. have recently attracted the attention of the scientific world because of their multiple biol. activity, leading to an increase of designed, synthesized and studied analogs.  In this paper, four 1,4-dimethylcarbazole derivs., analogs of Ellipticine, have been investigated for their ability to block cancer cells growth, with low effects on the proliferation of normal cells.  DNA topoisomerases inhibition assays, docking simulations, stability studies and effects on a membrane model are reported.  Particularly, compds. 2 and 3 have been found thermally stable and able to inhibit, strongly and selectively, the human DNA topoisomerase II.  These properties confer a good and broad antitumoral activity in vitro, with very low cytotoxic effect on the proliferation of normal cell lines and without damaging, in contrast with Ellipticine, the cell membrane model.  The presented outcomes set the most active compds. as good candidates for pre-clin. studies useful in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovndKvg18iarVg90H21EOLACvtfcHk0lgKBic1utWDsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1akt7bI&md5=88533ae53ed391ef972ef64e217476e5</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.09.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.09.039%26sid%3Dliteratum%253Aachs%26aulast%3DIacopetta%26aufirst%3DD.%26aulast%3DRosano%26aufirst%3DC.%26aulast%3DPuoci%26aufirst%3DF.%26aulast%3DParisi%26aufirst%3DO.%2BI.%26aulast%3DSaturnino%26aufirst%3DC.%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DLongo%26aufirst%3DP.%26aulast%3DCeramella%26aufirst%3DJ.%26aulast%3DMalzert-Fr%25C3%25A9on%26aufirst%3DA.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DRault%26aufirst%3DS.%26aulast%3DSinicropi%26aufirst%3DM.%2BS.%26atitle%3DMultifaceted%2520properties%2520of%25201%252C4-dimethylcarbazoles%253A%2520Focus%2520on%2520trimethoxybenzamide%2520and%2520trimethoxyphenylurea%2520derivatives%2520as%2520novel%2520human%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D96%26spage%3D263%26epage%3D272%26doi%3D10.1016%2Fj.ejps.2016.09.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Evodiamine and its role in chronic diseases</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1007/978-3-319-41342-6_14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2F978-3-319-41342-6_14" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2016&pages=315-328&author=Q.+Tanauthor=J.+Zhang&title=Evodiamine+and+its+role+in+chronic+diseases&doi=10.1007%2F978-3-319-41342-6_14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-41342-6_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-41342-6_14%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DEvodiamine%2520and%2520its%2520role%2520in%2520chronic%2520diseases%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2016%26volume%3D929%26spage%3D315%26epage%3D328%26doi%3D10.1007%2F978-3-319-41342-6_14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span> <span> </span><span class="NLM_article-title">Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2832</span>â <span class="NLM_lpage">2838</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2016.5575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3892%2Fmmr.2016.5575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27485202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSjurnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=2832-2838&author=L.+Linauthor=L.+Renauthor=L.+Wenauthor=Y.+Wangauthor=J.+Qi&title=Effect+of+evodiamine+on+the+proliferation+and+apoptosis+of+A549+human+lung+cancer+cells&doi=10.3892%2Fmmr.2016.5575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells</span></div><div class="casAuthors">Lin, Li; Ren, Li; Wen, Liujing; Wang, Yu; Qi, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2832-2838</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Evodia rutaecarpa is a plant, which has antitumor activity.  Evodiamine is an alkaloid with antitumor activity present in E. rutaecarpa and has potential to be developed into a therapeutic antitumor agent.  The present study investigated the effect of evodiamine on the proliferation of A549 human lung cancer cells and the mechanism underlying these effects.  The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase 3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor ÎB (NF ÎB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.  In conclusion, the evodiamine induced inhibition of the proliferation of A549 lung cancer cells may be attributable to its ability to promote oxidative injury in the cells, induce apoptosis, arrest the cell cycle and regulate the AKT/NF ÎB and SHH/GLI1 signaling pathways, subsequently controlling the expression of tumor assocd. genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyhYaYNGuufbVg90H21EOLACvtfcHk0lgKBic1utWDsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSjurnK&md5=bd1d900edec68f21b888081c1f72034b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.5575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.5575%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520evodiamine%2520on%2520the%2520proliferation%2520and%2520apoptosis%2520of%2520A549%2520human%2520lung%2520cancer%2520cells%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D2832%26epage%3D2838%26doi%3D10.3892%2Fmmr.2016.5575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting Î²-catenin-mediated angiogenesis</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">12791</span>â <span class="NLM_lpage">12803</span>, <span class="refDoi">Â DOI: 10.1007/s13277-016-5251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs13277-016-5251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmsbfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=12791-12803&author=L.+Shiauthor=F.+Yangauthor=F.+Luoauthor=Y.+Liuauthor=F.+Zhangauthor=M.+Zouauthor=Q.+Liu&title=Evodiamine+exerts+anti-tumor+effects+against+hepatocellular+carcinoma+through+inhibiting+%CE%B2-catenin-mediated+angiogenesis&doi=10.1007%2Fs13277-016-5251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting Î²-catenin-mediated angiogenesis</span></div><div class="casAuthors">Shi, Le; Yang, Fan; Luo, Fei; Liu, Yi; Zhang, Feng; Zou, Meijuan; Liu, Qizhan</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">12791-12803</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is a highly vascular tumor with high microvessel d. and high levels of circulating vascular endothelial growth factor (VEGF).  Thus, the angiogenesis pathway is an attractive therapeutic target for HCC.  The anti-tumor effects of evodiamine, a quinolone alkaloid isolated from Euodia rutaecarpa (Juss.) Benth.  (Rutaceae), were investigated in a mouse xenograft model using BALB/c nude mice, various HCC cell lines (HepG2, SMMC-7721, H22), and human umbilical vein endothelial cells (HUVECs).  The effects of evodiamine on tumor vols. and wts., levels of tumor markers, angiogenesis in vivo and in vitro, cell viability, and cell migration and invasion were measured, and the mechanism through which its effects are achieved was investigated.  Transcriptional regulation of VEGFa via interaction with Î²-catenin was established by luciferase activity assays and electrophoretic mobility shift assays.  In a s.c. H22 xenograft model, evodiamine inhibited tumor growth and reduced serum tumor markers and the levels of Î²-catenin and VEGFa.  It also blocked VEGF-induced angiogenesis in a Matrigel plug assay.  Evodiamine suppressed cellular proliferation, invasion, and migration and inhibited tube formation of HUVECs.  Moreover, in a concn.-dependent manner, evodiamine reduced the no. of capillary sprouts from Matrigel-embedded rat thoracic aortic rings.  Also, evodiamine suppressed various biomarkers of angiogenesis and the expression of Î²-catenin.  Evodiamine decreased Î²-catenin levels activated by LiCl, which led to reduced expression of VEGFa.  In addn., Î²-catenin interacted with VEGFa and transcriptionally regulated VEGFa, an effect inhibited by evodiamine in HCCs.  Moreover, in an SMMC-7721 xenograft model, evodiamine suppressed tumor growth, various biomarkers of angiogenesis, and the levels of Î²-catenin and VEGFa.  Evodiamine has anti-tumor effects on HCCs through inhibiting Î²-catenin, which interacts with and reduces VEGFa expression, thus inhibiting angiogenesis.  These results indicate that evodiamine, which inhibits cellular invasion and migration and blocks angiogenesis, is a potential therapeutic agent for HCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobKOTBDYV9pbVg90H21EOLACvtfcHk0lg1yIHW2jLeOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmsbfJ&md5=79676d37c9dd5c5ec4f976502cee3dc0</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1007%2Fs13277-016-5251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-016-5251-3%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DZou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DEvodiamine%2520exerts%2520anti-tumor%2520effects%2520against%2520hepatocellular%2520carcinoma%2520through%2520inhibiting%2520%25CE%25B2-catenin-mediated%2520angiogenesis%26jtitle%3DTumor%2520Biol.%26date%3D2016%26volume%3D37%26spage%3D12791%26epage%3D12803%26doi%3D10.1007%2Fs13277-016-5251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span> <span> </span><span class="NLM_article-title">Evodiamine inhibits PDGF-BB-induced proliferation of rat vascular smooth muscle cells through the suppression of cell cycle progression and oxidative stress</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4551</span>â <span class="NLM_lpage">4558</span>, <span class="refDoi">Â DOI: 10.3892/mmr.2016.5798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.3892%2Fmmr.2016.5798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27748810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1ejsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=4551-4558&author=X.+Geauthor=S.+Y.+Chenauthor=M.+Liuauthor=T.+M.+Liangauthor=C.+Liu&title=Evodiamine+inhibits+PDGF-BB-induced+proliferation+of+rat+vascular+smooth+muscle+cells+through+the+suppression+of+cell+cycle+progression+and+oxidative+stress&doi=10.3892%2Fmmr.2016.5798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Evodiamine inhibits PDGF BB induced proliferation of rat vascular smooth muscle cells through the suppression of cell cycle progression and oxidative stress</span></div><div class="casAuthors">Ge, Xie; Chen, Si-Yu; Liu, Mei; Liang, Ting-Ming; Liu, Chang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4551-4558</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Vascular smooth muscle cell (VSMC) proliferation is a key event in the development of in-stent restenosis.  Evodiamine is an indole alkaloid extd. from the Chinese medicine, evodia, and has been shown to inhibit tumor cell proliferation and protect the cardiovascular system.  However, whether evodiamine affects VSMC proliferation remains to be elucidated.  Therefore, the present study examd. the effects and the mechanisms of action of evodiamine on the proliferation of rat VSMCs.  The cells were treated with evodiamine alone or in combination with platelet-derived growth factor-BB (PDGF-BB) stimulation.  It was found that evodiamine inhibited PDGF-BB-induced VSMC proliferation in a dose-dependent manner, without inducing cell death.  Evodiamine also retarded cell cycle progression, evidenced by the suppression of the expression of cell cycle-promoting cyclin proteins and cyclin-dependent kinases.  In addn., evodiamine attenuated the PDGF-BB-induced phosphorylation of mitogen-activated protein kinases p38 and extracellular signal-regulated kinases 1/2, however, it had no effect on the phosphorylation of Akt.  Evodiamine also inhibited the increase of reactive oxygen species generation and upregulated the mRNA expression levels of genes encoding antioxidant enzymes.  These findings provide important insights into the mechanisms underlying the vasoprotective actions of evodiamine and suggest that it may be a useful therapeutic agent for the treatment of vascular occlusive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVTCjGQ3WNNrVg90H21EOLACvtfcHk0lg1yIHW2jLeOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1ejsLo%253D&md5=0800883e06a1209a3e30fbd4497b65d6</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2016.5798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2016.5798%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DT.%2BM.%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DEvodiamine%2520inhibits%2520PDGF-BB-induced%2520proliferation%2520of%2520rat%2520vascular%2520smooth%2520muscle%2520cells%2520through%2520the%2520suppression%2520of%2520cell%2520cycle%2520progression%2520and%2520oxidative%2520stress%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D4551%26epage%3D4558%26doi%3D10.3892%2Fmmr.2016.5798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Scaffold diversity inspired by the natural product evodiamine discovery of highly potent and multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6678</span>â <span class="NLM_lpage">6696</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00910</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00910" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6678-6696&author=S.+Wangauthor=K.+Fangauthor=G.+Dongauthor=S.+Chenauthor=N.+Liuauthor=Z.+Miaoauthor=J.+Yaoauthor=J.+Liauthor=W.+Zhangauthor=C.+Sheng&title=Scaffold+diversity+inspired+by+the+natural+product+evodiamine+discovery+of+highly+potent+and+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b00910"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00910%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DScaffold%2520diversity%2520inspired%2520by%2520the%2520natural%2520product%2520evodiamine%2520discovery%2520of%2520highly%2520potent%2520and%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6678%26epage%3D6696%26doi%3D10.1021%2Facs.jmedchem.5b00910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PogorelÄnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brvar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajc, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FilipiÄ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span> <span> </span><span class="NLM_article-title">Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIÎ±</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5762</span>â <span class="NLM_lpage">5768</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.10.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.bmcl.2014.10.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25453816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVenur3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5762-5768&author=B.+Pogorel%C4%8Dnikauthor=M.+Brvarauthor=I.+Zajcauthor=M.+Filipi%C4%8Dauthor=T.+Solmajerauthor=A.+Perdih&title=Monocyclic+4-amino-6-%28phenylamino%29-1%2C3%2C5-triazines+as+inhibitors+of+human+DNA+topoisomerase+II%CE%B1&doi=10.1016%2Fj.bmcl.2014.10.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIÎ±</span></div><div class="casAuthors">Pogorelcnik, Barbara; Brvar, Matjaz; Zajc, Irena; Filipic, Metka; Solmajer, Tom; Perdih, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5762-5768</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human DNA topoisomerase IIÎ± (htIIÎ±) is a validated target for the development of anticancer agents.  Starting from the available information about the binding of the purine-based htIIÎ± inhibitors in the ATP binding site the authors designed a virtual screening campaign combining structure-based and ligand-based pharmacophores with a mol. docking calcn. searching for compds. that would contain a monocycle mimetic of the purine moiety.  The authors discovered novel 4-amino-6-(phenylamino)-1,3,5-triazines 6, 7 and 11 as monocyclic htIIÎ± inhibitors targeting the ATP binding site.  Compd. 6 from the 1,3,5-triazine series also displayed cytotoxicity properties in hepatocellular carcinoma (HepG2) cell lines and selectivity against human umbilical vein endothelial (HUVEC) cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWXH0kKOtfdLVg90H21EOLACvtfcHk0lj7dlZopqhUNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVenur3E&md5=c013837cf454cc3a84be32f3d78ee506</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.042%26sid%3Dliteratum%253Aachs%26aulast%3DPogorel%25C4%258Dnik%26aufirst%3DB.%26aulast%3DBrvar%26aufirst%3DM.%26aulast%3DZajc%26aufirst%3DI.%26aulast%3DFilipi%25C4%258D%26aufirst%3DM.%26aulast%3DSolmajer%26aufirst%3DT.%26aulast%3DPerdih%26aufirst%3DA.%26atitle%3DMonocyclic%25204-amino-6-%2528phenylamino%2529-1%252C3%252C5-triazines%2520as%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5762%26epage%3D5768%26doi%3D10.1016%2Fj.bmcl.2014.10.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PogorelÄnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brvar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Å½egura, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FilipiÄ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solmajer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdih, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of mono- and disubstituted 1<i>H</i>-pyrazolo[3,4]pyrimidines and 9<i>H</i>-purines as catalytic inhibitors of human DNA topoisomerase IIÎ±</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">345</span>â <span class="NLM_lpage">359</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201402459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fcmdc.201402459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25522133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFShs7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=345-359&author=B.+Pogorel%C4%8Dnikauthor=M.+Brvarauthor=B.+%C5%BDeguraauthor=M.+Filipi%C4%8Dauthor=T.+Solmajerauthor=A.+Perdih&title=Discovery+of+mono-+and+disubstituted+1H-pyrazolo%5B3%2C4%5Dpyrimidines+and+9H-purines+as+catalytic+inhibitors+of+human+DNA+topoisomerase+II%CE%B1&doi=10.1002%2Fcmdc.201402459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mono- and Disubstituted 1H-Pyrazolo[3,4]pyrimidines and 9H-Purines as Catalytic Inhibitors of Human DNA Topoisomerase IIÎ±</span></div><div class="casAuthors">Pogorelcnik, Barbara; Brvar, Matjaz; Zegura, Bojana; Filipic, Metka; Solmajer, Tom; Perdih, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">345-359</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human DNA topoisomerase IIÎ± (htIIÎ±) is a validated target for the development of anticancer agents.  Based on structural data regarding the binding mode of AMP-PNP (5'-adenylyl-Î²,Î³-imidodiphosphate) to htIIÎ±, we designed a two-stage virtual screening campaign that combines structure-based pharmacophores and mol. docking.  In the first stage, we identified several monosubstituted 9H-purine compds. and a novel class of 1H-pyrazolo[3,4]pyrimidines as inhibitors of htIIÎ±.  In the second stage, disubstituted analogs with improved cellular activities were discovered.  Compds. from both classes were shown to inhibit htIIÎ±-mediated DNA decatenation, and surface plasmon resonance (SPR) expts. confirmed binding of these two compds. on the htIIÎ± ATPase domain.  Proposed complexes and interaction patterns between both compds. and htIIÎ± were further analyzed in mol. dynamics simulations.  Two compds. identified in the second stage showed promising anticancer activities in hepatocellular carcinoma (HepG2) and breast cancer (MCF-7) cell lines.  The discovered compds. are suitable starting points for further hit-to-lead development in anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQwpkZhauA7rVg90H21EOLACvtfcHk0lj7dlZopqhUNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFShs7jP&md5=1f8dab53f316854793616b978591bd79</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402459%26sid%3Dliteratum%253Aachs%26aulast%3DPogorel%25C4%258Dnik%26aufirst%3DB.%26aulast%3DBrvar%26aufirst%3DM.%26aulast%3D%25C5%25BDegura%26aufirst%3DB.%26aulast%3DFilipi%25C4%258D%26aufirst%3DM.%26aulast%3DSolmajer%26aufirst%3DT.%26aulast%3DPerdih%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520mono-%2520and%2520disubstituted%25201H-pyrazolo%255B3%252C4%255Dpyrimidines%2520and%25209H-purines%2520as%2520catalytic%2520inhibitors%2520of%2520human%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D345%26epage%3D359%26doi%3D10.1002%2Fcmdc.201402459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span> <span> </span><span class="NLM_article-title">QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase IIÎ±</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S51577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.2147%2FDDDT.S51577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=24516330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFyjtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=183-195&author=S.+Alamauthor=F.+Khan&title=QSAR+and+docking+studies+on+xanthone+derivatives+for+anticancer+activity+targeting+DNA+topoisomerase+II%CE%B1&doi=10.2147%2FDDDT.S51577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase II Î±</span></div><div class="casAuthors">Alam, Sarfaraz; Khan, Feroz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-195, 13</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Due to the high mortality rate in India, the identification of novel mols. is important in the development of novel and potent anticancer drugs.  Xanthones are natural constituents of plants in the families Bonnetiaceae and Clusiaceae, and comprise oxygenated heterocycles with a variety of biol. activities along with an anticancer effect.  To explore the anticancer compds. from xanthone derivs., a quant. structure activity relationship (QSAR) model was developed by the multiple linear regression method.  The structure-activity relationship represented by the QSAR model yielded a high activity-descriptors relationship accuracy (84%) referred by regression coeff. (r2=0.84) and a high activity prediction accuracy (82%).  Five mol. descriptors - dielec. energy, group count (hydroxyl), LogP (the logarithm of the partition coeff. between n-octanol and water), shape index basic (order 3), and the solvent-accessible surface area - were significantly correlated with anticancer activity.  Using this QSAR model, a set of virtually designed xanthone derivs. was screened out.  A mol. docking study was also carried out to predict the mol. interaction between proposed compds. and DNA (DNA) topoisomerase IIÂ´a.  The pharmacokinetics parameters, such as absorption, distribution, metab., excretion, and toxicity, were also calcd., and later an appraisal of synthetic accessibility of org. compds. was carried out.  The strategy used in this study may provide understanding in designing novel DNA topoisomerase IIÎ± inhibitors, as well as for other cancer targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjn75cri7W07Vg90H21EOLACvtfcHk0lj7dlZopqhUNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFyjtrY%253D&md5=f329803ad231a4c2ac5f19c365b07a60</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S51577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S51577%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DF.%26atitle%3DQSAR%2520and%2520docking%2520studies%2520on%2520xanthone%2520derivatives%2520for%2520anticancer%2520activity%2520targeting%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D183%26epage%3D195%26doi%3D10.2147%2FDDDT.S51577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunin, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuelsson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altera, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrow, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parman, T.</span></span> <span> </span><span class="NLM_article-title">Characterization of batracylin-induced renal and bladder toxicity in rats</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">519</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1177/0192623314548766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1177%2F0192623314548766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25274659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVGjsr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=519-529&author=M.+Davisauthor=D.+I.+Buninauthor=S.+J.+Samuelssonauthor=K.+P.+Alteraauthor=R.+J.+Kindersauthor=S.+M.+Lawrenceauthor=J.+Jiauthor=M.+M.+Amesauthor=S.+A.+Buhrowauthor=C.+Waldenauthor=J.+M.+Reidauthor=L.+L.+Rauschauthor=T.+Parman&title=Characterization+of+batracylin-induced+renal+and+bladder+toxicity+in+rats&doi=10.1177%2F0192623314548766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of batracylin-induced renal and bladder toxicity in rats</span></div><div class="casAuthors">Davis, Myrtle; Bunin, Deborah I.; Samuelsson, Steven J.; Altera, Kenneth P.; Kinders, Robert J.; Lawrence, Scott M.; Ji, Jiuping; Ames, Matthew M.; Buhrow, Sarah A.; Walden, Chad; Reid, Joel M.; Rausch, Linda L.; Parman, Toufan</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-529</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Batracylin (NSC-320846) is a dual inhibitor of DNA topoisomerases I and II.  Batracylin advanced as an anticancer agent to Phase I clin. trials where dose limiting hemorrhagic cystitis (bladder inflammation and bleeding) was obsd.  To further investigate batracylin's mechanism of toxicity, studies were conducted in Fischer 344 rats.  Once daily oral administration of 16 or 32 mg/kg batracylin to rats for 4 days caused overt toxicity.  Abnormal clin. observations and adverse effects on clin. pathol., urinalysis, and histol. indicated acute renal damage and urothelial damage and bone marrow dysfunction.  SEM revealed sloughing of the superficial and intermediate urothelial layers.  DNA damage was evident in kidney and bone marrow as indicated by histone Î³-H2AX immunofluorescence.  After a single oral administration of 16 or 32 mg/ kg, the majority of batracylin was converted to N-acetylbatracylin (NAB) with a half-life of 4 h to 11 h.  Mesna (Mesnex), a drug known to reduce the incidence of hemorrhagic cystitis induced by ifosfamide or cyclophosphamide, was administered to rats prior to batracylin, but did not alleviate batracylin-induced bladder and renal toxicity.  These findings suggest that batracylin results in DNA damage-based mechanisms of toxicity and not an acrolein-based mechanism of toxicity as occurs after ifosfamide or cyclophosphamide administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqTKsO9VUlXbVg90H21EOLACvtfcHk0lhDrJYOXCL-eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVGjsr3F&md5=050d29751f705725119e767657e804f8</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1177%2F0192623314548766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314548766%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DBunin%26aufirst%3DD.%2BI.%26aulast%3DSamuelsson%26aufirst%3DS.%2BJ.%26aulast%3DAltera%26aufirst%3DK.%2BP.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DLawrence%26aufirst%3DS.%2BM.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DBuhrow%26aufirst%3DS.%2BA.%26aulast%3DWalden%26aufirst%3DC.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DRausch%26aufirst%3DL.%2BL.%26aulast%3DParman%26aufirst%3DT.%26atitle%3DCharacterization%2520of%2520batracylin-induced%2520renal%2520and%2520bladder%2520toxicity%2520in%2520rats%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D519%26epage%3D529%26doi%3D10.1177%2F0192623314548766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzeng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of indeno[1,2-<i>b</i>]quinoxaline derivatives as potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">258</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2015.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26686931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Kmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=258-273&author=C.+H.+Tsengauthor=Y.+R.+Chenauthor=C.+C.+Tzengauthor=W.+Liuauthor=C.+K.+Chouauthor=C.+C.+Chiuauthor=Y.+L.+Chen&title=Discovery+of+indeno%5B1%2C2-b%5Dquinoxaline+derivatives+as+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2015.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indeno[1,2-b]quinoxaline derivatives as potential anticancer agents</span></div><div class="casAuthors">Tseng, Chih-Hua; Chen, You-Ren; Tzeng, Cherng-Chyi; Liu, Wangta; Chou, Chon-Kit; Chiu, Chien-Chih; Chen, Yeh-Long</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">258-273</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis of certain indeno[1,2-b]quinoxaline derivs. I [R = 3-(dimethylamino)propyl, 2-(dimethylamino)ethyl, 2-(pyrrolidin-1-yl)ethyl, 2-morpholinoethyl] for antiproliferative evaluation was reported.  Among them, I [R = 3-(dimethylamino)propyl] was active against the growth of MDA-MB231, PC-3 and Huh-7 with IC50 values of 0.87 (selectivity index, SI = 36.22), 0.82 (SI = 38.43), and 0.64 Î¼M (SI = 49.23) resp.  Compd. I [R = 3-(dimethylamino)propyl] was inactive against the growth of normal human fetal lung fibroblast cell line (MRC-5) with an IC50 value of 31.51 Î¼M.  Its analogs, I [R = 2-(dimethylamino)ethyl] and I [R = 2-(pyrrolidin-1-yl)ethyl], were also active against the growth of MB231, PC-3, and Huh-7 with IC50 values of <1.0 Î¼M in each case.  Results also indicated compds. I exhibited comparable inhibitory activities against topo I and topo II with the pos. compd. (E)-6-hydroxy-9-methoxy-11H-indeno[1,2-c]quinolin-11-one O-2-(pyrrolidin-1-yl)ethyl oxime at a concn. of 10 Î¼M.  Mechanism studies indicated that compd. I [R = 3-(dimethylamino)propyl] induced cell cycle arrest at S phase via activation of caspase-3, -7 and an increase in the protein expression of Bad and Bax but a decrease in expression of Bcl-2 and PARP, which consequently cause cell death.  In addn., compd. I [R = 3-(dimethylamino)propyl] attenuated the levels of phosphorylated Src, Akt-1, and Akt-2 protein levels but did not affect the total protein expression of Akt.  Human hepatocellular carcinoma cells also implanted into the yolk sac of zebrafish larvae and incubated larvae with various concns. of I [R = 3-(dimethylamino)propyl].  Results of the zebrafish xenograft assay confirmed the anti-tumor effect of I [R = 3-(dimethylamino)propyl] in-vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk_MC1CklJLVg90H21EOLACvtfcHk0lhDrJYOXCL-eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Kmsw%253D%253D&md5=701f724881ebf8199e32ad335bb85cc5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BR.%26aulast%3DTzeng%26aufirst%3DC.%2BC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DChiu%26aufirst%3DC.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BL.%26atitle%3DDiscovery%2520of%2520indeno%255B1%252C2-b%255Dquinoxaline%2520derivatives%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D258%26epage%3D273%26doi%3D10.1016%2Fj.ejmech.2015.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tabassum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arjmand, F.</span></span> <span> </span><span class="NLM_article-title">New modulated design, docking and synthesis of carbohydrate-conjugate heterobimetallic Cu<sup>II</sup>-Sn<sup>IV</sup> complex as potential topoisomerase II inhibitor: <i>In vitro</i> DNA binding, cleavage and cytotoxicity against human cancer cell lines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">694</span>â <span class="NLM_lpage">702</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.09.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.ejmech.2013.09.036" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=694-702&author=S.+Tabassumauthor=M.+Afzalauthor=F.+Arjmand&title=New+modulated+design%2C+docking+and+synthesis+of+carbohydrate-conjugate+heterobimetallic+CuII-SnIV+complex+as+potential+topoisomerase+II+inhibitor%3A+In+vitro+DNA+binding%2C+cleavage+and+cytotoxicity+against+human+cancer+cell+lines&doi=10.1016%2Fj.ejmech.2013.09.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.036%26sid%3Dliteratum%253Aachs%26aulast%3DTabassum%26aufirst%3DS.%26aulast%3DAfzal%26aufirst%3DM.%26aulast%3DArjmand%26aufirst%3DF.%26atitle%3DNew%2520modulated%2520design%252C%2520docking%2520and%2520synthesis%2520of%2520carbohydrate-conjugate%2520heterobimetallic%2520CuII-SnIV%2520complex%2520as%2520potential%2520topoisomerase%2520II%2520inhibitor%253A%2520In%2520vitro%2520DNA%2520binding%252C%2520cleavage%2520and%2520cytotoxicity%2520against%2520human%2520cancer%2520cell%2520lines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D694%26epage%3D702%26doi%3D10.1016%2Fj.ejmech.2013.09.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisceglie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musiari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alinovi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menozzi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polverini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasconi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span> <span> </span><span class="NLM_article-title">Quinoline-2-carboxaldehyde thiosemicarbazones and their Cu(II) and Ni(II) complexes as topoisomerase IIÎ± inhibitors</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2015.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2015.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26335598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2lsLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2015&pages=10-19&author=F.+Bisceglieauthor=A.+Musiariauthor=S.+Pinelliauthor=R.+Alinoviauthor=I.+Menozziauthor=E.+Polveriniauthor=P.+Tarasconiauthor=M.+Tavoneauthor=G.+Pelosi&title=Quinoline-2-carboxaldehyde+thiosemicarbazones+and+their+Cu%28II%29+and+Ni%28II%29+complexes+as+topoisomerase+II%CE%B1+inhibitors&doi=10.1016%2Fj.jinorgbio.2015.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Quinoline-2-carboxaldehyde thiosemicarbazones and their Cu(II) and Ni(II) complexes as topoisomerase IIa inhibitors</span></div><div class="casAuthors">Bisceglie, Franco; Musiari, Anastasia; Pinelli, Silvana; Alinovi, Rossella; Menozzi, Ilaria; Polverini, Eugenia; Tarasconi, Pieralberto; Tavone, Matteo; Pelosi, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-19</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of quinoline-2-carboxaldehyde thiosemicarbazones and their copper(II) and nickel(II) complexes were synthesized and characterized.  In all complexes the ligands are in the E configuration with respect to the imino bond and behave as tridentate binding ligands.  The copper(II) complexes form square planar derivs. with one mol. of terdentate ligand and chloride ion.  A further non-coordinated chloride ion compensates the overall charge.  Nickel(II) ions form instead octahedral complexes with two ligands for each metal ion, independently from the stoichiometric metal:ligand ratio used in the synthesis.  Ligands and complexes were tested for their antiproliferative properties on histiocytic lymphoma cell line U937.  Copper(II) derivs. are systematically more active than the ligands and the nickel complexes.  All copper derivs. result in inhibiting topoisomerase IIa in vitro.  Computational methods were used to propose a model to explain the different extent of inhibition presented by these compds.  The pos. charge of the dissocd. form of the copper complexes may play a key role in their action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN4G9akpb26bVg90H21EOLACvtfcHk0lhDrJYOXCL-eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2lsLzJ&md5=f388c698f63dce138a613317861b8881</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2015.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2015.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DBisceglie%26aufirst%3DF.%26aulast%3DMusiari%26aufirst%3DA.%26aulast%3DPinelli%26aufirst%3DS.%26aulast%3DAlinovi%26aufirst%3DR.%26aulast%3DMenozzi%26aufirst%3DI.%26aulast%3DPolverini%26aufirst%3DE.%26aulast%3DTarasconi%26aufirst%3DP.%26aulast%3DTavone%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DG.%26atitle%3DQuinoline-2-carboxaldehyde%2520thiosemicarbazones%2520and%2520their%2520Cu%2528II%2529%2520and%2520Ni%2528II%2529%2520complexes%2520as%2520topoisomerase%2520II%25CE%25B1%2520inhibitors%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2015%26volume%3D152%26spage%3D10%26epage%3D19%26doi%3D10.1016%2Fj.jinorgbio.2015.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGill, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisic, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deweese, J. E.</span></span> <span> </span><span class="NLM_article-title">Examination of the impact of copper(II) Î±(<i>N</i>)-heterocyclic thiosemicarbazone complexes on DNA topoisomerase IIÎ±</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">649</span>â <span class="NLM_lpage">658</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.5b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=649-658&author=J.+T.+Wilsonauthor=X.+Jiangauthor=B.+C.+McGillauthor=E.+C.+Lisicauthor=J.+E.+Deweese&title=Examination+of+the+impact+of+copper%28II%29+%CE%B1%28N%29-heterocyclic+thiosemicarbazone+complexes+on+DNA+topoisomerase+II%CE%B1&doi=10.1021%2Facs.chemrestox.5b00471"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00471%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DMcGill%26aufirst%3DB.%2BC.%26aulast%3DLisic%26aufirst%3DE.%2BC.%26aulast%3DDeweese%26aufirst%3DJ.%2BE.%26atitle%3DExamination%2520of%2520the%2520impact%2520of%2520copper%2528II%2529%2520%25CE%25B1%2528N%2529-heterocyclic%2520thiosemicarbazone%2520complexes%2520on%2520DNA%2520topoisomerase%2520II%25CE%25B1%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D649%26epage%3D658%26doi%3D10.1021%2Facs.chemrestox.5b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barra, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manente, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, I. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauro, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netto, A. V.</span></span> <span> </span><span class="NLM_article-title">Cationic Pd(II) complexes acting as topoisomerase II inhibitors: Synthesis, characterization, DNA interaction and cytotoxicity</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">168</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2016.02.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2016.02.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27045995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVWkt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2016&pages=165-168&author=F.+V.+Rochaauthor=C.+V.+Barraauthor=S.+S.+Garridoauthor=F.+A.+Manenteauthor=I.+Z.+Carlosauthor=J.+Ellenaauthor=A.+S.+Fuentesauthor=A.+Gautierauthor=L.+Morelauthor=A.+E.+Mauroauthor=A.+V.+Netto&title=Cationic+Pd%28II%29+complexes+acting+as+topoisomerase+II+inhibitors%3A+Synthesis%2C+characterization%2C+DNA+interaction+and+cytotoxicity&doi=10.1016%2Fj.jinorgbio.2016.02.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Cationic Pd(II) complexes acting as topoisomerase II inhibitors: Synthesis, characterization, DNA interaction and cytotoxicity</span></div><div class="casAuthors">Rocha, Fillipe V.; Barra, Carolina V.; Garrido, Saulo S.; Manente, Francine A.; Carlos, Iracilda Z.; Ellena, Javier; Fuentes, Andrea S. C.; Gautier, Arnaud; Morel, Laurent; Mauro, Antonio E.; Netto, Adelino V. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-168</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pd(II) 4-methyl-3-thiosemicarbazide complexes with interesting in vitro antitumor activity were synthesized.  These compds. are unable to interact to the DNA in low concn., but are capable of inhibiting human topoisomerase II and cathepsin B in the same range of concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomyX_JTIaqpbVg90H21EOLACvtfcHk0liAP-CxBstdGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVWkt7s%253D&md5=a68bb81e9c646e640e60a225e16e42fe</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2016.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2016.02.039%26sid%3Dliteratum%253Aachs%26aulast%3DRocha%26aufirst%3DF.%2BV.%26aulast%3DBarra%26aufirst%3DC.%2BV.%26aulast%3DGarrido%26aufirst%3DS.%2BS.%26aulast%3DManente%26aufirst%3DF.%2BA.%26aulast%3DCarlos%26aufirst%3DI.%2BZ.%26aulast%3DEllena%26aufirst%3DJ.%26aulast%3DFuentes%26aufirst%3DA.%2BS.%26aulast%3DGautier%26aufirst%3DA.%26aulast%3DMorel%26aufirst%3DL.%26aulast%3DMauro%26aufirst%3DA.%2BE.%26aulast%3DNetto%26aufirst%3DA.%2BV.%26atitle%3DCationic%2520Pd%2528II%2529%2520complexes%2520acting%2520as%2520topoisomerase%2520II%2520inhibitors%253A%2520Synthesis%252C%2520characterization%252C%2520DNA%2520interaction%2520and%2520cytotoxicity%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2016%26volume%3D159%26spage%3D165%26epage%3D168%26doi%3D10.1016%2Fj.jinorgbio.2016.02.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MitroviÄ, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SosiÄ, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span> <span> </span><span class="NLM_article-title">Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">16913</span>â <span class="NLM_lpage">16921</span>, <span class="refDoi">Â DOI: 10.1039/C6DT02369J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC6DT02369J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27711842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWlsbrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=16913-16921&author=A.+Mitrovi%C4%87author=J.+Kljunauthor=I.+Sosi%C4%8Dauthor=S.+Gobecauthor=I.+Turelauthor=J.+Kos&title=Clioquinol-ruthenium+complex+impairs+tumour+cell+invasion+by+inhibiting+cathepsin+B+activity&doi=10.1039%2FC6DT02369J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity</span></div><div class="casAuthors">Mitrovic, Ana; Kljun, Jakob; Sosic, Izidor; Gobec, Stanislav; Turel, Iztok; Kos, Janko</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">16913-16921</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Over the past few years, the organometalled compds., including ruthenium, gained a lot of attention as anticancer agents.  We report on the clioquinol-ruthenium complex [Ru(Î·6-p-cymene)(Cq)Cl] as a potent inhibitor of cathepsin B, a lysosomal cysteine peptidase, involved in tumor cell invasion and metastasis.  In the low micromolar concn. range, the clioquinol-ruthenium complex did not exhibit cytotoxic effects on MCF-10A neoT and U-87 MG cells; it did, however, significantly reduce their ability for extracellular matrix degrdn. and invasiveness in two independent cell-based models, measuring either elec. impedance in real time or the growth of multicellular tumor spheroids implanted in Matrigel, a model representing the extracellular matrix.  These results establish ruthenium based organometallic compds. as promising candidates for further pre-clin. studies as anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2u9JSigLoF7Vg90H21EOLACvtfcHk0liAP-CxBstdGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWlsbrK&md5=d738041691cff1b992272d50118f0186</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1039%2FC6DT02369J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT02369J%26sid%3Dliteratum%253Aachs%26aulast%3DMitrovi%25C4%2587%26aufirst%3DA.%26aulast%3DKljun%26aufirst%3DJ.%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DS.%26aulast%3DTurel%26aufirst%3DI.%26aulast%3DKos%26aufirst%3DJ.%26atitle%3DClioquinol-ruthenium%2520complex%2520impairs%2520tumour%2520cell%2520invasion%2520by%2520inhibiting%2520cathepsin%2520B%2520activity%26jtitle%3DDalton.%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D16913%26epage%3D16921%26doi%3D10.1039%2FC6DT02369J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G.</span></span> <span> </span><span class="NLM_article-title">Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">7817</span>â <span class="NLM_lpage">7823</span>, <span class="refDoi">Â DOI: 10.1039/c0dt01816c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc0dt01816c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=21629963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptleqs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=7817-7823&author=A.+Bergamoauthor=G.+Sava&title=Ruthenium+anticancer+compounds%3A+myths+and+realities+of+the+emerging+metal-based+drugs&doi=10.1039%2Fc0dt01816c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs</span></div><div class="casAuthors">Bergamo, Alberta; Sava, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">7817-7823</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Ru anticancer drugs have attracted an increasing interest in the last 20 years and 2 of them have entered clin. trials.  Compared to Pt drugs, the complexes based on Ru are often identified as less toxic and capable of overcoming the resistance induced by platinum drugs in cancer cells.  These activities were attributed to the transportation to tumor cells by transferrin and to the selective activation to more reactive species by the reducing environment of solid tumors as compared to healthy tissues.  Ru anticancer drugs were almost always designed to mimic platinum drugs, particularly for targeting DNA.  Indeed, none of the above properties has never been clearly demonstrated even for the Ru drugs that entered clin. trials.  The suggestion for the future is to change the perspective when designing new chem. entities, abandoning the philosophy that guided the actual panel of Ru drugs and to look further into the fine mechanism by which the most relevant ruthenium complexes available kill the target tumor cells, then focusing on targets selective of tumor cells and responsible for cell growth and malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo6uOiHOBkJLVg90H21EOLACvtfcHk0lh7Qb3UvlUE8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptleqs7c%253D&md5=834f2ebd83602caa4abfc34b9376cba3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2Fc0dt01816c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt01816c%26sid%3Dliteratum%253Aachs%26aulast%3DBergamo%26aufirst%3DA.%26aulast%3DSava%26aufirst%3DG.%26atitle%3DRuthenium%2520anticancer%2520compounds%253A%2520myths%2520and%2520realities%2520of%2520the%2520emerging%2520metal-based%2520drugs%26jtitle%3DDalton.%2520Trans.%26date%3D2011%26volume%3D40%26spage%3D7817%26epage%3D7823%26doi%3D10.1039%2Fc0dt01816c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-Loncella, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purazo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorchak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shriver, C. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cancer cell growth by ruthenium complexes</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">48</span>, <span class="refDoi">Â DOI: 10.1186/s12967-016-0797-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1186%2Fs12967-016-0797-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26867596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1ehsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=48&author=J.+Iidaauthor=E.+T.+Bell-Loncellaauthor=M.+L.+Purazoauthor=Y.+Luauthor=J.+Dorchakauthor=R.+Clancyauthor=J.+Slavikauthor=M.+L.+Cutlerauthor=C.+D.+Shriver&title=Inhibition+of+cancer+cell+growth+by+ruthenium+complexes&doi=10.1186%2Fs12967-016-0797-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cancer cell growth by ruthenium complexes</span></div><div class="casAuthors">Iida, Joji; Bell-Loncella, Elisabeth T.; Purazo, Marc L.; Lu, Yifeng; Dorchak, Jesse; Clancy, Rebecca; Slavik, Julianna; Cutler, Mary Lou; Shriver, Craig D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48/1-48/10</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Previous studies suggest that certain transition metal complexes, such as cisplatin, are efficacious for treating various cancer types, including ovarian, lung, and breast.  Methods: In order to further evaluate ruthenium (Ru) complexes as potential anti-cancer agents, we synthesized and evaluated Ru-arene complexes.  Two complexes with the general formula [Ru (Î·6-p-cym) (N-N) Cl]+ were tested for their abilities to inhibit cancer cells.  Results: The complex with o-phenylenediamine as the N-N ligand (o-PDA) significantly inhibited growth of breast (MDA-MB-231, MCF-7, SKBR-3, and SUM149), lymphoma (Raji), melanoma (Bowes), and osteosarcoma (HT1080); however, the complex with o-benzoquinonediimine (o-BQDI) was ineffective except for SUM149.  In contrast, o-PDA failed to inhibit growth of human breast epithelial cells, MCF-10A.  Treatment of MDA-MBA-231 cells with o-PDA resulted in a significant redn. of productions of PDGF-AA, GM-CSF, and VEGF-A proteins at the transcriptional levels.  Finally, we demonstrated that o-PDA synergistically inhibited MDA-MB-231 cell growth with cyclophosphamide but not doxorubicin or paclitaxel.  Conclusion: These results suggest that Ru-arene complexes are promising anti-cancer drugs that inhibit progression and metastasis by blocking multiple processes for breast and other types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GEM4VtJ0jrVg90H21EOLACvtfcHk0lh7Qb3UvlUE8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1ehsb8%253D&md5=b8d1aeb4e6d7d26deee78860b1886119</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1186%2Fs12967-016-0797-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-016-0797-9%26sid%3Dliteratum%253Aachs%26aulast%3DIida%26aufirst%3DJ.%26aulast%3DBell-Loncella%26aufirst%3DE.%2BT.%26aulast%3DPurazo%26aufirst%3DM.%2BL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDorchak%26aufirst%3DJ.%26aulast%3DClancy%26aufirst%3DR.%26aulast%3DSlavik%26aufirst%3DJ.%26aulast%3DCutler%26aufirst%3DM.%2BL.%26aulast%3DShriver%26aufirst%3DC.%2BD.%26atitle%3DInhibition%2520of%2520cancer%2520cell%2520growth%2520by%2520ruthenium%2520complexes%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2016%26volume%3D14%26spage%3D48%26doi%3D10.1186%2Fs12967-016-0797-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eble, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamo, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of adhesion, migration and of Î±5Î²1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">225</span>â <span class="NLM_lpage">235</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2016.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2016.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26961176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVGhtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=225-235&author=C.+Pelilloauthor=H.+Mollicaauthor=J.+A.+Ebleauthor=J.+Groscheauthor=L.+Herzogauthor=B.+Codanauthor=G.+Savaauthor=A.+Bergamo&title=Inhibition+of+adhesion%2C+migration+and+of+%CE%B15%CE%B21+integrin+in+the+HCT-116+colorectal+cancer+cells+treated+with+the+ruthenium+drug+NAMI-A&doi=10.1016%2Fj.jinorgbio.2016.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of adhesion, migration and of Î±5Î²1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A</span></div><div class="casAuthors">Pelillo, Chiara; Mollica, Hilaria; Eble, Johannes A.; Grosche, Julius; Herzog, Lea; Codan, Barbara; Sava, Gianni; Bergamo, Alberta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-235</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NAMI-A, imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate, is a ruthenium-based drug characterised by the selective activity against tumor metastases.  Previously we have shown the influence of the hepatic microenvironment to direct the arrest of the metastatic cells of colorectal cancer.  Here we used the exptl. model of HCT-116 colorectal cancer cells in vitro to explore whether the interference with Î±5Î²1 integrin may mechanistically explain the anti-metastatic effect of NAMI-A.  NAMI-A inhibits two important steps of the tumor metastatic progression of colorectal cancer, i.e. the adhesion and migration of the tumor cells on the extracellular matrix proteins.  The fibronectin receptor Î±5Î²1 integrin is likely involved in the anti-adhesive effects of NAMI-A on the HCT-116 colorectal cancer cells during their interaction with the extracellular matrix.  Mechanistically, NAMI-A decreases the Î±5Î²1 integrin expression, and reduces FAK (Focal Adhesion Kinase) auto-phosphorylation on Tyr397, an important signalling event, involved in Î±5Î²1 integrin activation.  These effects were validated by siRNA-induced knock down of the Î±5 integrin subunit and/or by the use of specific blocking mAbs against the active site of the integrin.  Our results demonstrate the relevance of Î±5Î²1 integrin for colorectal cancer.  We also show that the anti-metastatic effect of NAMI-A depends on the modulation of this integrin.  Thus, our data on NAMI-A support the new concept that metal-based drugs can inhibit tumor metastases through targeting of integrins and of other proteins which mediate tumor progression-related cell functions such as adhesion and migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbFwTSmGQ-I7Vg90H21EOLACvtfcHk0lh7Qb3UvlUE8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVGhtbg%253D&md5=5e6745e2a1335e276db5132381e3ad43</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2016.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2016.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DPelillo%26aufirst%3DC.%26aulast%3DMollica%26aufirst%3DH.%26aulast%3DEble%26aufirst%3DJ.%2BA.%26aulast%3DGrosche%26aufirst%3DJ.%26aulast%3DHerzog%26aufirst%3DL.%26aulast%3DCodan%26aufirst%3DB.%26aulast%3DSava%26aufirst%3DG.%26aulast%3DBergamo%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520adhesion%252C%2520migration%2520and%2520of%2520%25CE%25B15%25CE%25B21%2520integrin%2520in%2520the%2520HCT-116%2520colorectal%2520cancer%2520cells%2520treated%2520with%2520the%2520ruthenium%2520drug%2520NAMI-A%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2016%26volume%3D160%26spage%3D225%26epage%3D235%26doi%3D10.1016%2Fj.jinorgbio.2016.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunden, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenzel, M. H.</span></span> <span> </span><span class="NLM_article-title">Anti-metastatic effects of RAPTA-C conjuated polymeric micelles on two-dimensional (2D) breast tumor cells and three-dimensional (3D) multicellular tumor spheroids</span>. <i>Acta Biomater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">68</span>â <span class="NLM_lpage">76</span>, <span class="refDoi">Â DOI: 10.1016/j.actbio.2015.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.actbio.2015.12.020" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=68-76&author=H.+Luauthor=B.+M.+Blundenauthor=W.+Scaranoauthor=M.+Luauthor=M.+H.+Stenzel&title=Anti-metastatic+effects+of+RAPTA-C+conjuated+polymeric+micelles+on+two-dimensional+%282D%29+breast+tumor+cells+and+three-dimensional+%283D%29+multicellular+tumor+spheroids&doi=10.1016%2Fj.actbio.2015.12.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.actbio.2015.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.actbio.2015.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DBlunden%26aufirst%3DB.%2BM.%26aulast%3DScarano%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DStenzel%26aufirst%3DM.%2BH.%26atitle%3DAnti-metastatic%2520effects%2520of%2520RAPTA-C%2520conjuated%2520polymeric%2520micelles%2520on%2520two-dimensional%2520%25282D%2529%2520breast%2520tumor%2520cells%2520and%2520three-dimensional%2520%25283D%2529%2520multicellular%2520tumor%2520spheroids%26jtitle%3DActa%2520Biomater.%26date%3D2016%26volume%3D32%26spage%3D68%26epage%3D76%26doi%3D10.1016%2Fj.actbio.2015.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G.</span></span> <span> </span><span class="NLM_article-title">In vivo tumour and metastasis reduction and <i>in vitro</i> effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">79</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1016/j.jinorgbio.2009.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.jinorgbio.2009.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=19906432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=79-86&author=A.+Bergamoauthor=A.+Masiauthor=A.+F.+Peacockauthor=A.+Habtemariamauthor=P.+J.+Sadlerauthor=G.+Sava&title=In+vivo+tumour+and+metastasis+reduction+and+in+vitro+effects+on+invasion+assays+of+the+ruthenium+RM175+and+osmium+AFAP51+organometallics+in+the+mammary+cancer+model&doi=10.1016%2Fj.jinorgbio.2009.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo tumor and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model</span></div><div class="casAuthors">Bergamo, A.; Masi, A.; Peacock, A. F. A.; Habtemariam, A.; Sadler, P. J.; Sava, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-86</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have compared the organometallic arene complexes [(Î·6-biphenyl)M(ethylenediamine)Cl]+ RM175 (M = RuII) and its isostructural osmium(II) analog AFAP51 (M = OsII) for their ability to induce cell detachment resistance from fibronectin, collagen IV and poly--lysine, and cell re-adhesion after treatment, their effects on cell migration and cell viability, on matrix metalloproteinases prodn., and on primary tumor growth of MCa mammary carcinoma, the effect of human serum albumin on their cytotoxicity.  There are differences between ruthenium and osmium.  The Os complex is up to 6Ã more potent than RM175 towards highly-invasive breast MDA-MB-231, human breast MCF-7 and human epithelial HBL-100 cancer cells, but whereas RM175 was active against MCa mammary carcinoma in vivo and caused metastasis redn., AFAP51 was not.  Intriguingly the presence of human serum albumin in the growth medium enhanced the cytotoxicity of both compds.  RM175 increased the resistance of MDA-MB-231 cells to detachment from substrates and both compds. inhibited the prodn. of MMP-2.  These data confirm the key role of ruthenium itself in anti-metastatic activity.  It will be interesting to explore the activity of osmium arene complexes in other tumor models and the possibility of changing the non-arene ligands to tune the anticancer activity of osmium in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6s0C91SLLYrVg90H21EOLACvtfcHk0ljMRpGr4pYhfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhurnN&md5=0f04eebc507085087f8f8612b95553e0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2009.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2009.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DBergamo%26aufirst%3DA.%26aulast%3DMasi%26aufirst%3DA.%26aulast%3DPeacock%26aufirst%3DA.%2BF.%26aulast%3DHabtemariam%26aufirst%3DA.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26aulast%3DSava%26aufirst%3DG.%26atitle%3DIn%2520vivo%2520tumour%2520and%2520metastasis%2520reduction%2520and%2520in%2520vitro%2520effects%2520on%2520invasion%2520assays%2520of%2520the%2520ruthenium%2520RM175%2520and%2520osmium%2520AFAP51%2520organometallics%2520in%2520the%2520mammary%2520cancer%2520model%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2010%26volume%3D104%26spage%3D79%26epage%3D86%26doi%3D10.1016%2Fj.jinorgbio.2009.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Topoisomerase IIÎ± poisoning and DNA double-strand breaking by chiral ruthenium(II) complexes containing 2-furanyl-imidazo[4,5-<i>f</i>][1,10] phenanthroline derivatives</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">10546</span>â <span class="NLM_lpage">10555</span>, <span class="refDoi">Â DOI: 10.1039/C6DT01422D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC6DT01422D" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=10546-10555&author=C.+Qianauthor=J.+Wuauthor=L.+Jiauthor=H.+Chao&title=Topoisomerase+II%CE%B1+poisoning+and+DNA+double-strand+breaking+by+chiral+ruthenium%28II%29+complexes+containing+2-furanyl-imidazo%5B4%2C5-f%5D%5B1%2C10%5D+phenanthroline+derivatives&doi=10.1039%2FC6DT01422D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1039%2FC6DT01422D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01422D%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DTopoisomerase%2520II%25CE%25B1%2520poisoning%2520and%2520DNA%2520double-strand%2520breaking%2520by%2520chiral%2520ruthenium%2528II%2529%2520complexes%2520containing%25202-furanyl-imidazo%255B4%252C5-f%255D%255B1%252C10%255D%2520phenanthroline%2520derivatives%26jtitle%3DDalton.%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D10546%26epage%3D10555%26doi%3D10.1039%2FC6DT01422D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of polypyridyl ruthenium(II) complexes as DNA intercalators, DNA photocleavage reagents, and DNA topoisomerase and RNA polymerase inhibitors</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">367</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1002/cbdv.201100414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1002%2Fcbdv.201100414" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=367-384&author=X.+Chenauthor=F.+Gaoauthor=W.+Y.+Yangauthor=Z.+X.+Zhouauthor=J.+Q.+Linauthor=L.+N.+Ji&title=Structure-activity+relationship+of+polypyridyl+ruthenium%28II%29+complexes+as+DNA+intercalators%2C+DNA+photocleavage+reagents%2C+and+DNA+topoisomerase+and+RNA+polymerase+inhibitors&doi=10.1002%2Fcbdv.201100414"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201100414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201100414%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DW.%2BY.%26aulast%3DZhou%26aufirst%3DZ.%2BX.%26aulast%3DLin%26aufirst%3DJ.%2BQ.%26aulast%3DJi%26aufirst%3DL.%2BN.%26atitle%3DStructure-activity%2520relationship%2520of%2520polypyridyl%2520ruthenium%2528II%2529%2520complexes%2520as%2520DNA%2520intercalators%252C%2520DNA%2520photocleavage%2520reagents%252C%2520and%2520DNA%2520topoisomerase%2520and%2520RNA%2520polymerase%2520inhibitors%26jtitle%3DChem.%2520Biodiversity%26date%3D2013%26volume%3D10%26spage%3D367%26epage%3D384%26doi%3D10.1002%2Fcbdv.201100414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">DNA-binding, topoisomerases I and II inhibition and in vitro cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)<sub>2</sub>L]<sup>2+</sup> (L = dppz-11-CO<sub>2</sub>Me and dppz)</span>. <i>Spectrochim. Acta, Part A</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1016/j.saa.2014.06.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2Fj.saa.2014.06.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=25062055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=101-109&author=X.+Heauthor=L.+Jinauthor=L.+Tan&title=DNA-binding%2C+topoisomerases+I+and+II+inhibition+and+in+vitro+cytotoxicity+of+ruthenium%28II%29+polypyridyl+complexes%3A+%5BRu%28dppz%292L%5D2%2B+%28L+%3D+dppz-11-CO2Me+and+dppz%29&doi=10.1016%2Fj.saa.2014.06.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-binding, topoisomerases I and II inhibition and in vitro cytotoxicity of ruthenium(II) polypyridyl complexes: [Ru(dppz)2L]2+ (L = dppz-11-CO2Me and dppz)</span></div><div class="casAuthors">He, Xiaojun; Jin, Lianhe; Tan, Lifeng</div><div class="citationInfo"><span class="NLM_cas:title">Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">101-109</span>CODEN:
                <span class="NLM_cas:coden">SAMCAS</span>;
        ISSN:<span class="NLM_cas:issn">1386-1425</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Two ruthenium(II) polypyridyl complexes, [Ru(dppz)2dppz-11-CO2Me](ClO4)2 (Ru1) and [Ru(dppz)3](ClO4)2 (Ru2), have been synthesized and characterized (dppz = dipyrido[3,2-a:2',3'-c]phenazine; dppz-11-CO2Me = Me dipyrido[3,2-a:2',3'-c]phenazine-11-carboxylate).  The spectral characteristics of Ru1 and Ru2 were investigated by fluorescence spectroscopy and revealed that both complexes were sensitive to solvent polarity.  The binding properties of the two complexes towards calf-thymus DNA (CT-DNA) have been investigated by different spectrophotometric methods and viscosity measurements, indicating that both complexes bind to CT-DNA by intercalation, but with different binding affinities.  Topoisomerase inhibition and DNA strand passage assay demonstrates that the two complexes are dual inhibitors of topoisomerases I and IIa.  However, the cytotoxicity of both complexes has been evaluated by MTT assays and Giemsa staining expts.  The main results reveal that the ester functional group has a significant effect on the DNA-binding affinities and topoisomerases inhibition effects of Ru1 and Ru2, and further advance the authors' knowledge on the DNA-binding and topoisomerase inhibition by Ru(II) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppit6q12DgL7Vg90H21EOLACvtfcHk0ljMRpGr4pYhfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KlsrbL&md5=8e0cc6e987cdf93432132daa43790600</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.saa.2014.06.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.saa.2014.06.147%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26atitle%3DDNA-binding%252C%2520topoisomerases%2520I%2520and%2520II%2520inhibition%2520and%2520in%2520vitro%2520cytotoxicity%2520of%2520ruthenium%2528II%2529%2520polypyridyl%2520complexes%253A%2520%255BRu%2528dppz%25292L%255D2%252B%2520%2528L%2520%253D%2520dppz-11-CO2Me%2520and%2520dppz%2529%26jtitle%3DSpectrochim.%2520Acta%252C%2520Part%2520A%26date%3D2015%26volume%3D135%26spage%3D101%26epage%3D109%26doi%3D10.1016%2Fj.saa.2014.06.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of topoisomerases I and IIÎ± by ruthenium(II) complexes containing asymmetric tridentate ligands</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">17303</span>â <span class="NLM_lpage">17316</span>, <span class="refDoi">Â DOI: 10.1039/C4DT02142H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2FC4DT02142H" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=17303-17316&author=K.+Duauthor=J.+Liangauthor=Y.+Wangauthor=J.+Kouauthor=C.+Qianauthor=L.+Jiauthor=H.+Chao&title=Dual+inhibition+of+topoisomerases+I+and+II%CE%B1+by+ruthenium%28II%29+complexes+containing+asymmetric+tridentate+ligands&doi=10.1039%2FC4DT02142H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2FC4DT02142H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT02142H%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKou%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DDual%2520inhibition%2520of%2520topoisomerases%2520I%2520and%2520II%25CE%25B1%2520by%2520ruthenium%2528II%2529%2520complexes%2520containing%2520asymmetric%2520tridentate%2520ligands%26jtitle%3DDalton.%2520Trans.%26date%3D2014%26volume%3D43%26spage%3D17303%26epage%3D17316%26doi%3D10.1039%2FC4DT02142H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MuthnÃ¡, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TomÅ¡Ã­k, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havelek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KÃ¶hlerovÃ¡, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasilingam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ÄermÃ¡kovÃ¡, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StÃ­bal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ÅezÃ¡ÄovÃ¡, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¼ss-Fink, G.</span></span> <span> </span><span class="NLM_article-title">In-vitro and in-vivo evaluation of the anticancer activity of diruthenium-2, a new trithiolato arene ruthenium complex [(Î·<sup>6</sup>-<i>p</i>-MeC<sub>6</sub>H<sub>4</sub>Pr<sup><i>i</i></sup>)<sub>2</sub>Ru<sub>2</sub>(Î¼-S- <i>p</i>-C<sub>6</sub>H<sub>4</sub>OH)<sub>3</sub>]Cl</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">643</span>â <span class="NLM_lpage">650</span>, <span class="refDoi">Â DOI: 10.1097/CAD.0000000000000374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1097%2FCAD.0000000000000374" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=643-650&author=D.+Muthn%C3%A1author=P.+Tom%C5%A1%C3%ADkauthor=R.+Havelekauthor=R.+K%C3%B6hlerov%C3%A1author=V.+Kasilingamauthor=E.+%C4%8Cerm%C3%A1kov%C3%A1author=D.+St%C3%ADbalauthor=M.+%C5%98ez%C3%A1%C4%8Dov%C3%A1author=G.+S%C3%BCss-Fink&title=In-vitro+and+in-vivo+evaluation+of+the+anticancer+activity+of+diruthenium-2%2C+a+new+trithiolato+arene+ruthenium+complex+%5B%28%CE%B76-p-MeC6H4Pri%292Ru2%28%CE%BC-S-+p-C6H4OH%293%5DCl&doi=10.1097%2FCAD.0000000000000374"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000374%26sid%3Dliteratum%253Aachs%26aulast%3DMuthn%25C3%25A1%26aufirst%3DD.%26aulast%3DTom%25C5%25A1%25C3%25ADk%26aufirst%3DP.%26aulast%3DHavelek%26aufirst%3DR.%26aulast%3DK%25C3%25B6hlerov%25C3%25A1%26aufirst%3DR.%26aulast%3DKasilingam%26aufirst%3DV.%26aulast%3D%25C4%258Cerm%25C3%25A1kov%25C3%25A1%26aufirst%3DE.%26aulast%3DSt%25C3%25ADbal%26aufirst%3DD.%26aulast%3D%25C5%2598ez%25C3%25A1%25C4%258Dov%25C3%25A1%26aufirst%3DM.%26aulast%3DS%25C3%25BCss-Fink%26aufirst%3DG.%26atitle%3DIn-vitro%2520and%2520in-vivo%2520evaluation%2520of%2520the%2520anticancer%2520activity%2520of%2520diruthenium-2%252C%2520a%2520new%2520trithiolato%2520arene%2520ruthenium%2520complex%2520%255B%2528%25CE%25B76-p-MeC6H4Pri%25292Ru2%2528%25CE%25BC-S-%2520p-C6H4OH%25293%255DCl%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2016%26volume%3D27%26spage%3D643%26epage%3D650%26doi%3D10.1097%2FCAD.0000000000000374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilruba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalayda, G. V.</span></span> <span> </span><span class="NLM_article-title">Platinum-based drugs: past, present and future</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1103</span>â <span class="NLM_lpage">1124</span>, <span class="refDoi">Â DOI: 10.1007/s00280-016-2976-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1007%2Fs00280-016-2976-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26886018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2016&pages=1103-1124&author=S.+Dilrubaauthor=G.+V.+Kalayda&title=Platinum-based+drugs%3A+past%2C+present+and+future&doi=10.1007%2Fs00280-016-2976-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum-based drugs: past, present and future</span></div><div class="casAuthors">Dilruba, Shahana; Kalayda, Ganna V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1103-1124</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms.  Their clin. success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment.  Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clin. application so far.  Nedaplatin, lobaplatin and heptaplatin received only regional approval.  Some new platinum complexes and platinum drug formulations are undergoing clin. trials.  Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biol. active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems.  For each class of compds., a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clin. used platinum drugs, and the clin. perspectives are discussed.  A crit. anal. of lessons to be learned is presented.  Finally, a general outlook regarding future directions in the field of new platinum drugs is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfV4v-5JjduLVg90H21EOLACvtfcHk0lgtdwtXDTvn2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D&md5=1e1882f631ad56ef1a07b2075b1faa5e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-2976-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-2976-z%26sid%3Dliteratum%253Aachs%26aulast%3DDilruba%26aufirst%3DS.%26aulast%3DKalayda%26aufirst%3DG.%2BV.%26atitle%3DPlatinum-based%2520drugs%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D77%26spage%3D1103%26epage%3D1124%26doi%3D10.1007%2Fs00280-016-2976-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span> <span> </span><span class="NLM_article-title">Chiral ruthenium(II) complexes with phenolic hydroxyl groups as dual poisons of topoisomerases I and IIÎ±</span>. <i>Dalton. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">8907</span>â <span class="NLM_lpage">8917</span>, <span class="refDoi">Â DOI: 10.1039/c3dt50472g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1039%2Fc3dt50472g" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=8907-8917&author=P.+Zhangauthor=J.+Wangauthor=H.+Huangauthor=L.+Qiaoauthor=L.+Jiauthor=H.+Chao&title=Chiral+ruthenium%28II%29+complexes+with+phenolic+hydroxyl+groups+as+dual+poisons+of+topoisomerases+I+and+II%CE%B1&doi=10.1039%2Fc3dt50472g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1039%2Fc3dt50472g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3dt50472g%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DH.%26atitle%3DChiral%2520ruthenium%2528II%2529%2520complexes%2520with%2520phenolic%2520hydroxyl%2520groups%2520as%2520dual%2520poisons%2520of%2520topoisomerases%2520I%2520and%2520II%25CE%25B1%26jtitle%3DDalton.%2520Trans.%26date%3D2013%26volume%3D42%26spage%3D8907%26epage%3D8917%26doi%3D10.1039%2Fc3dt50472g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagenson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruangpradit, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, O. Q.</span></span> <span> </span><span class="NLM_article-title">Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7889</span>â <span class="NLM_lpage">7906</span>, <span class="refDoi">Â DOI: 10.1021/ic400339z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic400339z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=7889-7906&author=C.+R.+Wilsonauthor=A.+M.+Fagensonauthor=W.+Ruangpraditauthor=M.+T.+Mullerauthor=O.+Q.+Munro&title=Gold%28III%29+complexes+of+pyridyl-+and+isoquinolylamido+ligands%3A+structural%2C+spectroscopic%2C+and+biological+studies+of+a+new+class+of+dual+topoisomerase+I+and+II+inhibitors&doi=10.1021%2Fic400339z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fic400339z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic400339z%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BR.%26aulast%3DFagenson%26aufirst%3DA.%2BM.%26aulast%3DRuangpradit%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DM.%2BT.%26aulast%3DMunro%26aufirst%3DO.%2BQ.%26atitle%3DGold%2528III%2529%2520complexes%2520of%2520pyridyl-%2520and%2520isoquinolylamido%2520ligands%253A%2520structural%252C%2520spectroscopic%252C%2520and%2520biological%2520studies%2520of%2520a%2520new%2520class%2520of%2520dual%2520topoisomerase%2520I%2520and%2520II%2520inhibitors%26jtitle%3DInorg.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D7889%26epage%3D7906%26doi%3D10.1021%2Fic400339z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BornhÃ¤user, M.</span></span> <span> </span><span class="NLM_article-title">Vosaroxin in acute myeloid leukaemia</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1000</span>â <span class="NLM_lpage">1001</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00165-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1016%2FS1470-2045%2815%2900165-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=26234173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fos1Kjsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1000-1001&author=M.+Bornh%C3%A4user&title=Vosaroxin+in+acute+myeloid+leukaemia&doi=10.1016%2FS1470-2045%2815%2900165-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Vosaroxin in acute myeloid leukaemia</span></div><div class="casAuthors">Bornhauser Martin</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1000-1001</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2wvxYycAgy_6xYuD7tu2XfW6udTcc2eZxfscg6sxdsbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fos1Kjsg%253D%253D&md5=908d575de72d30b7ec27b71d062acc22</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900165-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900165-5%26sid%3Dliteratum%253Aachs%26aulast%3DBornh%25C3%25A4user%26aufirst%3DM.%26atitle%3DVosaroxin%2520in%2520acute%2520myeloid%2520leukaemia%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1000%26epage%3D1001%26doi%3D10.1016%2FS1470-2045%2815%2900165-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Short, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia â a critical review</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">529</span>â <span class="NLM_lpage">534</span>, <span class="refDoi">Â DOI: 10.1080/17474086.2016.1187063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=10.1080%2F17474086.2016.1187063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=27158854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFejur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=529-534&author=N.+J.+Shortauthor=F.+Ravandi&title=The+safety+and+efficacy+of+vosaroxin+in+patients+with+first+relapsed+or+refractory+acute+myeloid+leukemia+%E2%80%93+a+critical+review&doi=10.1080%2F17474086.2016.1187063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review</span></div><div class="casAuthors">Short, Nicholas J.; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">529-534</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) are dismal, and effective treatment options in this patient population are therefore desperately needed.  Vosaroxin is a first-in-class anticancer quinolone deriv. that has shown promising activity in patients with relapsed or refractory AML.  Areas Covered: Studies in relapsed/refractory AML, including a large randomized phase III trial, have shown improved response rates when vosaroxin was combined with cytarabine, which translated to prolonged survival in certain subsets of patients, including older patients.  Given the encouraging results of vosaroxin in the relapsed/refractory setting, several studies are also evaluating vosaroxin in older patients with untreated AML who are not candidates for intensive chemotherapy.  The results from clin. trials evaluating vosaroxin in both treatment naive and relapsed/refractory AML will be reviewed.  Expert Commentary: Vosaroxin has shown significant promise in the management of AML, esp. in older patients with relapsed/refractory disease.  As vosaroxin has been assocd. with increased toxicity in some studies, appropriate dosing and patient selection will be crucial to det. the future role of vosaroxin in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOE5EmlFsbVg90H21EOLACvtfcHk0lgVxr9QD0lx9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFejur8%253D&md5=fd9edad09939672351dc48b6237e1124</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1080%2F17474086.2016.1187063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2016.1187063%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DN.%2BJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520vosaroxin%2520in%2520patients%2520with%2520first%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%2520%25E2%2580%2593%2520a%2520critical%2520review%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2016%26volume%3D9%26spage%3D529%26epage%3D534%26doi%3D10.1080%2F17474086.2016.1187063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXM','PDB','1ZXM'); return false;">PDB: 1ZXM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QX3','PDB','3QX3'); return false;">PDB: 3QX3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G0V','PDB','4G0V'); return false;">PDB: 4G0V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ZXN','PDB','1ZXN'); return false;">PDB: 1ZXN</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01202&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-20%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01202%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01202" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998341ac413cb2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
